var images_info;if (!images_info) images_info =[]; images_info["87"]={"87000":{"type":"graphic_picture","displayName":"Tinea barbae 2","title":"Tinea barbae","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Tinea barbae</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/87000_Tinea_barbae_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Follicular pustules and crusted lesions in a patient with tinea barbae.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87000 Version 5.0</div></div></div>"},"87001":{"type":"graphic_figure","displayName":"Allergic child PI","title":"Child with allergies","html":"<div class=\"graphic\"><div style=\"width: 544px\" class=\"figure\"><div class=\"ttl\">Child with allergies</div><div class=\"cntnt\"><img style=\"width:524px; height:332px;\" src=\"images/PI/87001_AllergicchildPI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows a four-year-old child with allergies. Children with severe allergies sometimes have dark circles under their eyes. They also tend to breathe with their mouth open because their nose&nbsp;is stuffy.</div><div id=\"graphicVersion\">Graphic 87001 Version 3.0</div></div></div>"},"87005":{"type":"graphic_figure","displayName":"Penis PI","title":"Anatomy of penis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anatomy of penis</div><div class=\"cntnt\"><img style=\"width:286px; height:244px;\" src=\"images/PI/87005_Penis_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows the different parts of the penis.</div><div id=\"graphicVersion\">Graphic 87005 Version 1.0</div></div></div>"},"87006":{"type":"graphic_figure","displayName":"Paraphimosis PI","title":"Paraphimosis","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Paraphimosis</div><div class=\"cntnt\"><img style=\"width:498px; height:418px;\" src=\"images/PI/87006_Paraphimosis_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The foreskin can sometimes get stuck below the head of the penis. This is called \"paraphimosis.\" If this happens to you or your son, do not try to force the skin to move. Go to a hospital emergency room for treatment. If this problem is not treated right away, it can cause permanent damage.</div><div id=\"graphicVersion\">Graphic 87006 Version 2.0</div></div></div>"},"87007":{"type":"graphic_figure","displayName":"Abnormal growth in a child with Cushings disease","title":"Abnormal growth in a child with Cushing's disease","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">Abnormal growth in a child with Cushing's disease</div><div class=\"cntnt\"><img style=\"width:614px; height:794px;\" src=\"images/PEDS/87007_Abn_growth_child_cushing.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Growth chart of a girl diagnosed with Cushing's disease at age 11.25 years. The patient had poor height velocity since age 9.6 years in conjunction with a 2.25-year delayed bone age (leftward arrow from height point at actual age 11.25 years), and excessive weight gain over the same time period. An ACTH-producing pituitary adenoma was discovered and removed by transsphenoidal surgery at age 11.5 years. The patient subsequently had full biochemical recovery, initially followed by a significant improvement in height velocity and a significant reduction in weight (loss of 16 pounds over&nbsp;six months). With progressive puberty, the patient's bone age delay decreased (1.25 years at actual age 12.25 years, and 0.5 years at actual age 14 years) in association with physiological height plateauing. The progressive acceleration in bone age was likely due to the effects of pubertal estrogen. The bracket at the far right of the height curve represents the mid-parental target height range (Â±1 SD). As is typical in patients with childhood Cushing's disease, the mid-parental target height was not achieved.<SUP>[1]</SUP></div><div class=\"graphic_footnotes\">ACTH: adrenocorticotropic hormone; GnRH: gonadotropin hormone releasing hormone; SD: standard deviation; %: percent.</div><div class=\"graphic_reference\">Reference:<br /><ol>&#xD;&#xA;    <li>Chan LF, Storr HL, Grossman AB, Savage MO. Pediatric Cushing's syndrome: Clinical features, diagnosis, and treatment. Arq Bras Endocrinol Metabol 2007; 51:1261-1271.</li>&#xD;&#xA;</ol>&#xD;&#xA;<br />Courtesy of Mitchell Geffner, MD.</div><div id=\"graphicVersion\">Graphic 87007 Version 4.0</div></div></div>"},"87009":{"type":"graphic_picture","displayName":"Hemangioma PI","title":"Hemangioma on lip","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hemangioma on lip</div><div class=\"cntnt\"><img style=\"width:370px; height:277px;\" src=\"images/PI/87009_Hemangioma_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an example of a hemangioma.</div><div class=\"graphic_reference\">Courtesy of Denise W Metry, MD.</div><div id=\"graphicVersion\">Graphic 87009 Version 1.0</div></div></div>"},"87010":{"type":"graphic_algorithm","displayName":"EGFR inhbtr acneiform rash treatment","title":"Treatment of EGFR inhibitor-induced acneiform rash","html":"<div class=\"graphic\"><div style=\"width: 496px\" class=\"figure\"><div class=\"ttl\">Treatment of EGFR inhibitor-induced acneiform rash</div><div class=\"cntnt\"><img style=\"width:476px; height:520px;\" src=\"images/DERM/87010_EGFR_inhbtr_rash_treatment.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PI: prescribing information; %: percent.<br />* It is recommended that patients treated with EGFR inhibitors begin prophylactic rash therapy with doxycycline 100 mg twice a day or minocycline 100 mg daily and a low potency topical steroid twice a day for first six weeks of therapy.</div><div class=\"graphic_reference\">Modified from: Balagula E, Lacouture ME. Dermatologic toxicities. In: The MASCC Textbook of Cancer Supportive Care and Survivorship, Olver IN (Ed), Springer, New York 2010. Copyright &copy; 2010; with kind permission from Springer Science + Business Media B.V.</div><div id=\"graphicVersion\">Graphic 87010 Version 5.0</div></div></div>"},"87011":{"type":"graphic_picture","displayName":"Osteoblastic osteosarcoma","title":"Osteoblastic osteosarcoma","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Osteoblastic osteosarcoma</div><div class=\"cntnt\"><img style=\"width:515px; height:197px;\" src=\"images/ONC/87011_Osteoblastic_osteosarc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histologic appearance of an osteoblastic osteosarcoma with eosinophilic osteoid material (yellow arrows) produced by pleomorphic malignant osteoblasts with occasional malignant osteoblastic giant cells (white arrowhead). Note variable amounts of osteoid production.</div><div class=\"graphic_reference\">Courtesy of M John Hicks, DDS, MD, PhD.</div><div id=\"graphicVersion\">Graphic 87011 Version 1.0</div></div></div>"},"87012":{"type":"graphic_picture","displayName":"Chondroblastic osteosarcoma","title":"Chondroblastic osteosarcoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Chondroblastic osteosarcoma</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/ONC/87012_Chondroblast_osteosarcom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histologic appearance of a chondroblastic osteosarcoma with malignant chondrocytes and areas undergoing transformation to osteoid matrix associated with entrapped malignant cells (arrows).</div><div class=\"graphic_reference\">Courtesy of M John Hicks, DDS, MD, PhD.</div><div id=\"graphicVersion\">Graphic 87012 Version 2.0</div></div></div>"},"87013":{"type":"graphic_picture","displayName":"Fibroblastic osteosarcoma","title":"Fibroblastic osteosarcoma","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Fibroblastic osteosarcoma</div><div class=\"cntnt\"><img style=\"width:515px; height:194px;\" src=\"images/ONC/87013_Fibroblastic_osteosarc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histologic appearance of fibroblastic osteosarcoma, which is primarily comprised of malignant spindle cells without obvious osteoid production (A) and rare areas containing osteoid matrix (B, arrows) associated with the pleomorphic malignant tumor cells.</div><div class=\"graphic_reference\">Courtesy of M John Hicks, DDS, MD, PhD.</div><div id=\"graphicVersion\">Graphic 87013 Version 2.0</div></div></div>"},"87014":{"type":"graphic_picture","displayName":"Telangiectatic osteosarcoma","title":"Telangiectatic osteosarcoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Telangiectatic osteosarcoma</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/ONC/87014_Telangiectatic_osteosarc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histologic appearance of a telangiectatic osteosarcoma with typical blood-filled cyst-like structures (yellow thick arrows) surrounded by malignant osteoblastic cells and malignant osteoblastic giant cells (white thin arrows).</div><div class=\"graphic_reference\">Courtesy of M John Hicks, DDS, MD, PhD.</div><div id=\"graphicVersion\">Graphic 87014 Version 2.0</div></div></div>"},"87015":{"type":"graphic_picture","displayName":"Complete tumor necrosis of osteosarcoma","title":"Complete tumor necrosis of osteosarcoma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Complete tumor necrosis of osteosarcoma</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/ONC/87015_Comp_tumor_nec_osteosarc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histologic appearance of complete tumor necrosis of osteosarcoma following oncologic management; the specimen&nbsp;shows woven bony trabeculae with no viable osteocytes or osteoblasts.</div><div class=\"graphic_reference\">Courtesy of M John Hicks, DDS, MD, PhD.</div><div id=\"graphicVersion\">Graphic 87015 Version 1.0</div></div></div>"},"87016":{"type":"graphic_diagnosticimage","displayName":"Brown tumors of pelvic bones findings on CT","title":"Brown tumors of pelvic bones: Findings on CT","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Brown tumors of pelvic bones: Findings on CT</div><div class=\"cntnt\"><img style=\"width:576px; height:405px;\" src=\"images/RADIOL/87016_Brown_tumors_pelvic_bones.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CT scan of pelvis shows multiple lytic lesions in the pelvis (white arrows) consistent with brown tumors.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 87016 Version 2.0</div></div></div>"},"87017":{"type":"graphic_diagnosticimage","displayName":"Osteitis fibrosa cystica radiographs phalanges and clavicles","title":"Osteitis fibrosa cystica: Findings on radiographs of the phalanges and clavicles","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Osteitis fibrosa cystica: Findings on radiographs of the phalanges and clavicles</div><div class=\"cntnt\"><img style=\"width:597px; height:301px;\" src=\"images/RADIOL/87017_Ost_fibr_cyst_phal_clav.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Detail view of the hands shows subperiosteal resorption in the phalanges (arrows).<br />(B) Detail views of both distal clavicles show subchondral resorption bilaterally (arrows).</div><div class=\"graphic_reference\">Reproduced with permission from: Daffner RH. Clinical Radiology, The Essentials, 3rd Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87017 Version 2.0</div></div></div>"},"87018":{"type":"graphic_diagnosticimage","displayName":"Osteitis fibrosa cystica findings on skull radiograph","title":"Osteitis fibrosa cystica: Findings on skull radiograph","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Osteitis fibrosa cystica: Findings on skull radiograph</div><div class=\"cntnt\"><img style=\"width:598px; height:247px;\" src=\"images/RADIOL/87018_Ost_fibr_cyst_skull_xray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skull radiograph shows the typical \"salt and pepper\" appearance caused by osteitis fibrosa cystica (A). Skull radiograph of same patient&nbsp;six months after removal of the patient's parathyroid adenoma (B). The bones have returned to normal.</div><div class=\"graphic_reference\">Reproduced with permission from: Daffner RH. Clinical Radiology, The Essentials, 3rd Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87018 Version 2.0</div></div></div>"},"87019":{"type":"graphic_diagnosticimage","displayName":"Osteitis fibrosa cystica findings on radiograph of the phalanges","title":"Osteitis fibrosa cystica: Findings on radiograph of the phalanges","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Osteitis fibrosa cystica: Findings on radiograph of the phalanges</div><div class=\"cntnt\"><img style=\"width:597px; height:220px;\" src=\"images/RADIOL/87019_Ost_fibr_cyst_xray_phalang.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A and B) Posteroanterior (PA) hands. Note the radial margins of the proximal and middle phalanges bilaterally are frayed, irregular, and lace-like (arrows) owing to characteristic subperiosteal resorption. Also note the brown tumor (small arrowhead) and osteolysis of the distal phalanges (large arrowheads).</div><div class=\"graphic_reference\">Reproduced with permission from: Yochum TR, Rowe LJ. Yochum And Rowe's Essentials of Skeletal Radiology, Third Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87019 Version 3.0</div></div></div>"},"87020":{"type":"graphic_diagnosticimage","displayName":"Cephalopelvic disproportion in osteomalacia radiographic finding","title":"Cephalopelvic disproportion in osteomalacia: Radiographic findings","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cephalopelvic disproportion in osteomalacia: Radiographic findings</div><div class=\"cntnt\"><img style=\"width:384px; height:513px;\" src=\"images/RADIOL/87020_Cephalopelvic_disp_osteomal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Historical radiograph of a pregnant patient with osteomalacia secondary to lack of exposure to sunlight and dietary causes resulting in cephalopelvic disproportion. Examination of the pelvis shows distortion of the iliopubic regions (arrows) with narrowing of the pelvic outlet. The fetal head (arrowhead) is deep in the pelvis and appears too large for the pelvic outlet. The fetal spine is seen to the patient's right (dashed arrow).</div><div id=\"graphicVersion\">Graphic 87020 Version 2.0</div></div></div>"},"87021":{"type":"graphic_diagnosticimage","displayName":"Osteomalacia of the lumbar spine CT","title":"Osteomalacia of the lumbar spine: Computed tomography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Osteomalacia of the lumbar spine: Computed tomography</div><div class=\"cntnt\"><img style=\"width:317px; height:484px;\" src=\"images/ENDO/87021_Osteomalac_lumbar_spine_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 53-year-old man with osteomalacia. A CT examination revealed ill-defined trabeculae with ground glass appearance consistent with osteomalacia.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Joseph Farnam, MD.</div><div id=\"graphicVersion\">Graphic 87021 Version 2.0</div></div></div>"},"87023":{"type":"graphic_table","displayName":"Physical factors underlying recurrent infections in adults","title":"Anatomic and physiologic issues associated with recurrent infections in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Anatomic and physiologic issues associated with recurrent infections in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Head and neck</td> </tr> <tr> <td class=\"subtitle2_single\">Recurrent otitis media</td> </tr> <tr> <td class=\"indent1\">Cholesteatoma</td> </tr> <tr> <td class=\"indent1\">Tympanic membrane perforation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Eustachian tube dysfunction due to allergy or viral infection</td> </tr> <tr> <td class=\"subtitle2_single\">Sinusitis</td> </tr> <tr> <td class=\"indent1\">Ostiomeatal obstruction</td> </tr> <tr> <td class=\"indent1\">Nasal polyps</td> </tr> <tr> <td class=\"indent1\">Mucocele</td> </tr> <tr> <td class=\"indent1\">Allergic rhinitis</td> </tr> <tr> <td class=\"indent1\">Viral infection</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Inadequate therapy for acute sinusitis</td> </tr> <tr> <td class=\"subtitle2_single\">Cervical lymphadenitis</td> </tr> <tr> <td class=\"indent1\">Unrecognized branchial cleft cyst</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Inadequately treated dental disease</td> </tr> <tr> <td class=\"subtitle1_single\">Lungs</td> </tr> <tr> <td class=\"subtitle2_single\">Bronchopneumonia</td> </tr> <tr> <td class=\"indent1\">Smoking</td> </tr> <tr> <td class=\"indent1\">Acute exacerbations of chronic bronchitis</td> </tr> <tr> <td class=\"indent1\">Intrinsic airway disorders:</td> </tr> <tr> <td class=\"indent2\">Bronchiectasis, foreign body, bronchial stenosis, bronchomalacia, tracheobronchial fistula</td> </tr> <tr> <td class=\"indent1\">Recurrent aspiration (alcohol/drug use, seizure disorder)</td> </tr> <tr> <td class=\"indent1\">Esophageal disease (gastroesophageal reflux, Zenker's diverticulum, achalasia)</td> </tr> <tr> <td class=\"indent1\">Bronchial obstruction (extrinsic versus intrinsic obstruction)</td> </tr> <tr> <td class=\"indent1\">Unrecognized cystic fibrosis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Unrecognized ciliary dyskinesia</td> </tr> <tr> <td class=\"subtitle1_single\">Genitourinary tract</td> </tr> <tr> <td class=\"subtitle2_single\">Cystitis</td> </tr> <tr> <td class=\"indent1\">Urinary stasis</td> </tr> <tr> <td class=\"indent2\">Incomplete bladder emptying (bladder outlet obstruction, bladder atony/denervation)</td> </tr> <tr> <td class=\"indent1\">Compromised perineal hygiene (overactive bladder/urinary incontinence)</td> </tr> <tr> <td class=\"indent1\">Diaphragm use</td> </tr> <tr> <td class=\"indent1\">Prostatic infection</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Instrumentation (especially chronic urinary catheter)</td> </tr> <tr> <td class=\"subtitle2_single\">Pyelonephritis</td> </tr> <tr> <td class=\"indent1\">All of the conditions that predispose to cystitis plus:</td> </tr> <tr> <td class=\"indent2\">Renal calculi</td> </tr> <tr> <td class=\"indent2\">Ureteral obstruction (stone, stricture, malignancy)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Ureteral reflux</td> </tr> <tr> <td class=\"subtitle1_single\">Skin</td> </tr> <tr> <td class=\"subtitle2_single\">Cellulitis</td> </tr> <tr> <td class=\"indent1\">Recurrent trauma (eg, shaving legs, sports-related abrasions)</td> </tr> <tr> <td class=\"indent1\">Dermatophyte infection</td> </tr> <tr> <td class=\"indent1\">Lymphedema</td> </tr> <tr> <td class=\"indent1\">Postoperative lymphatic dysfunction (groin/axillary exploration, lymphadenectomy)</td> </tr> <tr> <td class=\"indent1\">Venous insufficiency/vein harvesting for coronary artery bypass grafting (CABG)</td> </tr> <tr> <td class=\"indent1\">Chronic edema (congestive heart failure, hepatic insufficiency, nephrotic syndrome)</td> </tr> <tr> <td class=\"indent1\">Prior cellulitis (lymphatic scarring)</td> </tr> <tr> <td class=\"indent1\">Obesity</td> </tr> <tr> <td class=\"indent1\">Filariasis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Poor hygiene</td> </tr> <tr> <td class=\"subtitle2_single\">Abscess</td> </tr> <tr> <td class=\"indent1\"><em>Staphylococcus aureus</em> carriage (methicillin-sensitive or methicillin-resistant), especially with recurrent trauma</td> </tr> <tr> <td class=\"indent1\">Autoinoculation (subcutaneous drug injection or \"skin popping,\" factitious)</td> </tr> <tr> <td class=\"indent1\">Crohn disease</td> </tr> <tr> <td class=\"indent1\">Hidradenitis suppurative (axillary, groin, periareolar)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Retained foreign body</td> </tr> <tr> <td class=\"subtitle1_single\">Central nervous system</td> </tr> <tr> <td class=\"subtitle2_single\">Meningitis</td> </tr> <tr> <td class=\"indent1\">Cranial vault defects (cribriform plate; sinus/mastoid defects; prior neurosurgery/trauma)</td> </tr> <tr> <td class=\"indent1\">Chronic mastoid/sinus infection</td> </tr> <tr> <td class=\"indent1\">Noninfectious meningitidis:</td> </tr> <tr> <td class=\"indent2\">Drug-related</td> </tr> <tr> <td class=\"indent2\">Intravenous immune globulin (IVIG)-related</td> </tr> <tr> <td class=\"indent2\">Mollaret's meningitis related to craniopharyngioma</td> </tr> <tr> <td class=\"indent2\">Neoplastic</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Autoimmune (Beh&#231;et's, Vogt-Koyanagi-Harada)</td> </tr> <tr> <td class=\"subtitle2_single\">Brain abscess</td> </tr> <tr> <td class=\"indent1\">Right-to-left circulatory shunting</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 87023 Version 6.0</div></div></div>"},"87024":{"type":"graphic_picture","displayName":"Lichen planus PI","title":"Lichen planus","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Lichen planus</div><div class=\"cntnt\"><img style=\"width:515px; height:430px;\" src=\"images/PI/87024_Lichen_planus_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lichen planus can look different on different people and on different body parts.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87024 Version 3.0</div></div></div>"},"87025":{"type":"graphic_figure","displayName":"Risk of stroke and intracranial bleeding based on INR","title":"Odds ratios for ischemic stroke and intracranial bleeding in relation to intensity of anticoagulation","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Odds ratios for ischemic stroke and intracranial bleeding in relation to intensity of anticoagulation</div><div class=\"cntnt\"><img style=\"width:482px; height:332px;\" src=\"images/CARD/87025_Risk_strk_intracran_bld_INR.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Adjusted odds ratios for ischemic stroke and intracranial bleeding in relation to intensity of anticoagulation.</div><div class=\"graphic_reference\">Reproduced with permission from: Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2011; 123:e269. Copyright Â© 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87025 Version 4.0</div></div></div>"},"87026":{"type":"graphic_figure","displayName":"Pacemaker failure to capture","title":"Pacemaker failure to capture","html":"<div class=\"graphic\"><div style=\"width: 586px\" class=\"figure\"><div class=\"ttl\">Pacemaker failure to capture</div><div class=\"cntnt\"><img style=\"width:566px; height:203px;\" src=\"images/CARD/87026_Pacemaker_fail_capture.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Dr. Jordan Prutkin.</div><div id=\"graphicVersion\">Graphic 87026 Version 1.0</div></div></div>"},"87027":{"type":"graphic_figure","displayName":"Lymph node compartments of the neck","title":"Lymph node compartments of the neck","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Lymph node compartments of the neck</div><div class=\"cntnt\"><img style=\"width:514px; height:497px;\" src=\"images/SURG/87027_Lymph_node_compartments.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 87027 Version 1.0</div></div></div>"},"87043":{"type":"graphic_table","displayName":"NF1 monitoring PI","title":"How doctors monitor NF1","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">How doctors monitor NF1</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of exam or check</td> <td class=\"subtitle1\">What the doctor will do</td> <td class=\"subtitle1\">Why it's important</td> </tr> <tr> <td>Physical exam (every year)</td> <td> <p>Check for new or changing growths or tumors.</p> <p>Check for high blood pressure.</p> <p>Measure height, weight, and head size.</p> Check that the bones in the arms, legs, and back look normal.</td> <td>NF1 can cause problems with the way the body forms and grows. It can also cause high blood pressure, which can lead to heart disease or other problems.</td> </tr> <tr> <td>Eye exam (every year)</td> <td>A full eye exam, including a vision check.</td> <td>NF1 can cause tumors to form on the nerves going to the eye. This can affect vision.</td> </tr> <tr> <td>Check for early puberty (every year)</td> <td>Check for signs of early puberty, such as: <ul> <li>Hair growth under the arms or between the legs </li> <li>Budding breasts (in girls) </li> <li>Growth of the penis or testicles (in boys) </li> </ul> </td> <td>Tumors caused by NF1 can press on or damage the part of the brain that controls the timing of puberty.</td> </tr> <tr> <td>Check on learning and memory (every year)</td> <td>Check that the child has gone through the normal stages of learning for his or <span style=\"color: black;\">her age. Check for learning problems, including attention deficit hyperactivity disorder </span>(also called ADHD).</td> <td>If the child has any learning problems, it's important to catch and treat them early.</td> </tr> <tr> <td>Review school progress (after child reaches school age)</td> <td>If progress in school is not going as it should, the doctor can recommend certain tests to find out what the problem is.</td> <td>If the child has problems in school, there are often programs and special classes and tutors that can help.</td> </tr> <tr> <td>Check on large or complex skin growths (every year)</td> <td>The doctor will ask the child whether any of the growths on his or her skin have grown or started to hurt more. This is especially important during the teenage years.</td> <td>Abnormal growths on the skin caused by NF1 can sometimes turn into cancer.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 87043 Version 2.0</div></div></div>"},"87044":{"type":"graphic_algorithm","displayName":"Treatment algorithm malignant pheochromocytoma and paraganglioma","title":"Treatment algorithm for malignant pheochromocytoma and paraganglioma","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Treatment algorithm for malignant pheochromocytoma and paraganglioma</div><div class=\"cntnt\"><img style=\"width:504px; height:595px;\" src=\"images/ONC/87044_Treat_algo_malig_pheo_para.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified with permission from: Adjalle R, Plouin PF, Pacak K, Lehnert H. Treatment of malignant pheochromocytoma. Horm Metab Res 2009; 41:687. Copyright Â© 2009 Thieme Publishers.</div><div id=\"graphicVersion\">Graphic 87044 Version 1.0</div></div></div>"},"87045":{"type":"graphic_figure","displayName":"Right recurrent laryngeal nerve","title":"Right recurrent laryngeal nerve","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Right recurrent laryngeal nerve</div><div class=\"cntnt\"><img style=\"width:502px; height:423px;\" src=\"images/SURG/87045_Parathyroid_surgery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral view of the right recurrent laryngeal nerve.</div><div id=\"graphicVersion\">Graphic 87045 Version 1.0</div></div></div>"},"87046":{"type":"graphic_figure","displayName":"Common locations of common enlarged parathyroid glands","title":"Common locations of common enlarged parathyroid glands","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Common locations of common enlarged parathyroid glands</div><div class=\"cntnt\"><img style=\"width:314px; height:518px;\" src=\"images/SURG/87046_Locations_parathyroids.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 87046 Version 1.0</div></div></div>"},"87054":{"type":"graphic_picture","displayName":"Dermatographism PI","title":"Physical hives caused by scraping or stroking (dermatographism)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Physical hives caused by scraping or stroking (dermatographism)</div><div class=\"cntnt\"><img style=\"width:360px; height:254px;\" src=\"images/PI/87054_Dermatographism_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These hives showed up 3 minutes after writing on this woman's skin with a small wooden stick.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87054 Version 2.0</div></div></div>"},"87055":{"type":"graphic_picture","displayName":"Lace up ankle brace","title":"Lace-up ankle brace","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Lace-up ankle brace</div><div class=\"cntnt\"><img style=\"width:585px; height:375px;\" src=\"images/EM/87055_Ankle_brace.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During functional rehabilitation of an ankle sprain, a lace-up ankle support, such as the one pictured here, reduces instability and protects the ankle from further injury.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2012 DJO, LLC. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87055 Version 1.0</div></div></div>"},"87057":{"type":"graphic_figure","displayName":"Pathway of the biosynthesis of DHA","title":"Pathway of the biosynthesis of docosahexaenoic acid","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Pathway of the biosynthesis of docosahexaenoic acid</div><div class=\"cntnt\"><img style=\"width:598px; height:366px;\" src=\"images/PEDS/87057_Pathway_biosynthesis_DHA.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pathway of the biosynthesis of docosahexaenoic acid (DHA) and inhibitory effects that the preterm diet and steroids could have on the ability to internally synthesize adequate DHA.</div><div class=\"graphic_footnotes\">LA: linolenic acid; ALA: alpha-linolenic acid; GLA: gamma-linolenic acid; SA: stearidonic acid; PGs: prostaglandins; DGLA: di-homo gamma-linolenic acid; ETA: eicosatetraenoic acid; AA: arachidonic acid; EPA: eicosapentaenoic acid; DPA: docosapentaenoic acid; DHA: docosahexaenoic acid.</div><div class=\"graphic_reference\">Reproduced with permission from: Valentine CJ. Maternal dietary DHA supplementation to improve inflammatory outcomes in the preterm infant. Advances in Nutrition: An International Review Journal (2012; 3:370-6). Copyright &copy; 2012 American Society for Nutrition.</div><div id=\"graphicVersion\">Graphic 87057 Version 4.0</div></div></div>"},"87059":{"type":"graphic_table","displayName":"Comparison of advantages of the exercise ECG versus imaging","title":"Comparison of advantages of the exercise ECG versus stress testing withÂ imaging","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of advantages of the exercise ECG versus stress testing with&nbsp;imaging</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Exercise treadmill testing (ETT)</td> <td class=\"subtitle1\">Imaging</td> </tr> <tr> <td>Lower cost</td> <td>Exercise or pharmacologic stress</td> </tr> <tr> <td>More widely available</td> <td>Higher sensitivity than ETT</td> </tr> <tr> <td>Less influenced by technical processing</td> <td>Incremental prognostic value over ETT</td> </tr> <tr> <td>Less technically demanding</td> <td>Localize ischemia</td> </tr> <tr> <td>No radiation</td> <td>Additional information on cardiac structure and function</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram.</div><div id=\"graphicVersion\">Graphic 87059 Version 2.0</div></div></div>"},"87060":{"type":"graphic_table","displayName":"Key considerations for breastfeeding","title":"Key considerations for breastfeeding","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key considerations for breastfeeding</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Key considerations for breastfeeding</td> </tr> <tr> <td>Human breast milk is specific to the needs of the infant and is the most complete and ideal source for infant nourishment in the first year of life.</td> </tr> <tr> <td class=\"subtitle1_single\">Key recommendations for initiation of breastfeeding</td> </tr> <tr> <td>Measurement of levels of lead in breast milk is not recommended.</td> </tr> <tr> <td>Mothers with BLLs &#60;40 mcg/dL should breastfeed.</td> </tr> <tr> <td>Mothers with confirmed BLLs &#8805;40 mcg/dL should begin breastfeeding when their blood lead levels drop below 40 mcg/dL. Until then, they should pump and discard their breast milk.</td> </tr> <tr> <td>These recommendations are not appropriate in countries where infant mortality from infectious diseases is high (World Health Organization Collaborative Study Team on the Role of Breastfeeding on the Prevention of Infant Mortality 2000).</td> </tr> <tr> <td class=\"subtitle1_single\">Key recommendations for continuation of breastfeeding</td> </tr> <tr> <td>Breastfeeding should continue for all infants with BLLs below 5 mcg/dL.</td> </tr> <tr> <td>Infants born to mothers with BLL &#8805;5 mcg/dL can continue to breastfeed unless there are indications that the breast milk is contributing to elevating BLLs. These infants should have blood lead tests at birth and be followed at regular intervals.</td> </tr> <tr> <td>For infants whose blood lead levels are rising or failing to decline by 5 mcg/dL or more, environmental and other sources of lead exposure should be evaluated. If no external source is identified, and maternal BLLs are &#62;20 mcg/dL and infant BLL &#8805;5 mcg/dL, then breast milk should be suspected as the source, and temporary interruption of breastfeeding until maternal blood lead levels decline should be considered.</td> </tr> <tr> <td class=\"subtitle1_single\">Key recommendations for use of reconstituted infant formula</td> </tr> <tr> <td>Infant formula requiring reconstitution should be made only with water from the cold water tap. Flush the tap for at least&nbsp;three minutes before use and then heat the water or use bottled or filtered tap water known to be free of lead.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BLL: blood lead level.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Guidelines for the Identification and Management of Lead Exposure in Pregnant and Lactating Women. 2010. Available at:&nbsp;<A style=\"FONT-STYLE: italic\" href=\"http://www.cdc.gov/nceh/lead/publications/LeadandPregnancy2010.pdf\" target=_blank>http://www.cdc.gov/nceh/lead/publications/LeadandPregnancy2010.pdf</A> (Accessed November 12, 2012).</div><div id=\"graphicVersion\">Graphic 87060 Version 4.0</div></div></div>"},"87063":{"type":"graphic_picture","displayName":"Counter force brace for epicondylitis","title":"Counter force brace for epicondylitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Counter force brace for epicondylitis</div><div class=\"cntnt\"><img style=\"width:396px; height:395px;\" src=\"images/EM/87063_Counter_brace_epicondyl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The initial management of lateral epicondylitis often involves the use of a counter force brace. Such bracing may reduce tendon and muscle strain at the origin of the forearm extensor muscles, thereby relieving pain and improving function.</div><div class=\"graphic_reference\">Reproduced with permission from: Aircast/ProCare Brand. Copyright &copy; 2008 DJO Incorporated. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87063 Version 3.0</div></div></div>"},"87064":{"type":"graphic_picture","displayName":"Duodenal ulcer with a visible vessel","title":"Duodenal ulcer with a visible vessel","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Duodenal ulcer with a visible vessel</div><div class=\"cntnt\"><img style=\"width:348px; height:375px;\" src=\"images/GAST/87064_Duoden_ulcer_w_vis_vess.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of a relatively small duodenal ulcer (arrow) with a large visible vessel at its inferior portion (arrowhead).</div><div id=\"graphicVersion\">Graphic 87064 Version 1.0</div></div></div>"},"87065":{"type":"graphic_picture","displayName":"Severe esophagitis","title":"Severe esophagitis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Severe esophagitis</div><div class=\"cntnt\"><img style=\"width:504px; height:435px;\" src=\"images/GAST/87065_Severe_esophagits.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of severe reflux esophagitis in a patient who presented with upper gastrointestinal bleeding.</div><div id=\"graphicVersion\">Graphic 87065 Version 1.0</div></div></div>"},"87066":{"type":"graphic_picture","displayName":"Nonbleeding esophageal varices","title":"Esophageal varices","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Esophageal varices</div><div class=\"cntnt\"><img style=\"width:355px; height:356px;\" src=\"images/GAST/87066_Nonbleed_esophag_varices.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic images from a patient with esophageal varices. Varices may or may not have stigmata of bleeding. These varices are large but do not have clear stigmata of bleeding, such as red wale signs.</div><div id=\"graphicVersion\">Graphic 87066 Version 1.0</div></div></div>"},"87067":{"type":"graphic_picture","displayName":"Bleeding esophageal varix","title":"Actively bleeding esophageal varix","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Actively bleeding esophageal varix</div><div class=\"cntnt\"><img style=\"width:271px; height:236px;\" src=\"images/GAST/87067_Bleed_esophageal_varix.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic view of an actively bleeding esophageal varix. The varix was banded successfully, and the bleeding stopped.</div><div id=\"graphicVersion\">Graphic 87067 Version 1.0</div></div></div>"},"87068":{"type":"graphic_picture","displayName":"Gastric varix","title":"Gastric varix","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Gastric varix</div><div class=\"cntnt\"><img style=\"width:504px; height:401px;\" src=\"images/GAST/87068_Gastric_varx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The image obtained at the time of endoscopy reveals a typical GOV (gastro-oesophageal variceal) lesion. The GOV nomenclature is used for varices that are continuous from the esophagus to the stomach (GOV1 include those that extend less than 5 cm from the GE junction, whereas GOV2 extend for further than this length [this is an instance of GOV2]). The large grape-like structure appears to emanate from the GE junction, typical of GOV lesions. Gastric varices can also be isolated, often when they arise as a result of splenic vein thrombosis.</div><div id=\"graphicVersion\">Graphic 87068 Version 1.0</div></div></div>"},"87070":{"type":"graphic_diagnosticimage","displayName":"Spine MRI following contaminated epidural injection","title":"Spine MRI of a patient who received a contaminated epidural injection of methylprednisolone","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Spine MRI of a patient who received a contaminated epidural injection of methylprednisolone</div><div class=\"cntnt\"><img style=\"width:512px; height:512px;\" src=\"images/ID/87070_ExserohilumMRIspine.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Sagittal T1 post-gadolinium image showing&nbsp;dural and leptomeningeal enhancement at L5/S1.<BR>(B) Sagittal post-gadolinium image showing&nbsp;dural and leptomeningeal contrast enhancement.<BR>(C and D) Axial post-gadolinium T1 images that&nbsp;correlate with&nbsp;images A and&nbsp;B, respectively, and show dural and nerve root enhancement (post-contrast).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Kerkering TM, Grifasi ML, Baffoe-Bonnie AW, et al. Early Clinical Observations in Prospectively Followed Patients With Fungal Meningitis Related to Contaminated Epidural Steroid Injections. Ann Intern Med 2012. Copyright Â© 2012 American College of Physicians.</div><div id=\"graphicVersion\">Graphic 87070 Version 12.0</div></div></div>"},"87075":{"type":"graphic_figure","displayName":"Pilonidal sinus and tract","title":"Pilonidal sinus and tract","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pilonidal sinus and tract</div><div class=\"cntnt\"><img style=\"width:402px; height:321px;\" src=\"images/SURG/87075_Pilonidal_sinus_and_tract.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 87075 Version 1.0</div></div></div>"},"87076":{"type":"graphic_diagnosticimage","displayName":"MRI arthrography of triangular fibrocartilage complex tear","title":"MRI arthrography of triangular fibrocartilage complex tear","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">MRI arthrography of triangular fibrocartilage complex tear</div><div class=\"cntnt\"><img style=\"width:440px; height:504px;\" src=\"images/RADIOL/87076_MRI_arthro_wrist_TFCC_tear.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A solution of gadolinium and iodinated contrast was injected into the right wrist joint under fluoroscopic guidance prior to evaluation by MRI. A small amount of contrast is seen traversing the fibrocartilage (arrow) and into the distal radioulnar joint (arrowhead) confirming the presence of a triangular fibrocartilage complex tear.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 87076 Version 2.0</div></div></div>"},"87077":{"type":"graphic_diagnosticimage","displayName":"MRI of triangular fibrocartilage complex tear","title":"MRI of triangular fibrocartilage complex tear","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">MRI of triangular fibrocartilage complex tear</div><div class=\"cntnt\"><img style=\"width:598px; height:370px;\" src=\"images/RADIOL/87077_Triang_fibrocartil_tear_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MRI following arthrography shows a tear in the triangular fibrocartilage complex (TFCC) of the right wrist. The T1 fat suppressed sequence (A) confirms the presence of the tear (arrow) with leakage of contrast into the distal radioulnar joint (arrowhead). Similar findings are seen in the STIR sequence (B).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 87077 Version 2.0</div></div></div>"},"87078":{"type":"graphic_figure","displayName":"Natal cleft","title":"Natal cleft","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Natal cleft</div><div class=\"cntnt\"><img style=\"width:421px; height:336px;\" src=\"images/SURG/87078_Natal_cleft.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image shows the location of the natal cleft, also called the intergluteal cleft. It extends from just below the sacrum to the perineum and ends superior to the anus.</div><div id=\"graphicVersion\">Graphic 87078 Version 1.0</div></div></div>"},"87084":{"type":"graphic_figure","displayName":"Ventilatory sensitivity to hypercapnia in ESRD pts on HD","title":"Ventilatory sensitivity to hypercapnia in end-stage renal disease patients whose apnea improved (A) or did not improve (B) following conversion from conventional hemodialysis to nocturnal hemodialysis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ventilatory sensitivity to hypercapnia in end-stage renal disease patients whose apnea improved (A) or did not improve (B) following conversion from conventional hemodialysis to nocturnal hemodialysis</div><div class=\"cntnt\"><img style=\"width:428px; height:621px;\" src=\"images/NEPH/87084_Vent_sens_hypercapn_ESRD_HD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows a reduction in the sensitivity of the ventilatory response among apneic patients whose apnea improved when they were converted from conventional to nocturnal hemodialysis.</div><div class=\"graphic_footnotes\">CHD: conventional hemodialysis; NHD: nocturnal hemodialysis.</div><div class=\"graphic_reference\">Reproduced from: Beecroft JM, Duffin J, Pierratos A, et al. Decreased chemosensitivity and improvement of sleep apnea by nocturnal hemodialysis. Sleep Med 2009; 10:47. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87084 Version 2.0</div></div></div>"},"87086":{"type":"graphic_figure","displayName":"Female pelvic bones ligaments","title":"Female pelvic bones and ligaments","html":"<div class=\"graphic\"><div style=\"width: 624px\" class=\"figure\"><div class=\"ttl\">Female pelvic bones and ligaments</div><div class=\"cntnt\"><img style=\"width:604px; height:458px;\" src=\"images/OBGYN/87086_Fem_pelvc_bn_ligamnts.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted with permission: Cleveland Clinic Center for Medical Art &amp; Photography &copy; 2004-2012. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 87086 Version 1.0</div></div></div>"},"87087":{"type":"graphic_picture","displayName":"Female pelvic bones 2","title":"Female pelvic bones","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Female pelvic bones</div><div class=\"cntnt\"><img style=\"width:515px; height:371px;\" src=\"images/OBGYN/87087_Fem_pelvic_bones_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Pelvis, female, anterior. Anterior view of the female pelvis.<br />(B) Pelvis, female, posterior. Posterior view of the female pelvis.<br />(C) Pelvis, female, superior. Superior view of the female pelvis.</div><div class=\"graphic_reference\">Reproduced with permission from: LifeART. Copyright Â© 2012 Lippincott Williams &amp; Wilkins. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87087 Version 1.0</div></div></div>"},"87088":{"type":"graphic_diagnosticimage","displayName":"Traumatic diaphragmatic hernia on computed tomography","title":"Traumatic diaphragmatic hernia on computed tomography","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Traumatic diaphragmatic hernia on computed tomography</div><div class=\"cntnt\"><img style=\"width:598px; height:406px;\" src=\"images/RADIOL/87088_CT_trauma_diaphrag_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CT scan shows a traumatic diaphragmatic hernia. Image A shows an intact left hemidiaphragm (arrow). More inferiorly, image B shows a disrupted hemidiaphragm with a fragment of mesentry protruding (small arrowhead) and a grade I liver laceration (large arrowhead). Image C shows a portion of the splenic flexure herniating (dashed arrow) and a subcapsular hematoma (thick arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 87088 Version 2.0</div></div></div>"},"87089":{"type":"graphic_diagnosticimage","displayName":"Barium enema traumatic diaphragmatic hernia of colon","title":"Barium enema traumatic diaphragmatic hernia of colon","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Barium enema traumatic diaphragmatic hernia of colon</div><div class=\"cntnt\"><img style=\"width:371px; height:509px;\" src=\"images/RADIOL/87089_Barium_enema_tr_diap_hernia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The single contrast barium enema shows the hepatic flexure herniated&nbsp;through the dome of the left hemidiaphragm (arrowhead). The hiatus lies between the two white arrows. The position of the hernia suggests a traumatic etiology.</div><div id=\"graphicVersion\">Graphic 87089 Version 1.0</div></div></div>"},"87090":{"type":"graphic_diagnosticimage","displayName":"Traumatic disruption of the diaphragm on plain film and CT","title":"Traumatic disruption of the diaphragm on plain film and CT","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Traumatic disruption of the diaphragm on plain film and CT</div><div class=\"cntnt\"><img style=\"width:598px; height:270px;\" src=\"images/RADIOL/87090_Xray_trau_disrup_left_hemid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Traumatic disruption of the left hemidiaphragm is shown on the plain chest film and computed tomography (CT) of the chest. The anteroposterior view of the chest (A) shows the herniated stomach. The course of the nasogastric tube is aberrant with its tip (arrowhead) positioned cranially. In the CT scan (B),&nbsp;the tip&nbsp;of the nasogastric tube (arrowhead) is within the&nbsp;abnormally positioned&nbsp;stomach (arrows), which is filled with food and fluid.</div><div id=\"graphicVersion\">Graphic 87090 Version 1.0</div></div></div>"},"87091":{"type":"graphic_figure","displayName":"Transverse female pelvis","title":"Transverse sections of the female pelvis","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Transverse sections of the female pelvis</div><div class=\"cntnt\"><img style=\"width:456px; height:425px;\" src=\"images/OBGYN/87091_Transverse_fem_pelvis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse sections of the female pelvis.<br />(A) Drawing of an anatomical section through the urinary bladder, uterus, and rectum.<br />(B) Transverse ultrasound scan.<br />(C) Drawing of an anatomical section through the urethra, vagina, and rectum.<br />(D) Transverse magnetic resonance image (MRI).</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Agur A. Essential Clinical Anatomy, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright Â© 2002 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87091 Version 1.0</div></div></div>"},"87092":{"type":"graphic_figure","displayName":"Female pelvic bones sagittal","title":"Sagittal view of the female pelvic bones","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Sagittal view of the female pelvic bones</div><div class=\"cntnt\"><img style=\"width:596px; height:508px;\" src=\"images/OBGYN/87092_Fem_pelv_bones_sagitt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted with permission: Cleveland Clinic Center for Medical Art &amp; Photography &copy; 2004-2012. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 87092 Version 1.0</div></div></div>"},"87093":{"type":"graphic_figure","displayName":"Female pelvis vessels nerves sagittal view","title":"Sagittal view of the female pelvic vessels and nerves","html":"<div class=\"graphic\"><div style=\"width: 654px\" class=\"figure\"><div class=\"ttl\">Sagittal view of the female pelvic vessels and nerves</div><div class=\"cntnt\"><img style=\"width:634px; height:570px;\" src=\"images/OBGYN/87093_Fem_pelv_vess_nerv_sag.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Gray's Atlas of Anatomy, Drake RL, Vogl AW, Mitchell AMW (Eds), Churchill Livingstone 2007. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87093 Version 1.0</div></div></div>"},"87094":{"type":"graphic_figure","displayName":"Suture site transvaginal suspension","title":"Site of suture placement for transvaginal apical suspension procedures","html":"<div class=\"graphic\"><div style=\"width: 614px\" class=\"figure\"><div class=\"ttl\">Site of suture placement for transvaginal apical suspension procedures</div><div class=\"cntnt\"><img style=\"width:594px; height:464px;\" src=\"images/OBGYN/87094_Sutur_st_transvag_susp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Location of suture placement for sacrospinous ligament fixation.<br />(B) Location of suture placement for iliococcygeous vaginal vault suspension.</div><div class=\"graphic_reference\">Reprinted with permission: Cleveland Clinic Center for Medical Art &amp; Photography Â© 2004-2012. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 87094 Version 1.0</div></div></div>"},"87097":{"type":"graphic_picture","displayName":"DEB milia","title":"Recessive dystrophic epidermolysis bullosa (EB) ","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Recessive dystrophic epidermolysis bullosa (EB) </div><div class=\"cntnt\"><img style=\"width:574px; height:381px;\" src=\"images/DERM/87097_Milia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erosions, crusts, atrophic scarring, and milia formation in recessive dystrophic EB.</div><div class=\"graphic_reference\"><FONT color=black>Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.</FONT></div><div id=\"graphicVersion\">Graphic 87097 Version 2.0</div></div></div>"},"87098":{"type":"graphic_figure","displayName":"Natal cleft with pilonidal sinus","title":"Natal cleft with pilonidal sinus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Natal cleft with pilonidal sinus</div><div class=\"cntnt\"><img style=\"width:331px; height:331px;\" src=\"images/SURG/87098_Natalcleftwithpilonidalsinus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure is a view from behind with the patient prone. It shows several skin pores (pits)&nbsp;in the midline of the natal cleft. A pilonidal sinus extends cephalad from the pores to the opening. </div><div id=\"graphicVersion\">Graphic 87098 Version 3.0</div></div></div>"},"87099":{"type":"graphic_picture","displayName":"Disseminated granuloma annulare leg PI","title":"Granuloma annulare on the leg","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Granuloma annulare on the leg</div><div class=\"cntnt\"><img style=\"width:432px; height:376px;\" src=\"images/PI/87099_Dissemin_granulom_leg_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photo shows generalized granuloma annulare. Each circle- and arc-shaped area has red, raised edges and a skin-colored center.</div><div id=\"graphicVersion\">Graphic 87099 Version 1.0</div></div></div>"},"87100":{"type":"graphic_picture","displayName":"Granuloma annulare hand PI","title":"Granuloma annulare on the hand","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Granuloma annulare on the hand</div><div class=\"cntnt\"><img style=\"width:432px; height:362px;\" src=\"images/PI/87100_Granuloma_annular_hand_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Granuloma annulare is a red, raised, circle-shaped rash that is not scaly.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright Â© 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87100 Version 2.0</div></div></div>"},"87101":{"type":"graphic_picture","displayName":"Granuloma annulare foot PI","title":"Granuloma annulare on the foot","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Granuloma annulare on the foot</div><div class=\"cntnt\"><img style=\"width:350px; height:398px;\" src=\"images/PI/87101_Granuloma_annular_foot_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a photo of granuloma annulare on a child's foot.</div><div class=\"graphic_reference\">Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright Â© 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87101 Version 2.0</div></div></div>"},"87102":{"type":"graphic_diagnosticimage","displayName":"Brodie abscess radiograph","title":"Brodie abscess radiograph","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Brodie abscess radiograph</div><div class=\"cntnt\"><img style=\"width:567px; height:532px;\" src=\"images/PEDS/87102_Brodie_abscess_radiograph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral (A) and frontal (B) radiographs of the right lower extremity demonstrate an ovoid lucent lesion in the medullary cavity of the proximal metadiaphysis of the tibia (arrows) with associated periosteal reaction (arrowheads). The lateral radiograph (A) also demonstrates irregular cortical lucency anteriorly suggesting an area of focal cortical disruption (dashed arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Abdulhadi MA, White AM, Pollock AN. Brodie abscess. Pediatr Emerg Care 2012; 28:1249. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87102 Version 5.0</div></div></div>"},"87112":{"type":"graphic_figure","displayName":"Lumbar puncture PI","title":"Lumbar puncture","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Lumbar puncture</div><div class=\"cntnt\"><img style=\"width:496px; height:610px;\" src=\"images/PI/87112_Lumbar_puncture_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During a lumbar puncture, the doctor inserts a needle between 2 of the bones that make up the spine. Then he or she uses the needle to collect a small sample of fluid from around the spinal cord. The needle goes in below the point where the spinal cord is a solid cord, so it is unlikely to get injured by the needle.</div><div id=\"graphicVersion\">Graphic 87112 Version 1.0</div></div></div>"},"87117":{"type":"graphic_figure","displayName":"Pulsed wave Doppler pulmonary venous flow","title":"Pulsed wave Doppler pulmonary venous flow","html":"<div class=\"graphic\"><div style=\"width: 676px\" class=\"figure\"><div class=\"ttl\">Pulsed wave Doppler pulmonary venous flow</div><div class=\"cntnt\"><img style=\"width:656px; height:454px;\" src=\"images/CARD/87117_Pulmonary_vein_flow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">From an apical four-chamber view, a pulse wave sample volume is positioned at the entrance of the right superior pulmonary vein showing the characteristic systolic \"s\" (1) and diastolic \"d\" (2) wave velocities in addition to flow reversal during atrial contraction \"a\" (3) wave.</div><div id=\"graphicVersion\">Graphic 87117 Version 1.0</div></div></div>"},"87118":{"type":"graphic_diagnosticimage","displayName":"PLAX echo Marfan aorta","title":"Echocardiogram of dilated aortic root in a patient with Marfan syndrome","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Echocardiogram of dilated aortic root in a patient with Marfan syndrome</div><div class=\"cntnt\"><img style=\"width:310px; height:298px;\" src=\"images/CARD/87118_PLAX_echo_Marfan_aorta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this parasternal long-axis echocardiographic view of a patient with Marfan syndrome, the aortic root is dilated at the level of the sinuses of Valsalva. The sinotubular junction is preserved with a normal ascending aorta diameter above the sinuses.</div><div class=\"graphic_footnotes\">Ao: ascending aorta; LA: left atrium; LV: left ventricle.</div><div class=\"graphic_reference\">Courtesy of Heidi Connolly, MD.</div><div id=\"graphicVersion\">Graphic 87118 Version 2.0</div></div></div>"},"87119":{"type":"graphic_diagnosticimage","displayName":"CT scan Marfan aorta","title":"Computed tomographic (CT) image of the ascending aorta in a patient with Marfan syndrome. ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Computed tomographic (CT) image of the ascending aorta in a patient with Marfan syndrome. </div><div class=\"cntnt\"><img style=\"width:292px; height:293px;\" src=\"images/CARD/87119_CT_scan_Marfan_aorta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this coronal CT view, the aortic root is dilated at the level of the sinuses of Valsalva.</div><div class=\"graphic_footnotes\">Ao: ascending aorta; LV: left ventricle.</div><div class=\"graphic_reference\">Courtesy of Heidi Connolly, MD.</div><div id=\"graphicVersion\">Graphic 87119 Version 2.0</div></div></div>"},"87123":{"type":"graphic_table","displayName":"EB lab monitoring","title":"Laboratory and imaging tests for monitoring patients with epidermolysis bullosa","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory and imaging tests for monitoring patients with epidermolysis bullosa</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\" colspan=\"2\">Test</td> <td class=\"subtitle1_single\">Frequency</td> </tr> <tr> <td rowspan=\"8\">Blood chemistry</td> <td>Renal function tests: BUN, creatinine, electrolytes (Na, K)</td> <td>Every six months unless abnormal</td> </tr> <tr> <td>Liver function tests: ALT, AST, ALP, bilirubin, albumin</td> <td>Every six months unless abnormal</td> </tr> <tr> <td>Bone profile: Ca, P, albumin, ALP, Vit D, PTH </td> <td>Every six months unless abnormal</td> </tr> <tr> <td>Trace elements: Zn, selenium, Mg, Cu, Ag</td> <td>Annually unless abnormal</td> </tr> <tr> <td>Vitamins (B1, B2, B3, B12, C, A)</td> <td>Annually unless abnormal</td> </tr> <tr> <td>Total iron-binding capacity or transferrin, serum iron, ferritin, soluble transferrin receptor</td> <td>Every three to six months depending upon degree of anemia and iron or transfusion requirements</td> </tr> <tr> <td>Urine dipstick test, protein and blood</td> <td>At each visit</td> </tr> <tr> <td>24-hour urine collection for albumin/creatinine ratio, protein excretion, creatinine clearance</td> <td>If renal function test is abnormal</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Hematology</td> <td>Full blood cell count</td> <td>Every three to six months depending upon the degree of anemia</td> </tr> <tr> <td>Red cell folate, serum folate</td> <td>Annually</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"5\">Radiology</td> <td>Radiograph: lateral thoracic and lumbar spine</td> <td>Annually from the age of four years</td> </tr> <tr> <td>Whole spine dual energy radiograph absorptiometry (DEXA) scan</td> <td>Annually</td> </tr> <tr> <td>Radiograph of left hand</td> <td>If evaluation of bone age is indicated</td> </tr> <tr> <td>Echocardiogram for heart muscle</td> <td>Annually from the age of two years</td> </tr> <tr> <td>Renal ultrasound for ureteric effects</td> <td>Annually in patients with JEB and JEB-PA</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Microbiology</td> <td>Wound swab</td> <td>If with clinical evidence of infection</td> </tr> <tr> <td>Urine culture</td> <td>If with positive dipstick</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Endocrinology<br /> (in cases of pubertal delay)</td> <td>Female: LH, FSH, estradiol; pelvic ultrasound to assess ovaries and uterus if indicated</td> <td rowspan=\"2\">As required for delayed puberty</td> </tr> <tr> <td>Male: LH, FSH, testosterone</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Original figure modified for this publication. Martinez AE. Tests to monitor in patients with severe types of epidermolysis bullosa. Dermatol Clin 2010; 28:271. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87123 Version 2.0</div></div></div>"},"87124":{"type":"graphic_picture","displayName":"Pityriasis rosea on abdomen","title":"Pityriasis rosea","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pityriasis rosea</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/87124_Pityriasisroseaabdomen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Oval, erythematous papules and small plaques are present on the abdomen.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87124 Version 4.0</div></div></div>"},"87125":{"type":"graphic_picture","displayName":"HIV-associated eosinophilic folliculitis","title":"HIV-associated eosinophilic folliculitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">HIV-associated eosinophilic folliculitis</div><div class=\"cntnt\"><img style=\"width:378px; height:504px;\" src=\"images/DERM/87125_HIV-asso_eosinophilic_foll.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous papules and excoriated papules are present on the back.</div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87125 Version 4.0</div></div></div>"},"87126":{"type":"graphic_picture","displayName":"Pityriasis rosea with herald patch","title":"Pityriasis rosea","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pityriasis rosea</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/87126_Pityrroseaheraldpatch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous papules and oval plaques are present on the trunk. A larger herald patch is on the right midback.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87126 Version 4.0</div></div></div>"},"87128":{"type":"graphic_picture","displayName":"Trichuriasis rectal prolapse","title":"Trichuriasis rectal prolapse","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trichuriasis rectal prolapse</div><div class=\"cntnt\"><img style=\"width:292px; height:192px;\" src=\"images/ID/87128_Trichuris_rect_prolapse.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Rectal prolapse due to trichuriasis. White adult worms can be seen on the surface of the mucosa.</div><div class=\"graphic_reference\">From the collection of Herman Zaiman, \"A Presentation of Pictorial Parasites.\" Reproduced with permission from: the American Society of Tropical Medicine and Hygiene.</div><div id=\"graphicVersion\">Graphic 87128 Version 1.0</div></div></div>"},"87129":{"type":"graphic_figure","displayName":"PFO PI","title":"Patent foramen ovale","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Patent foramen ovale</div><div class=\"cntnt\"><img style=\"width:537px; height:481px;\" src=\"images/PI/87129_PFO_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A patent foramen ovale is a small opening in the heart. The opening is between the upper 2 chambers of the heart, which are called the right atrium and left atrium.</div><div id=\"graphicVersion\">Graphic 87129 Version 1.0</div></div></div>"},"87130":{"type":"graphic_figure","displayName":"Cesarean delivery breech PI","title":"Cesarean delivery for a breech pregnancy","html":"<div class=\"graphic\"><div style=\"width: 539px\" class=\"figure\"><div class=\"ttl\">Cesarean delivery for a breech pregnancy</div><div class=\"cntnt\"><img style=\"width:519px; height:435px;\" src=\"images/PI/87130_Cesarean_delivery_breech_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During a c-section, the doctor makes an incision in the belly and then the uterus. The baby comes out through that incision, rather than through the vagina.</div><div id=\"graphicVersion\">Graphic 87130 Version 2.0</div></div></div>"},"87131":{"type":"graphic_figure","displayName":"Bakers cyst PI","title":"Baker's cyst","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Baker's cyst</div><div class=\"cntnt\"><img style=\"width:538px; height:532px;\" src=\"images/PI/87131_Bakers_cyst_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A Baker's cyst is a fluid-filled sac that forms at the back of the knee.</div><div id=\"graphicVersion\">Graphic 87131 Version 1.0</div></div></div>"},"87132":{"type":"graphic_picture","displayName":"RMSF rash PI","title":"Rash caused by Rocky Mountain spotted fever","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rash caused by Rocky Mountain spotted fever</div><div class=\"cntnt\"><img style=\"width:314px; height:178px;\" src=\"images/PI/87132_RMSF_rash_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is what the rash caused by Rocky Mountain spotted fever looks like. It usually does not show up until days after the fever starts.</div><div class=\"graphic_reference\">Reproduced from: Fatal Cases of Rocky Mountain Spotted Fever in Family Clusters - Three States, 2003. MMWR Morb Mortal Wkly Rep 2004; 53:407.</div><div id=\"graphicVersion\">Graphic 87132 Version 1.0</div></div></div>"},"87133":{"type":"graphic_picture","displayName":"RMSF ticks PI","title":"Ticks that can carry Rocky Mountain spotted fever","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Ticks that can carry Rocky Mountain spotted fever</div><div class=\"cntnt\"><img style=\"width:455px; height:436px;\" src=\"images/PI/87133_RMSF_ticks_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ticks shown in these pictures can infect people with the germ that causes Rocky Mountain spotted fever.</div><div class=\"graphic_reference\">Reproduced from: Champman AS, Bakken JS, Folk SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain Spotted Fever, Ehrlichoioses, and Anaplasmosis-United States: A practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep 2006; 55:1.</div><div id=\"graphicVersion\">Graphic 87133 Version 2.0</div></div></div>"},"87134":{"type":"graphic_table","displayName":"Consensus Sleep Diary","title":"Consensus Sleep Diary","html":"<div class=\"graphic\"><div style=\"width: 826px\" class=\"figure\"><div class=\"ttl\">Consensus Sleep Diary</div><div class=\"cntnt\"><img style=\"width:806px; height:948px;\" src=\"images/SLEEP/87134_Consensus_sleep_diary.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Questions 1 through 10 are to be completed within one hour of getting out of bed in the morning. Questions 11 through 15 are to be completed before bed.</div><div class=\"graphic_reference\">Reproduced with permission from: Camey CE, Buysse DJ, Ancoli-Israel S, et al. The Consensus Sleep Diary: Standardizing prospective sleep self-monitoring. Sleep 2012; 35:287. Copyright &copy; 2012 American Academy of Sleep Medicine.</div><div id=\"graphicVersion\">Graphic 87134 Version 6.0</div></div></div>"},"87135":{"type":"graphic_picture","displayName":"Indirect immunofluorescence on basement membrane zone-split skin","title":"Serum IgG basement membrane zone antibodies showing combined epidermal-dermal staining on split skin substrate in bullous pemphigoid by indirect immunofluorescence microscopy","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Serum IgG basement membrane zone antibodies showing combined epidermal-dermal staining on split skin substrate in bullous pemphigoid by indirect immunofluorescence microscopy</div><div class=\"cntnt\"><img style=\"width:576px; height:434px;\" src=\"images/DERM/87135_Idct_imflr_bm_mbr_zn-spl_sk.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Linear IgG antibody staining in a combined pattern, epidermal-dermal, on basement membrane zone-split skin substrate characteristic of bullous pemphigoid and, rarely, bullous lupus erythematosus. This pattern also is referred to as staining the roof and floor of the blister.</div><div class=\"graphic_reference\">Courtesy of Kristin M Leiferman, MD, Immunodermatology Laboratory, Department of Dermatology, University of Utah, Salt Lake City, Utah.</div><div id=\"graphicVersion\">Graphic 87135 Version 2.0</div></div></div>"},"87136":{"type":"graphic_diagnosticimage","displayName":"Cecal bascule - Abdominal films","title":"Cecal bascule - Abdominal films","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Cecal bascule - Abdominal films</div><div class=\"cntnt\"><img style=\"width:598px; height:338px;\" src=\"images/RADIOL/87136_Cecal_bascule_abd_films.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plain radiograph in a 51-year-old male with generalized abdominal pain showing a distended cecum cranially displaced to the epigastrium. An air-fluid level is demonstrated in the cecum in the upright examination (A, arrow) while a moderate amount of stool is seen within the dilated cecum in the supine view (B, arrows).</div><div class=\"graphic_reference\">Courtesy of Joseph Farnum, MD.</div><div id=\"graphicVersion\">Graphic 87136 Version 2.0</div></div></div>"},"87137":{"type":"graphic_diagnosticimage","displayName":"Cecal bascule - CT scan","title":"Cecal bascule - CT scan","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Cecal bascule - CT scan</div><div class=\"cntnt\"><img style=\"width:533px; height:665px;\" src=\"images/RADIOL/87137_Cecal_bascule_CT_scan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A multiplanar CT examination demonstrates a cecal bascule (B and C, arrow). Note the normal location of the ascending colon (A, arrow) and the region of fold with subsequent migration of the cecum in an anterior and cephalad direction (C, arrowhead). There is no evidence of vascular engorgement nor pericecal inflammatory change.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Joseph Farnum, MD.</div><div id=\"graphicVersion\">Graphic 87137 Version 4.0</div></div></div>"},"87139":{"type":"graphic_picture","displayName":"Spitz histo","title":"Histologic features of Spitz nevus","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Histologic features of Spitz nevus</div><div class=\"cntnt\"><img style=\"width:576px; height:342px;\" src=\"images/DERM/87139_spitz4-image.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histologically, Spitz nevus presents as&nbsp;a symmetric, well circumscribed, dome-shaped compound melanocytic nevus. The epidermis is acanthotic with vertical orientation of melanocytic nests.</div><div id=\"graphicVersion\">Graphic 87139 Version 1.0</div></div></div>"},"87140":{"type":"graphic_picture","displayName":"Spitz histo 2","title":"Histologic features of Spitz nevus","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Histologic features of Spitz nevus</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87140_spitz2-image.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large epithelioid and spindle cells with abundant eosinophilic glassy cytoplasm. The nuclei demonstrate uniformity and often possess a single centrally placed nucleolus.</div><div id=\"graphicVersion\">Graphic 87140 Version 1.0</div></div></div>"},"87141":{"type":"graphic_picture","displayName":"Atypical Spitz histo 2","title":"Histologic features of atypical Spitz tumor","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Histologic features of atypical Spitz tumor</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87141_AST_A5-image.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this Spitz tumor with atypical features, the lesion is dome-shaped and circumscribed with a symmetric profile.</div><div id=\"graphicVersion\">Graphic 87141 Version 1.0</div></div></div>"},"87142":{"type":"graphic_picture","displayName":"Atypical Spitz histo 3","title":"Histology of atypical Spitz tumor","html":"<div class=\"graphic\"><div style=\"width: 594px\" class=\"figure\"><div class=\"ttl\">Histology of atypical Spitz tumor</div><div class=\"cntnt\"><img style=\"width:574px; height:430px;\" src=\"images/DERM/87142_AST_A4-image.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atypical Spitz tumor. There is a lentiginous melanocytic proliferation with increased cytological atypia and pleomorphism. The lesion lacks eosinophilic globules (Kamino bodies).</div><div id=\"graphicVersion\">Graphic 87142 Version 1.0</div></div></div>"},"87143":{"type":"graphic_picture","displayName":"Atypical histo 4","title":"Cytologic features of atypical Spitz tumor","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Cytologic features of atypical Spitz tumor</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87143_AST_A-image.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atypical Spitz tumor. There is increased cytologic atypia within the deep dermal component with irregular nesting pattern.</div><div id=\"graphicVersion\">Graphic 87143 Version 1.0</div></div></div>"},"87144":{"type":"graphic_picture","displayName":"Spitzoid melanoma histo 1","title":"Spitzoid melanoma","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Spitzoid melanoma</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87144_SM12-image.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spitzoid melanoma lacks symmetry and circumscription. The melanocytes are epithelioid and spindled with focal pagetoid upward scatter of atypical melanocytes.</div><div id=\"graphicVersion\">Graphic 87144 Version 1.0</div></div></div>"},"87145":{"type":"graphic_picture","displayName":"Spitzoid melanoma histo 2","title":"Spitzoid melanoma","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Spitzoid melanoma</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87145_SM9-image.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The dermal compartment contains numerous mitotic figures including atypical forms. There is significant pleomorphism of atypical melanocytes present within the deep dermis.</div><div id=\"graphicVersion\">Graphic 87145 Version 1.0</div></div></div>"},"87147":{"type":"graphic_table","displayName":"Predicted body weight and tidal volume for women","title":"Predicted body weight and tidal volume for women","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Predicted body weight and tidal volume for women</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">Height</td> <td class=\"subtitle1\">PBW</td> <td class=\"subtitle1\" colspan=\"5\">Tidal volume</td> </tr> <tr> <td class=\"subtitle2\">Feet/inches</td> <td class=\"subtitle2\">Inches</td> <td class=\"subtitle2\">Centimeters</td> <td class=\"subtitle2\">kg</td> <td class=\"subtitle2\">4 mL/kg</td> <td class=\"subtitle2\">5 mL/kg</td> <td class=\"subtitle2\">6 mL/kg</td> <td class=\"subtitle2\">7 mL/kg</td> <td class=\"subtitle2\">8 mL/kg</td> </tr> <tr> <td class=\"centered\">4' 0\"</td> <td class=\"centered\">48</td> <td class=\"centered\">122</td> <td class=\"centered\">17.9</td> <td class=\"centered\">72</td> <td class=\"centered\">90</td> <td class=\"centered\">107</td> <td class=\"centered\">125</td> <td class=\"centered\">143</td> </tr> <tr> <td class=\"centered\">4' 1\"</td> <td class=\"centered\">49</td> <td class=\"centered\">124</td> <td class=\"centered\">20.2</td> <td class=\"centered\">81</td> <td class=\"centered\">101</td> <td class=\"centered\">121</td> <td class=\"centered\">141</td> <td class=\"centered\">162</td> </tr> <tr> <td class=\"centered\">4' 2\"</td> <td class=\"centered\">50</td> <td class=\"centered\">127</td> <td class=\"centered\">22.5</td> <td class=\"centered\">90</td> <td class=\"centered\">113</td> <td class=\"centered\">135</td> <td class=\"centered\">158</td> <td class=\"centered\">180</td> </tr> <tr> <td class=\"centered\">4' 3\"</td> <td class=\"centered\">51</td> <td class=\"centered\">130</td> <td class=\"centered\">24.8</td> <td class=\"centered\">99</td> <td class=\"centered\">124</td> <td class=\"centered\">149</td> <td class=\"centered\">174</td> <td class=\"centered\">198</td> </tr> <tr> <td class=\"centered\">4' 4\"</td> <td class=\"centered\">52</td> <td class=\"centered\">132</td> <td class=\"centered\">27.1</td> <td class=\"centered\">108</td> <td class=\"centered\">136</td> <td class=\"centered\">163</td> <td class=\"centered\">190</td> <td class=\"centered\">217</td> </tr> <tr> <td class=\"centered\">4' 5\"</td> <td class=\"centered\">53</td> <td class=\"centered\">135</td> <td class=\"centered\">29.4</td> <td class=\"centered\">118</td> <td class=\"centered\">147</td> <td class=\"centered\">176</td> <td class=\"centered\">206</td> <td class=\"centered\">235</td> </tr> <tr> <td class=\"centered\">4' 6\"</td> <td class=\"centered\">54</td> <td class=\"centered\">137</td> <td class=\"centered\">31.7</td> <td class=\"centered\">127</td> <td class=\"centered\">159</td> <td class=\"centered\">190</td> <td class=\"centered\">222</td> <td class=\"centered\">254</td> </tr> <tr> <td class=\"centered\">4' 7\"</td> <td class=\"centered\">55</td> <td class=\"centered\">140</td> <td class=\"centered\">34</td> <td class=\"centered\">136</td> <td class=\"centered\">170</td> <td class=\"centered\">204</td> <td class=\"centered\">238</td> <td class=\"centered\">272</td> </tr> <tr> <td class=\"centered\">4' 8\"</td> <td class=\"centered\">56</td> <td class=\"centered\">142</td> <td class=\"centered\">36.3</td> <td class=\"centered\">145</td> <td class=\"centered\">182</td> <td class=\"centered\">218</td> <td class=\"centered\">254</td> <td class=\"centered\">290</td> </tr> <tr> <td class=\"centered\">4' 9\"</td> <td class=\"centered\">57</td> <td class=\"centered\">145</td> <td class=\"centered\">38.6</td> <td class=\"centered\">154</td> <td class=\"centered\">193</td> <td class=\"centered\">232</td> <td class=\"centered\">270</td> <td class=\"centered\">309</td> </tr> <tr> <td class=\"centered\">4' 10\"</td> <td class=\"centered\">58</td> <td class=\"centered\">147</td> <td class=\"centered\">40.9</td> <td class=\"centered\">164</td> <td class=\"centered\">205</td> <td class=\"centered\">245</td> <td class=\"centered\">286</td> <td class=\"centered\">327</td> </tr> <tr> <td class=\"centered\">4' 11\"</td> <td class=\"centered\">59</td> <td class=\"centered\">150</td> <td class=\"centered\">43.2</td> <td class=\"centered\">173</td> <td class=\"centered\">216</td> <td class=\"centered\">259</td> <td class=\"centered\">302</td> <td class=\"centered\">346</td> </tr> <tr> <td class=\"centered\">5' 0\"</td> <td class=\"centered\">60</td> <td class=\"centered\">152</td> <td class=\"centered\">45.5</td> <td class=\"centered\">182</td> <td class=\"centered\">228</td> <td class=\"centered\">273</td> <td class=\"centered\">319</td> <td class=\"centered\">364</td> </tr> <tr> <td class=\"centered\">5' 1\"</td> <td class=\"centered\">61</td> <td class=\"centered\">155</td> <td class=\"centered\">47.8</td> <td class=\"centered\">191</td> <td class=\"centered\">239</td> <td class=\"centered\">287</td> <td class=\"centered\">335</td> <td class=\"centered\">382</td> </tr> <tr> <td class=\"centered\">5' 2\"</td> <td class=\"centered\">62</td> <td class=\"centered\">157</td> <td class=\"centered\">50.1</td> <td class=\"centered\">200</td> <td class=\"centered\">251</td> <td class=\"centered\">301</td> <td class=\"centered\">351</td> <td class=\"centered\">401</td> </tr> <tr> <td class=\"centered\">5' 3\"</td> <td class=\"centered\">63</td> <td class=\"centered\">160</td> <td class=\"centered\">52.4</td> <td class=\"centered\">210</td> <td class=\"centered\">262</td> <td class=\"centered\">314</td> <td class=\"centered\">367</td> <td class=\"centered\">419</td> </tr> <tr> <td class=\"centered\">5' 4\"</td> <td class=\"centered\">64</td> <td class=\"centered\">163</td> <td class=\"centered\">54.7</td> <td class=\"centered\">219</td> <td class=\"centered\">274</td> <td class=\"centered\">328</td> <td class=\"centered\">383</td> <td class=\"centered\">438</td> </tr> <tr> <td class=\"centered\">5' 5\"</td> <td class=\"centered\">65</td> <td class=\"centered\">165</td> <td class=\"centered\">57</td> <td class=\"centered\">228</td> <td class=\"centered\">285</td> <td class=\"centered\">342</td> <td class=\"centered\">399</td> <td class=\"centered\">456</td> </tr> <tr> <td class=\"centered\">5' 6\"</td> <td class=\"centered\">66</td> <td class=\"centered\">168</td> <td class=\"centered\">59.3</td> <td class=\"centered\">237</td> <td class=\"centered\">297</td> <td class=\"centered\">356</td> <td class=\"centered\">415</td> <td class=\"centered\">474</td> </tr> <tr> <td class=\"centered\">5' 7\"</td> <td class=\"centered\">67</td> <td class=\"centered\">170</td> <td class=\"centered\">61.6</td> <td class=\"centered\">246</td> <td class=\"centered\">308</td> <td class=\"centered\">370</td> <td class=\"centered\">431</td> <td class=\"centered\">493</td> </tr> <tr> <td class=\"centered\">5' 8\"</td> <td class=\"centered\">68</td> <td class=\"centered\">173</td> <td class=\"centered\">63.9</td> <td class=\"centered\">256</td> <td class=\"centered\">320</td> <td class=\"centered\">383</td> <td class=\"centered\">447</td> <td class=\"centered\">511</td> </tr> <tr> <td class=\"centered\">5' 9\"</td> <td class=\"centered\">69</td> <td class=\"centered\">175</td> <td class=\"centered\">66.2</td> <td class=\"centered\">265</td> <td class=\"centered\">331</td> <td class=\"centered\">397</td> <td class=\"centered\">463</td> <td class=\"centered\">530</td> </tr> <tr> <td class=\"centered\">5' 10\"</td> <td class=\"centered\">70</td> <td class=\"centered\">178</td> <td class=\"centered\">68.5</td> <td class=\"centered\">274</td> <td class=\"centered\">343</td> <td class=\"centered\">411</td> <td class=\"centered\">480</td> <td class=\"centered\">548</td> </tr> <tr> <td class=\"centered\">5' 11\"</td> <td class=\"centered\">71</td> <td class=\"centered\">180</td> <td class=\"centered\">70.8</td> <td class=\"centered\">283</td> <td class=\"centered\">354</td> <td class=\"centered\">425</td> <td class=\"centered\">496</td> <td class=\"centered\">566</td> </tr> <tr> <td class=\"centered\">6' 0\"</td> <td class=\"centered\">72</td> <td class=\"centered\">183</td> <td class=\"centered\">73.1</td> <td class=\"centered\">292</td> <td class=\"centered\">366</td> <td class=\"centered\">439</td> <td class=\"centered\">512</td> <td class=\"centered\">585</td> </tr> <tr> <td class=\"centered\">6' 1\"</td> <td class=\"centered\">73</td> <td class=\"centered\">185</td> <td class=\"centered\">75.4</td> <td class=\"centered\">302</td> <td class=\"centered\">377</td> <td class=\"centered\">452</td> <td class=\"centered\">528</td> <td class=\"centered\">603</td> </tr> <tr> <td class=\"centered\">6' 2\"</td> <td class=\"centered\">74</td> <td class=\"centered\">188</td> <td class=\"centered\">77.7</td> <td class=\"centered\">311</td> <td class=\"centered\">389</td> <td class=\"centered\">466</td> <td class=\"centered\">544</td> <td class=\"centered\">622</td> </tr> <tr> <td class=\"centered\">6' 3\"</td> <td class=\"centered\">75</td> <td class=\"centered\">190</td> <td class=\"centered\">80</td> <td class=\"centered\">320</td> <td class=\"centered\">400</td> <td class=\"centered\">480</td> <td class=\"centered\">560</td> <td class=\"centered\">640</td> </tr> <tr> <td class=\"centered\">6' 4\"</td> <td class=\"centered\">76</td> <td class=\"centered\">193</td> <td class=\"centered\">82.3</td> <td class=\"centered\">329</td> <td class=\"centered\">412</td> <td class=\"centered\">494</td> <td class=\"centered\">576</td> <td class=\"centered\">658</td> </tr> <tr> <td class=\"centered\">6' 5\"</td> <td class=\"centered\">77</td> <td class=\"centered\">196</td> <td class=\"centered\">84.6</td> <td class=\"centered\">338</td> <td class=\"centered\">423</td> <td class=\"centered\">508</td> <td class=\"centered\">592</td> <td class=\"centered\">677</td> </tr> <tr> <td class=\"centered\">6' 6\"</td> <td class=\"centered\">78</td> <td class=\"centered\">198</td> <td class=\"centered\">86.9</td> <td class=\"centered\">348</td> <td class=\"centered\">435</td> <td class=\"centered\">521</td> <td class=\"centered\">608</td> <td class=\"centered\">695</td> </tr> <tr> <td class=\"centered\">6' 7\"</td> <td class=\"centered\">79</td> <td class=\"centered\">201</td> <td class=\"centered\">89.2</td> <td class=\"centered\">357</td> <td class=\"centered\">446</td> <td class=\"centered\">535</td> <td class=\"centered\">624</td> <td class=\"centered\">714</td> </tr> <tr> <td class=\"centered\">6' 8\"</td> <td class=\"centered\">80</td> <td class=\"centered\">203</td> <td class=\"centered\">91.5</td> <td class=\"centered\">366</td> <td class=\"centered\">458</td> <td class=\"centered\">549</td> <td class=\"centered\">641</td> <td class=\"centered\">732</td> </tr> <tr> <td class=\"centered\">6' 9\"</td> <td class=\"centered\">81</td> <td class=\"centered\">206</td> <td class=\"centered\">93.8</td> <td class=\"centered\">375</td> <td class=\"centered\">469</td> <td class=\"centered\">563</td> <td class=\"centered\">657</td> <td class=\"centered\">750</td> </tr> <tr> <td class=\"centered\">6' 10\"</td> <td class=\"centered\">82</td> <td class=\"centered\">208</td> <td class=\"centered\">96.1</td> <td class=\"centered\">384</td> <td class=\"centered\">481</td> <td class=\"centered\">577</td> <td class=\"centered\">673</td> <td class=\"centered\">769</td> </tr> <tr> <td class=\"centered\">6' 11\"</td> <td class=\"centered\">83</td> <td class=\"centered\">211</td> <td class=\"centered\">98.4</td> <td class=\"centered\">394</td> <td class=\"centered\">492</td> <td class=\"centered\">590</td> <td class=\"centered\">689</td> <td class=\"centered\">787</td> </tr> <tr> <td class=\"centered\">7' 0\"</td> <td class=\"centered\">84</td> <td class=\"centered\">213</td> <td class=\"centered\">100.7</td> <td class=\"centered\">403</td> <td class=\"centered\">504</td> <td class=\"centered\">604</td> <td class=\"centered\">705</td> <td class=\"centered\">806</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PBW: predicted body weight.</div><div class=\"graphic_reference\">Reproduced with permission from: NHLBI ARDS Network. Available at: <A spellcheck=true href=\"http://www.ardsnet.org/\" target=_blank>http://www.ardsnet.org/</A> (Accessed on November 20, 2012). Copyright Â© 2012.</div><div id=\"graphicVersion\">Graphic 87147 Version 4.0</div></div></div>"},"87148":{"type":"graphic_table","displayName":"Dressings for EB simplex","title":"Dressings for epidermolysis bullosa (EB) simplex","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dressings for epidermolysis bullosa (EB) simplex</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Brand</td> <td class=\"subtitle1\">Indication</td> <td class=\"subtitle1\">Contraindications/comments</td> </tr> <tr class=\"divider_bottom\"> <td>Primary</td> <td> <p>Mepitel</p> Urgotul</td> <td>Wound</td> <td>Dowling-Meara</td> </tr> <tr class=\"divider_bottom\"> <td>Foam</td> <td> <p>Mepilex</p> <p>Mepilex Lite</p> Mepilex Transfer</td> <td>Protection</td> <td>May induce heat-related blistering</td> </tr> <tr class=\"divider_bottom\"> <td>Hydrogel</td> <td> <p>IntraSite</p> Conformable</td> <td> <p>Cooling</p> Pain reduction</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Biosynthetic cellulose</td> <td>Suprasorb X</td> <td> <p>Cooling</p> Pain reduction</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Bordered dressings</td> <td> <p>Mepilex Border</p> <p>Mepilex Border Lite</p> <p>Alleyvn Gentle Border</p> Urgotul Duo Border</td> <td>Protection</td> <td>Use silicone medical removers to avoid skin stripping</td> </tr> <tr class=\"divider_bottom\"> <td>Hydrofiber</td> <td>Aquacel</td> <td>Dowling-Meara</td> <td>&nbsp;</td> </tr> <tr> <td>Powder</td> <td> <p>Cornflour</p> Catrix</td> <td>Apply after lancing blisters</td> <td>Diaper area</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Original figure modified for this publication. Denyer JE. Wound management for children with epidermolysis bullosa. Dermatol Clin 2010; 28:257. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87148 Version 1.0</div></div></div>"},"87149":{"type":"graphic_table","displayName":"Dressings for junctional EB","title":"Dressings for junctional epidermolysis bullosa (EB)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dressings for junctional epidermolysis bullosa (EB)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup span=\"3\" width=\"23%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Brand</td> <td class=\"subtitle1\">Indication</td> <td class=\"subtitle1\">Contraindication</td> <td class=\"subtitle1\">Wear time</td> </tr> <tr class=\"divider_bottom\"> <td>Primary</td> <td>Urgotul</td> <td>Primary dressing</td> <td>&nbsp;</td> <td>Change every three to four days</td> </tr> <tr class=\"divider_bottom\"> <td>Hydrogel</td> <td> <p>IntraSite</p> Conformable</td> <td>Infant JEB-Herlitz</td> <td>&nbsp;</td> <td>Change daily</td> </tr> <tr class=\"divider_bottom\"> <td>Hydrofiber</td> <td>Aquacel</td> <td>Very moist wounds</td> <td>Lightly exuding or dry wounds</td> <td>Change every three to four days</td> </tr> <tr class=\"divider_bottom\"> <td>Soft silicone foam</td> <td> <p>Mepilex</p> <p>Mepilex Lite</p> Mepilex Transfer</td> <td> <p>Protection</p> Absorption</td> <td>&nbsp;</td> <td>As determined by level of exudate</td> </tr> <tr> <td>Polymeric membrane</td> <td>PolyMem</td> <td> <p>Chronic wounds</p> Critical colonization or infection</td> <td>&nbsp;</td> <td>As determined by level of exudate</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Original figure modified for this publication. Denyer JE. Wound management for children with epidermolysis bullosa. Dermatol Clin 2010; 28:257. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87149 Version 1.0</div></div></div>"},"87150":{"type":"graphic_table","displayName":"Dressings for dystrophic EB","title":"Dressings for dystrophic epidermolysis bullosa","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dressings for dystrophic epidermolysis bullosa</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Brand</td> <td class=\"subtitle1\">Indication</td> <td class=\"subtitle1\">Contraindication</td> <td class=\"subtitle1\">Wear time</td> </tr> <tr class=\"divider_bottom\"> <td>Soft silicone primary dressings</td> <td> <p>Mepitel</p> Silflex</td> <td>Moist wound</td> <td>Silicone sensitivity</td> <td>Change every three to four days</td> </tr> <tr class=\"divider_bottom\"> <td>Lipidocolloid primary dressings</td> <td>Urgotul</td> <td>Moist wounds, drier wounds, protection of vulnerable skin</td> <td>Where retention difficult</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Soft silicone foam dressings</td> <td> <p>Mepilex</p> <p>Mepilex Lite</p> Mepilex Transfer</td> <td> <p>Absorption of exudate</p> <p>Protection</p> <p>Lightly exuding wounds</p> Where conformability required &ndash; digits and axillae</td> <td>&nbsp;</td> <td>Change every three to four days</td> </tr> <tr class=\"divider_bottom\"> <td>Foam dressings</td> <td> <p>Alleyvn</p> Urgocell</td> <td> <p>Absorption</p> Protection</td> <td>May need to apply over primary dressings</td> <td>Change every three to four days</td> </tr> <tr class=\"divider_bottom\"> <td>Polymeric membrane</td> <td>PolyMem</td> <td>Where cleansing required</td> <td>&nbsp;</td> <td>As determined by level of exudate</td> </tr> <tr> <td>Bordered dressings</td> <td> <p>Mepilex Border</p> <p>Mepilex Border Lite</p> Alleyvn Gentle Border</td> <td> <p>Isolated wounds</p> Dominant and mild recessive DEB</td> <td>Use silicone medical removers to avoid skin stripping</td> <td>Change every three to four days</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Original figure modified for this publication. Denyer JE. Wound management for children with epidermolysis bullosa. Dermatol Clin 2010; 28:257. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87150 Version 1.0</div></div></div>"},"87151":{"type":"graphic_table","displayName":"Dressings for EB infected wounds","title":"Dressing for epidermolysis bullosa (EB) infected wounds","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dressing for epidermolysis bullosa (EB) infected wounds</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"8%\"></colgroup><colgroup span=\"4\" width=\"23%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"5\">Recommended dressings for infected and critically colonized wounds</td> </tr> <tr> <td class=\"subtitle2\">Type</td> <td class=\"subtitle2\">Brand</td> <td class=\"subtitle2\">Indication</td> <td class=\"subtitle2\">Contraindication</td> <td class=\"subtitle2\">Wear time</td> </tr> <tr> <td rowspan=\"4\">Honey</td> <td>&nbsp;</td> <td> <p>Malodorous wounds</p> Infection/critical colonization</td> <td> <p>Pain</p> <p>Environments where insects abound</p> May need to use over primary dressings</td> <td> <p>Change every three to seven days</p> May need to change secondary dressing more frequently due to increased exudate</td> </tr> <tr> <td>Algivon</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Medihoney Gel Sheet</td> <td>Sensitive wounds</td> <td>&nbsp;</td> <td>Replace when no evidence of gel sheet remains</td> </tr> <tr> <td>Mesitran ointment S</td> <td>Sensitive wounds</td> <td>&nbsp;</td> <td>Apply at each dressing change</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Silver</td> <td>Mepilex AG</td> <td>Wounds requiring foam dressing</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Urgotul Silver/SSD</td> <td>Primary dressing</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>PolyMem Silver</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Aquacel Ag</td> <td>EB simplex with diabetes mellitus</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_top\"> <td>Other</td> <td>Suprasorb X + PHMB (polyhexanide)</td> <td> <p>Pain</p> Itching</td> <td>&nbsp;</td> <td>Daily for optimum pain relief and cooling effect</td> </tr> <tr class=\"divider_top\"> <td>Other</td> <td>Cutimed Sorbact</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>As dictated by strikethrough on secondary dressing</td> </tr> <tr class=\"divider_top\"> <td>Other</td> <td>PolyMem</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>When strikethrough observed</td> </tr> <tr class=\"divider_top\"> <td>Other</td> <td>Crystacide</td> <td>Superficial infection</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Original figure modified for this publication. Denyer JE. Wound management for children with epidermolysis bullosa. Dermatol Clin 2010; 28:257. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87151 Version 2.0</div></div></div>"},"87152":{"type":"graphic_picture","displayName":"Classic juvenile pityriasis rubra pilaris","title":"Classic juvenile pityriasis rubra pilaris","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Classic juvenile pityriasis rubra pilaris</div><div class=\"cntnt\"><img style=\"width:576px; height:431px;\" src=\"images/DERM/87152_Clssc_jvnl_ptyrs_rubr_pilrs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Classical juvenile-onset pityriasis rubra pilaris (type III), presenting with hyperkeratotic red to orange follicular papules and plaques, with characteristic areas (islands) of uninvolved skin.</div><div id=\"graphicVersion\">Graphic 87152 Version 1.0</div></div></div>"},"87153":{"type":"graphic_picture","displayName":"Classic juvenile pityriasis rubra pilaris - Legs","title":"Classic juvenile pityriasis rubra pilaris","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Classic juvenile pityriasis rubra pilaris</div><div class=\"cntnt\"><img style=\"width:431px; height:576px;\" src=\"images/DERM/87153_Cl_juv_pity_rubra_pila_legs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperkeratotic red to orange follicular papules and plaques are on the legs.</div><div id=\"graphicVersion\">Graphic 87153 Version 2.0</div></div></div>"},"87154":{"type":"graphic_picture","displayName":"Classic juvenile pityriasis rubra pilaris - Back","title":"Classic juvenile pityriasis rubra pilaris","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Classic juvenile pityriasis rubra pilaris</div><div class=\"cntnt\"><img style=\"width:576px; height:431px;\" src=\"images/DERM/87154_Clsc_jvnl_ptyr_rub_plrs-bck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Characteristic pityriasiform scaling is present.</div><div id=\"graphicVersion\">Graphic 87154 Version 2.0</div></div></div>"},"87155":{"type":"graphic_algorithm","displayName":"Algorithm for choosing the optimal cardiac stress test","title":"Algorithm for choosing the optimal cardiac stress test","html":"<div class=\"graphic\"><div style=\"width: 756px\" class=\"figure\"><div class=\"ttl\">Algorithm for choosing the optimal cardiac stress test</div><div class=\"cntnt\"><img style=\"width:736px; height:693px;\" src=\"images/CARD/87155_Alg_chng_optl_crdc_strs_tst.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">LBBB: left bundle branch block; V: ventricular; LVH: left ventricular hypertrophy; LV: left ventricular; SPECT: single photon emission computed tomography; PET: positron emission tomography; ECG: electrocardiogram.</div><div id=\"graphicVersion\">Graphic 87155 Version 4.0</div></div></div>"},"87156":{"type":"graphic_figure","displayName":"Female levator muscle 3D form","title":"Female levator muscles: three-dimensional form","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Female levator muscles: three-dimensional form</div><div class=\"cntnt\"><img style=\"width:513px; height:466px;\" src=\"images/OBGYN/87156_Fem_levat_mscl_3D_form.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Digitally enhanced three-dimensional reconstructions of the female pelvic floor from a magnetic resonance image of the pelvis in a normal nulliparous 23-year-old woman.<br />(A) Anterior view of the levator ani muscle with normal resting tone.<br />(B) Sagittal view of the levator ani muscle, bony pelvis, vagina, and rectum.<br />(C) Posterior view of the levator ani muscle, obturator internus muscles, and bony pelvis.<br />(D) Lithotomy view.</div><div class=\"graphic_reference\">Reprinted with permission: Cleveland Clinic Center for Medical Art &amp; Photography Â© 2004-2012. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 87156 Version 1.0</div></div></div>"},"87159":{"type":"graphic_figure","displayName":"Levator ani nerve","title":"Female levator ani nerve","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Female levator ani nerve</div><div class=\"cntnt\"><img style=\"width:598px; height:498px;\" src=\"images/OBGYN/87159_Levator_ani_nerve.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted with permission: Cleveland Clinic Center for Medical Art &amp; Photography &copy; 2004-2012. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 87159 Version 1.0</div></div></div>"},"87160":{"type":"graphic_figure","displayName":"Female perineal membrane","title":"Female perineal membrane","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Female perineal membrane</div><div class=\"cntnt\"><img style=\"width:600px; height:396px;\" src=\"images/OBGYN/87160_Fem_perineal_membrane.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inferior view of the urogenital diaphragm.<br />(A) Male; on the left, the inferior fascia of the deep transversus perineus (perineal membrane or inferior fascia of the urogenital diaphragm) is intact, but has been removed on the right to expose the musculature.<br />(B) Female; the fascia of the deep transverse perineus has been removed on both sides to expose the muscle fibers.</div><div class=\"graphic_reference\">Reproduced with permission from: Oatis CA. Kinesiology: The Mechanics and Pathomechanics of Human Movement. Lippincott Williams &amp; Wilkins, Baltimore 2004. Copyright Â© 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87160 Version 1.0</div></div></div>"},"87161":{"type":"graphic_figure","displayName":"Urethrovaginal sphincter","title":"Female urethral and urethrovaginal sphincters","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Female urethral and urethrovaginal sphincters</div><div class=\"cntnt\"><img style=\"width:580px; height:339px;\" src=\"images/OBGYN/87161_Urethrovag_sphincter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Perineum. External urethral sphincter, urethrovaginal sphincter, and compressor urethrae.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Agur A. Essential Clinical Anatomy, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright Â© 2002 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87161 Version 1.0</div></div></div>"},"87162":{"type":"graphic_table","displayName":"NCCN criteria for palliative care assessment","title":"NCCN criteria for palliative care assessment","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCCN criteria for palliative care assessment</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Patient characteristics</td> <td class=\"subtitle1\">Social circumstances or issues related to anticipatory bereavement</td> </tr> <tr class=\"divider_bottom\"> <td>Limited options for treatment</td> <td>Limited access to care</td> </tr> <tr class=\"divider_bottom\"> <td>High risk of poor pain control or refractory pain. Risk factors include: <ul> <li>Neuropathic pain</li> <li>Incident or breakthrough pain</li> <li>Rapid escalation of opioid dose</li> <li>History of substance (drug, alcohol) abuse</li> <li>Impaired cognition</li> <li>Psychosocial/family distress</li> </ul> </td> <td>Familial factors, including: <ul> <li>Limitations of the family/caregiver</li> <li>Inadequate family support</li> <li>Family discord</li> <li>History of intensely dependent relationship(s)</li> <li>Parental concerns regarding care of dependents</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>High symptom burden or distress score</td> <td>Financial limitations</td> </tr> <tr class=\"divider_bottom\"> <td>Intensive care unit admission with multiple complications or need for prolonged ventilator support</td> <td>Unresolved grief or multiple prior losses</td> </tr> <tr class=\"divider_bottom\"> <td>Physical symptoms other than pain that are refractory to conventional management</td> <td>Spiritual or existential crisis</td> </tr> <tr class=\"divider_bottom\"> <td>Cognitive impairment</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Severe or multiple comorbid conditions</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Communication barriers related to language, literacy, or physical issues</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Request for hastened death</td> <td>&nbsp;</td> </tr> <tr> <td>Inability to engage in advance care planning and care plan</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Source: NCCN Guidelines Version 2.2012. Palliative Care.</div><div id=\"graphicVersion\">Graphic 87162 Version 1.0</div></div></div>"},"87163":{"type":"graphic_table","displayName":"Symptom prevalence in palliative care patients","title":"Symptom prevalence in palliative care patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Symptom prevalence in palliative care patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"14%\"></colgroup><colgroup span=\"6\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Domain</td> <td class=\"subtitle1\" rowspan=\"2\">Problems/Symptom complex&nbsp;</td> <td class=\"subtitle1\" colspan=\"6\">Minimum-maximum prevalence % of each problem<br /> Total sample of patients (<em>N</em>) for each problem<br /> Total number of studies (<em>n</em>) for each problem<br /> Number of studies that report prevalence for a problem as &#8805;50% (<em>n</em> &#8805;50%)</td> </tr> <tr> <td class=\"subtitle2\">Cancer</td> <td class=\"subtitle2\">Chronic obstructive pulmonary disease (COPD)</td> <td class=\"subtitle2\">Chronic heart failure (CHF)</td> <td class=\"subtitle2\">End-stage renal disease (ESRD)</td> <td class=\"subtitle2\">Dementia</td> <td class=\"subtitle2\">Acquired immune deficiency syndrome (AIDS)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"36\"><strong>Physical:</strong></td> <td class=\"divider_bottom\" rowspan=\"4\">Fatigue/tiredness/weakness<br /> </td> <td>23 to 100%</td> <td>32 to 96%</td> <td>42 to 82%</td> <td>13 to 100%</td> <td>22%</td> <td>43 to 95%</td> </tr> <tr> <td><em>N</em> = 23,825</td> <td><em>N</em> = 500</td> <td><em>N</em> = 212</td> <td><em>N</em> = 1403</td> <td><em>N</em> = 50</td> <td><em>N</em> = 528</td> </tr> <tr> <td><em>n</em> = 34</td> <td><em>n</em> = 5</td> <td><em>n</em> = 3</td> <td><em>n</em> = 11</td> <td><em>n</em> = 1</td> <td><em>n</em> = 3</td> </tr> <tr class=\"divider_bottom\"> <td><em>n</em> &#8805;50% = 25</td> <td><em>n</em> &#8805;50% = 3</td> <td><em>n</em> &#8805;50% = 2</td> <td><em>n</em> &#8805;50% = 7</td> <td>&nbsp;</td> <td><em>n</em> &#8805;50% = 2</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Anorexia<br /> </td> <td>76 to 95%</td> <td>64 to 67%</td> <td>&ndash;</td> <td>38 to 64%</td> <td>&ndash;</td> <td>82%</td> </tr> <tr> <td><em>N</em> = 1098</td> <td><em>N</em> = 87</td> <td>&ndash;</td> <td><em>N</em> = 788</td> <td>&ndash;</td> <td><em>N</em> = 52</td> </tr> <tr> <td><em>n</em> = 3</td> <td><em>n</em> = 1</td> <td>&ndash;</td> <td><em>n</em> = 4</td> <td>&ndash;</td> <td><em>n</em> = 1</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&ndash;</td> <td><em>n</em> &#8805;50% = 3</td> <td>&ndash;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Pain (including different origins)<br /> </td> <td>30 to 94%</td> <td>21 to 77%</td> <td>14 to 78%</td> <td>11 to 83%</td> <td>14 to 63%</td> <td>30 to 98%</td> </tr> <tr> <td><em>N</em> = 29,966</td> <td><em>N</em> = 1730</td> <td><em>N</em> = 1230</td> <td><em>N</em> = 814</td> <td><em>N</em> = 745</td> <td><em>N</em> = 1325</td> </tr> <tr> <td><em>n</em> = 47</td> <td><em>n</em> = 7</td> <td><em>n</em> = 7</td> <td><em>n</em> = 9</td> <td><em>n</em> = 6</td> <td><em>n</em> = 6</td> </tr> <tr class=\"divider_bottom\"> <td><em>n</em> &#8805;50% = 4</td> <td><em>n</em> &#8805;50% = 3</td> <td><em>n</em> &#8805;50% = 2</td> <td><em>n</em> &#8805;50% = 6</td> <td><em>n</em> &#8805;50% = 1</td> <td><em>n</em> &#8805;50% = 5</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Nausea-vomiting<br /> </td> <td>2 to 78%</td> <td>4%</td> <td>2 to 48%</td> <td>8 to 52%</td> <td>8%</td> <td>41 to 57%</td> </tr> <tr> <td><em>N</em> = 31,743</td> <td><em>N</em> = 81</td> <td><em>N</em> = 812</td> <td><em>N</em> = 1176</td> <td><em>N</em> = 50</td> <td><em>N</em> = 914</td> </tr> <tr> <td><em>n</em> = 48</td> <td><em>n</em> = 1</td> <td><em>n</em> = 4</td> <td><em>n</em> = 9</td> <td><em>n</em> = 1</td> <td><em>n</em> = 4</td> </tr> <tr class=\"divider_bottom\"> <td><em>n</em> &#8805;50% = 3</td> <td>&nbsp;</td> <td>&nbsp;</td> <td><em>n</em> &#8805;50% = 1</td> <td>&nbsp;</td> <td><em>n</em> &#8805;50% = 1</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Breathlessness/dyspnea/shortness of breath/respiratory distress<br /> </td> <td>16 to 77%</td> <td>56 to 98%</td> <td>18 to 88%</td> <td>11 to 82%</td> <td>12 to 52%</td> <td>43 to 62%</td> </tr> <tr> <td><em>N</em> = 33,175</td> <td><em>N</em> = 1835</td> <td><em>N</em> = 1230</td> <td><em>N</em> = 1031</td> <td><em>N</em> = 674</td> <td><em>N</em> = 811</td> </tr> <tr> <td><em>n</em> = 40</td> <td><em>n</em> = 8</td> <td><em>n</em> = 7</td> <td><em>n</em> = 11</td> <td><em>n</em> = 5</td> <td><em>n</em> = 3</td> </tr> <tr class=\"divider_bottom\"> <td><em>n</em> &#8805;50% = 16</td> <td>&nbsp;</td> <td><em>n</em> &#8805;50% = 5</td> <td><em>n</em> &#8805;50% = 4</td> <td><em>n</em> &#8805;50% = 1</td> <td><em>n</em> &#8805;50% = 3</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Insomnia/poor sleeping/difficulty sleeping/sleep disturbance<br /> </td> <td>3 to 67%</td> <td>15 to 77%</td> <td>36 to 48%</td> <td>1 to 83%</td> <td>14%</td> <td>40 to 74%</td> </tr> <tr> <td><em>N</em> = 21,725</td> <td><em>N</em> = 419</td> <td><em>N</em> = 746</td> <td><em>N</em> = 2265</td> <td><em>N</em> = 123</td> <td><em>N</em> = 811</td> </tr> <tr> <td><em>n</em> = 33</td> <td><em>n</em> = 4</td> <td><em>n</em> = 3</td> <td><em>n</em> = 18</td> <td><em>n</em> = 1</td> <td><em>n</em> = 3</td> </tr> <tr class=\"divider_bottom\"> <td><em>n</em> &#8805;50% = 11</td> <td><em>n</em> &#8805;50% = 3</td> <td>&nbsp;</td> <td><em>n</em> &#8805;50% = 7</td> <td>&nbsp;</td> <td><em>n</em> &#8805;50% = 3</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Confusion/delirium/cognitive failure/cognitive symptoms<br /> </td> <td>2 to 68%</td> <td>14 to 33%</td> <td>15 to 48%</td> <td>35 to 70%</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td><em>N</em> = 18,768</td> <td><em>N</em> = 309</td> <td><em>N</em> = 433</td> <td><em>N</em> = 32</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td><em>n</em> = 25</td> <td><em>n</em> = 2</td> <td><em>n</em> = 3</td> <td><em>n</em> = 1</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td><em>n</em> &#8805;50% = 3</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Constipation<br /> </td> <td>4 to 64%</td> <td>12 to 44%</td> <td>12 to 42%</td> <td>8 to 65%</td> <td>40%</td> <td>19 to 35%</td> </tr> <tr> <td><em>N</em> = 30,841</td> <td><em>N</em> = 150</td> <td><em>N</em> = 746</td> <td><em>N</em> = 1136</td> <td><em>N</em> = 50</td> <td><em>N</em> = 759</td> </tr> <tr> <td><em>n</em> = 42</td> <td><em>n</em> = 2</td> <td><em>n</em> = 3</td> <td><em>n</em> = 7</td> <td><em>n</em> = 1</td> <td><em>n</em> = 2</td> </tr> <tr class=\"divider_bottom\"> <td><em>n</em> &#8805;50% = 10</td> <td>&nbsp;</td> <td>&nbsp;</td> <td><em>n</em> &#8805;50% = 3</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Diarrhea<br /> </td> <td>1 to 25%</td> <td>&ndash;</td> <td>12%</td> <td>8 to 36%</td> <td>&ndash;</td> <td>29 to 53%</td> </tr> <tr> <td><em>N</em> = 17,813</td> <td>&ndash;</td> <td><em>N</em> = 146</td> <td><em>N</em> = 105</td> <td>&ndash;</td> <td><em>N</em> = 862</td> </tr> <tr> <td><em>n</em> = 24</td> <td>&ndash;</td> <td><em>n</em> = 2</td> <td><em>n</em> = 4</td> <td>&ndash;</td> <td><em>n</em> = 3</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>&ndash;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&ndash;</td> <td><em>n</em> &#8805;50% = 2</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"12\"><strong>Psychological:</strong></td> <td class=\"divider_bottom\" rowspan=\"4\">Depression/depressive mood/sadness/low mood<br /> </td> <td>4 to 80%</td> <td>17 to 77%</td> <td>6 to 59%</td> <td>2 to 61%</td> <td>46%</td> <td>17 to 82%</td> </tr> <tr> <td><em>N</em> = 16,200</td> <td><em>N</em> = 752</td> <td><em>N</em> = 892</td> <td><em>N</em> = 7644</td> <td><em>N</em> = 123</td> <td><em>N</em> = 1211</td> </tr> <tr> <td><em>n</em> = 26</td> <td><em>n</em> = 7</td> <td><em>n</em> = 5</td> <td><em>n</em> = 23</td> <td><em>n</em> = 1</td> <td><em>n</em> = 6</td> </tr> <tr class=\"divider_bottom\"> <td><em>n</em> &#8805;50% = 10</td> <td><em>n</em> &#8805;50% = 4</td> <td><em>n</em> &#8805;50% = 1</td> <td><em>n</em> &#8805;50% = 3</td> <td>&nbsp;</td> <td><em>n</em> &#8805;50% = 4</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Anxiety/nervousness/agitation<br /> </td> <td>3 to 74%</td> <td>23 to 53%</td> <td>2 to 49%</td> <td>7 to 52%</td> <td>8 to 72%</td> <td>13 to 76%</td> </tr> <tr> <td><em>N</em> = 14,724</td> <td><em>N</em> = 455</td> <td><em>N</em> = 892</td> <td><em>N</em> = 818</td> <td><em>N</em> = 708</td> <td><em>N</em> = 923</td> </tr> <tr> <td><em>n</em> = 19</td> <td><em>n</em> = 4</td> <td><em>n</em> = 5</td> <td><em>n</em> = 10</td> <td><em>n</em> = 5</td> <td><em>n</em> = 4</td> </tr> <tr class=\"divider_bottom\"> <td><em>n</em> &#8805;50% = 7</td> <td><em>n</em> &#8805;50% = 1</td> <td>&nbsp;</td> <td><em>n</em> &#8805;50% = 1</td> <td><em>n</em> &#8805;50% = 2</td> <td><em>n</em> &#8805;50% = 2</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Worry<br /> </td> <td>3 to 71%</td> <td>65%</td> <td>&ndash;</td> <td>32 to 55%</td> <td>&ndash;</td> <td>51 to 86%</td> </tr> <tr> <td><em>N</em> = 1500</td> <td><em>N</em> = 60</td> <td>&ndash;</td> <td><em>N</em> = 30</td> <td>&ndash;</td> <td><em>N</em> = 759</td> </tr> <tr> <td><em>n</em> = 8</td> <td><em>n</em> = 1</td> <td>&ndash;</td> <td><em>n</em> = 2</td> <td>&ndash;</td> <td><em>n</em> = 2</td> </tr> <tr class=\"divider_bottom\"> <td><em>n</em> &#8805;50% = 3</td> <td>&nbsp;</td> <td>&ndash;</td> <td><em>n</em> &#8805;50% = 1</td> <td>&ndash;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"12\"><strong>Spiritual:</strong></td> <td class=\"divider_bottom\" rowspan=\"4\">Well-being<br /> </td> <td>91%</td> <td>14%</td> <td>5%</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td><em>N</em> = 406</td> <td><em>N</em> = 81</td> <td><em>N</em> = 66</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td><em>n</em> = 1</td> <td><em>n</em> = 1</td> <td><em>n</em> = 1</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Spiritual pain<br /> </td> <td>44%</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td><em>N</em> = 91</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td><em>n</em> = 1</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Spiritual well-being<br /> </td> <td>&ndash;</td> <td>&ndash;</td> <td>6%</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td>&ndash;</td> <td>&ndash;</td> <td><em>N</em> = 66</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr> <td>&ndash;</td> <td>&ndash;</td> <td><em>n</em> = 1</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td>&ndash;</td> <td>&ndash;</td> <td>&nbsp;</td> <td>&ndash;</td> <td>&ndash;</td> <td>&ndash;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A dash indicates that no data were found for this specific problem in this specific diagnostic group.</div><div class=\"graphic_reference\">Original figure modified for this publication. Moens K, Higginson IJ, Harding R, et al. Are there differences in the prevalence of palliative care-related problems in people living with advanced cancer and eight non-cancer conditions? A systematic review. J Pain Symptom Manage 2014; 48:660. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87163 Version 3.0</div></div></div>"},"87164":{"type":"graphic_figure","displayName":"Female pelvic anatomy sagittal ","title":"Female pelvic anatomy sagittal view","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Female pelvic anatomy sagittal view</div><div class=\"cntnt\"><img style=\"width:572px; height:606px;\" src=\"images/OBGYN/87164_Fem_pelvic_anatom_sagit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Uterus and vagina. Median section of vagina.<br />(B) Magnetic resonance images (MRIs) of the female pelvis. Median (above) and coronal (below) MRIs showing the uriary bladder, body of the uterus, vagina, and intestine.</div><div class=\"graphic_reference\">(A) Reproduced with permission from: Moore KL, Agur A. Essential Clinical Anatomy, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright Â© 2002 Lippincott Williams &amp; Wilkins.<br />(B) Photo courtesy of Dr. Shirley McCarthy. Reproduced with permission from: Moore KL, Dalley AF. Clinically Oriented Anatomy, 5th edition, Lippincott Williams &amp; Williams, Philadelphia 2005. Copyright Â© 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87164 Version 1.0</div></div></div>"},"87165":{"type":"graphic_figure","displayName":"Urethral sphincter","title":"Urethral sphincter","html":"<div class=\"graphic\"><div style=\"width: 502px\" class=\"figure\"><div class=\"ttl\">Urethral sphincter</div><div class=\"cntnt\"><img style=\"width:482px; height:458px;\" src=\"images/OBGYN/87165_Urethral_sphincter.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urethra.<br />(A) External urethral sphincter and compressor urethrae muscle of the male. Lateral view.<br />(B) External urethral sphincter, compressor urethrae, and urethrovaginal sphincter muscles of the female. Lateral view.</div><div class=\"graphic_reference\">Reproduced with permission from: Moore KL, Agur A. Essential Clinical Anatomy, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright Â© 2002 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87165 Version 1.0</div></div></div>"},"87166":{"type":"graphic_figure","displayName":"Female genitourinary system","title":"Female genitourinary system","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Female genitourinary system</div><div class=\"cntnt\"><img style=\"width:504px; height:477px;\" src=\"images/OBGYN/87166_Fem_genitourinary_sys.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Female genitourinary system (GU). Anterior view of the female genitourinary system, including the ovaries, uterine tubes, uterus and bladder.</div><div class=\"graphic_reference\">Reproduced with permission from: LifeART. Copyright Â© 2012 Lippincott Williams &amp; Wilkins. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87166 Version 1.0</div></div></div>"},"87167":{"type":"graphic_figure","displayName":"Bladder trigone","title":"Bladder trigone","html":"<div class=\"graphic\"><div style=\"width: 538px\" class=\"figure\"><div class=\"ttl\">Bladder trigone</div><div class=\"cntnt\"><img style=\"width:518px; height:479px;\" src=\"images/OBGYN/87167_Bladder_trigone.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 87167 Version 3.0</div></div></div>"},"87168":{"type":"graphic_figure","displayName":"Muscles obturator space","title":"Muscles of the obturator space","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Muscles of the obturator space</div><div class=\"cntnt\"><img style=\"width:540px; height:440px;\" src=\"images/OBGYN/87168_Muscles_obturator_space.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reprinted with permission: Cleveland Clinic Center for Medical Art &amp; Photography &copy; 2004-2012. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 87168 Version 1.0</div></div></div>"},"87169":{"type":"graphic_table","displayName":"Pain management in EB","title":"Pain management in epidermolysis bullosa (EB)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pain management in epidermolysis bullosa (EB)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Daily activities</td> <td class=\"subtitle1\">Dressings and baths</td> <td class=\"subtitle1\">Acute injury</td> <td class=\"subtitle1\">Perioperative</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Topical therapy</strong></td> <td> <p>Occlusive and protective dressings</p> Skin grafts</td> <td> <p>Occlusive dressings</p> <p>Bath additives (salt)</p> Adhesive removers</td> <td> <p>Occlusive dressings</p> <p>Skin grafts</p> <p>Topical lidocaine</p> Topical morphine</td> <td> <p>Operative preparation</p> <p>Lubrication</p> Padding</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Traditional systemic therapy</strong></td> <td> <p>Paracetamol</p> <p>Ibuprofen</p> Low-strength opioids</td> <td> <p>Paracetamol</p> <p>Ibuprofen</p> Low-strength and high-strength opioid combinations</td> <td> <p>Paracetamol</p> <p>Ibuprofen</p> Low-strength and high-strength opioid combinations</td> <td> <p>Paracetamol</p> <p>Ibuprofen</p> <p>Low-strength and high-strength opioid combinations</p> <p>Anti-anxiolytics</p> <p>Ketamine</p> <p>Nerve blocks</p> Propofol</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Non-traditional systemic therapy</strong></td> <td> <p>Tricyclic antidepressants</p> <p>Anticonvulsants</p> <p>Tetrahydrocannabinol</p> Dronabinol</td> <td> <p>Tricyclic antidepressants</p> <p>Anticonvulsants</p> <p>Tetrahydrocannabinol</p> Dronabinol</td> <td> <p>Tricyclic antidepressants</p> <p>Anticonvulsants</p> <p>Tetrahydrocannabinol</p> Dronabinol</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Psychological techniques</strong></td> <td> <p>Relaxation</p> <p>Visualization</p> Yoga, meditation</td> <td> <p>Relaxation</p> <p>Visualization</p> Self-hypnosis</td> <td> <p>Relaxation</p> <p>Visualization</p> Self-hypnosis</td> <td> <p>Relaxation</p> <p>Visualization</p> Self-hypnosis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Original figure modified for this publication. Goldschneider KR, Lucky AW. Pain management in epidermolysis bullosa. Dermatol Clin 2010; 28:273. Table reproduced with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87169 Version 2.0</div></div></div>"},"87170":{"type":"graphic_figure","displayName":"Excision of pilonidal tract and sinus ","title":"Excision of pilonidal tract and sinus","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Excision of pilonidal tract and sinus</div><div class=\"cntnt\"><img style=\"width:542px; height:252px;\" src=\"images/SURG/87170_Excisionpilonidaltractandsinus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The entire extent of pilonidal disease is encised en bloc to the level of the sacrococcygeal fascia.<br />(A) depicts a pilonidal sinus and tract.<br />(B) depicts the extext of the excision.<br />(C) depicts the depth of&nbsp;the incision to the level of the sacrococcygeal fascia.</div><div id=\"graphicVersion\">Graphic 87170 Version 2.0</div></div></div>"},"87171":{"type":"graphic_figure","displayName":"Primary closure of excised pilonidal disease","title":"Primary closure of excised pilonidal disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary closure of excised pilonidal disease</div><div class=\"cntnt\"><img style=\"width:298px; height:262px;\" src=\"images/SURG/87171_Primary_closure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Following excision of the pilonidal disease, the wound is managed with a primary closure with nonabsorbable sutures.</div><div id=\"graphicVersion\">Graphic 87171 Version 2.0</div></div></div>"},"87172":{"type":"graphic_figure","displayName":"Marsupialized pilonidal wound closure","title":"Marsupialized pilonidal wound closure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Marsupialized pilonidal wound closure</div><div class=\"cntnt\"><img style=\"width:298px; height:262px;\" src=\"images/SURG/87172_Marsupialized_closure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pilonidal disease has been completely excised. The wound is partially closed by marsupializing the skin edges to the sacrococcygeal fascia.</div><div id=\"graphicVersion\">Graphic 87172 Version 1.0</div></div></div>"},"87173":{"type":"graphic_diagnosticimage","displayName":"Chest radiograph of complete AV canal defect","title":"Chest radiograph of complete atrioventricular canal defect","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of complete atrioventricular canal defect</div><div class=\"cntnt\"><img style=\"width:464px; height:504px;\" src=\"images/PEDS/87173_Chest_radio_comp_AV_def.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph of complete atrioventricular canal defect in an infant demonstrating the characteristic findings of cardiomegaly and increased pulmonary markings.</div><div id=\"graphicVersion\">Graphic 87173 Version 3.0</div></div></div>"},"87174":{"type":"graphic_diagnosticimage","displayName":"MRI vertebral osteomyelitis","title":"ThreeÂ magnetic resonanceÂ images of vertebral osteomyelitis due to methicillin-resistant<EM> Staphylococcus aureus</EM>","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Three&nbsp;magnetic resonance&nbsp;images of vertebral osteomyelitis due to methicillin-resistant<EM> Staphylococcus aureus</EM></div><div class=\"cntnt\"><img style=\"width:612px; height:648px;\" src=\"images/ID/87174_MRI_vertebral_osteomyelitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) T2-weighted axial image shows collections in the psoas muscles bilaterally (arrows) representing abscesses.<br />(B) T2-weighted sagittal image demonstrates increased signal in the L2/3 and L3/4 intervertebral disc spaces (arrows).<br />(C) Post-contrast sagittal fat saturated T1-weighted image shows enhancement in the intervertebral disc spaces (arrows) and adjacent L2 to L4 vertebral bodies (arrowheads).</div><div class=\"graphic_reference\">Courtesy of Jenny Hoang, MBBS, Duke University Medical Center.</div><div id=\"graphicVersion\">Graphic 87174 Version 4.0</div></div></div>"},"87175":{"type":"graphic_figure","displayName":"Rhomboid flap closure for pilonidal disease excision","title":"Rhomboid flap closure for pilonidal disease excision","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Rhomboid flap closure for pilonidal disease excision</div><div class=\"cntnt\"><img style=\"width:517px; height:263px;\" src=\"images/SURG/87175_Rhomboidflapclosure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intergluteral pilonidal disease is completely excised and closed with a rhomboid (Limberg) flap. (A) depicts the incisions and (B) depicts the rotation of the flap.</div><div id=\"graphicVersion\">Graphic 87175 Version 2.0</div></div></div>"},"87176":{"type":"graphic_figure","displayName":"Z-plasty closure for excision of pilonidal disease","title":"Z-plasty closure for excision of pilonidal disease","html":"<div class=\"graphic\"><div style=\"width: 562px\" class=\"figure\"><div class=\"ttl\">Z-plasty closure for excision of pilonidal disease</div><div class=\"cntnt\"><img style=\"width:542px; height:229px;\" src=\"images/SURG/87176_Zplastyclosure.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) depicts an elliptical excision of the pilonidal sinuses and tracts down to the level of the sacrococcygeal fascia. Extensions from the superior and inferior angles are made at a 30 degree lateral angle. <br />(B) depicts the rotation of the full-thickness flap to cover the defect.<br />(C) depicts the final closed incision.</div><div id=\"graphicVersion\">Graphic 87176 Version 2.0</div></div></div>"},"87177":{"type":"graphic_table","displayName":"Cisplatin plus FU with RT for anal cancer","title":"Cisplatin and fluorouracil chemotherapy with concurrent radiotherapy for anal cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cisplatin and fluorouracil chemotherapy with concurrent radiotherapy for anal cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> Chemotherapy for 12.5 weeks and radiotherapy for five weeks.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days<sup>&#182;</sup></td> </tr> <tr> <td>Cisplatin</td> <td>75 mg/m<sup>2</sup> IV</td> <td> <p>Dilute in 250 mL normal saline (NS)* and administer over 30 minutes. Do not administer with aluminum needles or sets.</p> Alternative: Dilute in 2000 mL 5% dextrose (D5W) in 1/2 or 1/3 NS containing 37.5 g of mannitol and infuse over a six to eight hour period.<sup>[2]</sup> Do not administer with aluminum needles or sets.</td> <td>Days 1 and 29</td> </tr> <tr> <td>Fluorouracil</td> <td>1000 mg/m<sup>2</sup> per day IV</td> <td>Dilute in 500 to 1000 mL D5W* and administer as continuous infusion over 24 hours for four days (96 hours). Administer after completion of cisplatin.</td> <td>Days 1 through 4, and days 29 through 32</td> </tr> <tr class=\"divider_bottom\"> <td>Radiotherapy (45 to 59 Gy)</td> <td>1.8 Gy per day, five days per week</td> <td>Begin within 24 hours of the administration of chemotherapy.</td> <td>Start on day 1 (total of five weeks)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. </li> <li>Alternative: Pretreatment hydration with 1 to 2 L of fluid infused for 8 to 12 hours prior to each dose of cisplatin.<sup>[2]</sup> </li> <li>Supplemental electrolytes as per institutional guidelines. </li> <li>Refer to UpToDate topic on \"Cisplatin nephrotoxicity\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>HIGH (&#62;90% frequency of emesis) with high potential for delayed emesis on days 1 to 4, 29 to 32, 57 to 60, and 85 to 88.<br /> LOW risk on other days. </li> <li>Refer to UpToDate topics on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\" and \"Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Routine prophylaxis is not indicated. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Cisplatin and fluorouracil are irritants but can cause significant tissue damage with a large volume, concentrated extravasation; avoid extravasation.<sup>[2,3]</sup> </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF not indicated; use of G-CSF should be avoided in patients receiving concomitant chemoradiotherapy.<sup>[4]</sup> </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. A lower starting dose of fluorouracil may be needed for patients with liver impairment. </li> <li>Refer to UpToDate topics on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\" and \"Chemotherapy hepatoxicity and dose modification in patients with liver disease\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential prior to each new chemotherapy cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes and liver and renal function prior to each new chemotherapy cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess change in neurologic function prior to each treatment. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for diarrhea, stomatitis, and cutaneous toxicity (palmar-plantar erythrodysesthesias). </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Doses of cisplatin and fluorouracil were reduced by 50% for grade 4 neutropenia or febrile neutropenia during therapy.<sup>[1]</sup> Temporarily suspend chemoradiotherapy for grade 3 or 4 neutropenia until recovery to grade &#8804;2. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Diarrhea</strong></td> <td colspan=\"3\"> <ul> <li>The original protocol did not specify a dose reduction scheme for diarrhea. Others suggest holding all therapy for grade 3 or worse gastrointestinal toxicity during combined modality treatment, and reinitiation after resolution to grade 1 with a dose reduction of fluorouracil.<sup>[5]</sup> </li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after fluorouracil should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. </li> <li>Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Nephrotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Hold cisplatin until serum creatinine is &#60;1.5 mg/dL and/or blood urea nitrogen is &#60;25 mg/dL.<sup>[2]</sup> For grade 2 or greater nephrotoxicity during treatment (creatinine &#62;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle, and cisplatin dose reduced if &#60;60 mL/min. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurologic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Neuropathy usually is seen with cumulative doses of cisplatin &#62;400 mg/m<sup>2</sup>, although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. In one study, cisplatin dose was reduced for \"moderate\" neurotoxicity.<sup>[5]</sup> </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of platinum-based chemotherapy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Stomatitis</strong></td> <td colspan=\"3\"> <ul> <li>Reduce dose of fluorouracil for grade 3 stomatitis or esophagopharyngitis.<sup>[5]</sup> </li> <li>Refer to UpToDate topic on \"Oral toxicity associated with chemotherapy\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte colony stimulating factors; CBC: complete blood count.<br />* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />Â¶ The original protocol included two 28-day courses of induction chemotherapy using the same doses and schedule of cisplatin and fluorouracil prior to concomitant chemoradiotherapy.<br />Î No suggested dose modifications were cited by the original authors.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Ajani JA, et al. JAMA 2008; 299:1914.</LI>&#xD;&#xA;<LI>Cisplatin injection, powder, lyophilized, for solution. United States Prescribing Information. US National Library of Medicine. (Available online at http://dailymed.nlm.nih.gov, accessed June 12, 2012).</LI>&#xD;&#xA;<LI>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at http://dailymed.nlm.nih.gov, accessed June 12, 2012).</LI>&#xD;&#xA;<LI>Neupogen (filgrastim) injection. United States Prescribing Information. US National Library of Medicine. (Available online at http://dailymed.nlm.nih.gov, accessed June 12, 2012).</LI>&#xD;&#xA;<LI>Meropol NJ, et al. J Clin Oncol 2008; 26:3229.</LI></OL></div><div id=\"graphicVersion\">Graphic 87177 Version 10.0</div></div></div>"},"87178":{"type":"graphic_table","displayName":"Mitomycin plus FU and RT for anal cancer","title":"Mitomycin and fluorouracil chemotherapy with concurrent radiotherapy* as non-surgical treatment for anal cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Mitomycin and fluorouracil chemotherapy with concurrent radiotherapy* as non-surgical treatment for anal cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> Chemotherapy 28 days.<br /> <strong>Duration of therapy:</strong> Chemotherapy for two cycles (cycle 2 starts on day 29) and radiotherapy for one cycle.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Mitomycin</td> <td>10 mg/m<sup>2</sup> IV (maximum 20 mg per dose)</td> <td>Infuse as slow IV push or slow infusion in normal saline (over 15 to 30 minutes).<sup>[2]</sup></td> <td>Days 1 and 29<sup>&#182;</sup></td> </tr> <tr> <td>Fluorouracil</td> <td>1000 mg/m<sup>2</sup> per day IV (maximum daily dose 2000 mg)</td> <td>Dilute in 500 to 1000 mL 5% dextrose and administer as continuous infusion over 24 hours per day for four days (96 hours).</td> <td>Days 1 through 4, and days 29 through 32</td> </tr> <tr class=\"divider_bottom\"> <td>Radiotherapy (45 to 50.4 Gy)</td> <td>1.8 Gy daily, five days per week</td> <td>Begin within 24 hours of the administration of chemotherapy.</td> <td>Start on day 1 (total of five weeks)</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>LOW on all days. </li> <li>Refer to UpToDate topics on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\" and \"Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Routine prophylaxis is not indicated. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Mitomycin is a potent vesicant and can cause ulceration, necrosis, cellulitis, and tissue sloughing; avoid extravasation.<sup>[2]</sup> Fluorouracil is an irritant but can cause significant tissue damage with a large volume, concentrated extravasation; avoid extravasation.<sup>[3]</sup> </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF not indicated; use of G-CSF should be avoided in patients receiving concomitant chemoradiotherapy. </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Lower initial doses of mitomycin may be needed in patients with renal insufficiency. Do not use mitomycin if serum creatinine &#62;1.7 mg/dL.<sup>[2]</sup> A lower starting dose of fluorouracil may be needed for patients with liver impairment. </li> <li>Refer to UpToDate topics on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential weekly during treatment. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes and liver and renal function prior to each new chemotherapy cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for signs and symptoms of drug-induced thrombotic microangiopathy (TMA), which usually involves microangiopathic hemolytic anemia, thrombocytopenia, and irreversible renal failure. Other symptoms such as pulmonary edema, neurologic deficits, and hypertension may be present. Usually associated with cumulative doses &#8805;50 mg/m<sup>2</sup>. Discontinue mitomycin immediately and permanently. </li> <li>Refer to UpToDate topic on \"Drug-induced thrombotic microangiopathy\". </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess change in neurologic function prior to each new chemotherapy cycle </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for diarrhea, stomatitis, and cutaneous toxicity (palmar-plantar erythrodysesthesias) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for signs and symptoms of mitomycin C-associated acute lung injury. </li> <li>Refer to UpToDate topic on \"Mitomycin-C pulmonary toxicity\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Thrombocytopenia with or without neutropenia may occur anytime within eight weeks, with an average time of four weeks. If the nadir WBC count was &#60;2400 cells/microL but &#62;1000 cells/microL or nadir platelet count was &#62;50,000/microL but &#60;85,000/microL, the day 29 dose of mitomycin was reduced to 7.5 mg/m<sup>2</sup>.<sup>[1]</sup> If the nadir WBC count was &#60;1000/microL or the nadir platelet count &#60;50,000/microL, the day 29 dose of mitomycin C was reduced to 5 mg/m<sup>2</sup>. If on day 28, the WBC count was &#60;2400 cells/microL and/or the platelet count &#60;85,000/microL, cycle 2 of both chemotherapy and RT was delayed one week. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Local skin reaction</strong></td> <td colspan=\"3\"> <ul> <li>The original protocol permitted a treatment interruption up to 10 days if severe local skin reaction developed.<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Diarrhea, stomatitis</strong></td> <td colspan=\"3\"> <ul> <li>Reduce dose of fluorouracil by 20% for grade 3 or 4 diarrhea or stomatitis. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Thrombotic microangiopathy</strong></td> <td colspan=\"3\"> <ul> <li>Thrombotic microangiopathy (TMA, also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with mitomycin.<sup>[2]</sup> Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP. </li> <li>Refer to UpToDate topic on \"Drug-induced thrombotic microangiopathy\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Mitomycin should be discontinued for any signs or symptoms of acute lung injury.<sup>[2]</sup> </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte colony stimulating factors; CBC: complete blood count; WBC: white blood cell.<br />* Modification of the original Wayne State (Nigro) regimen.<SUP>[4]</SUP><br />Â¶ Deletion of the day 29 dose of mitomycin, as was done in the control arm of the ACT II trial, may improve tolerability.<SUP>[5]</SUP></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Flam M, et al. J Clin Oncol 1996; 14:2527.</LI>&#xD;&#xA;<LI>Mitomycin injection. United States Prescribing Information. US National Library of Medicine. (Available online at http://dailymed.nlm.nih.gov, accessed June 12, 2012).</LI>&#xD;&#xA;<LI>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at http://dailymed.nlm.nih.gov, accessed June 12, 2012).</LI>&#xD;&#xA;<LI>Nigro N et al. Dis Colon Rectum 1974; 17:354.</LI>&#xD;&#xA;<LI>James RD et al. Lancet Oncol 2013; 14:516.</LI></OL></div><div id=\"graphicVersion\">Graphic 87178 Version 15.0</div></div></div>"},"87179":{"type":"graphic_figure","displayName":"Survival according to presence or absence of sleep ap PD pts","title":"Estimate of survival according to absence or presence of significant sleep apnea among peritoneal dialysis patients","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Estimate of survival according to absence or presence of significant sleep apnea among peritoneal dialysis patients</div><div class=\"cntnt\"><img style=\"width:480px; height:336px;\" src=\"images/NEPH/87179_Surv_pres_abs_sleep_PD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This figure shows a Kaplan-Meier estimate of survival among patients with and without significant sleep apnea (defined as AHI &ge;15/hour or &lt;15/hour, respectively). p = 0.015.</div><div class=\"graphic_footnotes\">AHI: Apnea-Hypopnea Index.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Kidney International. Tang SC, Lam B, Yao TJ, et al. Sleep apnea is a novel risk predictor of cardiovascular morbidity and death in patients receiving peritoneal dialysis. Kidney Int 2010; 77:1031. Copyright &copy; 2010. <a href=\"http://www.nature.com/ki/index.html\" target=\"_blank\">http://www.nature.com/ki/index.html</a>.</div><div id=\"graphicVersion\">Graphic 87179 Version 2.0</div></div></div>"},"87180":{"type":"graphic_picture","displayName":"Pemphigus erythematosus","title":"Pemphigus erythematosus","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Pemphigus erythematosus</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87180_Pemphigus_erythematosus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erosions are on the malar region of the face.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87180 Version 4.0</div></div></div>"},"87182":{"type":"graphic_table","displayName":"Doxorubin plus cisplatin osteosarcoma","title":"Doxorubicin plus cisplatin for treatment of osteosarcoma in adults or children<SUP>[1,2]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Doxorubicin plus cisplatin for treatment of osteosarcoma in adults or children<SUP>[1,2]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days.<br /> <strong>Duration of therapy:</strong> 6 cycles (adjuvant or neoadjuvant).</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Doxorubicin</td> <td>25 mg/m<sup>2</sup> per day IV*</td> <td>Administer undiluted (2 mg/mL) as an IV push over three to five minutes into a free flowing IV infusion of normal saline (NS) or 5% dextrose in water (D5W). If needed, each day's dose of doxorubicin can be diluted in NS or D5W and given as a slow IV infusion administered over 15 to 60 minutes<sup>[3]</sup> or administered by continuous infusion over 72 hours.<sup>[4]</sup></td> <td>Days 1, 2, and 3</td> </tr> <tr class=\"divider_bottom\"> <td>Cisplatin</td> <td>100 mg/m<sup>2</sup> IV<sup>&#182;</sup></td> <td> <p>Dilute in 250 mL NS and administer over 60 minutes (or at a rate of 1 mg per minute). Do not administer with aluminum needles or sets.<sup>[1,5]</sup></p> Alternative: Dilute in 2 L NS, D5W in one-half or one-third NS containing 37.5 g of mannitol and infuse over six to eight hours.<sup>[1]</sup> Do not administer with aluminum needles or sets.</td> <td>Day 1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. </li> <li>Alternatively, hydration with 1 to 2 L of NS-based fluid infused over 4 to 12 hours prior to and immediately after each dose of cisplatin.<sup>[5]</sup> </li> <li>Refer to UpToDate topic on \"Cisplatin nephrotoxicity\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>HIGH (&#62;90% frequency of emesis). </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Routine prophylaxis not indicated. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Doxorubicin is a vesicant; avoid extravasation. Administer infusional regimens through a central venous line. Monitor IV or catheter site continuously throughout drug administration. Cisplatin is an irritant but can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Routine primary prophylaxis with G-CSF was not used in this trial.<sup>[1]</sup> However, the reported incidence of myelosuppression associated with infection (grade 3 or 4, according to National Cancer Institute Common Toxicity Criteria) was 19%. The decision to use G-CSF should be individualized, depending on other risk factors for prolonged neutropenia. </li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. Patients with a serum creatinine &#62;1.69 mg/dL (&#62;150 micromol/L) were excluded from the original trial.<sup>[1]</sup> Many clinicians would decrease the initial dose of cisplatin for a creatinine clearance &#60;50 mL/min. </li> <li>Refer to UpToDate topic on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> <li>A lower starting dose for doxorubicin may be needed in patients with hepatic impairment. </li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiac issues</strong></td> <td colspan=\"3\"> <ul> <li>Doxorubicin is associated with cardiomyopathy, the incidence of which is related to cumulative dose (cumulative lifetime dose should not exceed 450 mg/m<sup>2</sup>). Assess baseline LVEF prior to administration. Doxorubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmia, or previous therapy with high cumulative doses of doxorubicin or any other anthracyclines.<sup>[3]</sup> </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential and platelet count every three weeks prior to each new treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Serum electrolytes and liver and renal function tests every three weeks prior to each new treatment cycle. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor cumulative doxorubicin dose. Reassess LVEF periodically during therapy as clinically indicated. There are no prospective data on the use of dexrazoxane in osteosarcoma therapy, particularly in children. Some clinicians would add dexrazoxane to reduce incidence of cardiotoxicity once cumulative doxorubicin dose reaches 225 to 300 mg/m<sup>2</sup>. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Audiometry at baseline; monitor for hearing loss prior to each dose of cisplatin; repeat audiometry as clinically indicated. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Reduce doses of doxorubicin and cisplatin by 15% for any intracycle grade 3 hematologic toxicity (as assessed by WHO criteria) and by 30% for any grade 4 toxicity.<sup>[1]</sup> For each new cycle, delay chemotherapy until the white blood cell count was &#62;3000 cells/microL, absolute neutrophil count &#62;1500 cells/microL, and platelet count &#62;100,000/microL with repeat CBC with differential performed weekly. Discontinue chemotherapy if recovery was not apparent after three weeks. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Mucosal toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Reduce doxorubicin dose by 20% for WHO grade 3 or 4 mucositis.<sup>[1]</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Neuropathy usually is seen with cumulative doses of cisplatin &#62;400 mg/m<sup>2</sup>, although there is marked inter-individual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. However, if the neuropathy interferes with function, risk of potentially disabling neurotoxicity must be weighed against benefit of continued treatment. </li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of non-platinum cancer chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Nephrotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>In the original study, doses were not adjusted for reversible renal toxicity; however, repeat courses of cisplatin were not given if the serum creatinine level remained above 1.7 mg/dL.<sup>[1]</sup> For grade &#8805;2 nephrotoxicity during treatment (creatinine &#62;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle, with dose reduction of cisplatin if &#60;60 mL/min. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Cardiotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Guidelines for managing doxorubicin dose in patients with symptomatic cardiac dysfunction or asymptomatic changes in LVEF during therapy are addressed in detail separately. </li> <li>Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte colony stimulating factor; CBC: complete blood count; LVEF: left ventricular ejection fraction; WHO: World Health Organization.<br />* Alternative administration schedule of doxorubicin, as was used in the COG AOST 0331 (EURAMOS1) trial: 37.5 mg/m<SUP>2</SUP> per day IV push or by continuous infusion on days 1 and 2 of each treatment course (total dose 75 mg/m<SUP>2</SUP> over 48 hours).<SUP>[6]</SUP><br />Â¶ Alternative cisplatin dosing schedule, as was used in the COG AOST 0331 (EURAMOS1) trial: 60 mg/m<SUP>2</SUP> per day over four hours on days 1 and 2 of each treatment course (total dose 120 mg/m<SUP>2</SUP> per cycle).<SUP>[6]</SUP></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Bramwell V, et al. J Clin Oncol 1999; 17:3260.</LI>&#xD;&#xA;<LI>Souhami R, et al. Lancet 1997; 350:911.</LI>&#xD;&#xA;<LI>Doxorubicin hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on November 20, 2012).</LI>&#xD;&#xA;<LI>Meyers PA, et al. J Clin Oncol 2005; 23:2004.</LI>&#xD;&#xA;<LI>Cisplatin injection, powder, lyophilized, for solution. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on November 20, 2012).</LI>&#xD;&#xA;<LI>http://www.clinicaltrials.gov/ct2/show/NCT00134030?term=AOST+0331&amp;rank=1, accessed July 19, 2012.</LI></OL></div><div id=\"graphicVersion\">Graphic 87182 Version 8.0</div></div></div>"},"87183":{"type":"graphic_figure","displayName":"Potential symptoms and signs of anaphylaxis during pregnancy","title":"Potential symptoms and signs of anaphylaxis during pregnancy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Potential symptoms and signs of anaphylaxis during pregnancy</div><div class=\"cntnt\"><img style=\"width:424px; height:536px;\" src=\"images/ALLRG/87183_Pot_symp_anaphyl_preg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Potential symptoms and signs of anaphylaxis during pregnancy. Sudden onset of symptoms and signs in two or more body organ systems is characteristic. Most symptoms and signs are similar to those in nonpregnant patients with anaphylaxis. Itching in the vulvar/vaginal areas, low back pain, uterine cramps, fetal distress, and preterm labor can occur.</div><div class=\"graphic_reference\">Reproduced from: Simons FER, Schatz M. Anaphylaxis during pregnancy. J Allergy Clin Immunol 2012; 130:597. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87183 Version 3.0</div></div></div>"},"87184":{"type":"graphic_figure","displayName":"Treatment of anaphylaxis during pregnancy","title":"Treatment of anaphylaxis during pregnancy","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Treatment of anaphylaxis during pregnancy</div><div class=\"cntnt\"><img style=\"width:564px; height:641px;\" src=\"images/ALLRG/87184_Treatanaphdurpregn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Treatment of anaphylaxis during pregnancy. This involves prompt intramuscular injection of 0.3 mg (0.3 mL) of epinephrine using a 1 mg/mL (1:1000) dilution; high-flow supplemental oxygen; the mother positioned on her left side to improve venous return to the heart; maintenance of a minimum systolic blood pressure <SPAN style=\"COLOR: black\">of 90 mmHg for adequate placental perfusion; continuous electronic monitoring; cardiopulmonary resuscitation when indicated; and emergency cesarean delivery when indicated.</SPAN></div><div class=\"graphic_reference\">Reproduced from: Simons FER, Schatz M. Anaphylaxis during pregnancy. J Allergy Clin Immunol 2012; 130:597. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87184 Version 3.0</div></div></div>"},"87187":{"type":"graphic_figure","displayName":"Tracheobronchial anatomic distances","title":"Tracheobronchial anatomic distances","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tracheobronchial anatomic distances</div><div class=\"cntnt\"><img style=\"width:405px; height:606px;\" src=\"images/ANEST/87187_Tracheobronchial_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Average length from the incisors to the vocal cords is 15 cm, and&nbsp;from the vocal cords to the tracheal carina is 12 cm. The average distance from the tracheal carina to the take-off of the right upper bronchus is 2.0 cm in men and 1.5 cm in women. The distance from the tracheal carina to the take-off of the left upper and left lower lobe is approximately 5.0 cm in men and 4.5 cm in women. These anatomical distances apply to individuals with a height of 170 cm.</div><div class=\"graphic_reference\">Reproduced with permission from: Campos JH. Update on tracheobronchial anatomy and flexible fiberoptic bronchoscopy in thoracic anesthesia. Curr Opin Anaesthesiol 2009; 22:4. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87187 Version 5.0</div></div></div>"},"87188":{"type":"graphic_picture","displayName":"Bronchoscopic view of trachea and carina","title":"Bronchoscopic view of trachea and carina ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchoscopic view of trachea and carina </div><div class=\"cntnt\"><img style=\"width:157px; height:160px;\" src=\"images/ANEST/87188_Endosviewtrachcarin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><OL>&#xD;&#xA;<LI>The membranous trachea</LI>&#xD;&#xA;<LI>The carinal bifurcation is sharp (12&nbsp;to 6 o'clock)</LI>&#xD;&#xA;<LI>First&nbsp;generation bronchi are large and have no bifurcations in sight</LI></OL></div><div id=\"graphicVersion\">Graphic 87188 Version 2.0</div></div></div>"},"87189":{"type":"graphic_picture","displayName":"Bronchoscopic view of right mainstem bronchus","title":"Bronchoscopic view of right mainstem bronchus","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchoscopic view of right mainstem bronchus</div><div class=\"cntnt\"><img style=\"width:189px; height:186px;\" src=\"images/ANEST/87189_Bronchoviewrightmain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;RMB is short with an average length of 2.5 cm (line), and leads directly to the RBI. The&nbsp;RUL is visible at 3 to 4 o'clock.</div><div class=\"graphic_footnotes\">RMB: right mainstem bronchus; LMB: left mainstem bronchus; RBI: right bronchus intermedius; RUL: right upper lobe bronchus.</div><div id=\"graphicVersion\">Graphic 87189 Version 4.0</div></div></div>"},"87190":{"type":"graphic_figure","displayName":"Ludwig scale for female pattern hair loss","title":"Ludwig scale for female pattern hair loss","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Ludwig scale for female pattern hair loss</div><div class=\"cntnt\"><img style=\"width:487px; height:620px;\" src=\"images/DERM/87190_Ludwig_scale_for_female_pattern_hair_loss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">*Mild to marked decreases in hair density are the norm in female pattern hair loss. Female pattern hair loss manifesting with complete loss of hair fibers in the involved area is rare.</div><div class=\"graphic_reference\">Source: Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol 1977; 97:247.</div><div id=\"graphicVersion\">Graphic 87190 Version 2.0</div></div></div>"},"87191":{"type":"graphic_table","displayName":"Principles of consultation etiquette","title":"Principles of medical consultation etiquette","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Principles of medical consultation etiquette</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ol> <li>Determine the question (How can I help you in your care of patient X?). </li> <li>Triage urgency of the consultation&nbsp;(emergent versus urgent versus elective). </li> <li>Gather your own data (thorough history and focused physical examination). </li> <li>Brevity (focus your consult notes on assessment/recommendations). </li> <li>Specificity (goal-oriented recommendations). </li> <li>Plan ahead (contingency plans for anticipated future problems). </li> <li>Honor \"turf\" (be careful to address the problem for which you were called). </li> <li>Teach&#8212;with tact (viewing every consultation as a teaching, and marketing, opportunity). </li> <li>Personal contact (respond directly to the requesting physician). </li> <li>Follow-up (including your ongoing role and knowing when to sign off). </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Meier DE, Beresford L. Consultation etiquette challenges palliative care to be on its best behavior. J Palliat Med 2007; 10:7. Copyright &copy; 2007 Mary Ann Liebert, Inc. Publishers.</div><div id=\"graphicVersion\">Graphic 87191 Version 1.0</div></div></div>"},"87192":{"type":"graphic_picture","displayName":"Bronchoscopic view of right upper lobe bronchus","title":"Bronchoscopic view of right upper lobe bronchus ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchoscopic view of right upper lobe bronchus </div><div class=\"cntnt\"><img style=\"width:167px; height:170px;\" src=\"images/ANEST/87192_Broncho_view_rt_up_lobe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The anterior, posterior, and apical segments of the right upper lobe bronchi&nbsp;form a characteristic bronchial trifurcation.</div><div id=\"graphicVersion\">Graphic 87192 Version 1.0</div></div></div>"},"87193":{"type":"graphic_picture","displayName":"Female pattern hair loss 1","title":"Female pattern hair loss","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Female pattern hair loss</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/87193_Fem_pattern_hair_loss_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A marked reduction in terminal hair density is present on the crown of the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87193 Version 3.0</div></div></div>"},"87194":{"type":"graphic_picture","displayName":"Female pattern hair loss 2","title":"Female pattern hair loss","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Female pattern hair loss</div><div class=\"cntnt\"><img style=\"width:443px; height:590px;\" src=\"images/DERM/87194_Fem_pattern_hair_loss_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A marked reduction in terminal hair density is present on the crown of the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87194 Version 4.0</div></div></div>"},"87195":{"type":"graphic_picture","displayName":"Female pattern hair loss 3","title":"Female pattern hair loss","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Female pattern hair loss</div><div class=\"cntnt\"><img style=\"width:504px; height:379px;\" src=\"images/DERM/87195_Fem_pattern_hair_loss_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A marked reduction in terminal hair density is present on the crown of the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87195 Version 3.0</div></div></div>"},"87197":{"type":"graphic_picture","displayName":"Diffuse alopecia areata","title":"Diffuse alopecia areata","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Diffuse alopecia areata</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/87197_Diffuse_alopecia_areata.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse, nonscarring hair loss is present on the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87197 Version 3.0</div></div></div>"},"87198":{"type":"graphic_picture","displayName":"Central centrifugal cicatricial alopecia","title":"Central centrifugal cicatricial alopecia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Central centrifugal cicatricial alopecia</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/DERM/87198_Cent_centrifug_cicat_alop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Central centrifugal cicatricial alopecia is a form of scarring alopecia. An area of hair loss is present on the vertex of the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87198 Version 3.0</div></div></div>"},"87199":{"type":"graphic_table","displayName":"Antimicrobial prophylaxis for genitourinary surgery","title":"Antimicrobial prophylaxis for genitourinary surgery in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antimicrobial prophylaxis for genitourinary surgery in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Nature of operation</td> <td class=\"subtitle1\">Common pathogens</td> <td class=\"subtitle1\">Recommended antimicrobials</td> <td class=\"subtitle1\">Usual adult dose*</td> <td class=\"subtitle1\">Redose interval<sup>&#182;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Cystoscopy alone</td> <td class=\"divider_bottom\" rowspan=\"2\">Enteric gram-negative bacilli, enterococci</td> <td>High-risk<sup>&#916;</sup> only: ciprofloxacin<sup>&#9674;</sup></td> <td>500 mg orally or 400 mg IV</td> <td>N/A</td> </tr> <tr class=\"divider_bottom\"> <td><strong>OR</strong> trimethoprim-sulfamethoxazole</td> <td>One 160/800 mg (double strength, DS) tablet orally</td> <td>N/A</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Cystoscopy with manipulation or upper tract instrumentation<sup>&#167;</sup></td> <td class=\"divider_bottom\" rowspan=\"2\">Enteric gram-negative bacilli, enterococci</td> <td>Ciprofloxacin<sup>&#9674;</sup></td> <td>500 mg orally or 400 mg IV</td> <td>N/A</td> </tr> <tr class=\"divider_bottom\"> <td><strong>OR</strong> trimethoprim-sulfamethoxazole</td> <td>One 160/800 mg (double strength, DS) tablet orally</td> <td>N/A</td> </tr> <tr> <td>Open or laparoscopic surgery<sup>&#165;</sup></td> <td>Enteric gram-negative bacilli, enterococci</td> <td>Cefazolin<sup>&#135;</sup></td> <td> <p>&#60;120 kg: 2 g IV</p> &#8805;120 kg: 3 g IV</td> <td>4 hours</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous.<br />* Parenteral prophylactic antimicrobials can be given as a single IV dose begun within 60 minutes before the procedure. If a fluoroquinolone is used, the infusion should be started within 60 to 120 minutes before the initial incision to have adequate tissue levels at the time of incision and to minimize the possibility of an infusion reaction close to the time of induction of anesthesia.<br />Â¶ For prolonged procedures (&gt;3 hours) or those with major blood loss, or in patients with extensive burns, additional intraoperative doses should be given at intervals one to two times the half-life of the drug for the duration of the procedure in patients with normal renal function.<br />Î Urine culture positive or unavailable, preoperative catheter, transrectal prostatic biopsy, or placement of prosthetic material.<br /><FONT class=lozenge>â</FONT> Due to increasing resistance of <EM>Escherichia coli</EM> to fluoroquinolones and ampicillin-sulbactam, local sensitivity profiles should be reviewed prior to use.<br />Â§ Shock wave lithotripsy, ureteroscopy.<br />Â¥ Including percutaneous renal surgery, procedures with entry into the urinary tract, and those involving implantation of a prosthesis. If manipulation of bowel is involved, prophylaxis is given according to colorectal guidelines.<br />â¡ For patients allergic to penicillins and cephalosporins, clindamycin (900 mg IV) or vancomycin (15 mg/kg IV not to exceed 2 g) with either gentamicin (5 mg/kg IV), ciprofloxacin (400 mg IV), levofloxacin (500 mg IV), or aztreonam (2 g IV) is a reasonable alternative.</div><div class=\"graphic_reference\">Adapted from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Antimicrobial prophylaxis for surgery. Med Lett Drugs Ther 2016; 58:63.</LI>&#xD;&#xA;<LI>Bratzler DW, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt) 2013; 14:73.</LI></OL></div><div id=\"graphicVersion\">Graphic 87199 Version 12.0</div></div></div>"},"87200":{"type":"graphic_table","displayName":"Antimicrobial prophylaxis for gynecologic and obstetric surgery","title":"Antimicrobial prophylaxis for gynecologic and obstetric surgery in adults*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antimicrobial prophylaxis for gynecologic and obstetric surgery in adults*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Procedure</td> <td class=\"subtitle1\">Preferred regimen<sup>&#182;</sup></td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Alternative regimens<sup>&#916;</sup></td> <td class=\"subtitle1\">Dose</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"14\"> <p>Hysterectomy (abdominal, vaginal, laparoscopic, or robotic)</p> Urogynecology procedures including those involving mesh</td> <td class=\"divider_bottom\" rowspan=\"14\">Cefazolin, cefoxitin or cefotetan</td> <td class=\"divider_bottom\" rowspan=\"14\"> <p>Cefazolin:</p> <p class=\"indent1\">&#60;120 kg: 2 g IV</p> <p class=\"indent1\">&#8805;120 kg: 3 g IV</p> <br /> <p>Cefoxitin or cefotetan:</p> <p class=\"indent1\">2 g IV</p> </td> <td class=\"subtitle2_left\" colspan=\"2\">Regimen:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ampicillin-sulbactam</td> <td>3 g IV</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Regimen:</td> </tr> <tr> <td class=\"indent1\">Clindamycin <strong>OR</strong></td> <td>900 mg IV<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Vancomycin<sup>&#182;</sup></td> <td>15 mg/kg IV (not to exceed 2 g per dose)</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\"><strong>PLUS</strong> one of the following:</td> </tr> <tr> <td class=\"indent1\">Gentamicin <strong>OR</strong></td> <td>5 mg/kg IV (if overweight or obese, based on dosing weight)<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\">Aztreonam <strong>OR</strong></td> <td>2 g IV</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Fluoroquinolone<sup>&#182;</sup><sup>&#165;</sup></td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Regimen:</td> </tr> <tr> <td class=\"indent1\">Metronidazole</td> <td>500 mg IV</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\"><strong>PLUS</strong> one of the following:</td> </tr> <tr> <td class=\"indent1\">Gentamicin <strong>OR</strong></td> <td>5 mg/kg IV (if overweight or obese, based on dosing weight)<sup>&#167;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Fluoroquinolone<sup>&#182;</sup><sup>&#165;</sup></td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"11\">Cesarean section</td> <td class=\"divider_bottom\" rowspan=\"11\">Cefazolin</td> <td class=\"divider_bottom\" rowspan=\"11\"> <p>&#60;120 kg: 2 g IV</p> &#8805;120 kg: 3 g IV</td> <td class=\"subtitle2_left\" colspan=\"2\">Regimen:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ampicillin-sulbactam</td> <td>3 g IV</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Regimen:</td> </tr> <tr> <td class=\"indent1\">Clindamycin <strong>OR</strong></td> <td>900 mg IV<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Vancomycin<sup>&#182;</sup></td> <td>15 mg/kg IV (not to exceed 2 g per dose)</td> </tr> <tr> <td class=\"indent2\" colspan=\"2\"><strong>PLUS</strong> one of the following:</td> </tr> <tr> <td class=\"indent1\">Gentamicin <strong>OR</strong></td> <td>5 mg/kg IV (if overweight or obese, based on dosing weight)<sup>&#167;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Aztreonam</td> <td>2 g IV</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Regimen:</td> </tr> <tr> <td class=\"indent1\">Metronidazole <strong>PLUS</strong></td> <td>500 mg IV</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Gentamicin</td> <td>5 mg/kg IV (if overweight or obese, based on dosing weight)<sup>&#167;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Abortion, surgical</td> <td class=\"divider_bottom\" rowspan=\"2\">Doxycycline</td> <td class=\"divider_bottom\" rowspan=\"2\">100 mg orally one hour before procedure and 200 mg orally after procedure</td> <td>Metronidazole</td> <td>500 mg orally twice daily for five days</td> </tr> <tr class=\"divider_bottom\"> <td>Azithromycin</td> <td>1 g orally one hour before procedure</td> </tr> <tr class=\"divider_bottom\"> <td>Hysterosalpingogram or chromotubation</td> <td>Doxycycline<sup>&#135;</sup></td> <td>100 mg orally twice daily for five days</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td> <p>Laparoscopy (diagnostic, tubal sterilization, operative except for hysterectomy)</p> <p>Other transcervical procedures:</p> <p class=\"indent1\">Hysteroscopy (diagnostic or operative, including hysteroscopic sterilization)</p> <p class=\"indent1\">Intrauterine device insertion</p> <p class=\"indent1\">Endometrial biopsy</p> </td> <td colspan=\"4\">None</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; IDSA: Infectious Diseases Society of America; ASHP: American Society of Health-System Pharmacists; ACOG: American College of Obstetricians and Gynecologists.<br />* Common pathogens: Enteric gram-negative bacilli, anaerobes, group B <EM>Streptococcus</EM>, enterococci.<br />Â¶ Parenteral prophylactic antimicrobials can be given as a single IV dose begun within 60 minutes before the procedure. If vancomycin or a fluoroquinolone is used, the infusion should be given over 60 to 90 minutes and started within 60 to 120 minutes before the initial incision.<br />Î An alternative regimen should be used in women with history of immediate hypersensitivity to beta-lactam agents. Due to increasing resistance of <EM>Escherichia coli</EM> to ampicillin-sulbactam and fluoroquinolones, local sensitivity profiles should be reviewed prior to use.<br /><FONT class=lozenge>â</FONT> When clindamycin prophylaxis is warranted, UpToDate authors prefer a single dose of 900 mg based upon pharmacokinetic considerations according to 2013 IDSA/ASHP surgical antibiotic prophylaxis guidelines.<SUP>[1]</SUP> However, a 600 mg dose consistent with ACOG guidance may be sufficient.<SUP>[2,3]</SUP><br />Â§ Gentamicin use for surgical antibiotic prophylaxis should be limited to a single dose given preoperatively. Based on evidence from colorectal procedures, a single dose of approximately 5 mg/kg gentamicin appears more effective for the prevention of surgical site infection than multiple doses of gentamicin 1.5 mg/kg every eight hours.<SUP>[4]</SUP> However, a lower dose of 1.5 mg/kg, consistent with ACOG guidance, may be adequate.<SUP>[2,3]</SUP> For overweight and obese patients (ie, actual weight is &gt;125% of ideal body weight), a dosing weight should be used. A calculator to determine ideal body weight and dosing weight is available in UpToDate.<br />Â¥ Ciprofloxacin 400 mg IV <STRONG>OR</STRONG> levofloxacin 500 mg IV <STRONG>OR</STRONG> moxifloxacin 400 mg IV. Fluoroquinolones are contraindicated in pregnancy and in women who are breastfeeding.<br />â¡ Prophylaxis is warranted for patients with history of pelvic inflammatory disease or if the procedure demonstrates dilated fallopian tubes. No prophylaxis is indicated for patients without dilated tubes.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 2013; 70:195.</LI>&#xD;&#xA;<LI>ACOG practice bulletin No. 104: Antibiotic prophylaxis for gynecologic procedures. Obstet Gynecol 2009; 113:1180.</LI>&#xD;&#xA;<LI>ACOG practice bulletin No. 120: Use of prophylactic antibiotics in labor and delivery. Obstet Gynecol 2011;117:1472.</LI>&#xD;&#xA;<LI>Zelenitsky SA, Silverman RE, Duckworth H, Harding GK. A prospective, randomized, double-blind study of single high dose versus multiple standard dose gentamicin both in combination with metronidazole for colorectal surgical prophylaxis. J Hosp Infect 2000; 46:135.</LI></OL>Adapted from: Antimicrobial prophylaxis for surgery. Med Lett Drugs Ther 2016; 58:63.</div><div id=\"graphicVersion\">Graphic 87200 Version 28.0</div></div></div>"},"87201":{"type":"graphic_table","displayName":"Antimicrobial prophylaxis for head and neck surgery","title":"Antimicrobial prophylaxis for head and neck surgery in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antimicrobial prophylaxis for head and neck surgery in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Nature of operation</td> <td class=\"subtitle1\">Common pathogens</td> <td class=\"subtitle1\">Recommended antimicrobials</td> <td class=\"subtitle1\">Usual adult dose*</td> <td class=\"subtitle1\">Redose interval<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Clean</td> <td class=\"centered\">&ndash;</td> <td>None</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Clean with placement of prosthesis (excludes tympanostomy tube placement)</td> <td class=\"divider_bottom\" rowspan=\"4\"><em>Staphylococcus aureus</em>, <em>S. epidermidis</em>, streptococci</td> <td>Cefazolin*</td> <td> <p>&#60;120 kg: 2 g IV</p> &#8805;120 kg: 3 g IV</td> <td>4 hours</td> </tr> <tr> <td><strong>OR</strong> cefuroxime</td> <td>1.5 g IV</td> <td>4 hours</td> </tr> <tr> <td><strong>OR</strong> vancomycin<sup>&#916;</sup></td> <td>15 mg/kg (max 2 g)</td> <td>N/A</td> </tr> <tr class=\"divider_bottom\"> <td><strong>OR</strong> clindamycin</td> <td>600 to 900 mg IV</td> <td>N/A</td> </tr> <tr> <td rowspan=\"6\">Clean-contaminated</td> <td rowspan=\"6\">Anaerobes, enteric gram-negative bacilli, <em>S. aureus</em></td> <td>Cefazolin</td> <td> <p>&#60;120 kg: 2 g IV</p> &#8805;120 kg: 3 g IV</td> <td>4 hours</td> </tr> <tr> <td>PLUS metronidazole</td> <td>500 mg IV</td> <td>N/A</td> </tr> <tr> <td><strong>OR</strong> cefuroxime</td> <td>1.5 g IV</td> <td>4 hours</td> </tr> <tr> <td>PLUS metronidazole</td> <td>500 mg IV</td> <td>N/A</td> </tr> <tr> <td><strong>OR</strong> ampicillin-sulbactam<sup>&#9674;</sup></td> <td>3 g IV</td> <td>2 hours</td> </tr> <tr> <td><strong>OR</strong> clindamycin</td> <td>900 mg IV</td> <td>6 hours</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous.<br />* Parenteral prophylactic antimicrobials can be given as a single IV dose begun within 60 minutes before the procedure. If vancomycin is used, the infusion should be started within 60 to 120 minutes before the initial incision to have adequate tissue levels at the time of incision and to minimize the possibility of an infusion reaction close to the time of induction of anesthesia.<br />Â¶ For prolonged procedures (&gt;3 hours) or those with major blood loss, or in patients with extensive burns, additional intraoperative doses should be given at intervals one to two times the half-life of the drug for the duration of the procedure in patients with normal renal function.<br />Î Use of vancomycin is appropriate in hospitals in which methicillin-resistant <EM>S. aureus</EM> (MRSA) or <EM>S. epidermidis</EM> are frequent causes of postoperative wound infection, in patients previously colonized with MRSA, or for those who are allergic to penicillins or cephalosporins. Rapid IV administration may cause hypotension, which could be especially dangerous during induction of anesthesia. Even when the drug is given over 60 minutes, hypotension may occur; treatment with diphenhydramine and further slowing of the infusion rate may be helpful. For procedures in which enteric gram-negative bacilli are common pathogens, many experts would add another drug such as an aminoglycoside (such as gentamicin 5 mg/kg IV), aztreonam (2 g IV), or a fluoroquinolone (such as levofloxacin 500 mg IV or ciprofloxacin 400 mg IV).<br /><FONT class=lozenge>â</FONT> Some experts recommend an additional dose when patients are removed from bypass during open-heart surgery.</div><div class=\"graphic_reference\">Adapted from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Antimicrobial prophylaxis for surgery. Med Lett Drugs Ther 2016; 58:63.</LI>&#xD;&#xA;<LI>Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt) 2013; 14:73.</LI></OL></div><div id=\"graphicVersion\">Graphic 87201 Version 11.0</div></div></div>"},"87202":{"type":"graphic_table","displayName":"Antimicrobial prophylaxis for neurosurgery","title":"Antimicrobial prophylaxis for neurosurgery in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antimicrobial prophylaxis for neurosurgery in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Nature of operation</td> <td class=\"subtitle1\">Common pathogens</td> <td class=\"subtitle1\">Recommended antimicrobials</td> <td class=\"subtitle1\">Usual adult dose*</td> <td class=\"subtitle1\">Redose interval<sup>&#182;</sup></td> </tr> <tr> <td rowspan=\"3\"> <p>Elective craniotomy</p> <p>Cerebrospinal fluid shunting procedures</p> Implantation of intrathecal pumps</td> <td rowspan=\"3\"><em><span>Staphylococcus</span>&nbsp;aureus</em>, <em>S. epidermidis</em></td> <td>Cefazolin</td> <td> <p>&#60;120 kg: 2 g</p> &#8805;120 kg: 3 g</td> <td>4 hours</td> </tr> <tr> <td><strong>OR</strong> vancomycin<sup>&#916;</sup></td> <td>15 mg/kg IV (max 2 g)</td> <td>12 hours</td> </tr> <tr> <td><strong>OR</strong> clindamycin</td> <td>900 mg IV</td> <td>6 hours</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous.<br />* Parenteral prophylactic antimicrobials can be given as a single IV dose begun within 60 minutes before the procedure. If vancomycin is used, the infusion should be started within 60 to 120 minutes before the initial incision to have adequate tissue levels at the time of incision and to minimize the possibility of an infusion reaction close to the time of induction of anesthesia.<br />Â¶ For prolonged procedures (&gt;3 hours) or those with major blood loss, or in patients with extensive burns, additional intraoperative doses should be given at intervals one to two times the half-life of the drug (cefazolin every four hours, clindamycin every six hours, vancomycin every 12 hours) for the duration of the procedure in patients with normal renal function.<br />Î Use of vancomycin is appropriate in hospitals in which methicillin-resistant <EM>S. aureus</EM> (MRSA) and <EM>S. epidermidis</EM> are a frequent cause of postoperative wound infection, in patients previously colonized with MRSA, or for those who are allergic to penicillins or cephalosporins. Rapid IV administration may cause hypotension, which could be especially dangerous during induction of anesthesia. Even when the drug is given over 60 minutes, hypotension may occur; treatment with diphenhydramine and further slowing of the infusion rate may be helpful. For procedures in which enteric gram-negative bacilli are common pathogens, many experts would add another drug such as an aminoglycoside (such as gentamicin 5 mg/kg IV), aztreonam (2 g IV), or a fluoroquinolone (such as ciprofloxacin 400 mg IV or levofloxacin 500 mg IV).</div><div class=\"graphic_reference\">Adapted from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Antimicrobial prophylaxis for surgery. Med Lett Drugs Ther 2016; 58:63.</LI>&#xD;&#xA;<LI>Bratzler DW, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt) 2013; 14:73.</LI></OL></div><div id=\"graphicVersion\">Graphic 87202 Version 10.0</div></div></div>"},"87204":{"type":"graphic_table","displayName":"Antimicrobial prophylaxis for orthopedic surgery","title":"Antimicrobial prophylaxis for orthopedic surgery in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antimicrobial prophylaxis for orthopedic surgery in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Nature of operation</td> <td class=\"subtitle1\">Common pathogens</td> <td class=\"subtitle1\">Recommended antimicrobials</td> <td class=\"subtitle1\">Usual adult dose*</td> <td class=\"subtitle1\">Redose interval<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Clean operation involving hand, knee, or foot with no implantation of foreign material</td> <td class=\"centered\">&ndash;</td> <td>None</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td rowspan=\"3\"> <p>Spinal procedures</p> <p>Hip fracture</p> <p>Internal fixation</p> <p>Total joint replacement</p> <p>Removal of orthopedic hardware used for treatment of lower extremity fractures<sup>&#167;</sup></p> </td> <td rowspan=\"3\"><em>Staphylococcus aureus</em>, <em>Staphylococcus epidermidis</em></td> <td>Cefazolin<sup>&#916;</sup></td> <td> <p>&#60;120 kg: 2 g IV</p> &#8805;120 kg: 3 g IV</td> <td>Four&nbsp;hours</td> </tr> <tr> <td><strong>OR</strong> vancomycin<sup>&#916;</sup><sup>&#9674;</sup></td> <td>15 mg/kg IV (max 2 g)</td> <td>N/A</td> </tr> <tr> <td><strong>OR</strong> clindamycin</td> <td>900 mg IV</td> <td>Six&nbsp;hours</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; N/A: not applicable.<br />* Parenteral prophylactic antimicrobials can be given as a single IV dose begun within 60 minutes before the procedure. If vancomycin is used, the infusion should be started within 60 to 120 minutes before the initial incision to have adequate tissue levels at the time of incision and to minimize the possibility of an infusion reaction close to the time of induction of anesthesia.<br />Â¶ For prolonged procedures (&gt;3 hours) or those with major blood loss or in patients with extensive burns, additional intraoperative doses should be given at intervals one to two times the half-life of the drug for the duration of the procedure in patients with normal renal function.<br />Î If a tourniquet is to be used in the procedure, the entire dose of antibiotic must be infused prior to its inflation.<br /><FONT class=lozenge>â</FONT> Use of vancomycin is appropriate in hospitals in which methicillin-resistant <EM>Staphylococcus aureus</EM> (MRSA) and <EM>Staphylococcus epidermidis</EM> are a frequent cause of postoperative wound infection, in patients previously colonized with MRSA, or for those who are allergic to penicillins or cephalosporins. Rapid IV administration may cause hypotension, which could be especially dangerous during induction of anesthesia. Even when the drug is given over 60 minutes, hypotension may occur; treatment with diphenhydramine and further slowing of the infusion rate may be helpful. Some experts would give 15 mg/kg of vancomycin to patients weighing more than 75 kg, up to a maximum of 1.5 g, with a slower infusion rate (90 minutes for 1.5 g).<br />âÂ§ The role of antimicrobial prophylaxis prior to removal of orthopedic hardware used for treatment of lower extremity factures is controversial. According to the guidelines issued by the United States Centers for Disease Control and Prevention, this is considered a \"clean\" surgical procedure (ie, without skin contamination or local infection), for which preoperative antibiotic prophylaxis is not routinely recommended. However, relatively high rates of surgical site infection have been reported for this procedure; therefore, we favor administration of preoperative antimicrobial prophylaxis. Refer to the text for further discussion.</div><div class=\"graphic_reference\">Adapted from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Antimicrobial prophylaxis for surgery. Med Lett Drugs Ther 2016; 58:63.</LI>&#xD;&#xA;<LI>Bratzler DW, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt) 2013; 14:73.</LI></OL></div><div id=\"graphicVersion\">Graphic 87204 Version 17.0</div></div></div>"},"87205":{"type":"graphic_table","displayName":"Antimicrobial prophylaxis for thoracic surgery","title":"Antimicrobial prophylaxis for thoracic (noncardiac) surgery in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antimicrobial prophylaxis for thoracic (noncardiac) surgery in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Nature of operation</td> <td class=\"subtitle1\">Common pathogens</td> <td class=\"subtitle1\">Recommended antimicrobials</td> <td class=\"subtitle1\">Usual adult dose*</td> <td class=\"subtitle1\">Redose interval<sup>&#182;</sup></td> </tr> <tr> <td rowspan=\"4\">Thoracic (noncardiac) procedures: lobecotomy, pneumonectomy, lung resection, thoractomy</td> <td rowspan=\"4\"><em><span>Staphylococcus</span> aureus</em>,<em> S. epidermidis</em>, streptococci, enteric gram-negative bacilli</td> <td>Cefazolin</td> <td> <p>&#60;120 kg: 2 g IV</p> &#8805;120 kg: 3 g IV</td> <td>4 hours</td> </tr> <tr> <td><strong>OR</strong> ampicillin-sulbactam<sup>&#916;</sup></td> <td>3 g IV</td> <td>2 hours</td> </tr> <tr> <td><strong>OR</strong> vancomycin<sup>&#9674;</sup></td> <td>15 mg/kg IV (max 2 g)</td> <td>N/A</td> </tr> <tr> <td><strong>OR</strong> clindamycin</td> <td>900 mg IV</td> <td>6 hours</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous.<br />* Parenteral prophylactic antimicrobials can be given as a single IV dose begun within 60 minutes before the procedure. If vancomycin is used, the infusion should be started within 60 to 120 minutes before the initial incision to have adequate tissue levels at the time of incision and to minimize the possibility of an infusion reaction close to the time of induction of anesthesia.<br />Â¶ For prolonged procedures (&gt;3 hours) or those with major blood loss, or in patients with extensive burns, additional intraoperative doses should be given at intervals one to two times the half-life of the drug for the duration of the procedure in patients with normal renal function.<br />Î Due to increasing resistance of <EM>Escherichia coli</EM> to fluoroquinolones and ampicillin-sulbactam, local sensitivity profiles should be reviewed prior to use.<br /><FONT class=lozenge>â</FONT> Use of vancomycin is appropriate in hospitals in which methicillin-resistant <EM>S. aureus</EM> (MRSA) and <EM>S. epidermidis</EM> are a frequent cause of postoperative wound infection, in patients previously colonized with MRSA, or for those who are allergic to penicillins or cephalosporins. Rapid IV administration may cause hypotension, which could be especially dangerous during induction of anesthesia. Even when the drug is given over 60 minutes, hypotension may occur; treatment with diphenhydramine and further slowing of the infusion rate may be helpful. For procedures in which enteric gram-negative bacilli are common pathogens, many experts would add another drug such as an aminoglycoside (gentamicin 5 mg/kg IV), aztreonam (2 g IV), or a fluoroquinolone (ciprofloxacin 400 mg IV or levofloxacin 500 mg IV).</div><div class=\"graphic_reference\">Adapted from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Antimicrobial prophylaxis for surgery. Med Lett Drugs Ther 2016; 58:63.</LI>&#xD;&#xA;<LI>Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt) 2013; 14:73.</LI></OL></div><div id=\"graphicVersion\">Graphic 87205 Version 11.0</div></div></div>"},"87206":{"type":"graphic_table","displayName":"Antimicrobial prophylaxis for vascular surgery","title":"Antimicrobial prophylaxis for vascular surgery in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antimicrobial prophylaxis for vascular surgery in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Nature of operation</td> <td class=\"subtitle1\">Common pathogens</td> <td class=\"subtitle1\">Recommended antimicrobials</td> <td class=\"subtitle1\">Usual adult dose*</td> <td class=\"subtitle1\">Redose interval<sup>&#182;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Arterial surgery involving a prosthesis, the abdominal aorta, or a groin incision</td> <td class=\"divider_bottom\" rowspan=\"3\"><em>Staphylococcus aureus</em>, <em>S. epidermidis</em>, enteric gram-negative bacilli</td> <td>Cefazolin</td> <td> <p>&#60;120 kg: 2 g IV</p> &#8805;120 kg: 3 g IV</td> <td>4 hours</td> </tr> <tr> <td><strong>OR</strong> vancomycin<sup>&#916;</sup></td> <td>15 mg/kg IV (max 2 g)</td> <td>N/A</td> </tr> <tr> <td class=\"divider_bottom\"><strong>OR</strong> clindamycin</td> <td class=\"divider_bottom\">900 mg IV</td> <td class=\"divider_bottom\">6 hours</td> </tr> <tr> <td rowspan=\"3\">Lower extremity amputation for ischemia</td> <td rowspan=\"3\"><em>S. aureus</em>, <em>S. epidermidis</em>, enteric gram-negative bacilli, clostridia</td> <td>Cefazolin</td> <td> <p>&#60;120 kg: 2 g IV</p> &#8805;120 kg: 3 g IV</td> <td>4 hours</td> </tr> <tr> <td><strong>OR</strong> vancomycin<sup>&#916;</sup></td> <td>15 mg/kg IV (max 2 g)</td> <td>N/A</td> </tr> <tr> <td><strong>OR</strong> clindamycin</td> <td>900 mg IV</td> <td>6 hours</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous.<br />* Parenteral prophylactic antimicrobials can be given as a single IV dose begun within 60 minutes before the procedure. If vancomycin is used, the infusion should be started within 60 to 120 minutes before the initial incision to have adequate tissue levels at the time of incision and to minimize the possibility of an infusion reaction close to the time of induction of anesthesia.<br />Â¶ For prolonged procedures (&gt;3 hours) or those with major blood loss, or in patients with extensive burns, additional intraoperative doses should be given at intervals one to two times the half-life of the drug for the duration of the procedure in patients with normal renal function.<br />Î Use of vancomycin is appropriate in hospitals in which methicillin-resistant <EM>S. aureus</EM> (MRSA) and <EM>S. epidermidis</EM> are a frequent cause of postoperative wound infection, in patients previously colonized with methicillin-resistant <EM>S. aureus</EM>, or for those who are allergic to penicillins or cephalosporins. Rapid IV administration may cause hypotension, which could be especially dangerous during induction of anesthesia. Even when the drug is given over 60 minutes, hypotension may occur; treatment with diphenhydramine and further slowing of the infusion rate may be helpful. For procedures in which enteric gram-negative bacilli are common pathogens, many experts would add another drug such as an aminoglycoside (such as gentamicin 5 mg/kg IV), aztreonam (2 g), or a fluoroquinolone (such as ciprofloxacin 400 mg IV or levofloxacin 500 mg IV).</div><div class=\"graphic_reference\">Adapted from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Antimicrobial prophylaxis for surgery. Med Lett Drugs Ther 2016; 58:63.</LI>&#xD;&#xA;<LI>Bratzler DW, et al. Clinical guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt) 2013; 14:73.</LI></OL></div><div id=\"graphicVersion\">Graphic 87206 Version 10.0</div></div></div>"},"87207":{"type":"graphic_picture","displayName":"Old World CL due to L major","title":"Old World CL ulcers covered with typical eschar","html":"<div class=\"graphic\"><div style=\"width: 595px\" class=\"figure\"><div class=\"ttl\">Old World CL ulcers covered with typical eschar</div><div class=\"cntnt\"><img style=\"width:575px; height:425px;\" src=\"images/ID/87207_Old_wrld_cutns_lshmns_L_mjr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A previously healthy, 23-year-old soldier noted lesions on his neck two months after deployment near the Iraq-Iran border. He did not have fever, chills, or any systemic symptoms. A physical examination revealed five painless, mildly pruritic, indurated lesions on his neck that had raised borders and a central scale. There were two similar lesions on his right lower extremity. He had mildly tender posterior auricular adenopathy, but there were no other abnormal findings on physical examination.</div><div class=\"graphic_reference\">From: Polhemus ME, Aronson N, Weina P, et al. A US soldier who returned from Iraq with nonhealing sores. Clin Infect Dis 2004; 39:1008.</div><div id=\"graphicVersion\">Graphic 87207 Version 3.0</div></div></div>"},"87208":{"type":"graphic_picture","displayName":"Splinter hemorrhage","title":"Splinter hemorrhage","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Splinter hemorrhage</div><div class=\"cntnt\"><img style=\"width:710px; height:608px;\" src=\"images/NEURO/87208_Splinter_hemorrhage.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 87208 Version 1.0</div></div></div>"},"87209":{"type":"graphic_table","displayName":"Distinctive and overlapping symptoms of depression and anxiety","title":"Distinctive and overlapping symptoms of depression and anxiety","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distinctive and overlapping symptoms of depression and anxiety</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Symptoms specific to depression</td> <td class=\"subtitle1\">Symptoms common to anxiety and depression</td> <td class=\"subtitle1\">Symptoms specific to anxiety</td> </tr> <tr> <td>Depressed or hopeless</td> <td>Irritability</td> <td>Excessive worry</td> </tr> <tr> <td>Loss of interest</td> <td>Agitation/restlessness</td> <td>Autonomic hyperactivity</td> </tr> <tr> <td>Weight change</td> <td>Concentration difficulties</td> <td>Exaggerated startle response</td> </tr> <tr> <td>Poor appetite</td> <td>Insomnia</td> <td>Muscle tension</td> </tr> <tr> <td>Motor retardation</td> <td>Fatigue</td> <td>&nbsp;</td> </tr> <tr> <td>Guilt/worthlessness</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>Thoughts of death</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Kendall PC, Watson D. Anxiety and Depression: distinctive and overlapping features, Academic Press, San Diego, CA 1989. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87209 Version 1.0</div></div></div>"},"87210":{"type":"graphic_picture","displayName":"Sinclair scale for female pattern hair loss","title":"Sinclair scale for female pattern hair loss","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">Sinclair scale for female pattern hair loss</div><div class=\"cntnt\"><img style=\"width:460px; height:360px;\" src=\"images/DERM/87210_Snclr_scle_feml_ptn_hr_loss.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Sperling LC, Sinclair RD, Shabrawi-Caelen LE. Alopecias. In: Dermatology, 3rd ed, Bolognia JL, Jorizzo JL, Schaffer JV, et al (Eds), Saunders 2012. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87210 Version 2.0</div></div></div>"},"87211":{"type":"graphic_picture","displayName":"Bronchoscopic view of right bronchus intermedius","title":"Bronchoscopic view of right bronchus intermedius ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchoscopic view of right bronchus intermedius </div><div class=\"cntnt\"><img style=\"width:405px; height:198px;\" src=\"images/ANEST/87211_Bronchoviewrtbronch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Proximal view of right bronchus intermedius.<br />(B) Distal view right bronchus intermedius.<br />The longitudinal bundles lead into the&nbsp;RLL (lines at 6 o'clock in proximal view). The RLL has segmental bronchi immediately visible. The smaller RML bronchus does not have visible segmental bronchi. The RML-RLL carina is normally oriented at 3 to 9 o'clock. The superior segmental bronchus is seen within RLL at 5 to 6 o'clock.</div><div class=\"graphic_footnotes\">RLL: right lower lobe; RML: right middle lobe.</div><div id=\"graphicVersion\">Graphic 87211 Version 2.0</div></div></div>"},"87212":{"type":"graphic_picture","displayName":"Bronchoscopic view of left mainstem bronchus","title":"Bronchoscopic view of left mainstem bronchus ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchoscopic view of left mainstem bronchus </div><div class=\"cntnt\"><img style=\"width:186px; height:182px;\" src=\"images/ANEST/87212_Broncho_view_left_main.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left mainstem bronchus is long, with an average length of 5 cm. The bifurcation of left upper and lower lobes is not visible from the carina.</div><div class=\"graphic_footnotes\">LMB: left mainstem bronchus; RMB: right mainstem bronchus.</div><div id=\"graphicVersion\">Graphic 87212 Version 1.0</div></div></div>"},"87213":{"type":"graphic_picture","displayName":"Bronchoscopic view of left upper and left lower lobe bronchi","title":"Bronchoscopic view of left upper lobe and left lower lobe bronchi","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bronchoscopic view of left upper lobe and left lower lobe bronchi</div><div class=\"cntnt\"><img style=\"width:179px; height:178px;\" src=\"images/ANEST/87213_Broncho_view_left_upper.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The longitudinal elastic bundles run posteriorly into lower lobe (short lines). The LLL-LUL carina is angled in the 8 to 2 o'clock position (long line).</div><div class=\"graphic_footnotes\">LUL: left upper lobe; LLL: left lower lobe.</div><div id=\"graphicVersion\">Graphic 87213 Version 1.0</div></div></div>"},"87217":{"type":"graphic_table","displayName":"Guidelines cGVHD","title":"Guidelines for screening, prevention, and management of late complications in patients with oral cGVHD","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for screening, prevention, and management of late complications in patients with oral cGVHD</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Late complication</td> <td class=\"subtitle1\">Prevention</td> <td class=\"subtitle1\">Screening</td> <td class=\"subtitle1\">Management</td> </tr> <tr class=\"divider_bottom\"> <td>Oral squamous cell carcinoma</td> <td> <p>Smoking cessation</p> Moderate alcohol consumption</td> <td> <p>Annual clinical examination</p> Biopsy of atypical/suspicious lesions</td> <td>Referral to multidisciplinary head and neck oncology center</td> </tr> <tr class=\"divider_bottom\"> <td>Rampant dental caries</td> <td> <p>Minimize intake of refined carbohydrates (especially sugar-containing soft drinks)</p> <p>Brush at least twice daily, after eating when possible</p> <p>Floss daily</p> <p>Fluoride 1.1% gel paint on or in custom trays, daily</p> <p>Remineralizing agent, apply with fluoride</p> Professional fluoride varnish application</td> <td> <p>Increased risk in patients with significant salivary gland cGVHD</p> <p>Increased risk in patients with orofacial sclerotic cGVHD</p> <p>Increased risk in patients were severe mucosal disease and avoidance of oral hygiene</p> <p>Examine teeth for evidence of cervical demineralization/decay</p> Twice annual dental visits<br /> <ul> <li>Soft and hard tissue examination </li> <li>Bitewing radiographs (annual) </li> </ul> </td> <td> <p>Treat dental caries as soon as diagnosed</p> <p>Careful follow-up for new or recurrent caries</p> <p>Reinforce oral hygiene and dietary habits</p> Reinforce daily preventive measures</td> </tr> <tr class=\"divider_bottom\"> <td>Fibrosis</td> <td>No known preventive measures</td> <td> <p>Ask patient if aware of tightness/limited opening</p> <p>Extensive sclerotic skin disease, especially with neck involved</p> Examine for intraoral buccal fibrotic bands by palpation</td> <td> <p>Physical therapy</p> <p>Intralesional steroid therapy</p> <p>Surgery</p> Systemic therapy for systemic involvement</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">cGVHD: chronic graft versus host disease.</div><div class=\"graphic_reference\">This research was originally published in Blood. Treister N, Duncan C, Cutler C, Lehmann L. How we treat oral chronic graft-versus-host disease. Blood 2012; 120:3407. Copyright Â© 2012 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 87217 Version 2.0</div></div></div>"},"87218":{"type":"graphic_figure","displayName":"Primary closure off-midline for intergluteral pilonidal disease","title":"Primary closure off-midline for intergluteral pilonidal disease","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Primary closure off-midline for intergluteral pilonidal disease</div><div class=\"cntnt\"><img style=\"width:298px; height:262px;\" src=\"images/SURG/87218_Primary_closure_off-midline.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Following an excision of pilonidal disease, if a primary wound closure is performed, the optimal location of the incision is off-midline (lateral).</div><div id=\"graphicVersion\">Graphic 87218 Version 2.0</div></div></div>"},"87219":{"type":"graphic_diagnosticimage","displayName":"Femoral hernia on computed tomography","title":"Femoral hernia on computed tomography","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Femoral hernia on computed tomography</div><div class=\"cntnt\"><img style=\"width:463px; height:581px;\" src=\"images/RADIOL/87219_Femoral_hernia_on_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) scan through the femoral heads (A) shows a fat-filled localized mass (white arrow) lateral to the pubic tubercle (white arrowhead) associated with compression of the left femoral vein (white dashed arrow). These findings are consistent with a femoral hernia. The pear-shaped hernia sac is better appreciated in the coronal view (B), which is magnified in (C). There is no evidence of bowel obstruction.</div><div id=\"graphicVersion\">Graphic 87219 Version 1.0</div></div></div>"},"87220":{"type":"graphic_diagnosticimage","displayName":"Inguinal hernia on computed tomography","title":"Inguinal hernia on computed tomography","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Inguinal hernia on computed tomography</div><div class=\"cntnt\"><img style=\"width:599px; height:215px;\" src=\"images/RADIOL/87220_Inguin_hern_compu_tomo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography (CT) scan of through the femoral heads (A) shows a large hernia&nbsp;(arrowhead) medial to the pubic tubercle (arrow).&nbsp;In spite of the size of the hernia, there is no evidence for left femoral vein compression (dashed arrow), which helps to distinguish this inguinal hernia&nbsp;from a femoral hernia. The hernia is of sufficient volume to displace the base of the penis (short arrow, B). Fat (arrowhead) and small bowel (thick arrow) are present in the hernia sac (B). Artifact across the pelvis is caused by bilateral hip replacements.</div><div id=\"graphicVersion\">Graphic 87220 Version 1.0</div></div></div>"},"87221":{"type":"graphic_diagnosticimage","displayName":"Chest x-ray emphysema","title":"Chest x-ray emphysema","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Chest x-ray emphysema</div><div class=\"cntnt\"><img style=\"width:598px; height:414px;\" src=\"images/RADIOL/87221_Chest_xray_emphysema.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The posteroanterior (A) and lateral (B) chest x-rays of a 71-year-old female with emphysema show increased lung volumes with flattened hemidiaphragms on the lateral examination (arrow) and increase in the retrosternal space (arrowhead). The normal retrosternal airspace is less than 2.5 cm. A prominent pulmonary artery on the posteroanterior view (dashed arrow) reflects secondary pulmonary hypertension.</div><div id=\"graphicVersion\">Graphic 87221 Version 2.0</div></div></div>"},"87222":{"type":"graphic_diagnosticimage","displayName":"Grade IV GMH-IVH in preterm infant","title":"Grade IV germinal matrix hemorrhage-intraventricular hemorrhage in preterm infant","html":"<div class=\"graphic\"><div style=\"width: 785px\" class=\"figure\"><div class=\"ttl\">Grade IV germinal matrix hemorrhage-intraventricular hemorrhage in preterm infant</div><div class=\"cntnt\"><img style=\"width:765px; height:661px;\" src=\"images/RADIOL/87222_Gr4GMHIVHpreterminfant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cranial ultrasound images of a preterm infant, gestational age 26 weeks, with a left-sided periventricular hemorrhagic infarction (PVHI; arrows), also called grade IV germinal matrix hemorrhage-intraventricular hemorrhage. Coronal (A) and parasagittal (B) views. Magnetic resonance image, T2-weighted sequence at 30 weeks postmenstrual age, of the same infant, showing the left-sided PVHI with cystic evolution (arrows). Axial (C) and parasagittal (D) views.</div><div class=\"graphic_reference\"><EM>Courtesy of Linda S de Vries, MD, PhD and Lara M Leijser, MD, PhD, MSc. </EM></div><div id=\"graphicVersion\">Graphic 87222 Version 4.0</div></div></div>"},"87223":{"type":"graphic_diagnosticimage","displayName":"Images of posthemorrhagic hydrocephalus","title":"Ultrasound and MRI of posthemorrhagic hydrocephalus in a patient with grade IV IVH","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Ultrasound and MRI of posthemorrhagic hydrocephalus in a patient with grade IV IVH</div><div class=\"cntnt\"><img style=\"width:534px; height:597px;\" src=\"images/RADIOL/87223_Images_posthem_hydrocephal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Follow-up ultrasound and MRI performed six months after initial imaging demonstrated grade IV IVH in a preterm infant. Coronal (A) and sagittal&nbsp; (B) ultrasound images demonstrate marked hydrocephalus (arrow). In addition, IT2-weighted (C) and FLAIR (D) MRI demonstrates massively enlarged right lateral ventricle (short arrow) with near-complete absence of the right hemispheric white matter and relative sparing of right frontal lobe white matter (dashed arrow).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; IVH: intraventricular hemorrhage.</div><div class=\"graphic_reference\">Courtesy of Joseph Farnam, MD.</div><div id=\"graphicVersion\">Graphic 87223 Version 1.0</div></div></div>"},"87224":{"type":"graphic_picture","displayName":"Typical form episcleritis","title":"Episcleritis","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Episcleritis</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/PC/87224_Typical_form_episcleritis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical form with sectoral injection.</div><div class=\"graphic_reference\">Image created by Christopher J Rapuano, MD. Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87224 Version 3.0</div></div></div>"},"87225":{"type":"graphic_picture","displayName":"Corneal abrasion II","title":"Corneal abrasion","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Corneal abrasion</div><div class=\"cntnt\"><img style=\"width:540px; height:405px;\" src=\"images/PC/87225_Corneal_abrasion_II.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Corneal abrasion unmasked with use of fluorescein dye. Blue light will further enhance visualization of abraded region where exposed basement membrane picks up the dye. The dye has diffused under the edge of intact epithelium, making the boundary appear less distinct than it actually is.</div><div class=\"graphic_reference\">Image created by Christopher J Rapuano, MD. Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87225 Version 3.0</div></div></div>"},"87226":{"type":"graphic_picture","displayName":"Corneal foreign body","title":"Corneal foreign body","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Corneal foreign body</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/PC/87226_Corneal_foreign_body.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Corneal foreign body that has been present for several days, resulting in inflammatory reaction to iron in the foreign body and causing local haze and surface breakdown that picks up stain.</div><div class=\"graphic_reference\">Image created by Christopher J Rapuano, MD. Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87226 Version 3.0</div></div></div>"},"87227":{"type":"graphic_picture","displayName":"Bag mask technique for edentulous patient","title":"Bag mask technique for edentulous patient","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Bag mask technique for edentulous patient</div><div class=\"cntnt\"><img style=\"width:576px; height:384px;\" src=\"images/EM/87227_Bag_mask_tech_edentulous.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In edentulous adults, placing the caudad end of the mask between the lower lip and the alveolar ridge may improve ventilation.</div><div class=\"graphic_reference\">Courtesy of Kathleen Wittels, MD.</div><div id=\"graphicVersion\">Graphic 87227 Version 1.0</div></div></div>"},"87231":{"type":"graphic_algorithm","displayName":"Algorithm for HBV during pregnancy","title":"Algorithm for hepatitis B virus during pregnancy","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Algorithm for hepatitis B virus during pregnancy</div><div class=\"cntnt\"><img style=\"width:580px; height:432px;\" src=\"images/GAST/87231_Algo_HBV_pregnancy.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">Anti-HBc: hepatitis B core antibody; anti-HBe: hepatitis B e antibody; anti-HBs: hepatitis B surface antibody; HBeAg: hepatitis B e antigen; HBIG: hepatitis B immune globulin; HBsAg: hepatitis B surface antigen; HBV: hepatitis B virus.<br />* Check anti-HBs and anti-HBc if mother is at high risk for HBV infection (eg, injection drug user, sexual partner or household contact has chronic HBV). Mothers with no evidence of prior HBV infection (ie, negative for HBsAg, anti-HBs, and anti-HBc ) should be vaccinated.<br />Â¶ Women who have a high HBV DNA (&gt;200,000 int. units/mL), elevated aminotransferase levels, and/or a positive HBeAg should be referred to a hepatologist to see if early initiation of antiviral medications is needed.<br />Î Start at 28 to 30 weeks gestation. We prefer<SPAN style=\"COLOR: black\">&nbsp;tenofovir disoproxil fumarate </SPAN>rather than other antiviral agents. Refer to the topic on Hepatitis B and pregnancy for a more detailed discussion of treatment.<br /><FONT class=lozenge>â</FONT> For those who continue antiviral therapy after delivery, the pros and cons of breastfeeding must be discussed with the mother. Refer to the topic on Hepatitis B and pregnancy for more detailed discussions of breastfeeding.</div><div id=\"graphicVersion\">Graphic 87231 Version 7.0</div></div></div>"},"87241":{"type":"graphic_table","displayName":"Motivational interviewing technique - Engaging","title":"Motivational interviewing technique - Engaging","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Motivational interviewing technique - Engaging</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Non-motivational interviewing (MI) approach: Engaging</td> </tr> <tr> <td>The first vignette illustrates a routine clinic visit that is unlikely to lead to change, or worse, may further demoralize the patient. MI-inconsistent techniques are identified following the physician's statements.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> Hi Mrs. X, glad to see you today. How are you feeling?</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Well, my asthma is acting up again. I might need a different medicine.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> Are you still smoking? (Closed question)</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Yes, but I'm cutting back.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>Doctor:</strong> You know that smoking aggravates your asthma and puts you at higher risk for other problems. (Providing information, overlooking change talk)</p> What have you tried to help you quit smoking? (Open question, possible premature focus)</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Oh, everything. It's so hard to quit.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> Well, I can write a prescription for one of the newer medications to help you quit. It's quite effective. (Providing information, likely premature focus)</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Well, okay&hellip;</td> </tr> <tr> <td>In above vignette, the doctor rushes to a premature solution, and misses opportunities to elicit the patient's strengths and knowledge. By bypassing the processes of collaborative agenda setting and gathering more context for the patient's symptoms, the doctor fails to elicit or build the patient's motivation to change.</td> </tr> <tr> <td class=\"subtitle1_single\">Motivational interviewing (MI) approach: Engaging</td> </tr> <tr> <td>Compare the standard approach above to the following MI approach. MI-consistent techniques are identified following the physician's statements.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> Hi there Mrs. X, glad to see you today. How are you feeling?</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Well, my asthma is acting up again. I might need a different medicine.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>Doctor:</strong> You're thinking maybe a new medication would help. (Reflection) Let's put that on the list of possibilities. (Avoiding premature focus, agenda setting) First, let me listen to your breathing. Okay, I hear the trouble you're having. (Providing information)</p> <p>I'd like to spend about five minutes talking about your asthma broadly, before we decide together on the best approach to manage it. (Agenda setting, collaborative spirit)</p> How does that sound? (Open question)</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> OK, that sounds good.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> Tell me what concerns you most about your asthma. (Open question)</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Well, it's really scary when I have an attack. I'm afraid I could die from this. But even on a regular day, I have less energy, and I feel older, due to it.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> So attacks make you worry you might die, and they are truly scary. (Reflection) But even on a daily basis, your life is diminished due to the asthma. (Complex reflection)</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Exactly. It's such a handicap! I wish I could get rid of it.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> I bet you've thought about how you could lessen your symptoms and reduce the impact of asthma on your life. (Affirmation)</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Yes, I have. I think the first thing I should do is quit smoking.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> You're clearly aware that smoking is making things worse, and you think you should quit. (Reflection)</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Yes, and I've already cut way back. I don't smoke in the house or car anymore, and I'm down to half a pack, where I was smoking a pack a day.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> You've already made a serious dent in the number of cigarettes per day. (Affirmation, reflection) How has that gone for you? (Open question)</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Well, I made up my mind, and am keeping track of my smoking. I have a chart and I check off when I have a cigarette, and I stretch out the time between them.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> You're really taking it seriously. (Affirmation) You're already doing some of the things that experts recommend to make quitting work for you. (Providing information) What else have you thought about trying? (Open question)</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Well, I heard there were some new medicines to help you quit. But I figured I have to be more ready. Can you tell me about the newer options?</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> You're not sure you're totally ready. (Reflection) I hear a lot of commitment from you in what you're already doing. (Reflection) Maybe considering a medication might be a next step to help you be even more ready. (Providing information) I'd be happy to review some of the information about the new medicines&hellip; (Providing information) &hellip;and then we can talk further about what the best next steps are for you.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 87241 Version 1.0</div></div></div>"},"87242":{"type":"graphic_picture","displayName":"Rectal adenoma","title":"Adenoma in the rectum","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Adenoma in the rectum</div><div class=\"cntnt\"><img style=\"width:516px; height:409px;\" src=\"images/GAST/87242_Rectal_adenoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Adenoma in the rectum shown with the colonoscope in retroflexion. The right margins of the adenoma are well demarcated using high-definition white-light endoscopy (arrowheads).<BR>(B) The same polyp seen using blue light (narrow band imaging). The use of blue light enhances differences between polyp and normal mucosa.<BR>(C) Following endoscopic resection, a clean resection margin is seen using high-definition white-light endoscopy. A hemostatic clip (arrow) was placed on a visible non-bleeding vessel.</div><div id=\"graphicVersion\">Graphic 87242 Version 1.0</div></div></div>"},"87243":{"type":"graphic_table","displayName":"Motivational interviewing technique - Focusing","title":"Motivational interviewing technique - Focusing","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Motivational interviewing technique - Focusing</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Non-motivational interview (MI) approach: Focusing</td> </tr> <tr> <td>In the first vignette, a doctor uses a standard checklist approach to review issues with a cardiac rehabilitation patient. MI-inconsistent techniques are identified following the physician's statements.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> Hi Mr. Y, I'm Doctor A. It's nice to meet you. I have your chart here. I see you've had a rough time of it lately.</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Yes, I never thought I'd have a heart attack. Now the nurses have me half scared to death that I'll have another one if I don't change my life completely.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> Well, it's their job to give you the information you need. (Ignoring patient emotions) So my job is to review how you're doing in a number of areas, and to set some goals for you to keep your heart as healthy as possible. (Providing information)</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Okay.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> So for most people, the big areas are, first, cholesterol and lipids, which are related to diet, exercise, genetics, and medicines, and second, personal habits like smoking, drinking, being too sedentary or too stressed. (Providing information) Let's go through the list and see what you might do to improve your heart health. (Non-collaborative agenda setting)</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Okay.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> I see you're a non-smoker, so that's great - one less thing to worry about! (Providing information)</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Yes, and I don't drink much either. But I do have a lot of stress.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> So, how much are you drinking, typically? (Ignoring opportunity to reflect on drinking or stress)</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Oh, a few beers a week. Maybe wine with dinner out once a week.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> So when you say a few, how many per night do you mean? (Closed question)</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Well, probably three or four beers a night on work nights to relax. I have put on weight - now I have this beer gut - as I've gotten older and work at a desk job all day.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> So, are you thinking about cutting down on your beer, and getting rid of that beer gut with some exercise? (Closed question) You're drinking more than the limit for a healthy man. (Providing information) And one of the best things for your heart is brisk walking 45 to 60 minutes a day, four to five times a week. (Providing information) You probably should substitute walking for drinking those beers! (Providing advice without permission)</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Well, I could walk my dog each afternoon, but I really like the beer to unwind after work.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> That sounds great - healthy for you and your dog! I have some brochures here about steps to take to cut down your drinking. (Providing information) Take these home, read them over, and then when you come back you can tell me how you did! (Providing advice without permission)</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Well, okay...</td> </tr> <tr> <td>This conversation, rather than helping the patient focus on a realistic, achievable, and meaningful change, is likely to result in him leaving less internally motivated, and more helpless to make a long list of changes. The doctor overlooks the opportunity to reflect the patient's perspective, and misses the life context that can serve as a facilitator of, or a barrier to, healthy change.</td> </tr> <tr> <td class=\"subtitle1_single\">Motivational interviewing (MI) approach: Focusing</td> </tr> <tr> <td>In contrast, let's review an MI-consistent conversation during the process of focusing.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> Hi Mr. Y, I'm Doctor A. It's nice to meet you. I have your chart here. I see you've had a rough time of it lately.</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Yes, I never thought I'd have a heart attack. Now the nurses have me half scared to death that I'll have another one if I don't change my life completely.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> It's been a frightening experience in many ways. (Reflection) It seems like you have to change your whole life immediately, or risk another attack. (Complex reflection) I'm really glad you're here today. (Affirmation) While I know a lot about the heart, your rehabilitation after a heart attack isn't just up to me. It's a team effort. You are the expert on you, and what's realistic for you. (Providing information, inviting collaboration) I see my job right now as guiding you through a number of areas, to select one or two you are most ready to adjust, not to push you to make changes all at once. (Providing information, agenda setting) We'll figure out together where you're likely to get the most gain, and which other areas can be set aside for now. (Providing information, agenda setting) Together, we can figure out some small, achievable changes that will help you to keep your heart as healthy as possible. (Providing information)</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Okay - wow, that's a relief. It sounds like I might be able to make some small adjustments that will help, rather than overhauling everything right away.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> That's right. (Affirmation) Changes you can make, that you can live with, are more likely to stick. (Providing information) What areas are you thinking about changing? (Open question)</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Well, clearly I need to lose some weight, and get rid of my beer gut.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> Tell me about your exercise and drinking habits up until now. (Open question)</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Well, I don't get much exercise. I'm penned up in an office most of the time, and when I'm stressed, I like to unwind with a few beers.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> It's been hard for you to be active. (Reflection) Your job makes you feel a bit penned in. (Reflection) And when you're stressed, it's relaxes you to have a few beers. (Reflection)</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Right. But I have been thinking about what the nurses told me, to walk more, and even across the day. So I'm considering how to walk more frequently, but I'm not really wanting to cut out my beer completely.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> You really have been giving this a lot of thought. (Affirmation) You're right, some exercise changes could get you a lot of benefit, heart-wise. (Providing information) You're thinking about how to incorporate more walking, and also considering whether to do anything about your beer intake, but you're not sure about that one yet. (Reflection) Tell me a little more about how beer fits in your day. (Open question)</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Well, when I get home, I'm pretty tense. I like to have a beer or two before dinner. Then we usually have wine with dinner, but just a glass of red wine, good for the heart, you know? Maybe later I'll have one or two more beers, but not every day.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> So beer before dinner, one or two to relax, then a glass of red wine with dinner, and sometimes a couple of beers later on. So maybe between three and five drinks each day.</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Well, and on the weekends, sometimes more, if I go fishing or to the races. Maybe two six-packs on those weekend days.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> Beer is a part of your routine for relaxing and also for your social and recreational time.</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Yeah, I guess so, and thinking about it now, I must be drinking about 36 beers a week. That seems like a lot, now that we are talking about it. No wonder I got this beer gut.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> You're adding it up, and it's more than you realized. It might account for putting on that weight in the middle. (Complex reflection) What do you make of this, now that we're talking about it? (Open question)</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Well, I think I should cut back. I'd like to lose this extra weight, and find some other way to deal with my stress. I'm not sure what to do though, instead of enjoying a beer.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> You're making a commitment to get healthy, and now you're considering how to get there. (Reflection)</td> </tr> <tr> <td class=\"indent1\"><strong>Patient:</strong> Yeah. So I'm interested in your thoughts about how to get started.</td> </tr> <tr> <td class=\"indent1\"><strong>Doctor:</strong> Okay, so we'll work together to create a plan that can work for you. (Collaborative spirit, conveying optimism, providing information)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 87243 Version 1.0</div></div></div>"},"87244":{"type":"graphic_table","displayName":"Motivational interviewing technique - Evoking","title":"Motivational interviewing technique - Evoking","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Motivational interviewing technique - Evoking</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>Doctor:</strong> You've identified drinking as something you'd like to consider changing. I'd like to understand more about how you view your drinking. On a scale of 0 to 10, with 0 being not at all important, and 10 being extremely important, how important is it for you to change your drinking now? (Open questions using scaling ruler strategy)</td> </tr> <tr> <td><strong>Patient:</strong> Well, like I said, I really want to get rid of this beer gut, even though I enjoy my beer. So I'd say it's an 8 out of 10.</td> </tr> <tr> <td><strong>Doctor:</strong> You want to be trimmer and healthier, but you do like the relaxing times you spend drinking beer. (Reflection) You're giving it a pretty high level of importance, an 8. (Reflection) What makes it an 8 and not a 0? (Open evocative question)</td> </tr> <tr> <td><strong>Patient:</strong> Well, several reasons. First, I'm seeing now that I'm drinking way more than I realized. Six six-packs a week is a lot. I should be drinking less than half of that. I'd save money, and probably shed some of this excess weight. Plus, my wife has been nagging me about it, and she'd probably be happy to see me cut back.</td> </tr> <tr> <td><strong>Doctor:</strong> So for several reasons, it's really important: to drink less overall, save some money, drop a few pounds, and please your wife. (Reflection) What else? (Open question)</td> </tr> <tr> <td><strong>Patient:</strong> Well the biggest thing is my fear of another heart attack. The nurses told me that really only very moderate drinking is healthy. They were focusing on one glass of red wine only. So if I can drop a lot of the beer, maybe I can reduce the risk of having another heart attack.</td> </tr> <tr> <td><strong>Doctor:</strong> It's really important for you to get that heart attack risk down. (Reflection) And for that, you're willing to make some sacrifices. (Complex reflection)</td> </tr> <tr> <td><strong>Patient:</strong> I am. It's time to get serious.</td> </tr> <tr> <td><strong>Doctor:</strong> What's the next step? (Open evocative question)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 87244 Version 1.0</div></div></div>"},"87245":{"type":"graphic_table","displayName":"Motivational interviewing technique - Planning","title":"Motivational interviewing technique - Planning","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Motivational interviewing technique - Planning</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>Doctor:</strong> So Susan, it sounds like you're really ready to stop smoking weed every day. You've noticed that your concentration and memory are not as good as they were, and you're tired of feeling too zoned out to shop for groceries, help with your kids' homework, and keep up with your job schedule. You've always liked the feeling of being high, but now you're wanting to set a good example for your kids, and \"being high through life\", as you put it, doesn't really fit with that. (Summary of previous conversation)</td> </tr> <tr> <td><strong>Patient:</strong> Exactly. That's exactly how I feel. I'm ready to do it, but I know I have to think it through - it would be hard to just go cold turkey.</td> </tr> <tr> <td><strong>Doctor:</strong> We talked before about how you used to use other drugs, but you quit. (Reflection) You were successful in stopping your cocaine use, and it's been over 5 years since you used, and you're glad about that. (Affirmation) Tell me more about how you were able to do that, and what parts of that change might be relevant now, as you consider quitting smoking weed? (Open question)</td> </tr> <tr> <td><strong>Patient:</strong> Crack is different than weed; it takes over your life, and makes you act different. I could tell that if I didn't stop, it would not take me anywhere I wanted to go.</td> </tr> <tr> <td><strong>Doctor:</strong> So with crack, you looked ahead, and didn't like what you saw if you kept using. Maybe looking ahead with weed would be helpful. If you do the same thing, look ahead, imagine that you keep smoking weed daily like you are now, what do you see?</td> </tr> <tr> <td><strong>Patient:</strong> Probably nothing much. I'd continue to make mistakes, small stuff, but every day, like missing my shifts at work. I might even get fired, because they're starting a drug testing program. I might not be the best mom, because I'm too zoned out to really pay attention like my children need me to. Most of all, I'd feel like I'd wasted years, literally. I don't like that future much.</td> </tr> <tr> <td><strong>Doctor:</strong> So looking ahead with smoking weed, you see a future that looks a lot like having more of the same kinds of problems as you have now, and worse, you'd feel bad about yourself, like you'd been less than you could have been. (Complex reflection)</td> </tr> <tr> <td><strong>Patient:</strong> Yeah, but I don't seem to be able to smoke just a little. I think what I'm getting to realize is that I probably need to quit smoking altogether, to have the kind of life I want.</td> </tr> <tr> <td><strong>Doctor:</strong> So while part of you would like to find a way to smoke weed sometimes, another part thinks you need to give it up entirely. (Complex reflection)</td> </tr> <tr> <td><strong>Patient:</strong> Yes. I want to quit completely. I want to clean it out of my system. It's next month that work starts drug testing, and I've heard it takes a month to clean it out of you.</td> </tr> <tr> <td><strong>Doctor:</strong> That's about right, depending on your weight, body composition, and a few other things. (Affirmation, providing information) So you'd like to start right away, and clean the marijuana out of your system. (Reflection)</td> </tr> <tr> <td><strong>Patient:</strong> Yes, and that should work because I'm down to about one joint's worth left. I need to tell my friend that I'm not ordering any more.</td> </tr> <tr> <td><strong>Doctor:</strong> So a first step is to not replace it when you run out, which will be soon. (Reflection)</td> </tr> <tr> <td><strong>Patient:</strong> Yeah, like tomorrow.</td> </tr> <tr> <td><strong>Doctor:</strong> Tell me more about how you'll quit and stay quit. (Open question)</td> </tr> <tr> <td><strong>Patient:</strong> Well, I already told my husband I'm going to do this. Also, I talked about it with some of my close friends who usually smoke it with me. They all understand, and they're planning not to offer it to me. But even if they do, I will say, no thanks. But at first, I probably need to hang out with them in other ways, like going out to movies or out to eat, rather than just hang at each other's houses.</td> </tr> <tr> <td><strong>Doctor:</strong> You've given this a lot of thought, and you've already taken important steps - letting people know what you're doing it, asking for their help, and planning what you'll do if it's offered. (Affirmation)</td> </tr> <tr> <td><strong>Patient:</strong> Yes I have. I think I'm ready.</td> </tr> <tr> <td><strong>Doctor:</strong> How confident are you, on a scale of 0 to 10, that you can quit smoking weed now? (Open question using scaling ruler strategy)</td> </tr> <tr> <td><strong>Patient:</strong> I'm a 9. I think I'm ready, and I have a plan.</td> </tr> <tr> <td><strong>Doctor:</strong> What makes it a 9 and not a 0?</td> </tr> <tr> <td><strong>Patient:</strong> Like we talked about, I was able to quit using crack cocaine. I saw how it was going to ruin my life, and I said no way. It's the same with weed. I can see a bad path there, and I am ready to start a new phase of my life. I think I have enough support, and now it's time to start.</td> </tr> <tr> <td><strong>Doctor:</strong> You're committed. You're ready. I'm here to help in any way you need. I'm looking forward to hearing how it goes, next time you come in. Good luck!</td> </tr> <tr> <td><strong>Patient:</strong> Thanks - I'll call you if I need anything.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 87245 Version 1.0</div></div></div>"},"87246":{"type":"graphic_picture","displayName":"Colon polyp piecemeal excision","title":"Colon adenoma removed with piecemeal excision","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Colon adenoma removed with piecemeal excision</div><div class=\"cntnt\"><img style=\"width:515px; height:407px;\" src=\"images/GAST/87246_Colon_polyp_pieceml_ex.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Colon adenoma seen in blue light (narrow band imaging). The use of blue light enhances differences between polyp and normal mucosa.<br />(B) After piecemeal resection, small areas of possible remnant tissue can be seen (arrows).<br />(C) Endoscopic image following selective treatment of residual tissue with argon plasma coagulation.</div><div id=\"graphicVersion\">Graphic 87246 Version 1.0</div></div></div>"},"87247":{"type":"graphic_figure","displayName":"T-tube drainage after common bile duct exploration","title":"T-tube drainage after common bile duct exploration","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">T-tube drainage after common bile duct exploration</div><div class=\"cntnt\"><img style=\"width:460px; height:633px;\" src=\"images/SURG/87247_T-tube drainage.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 87247 Version 1.0</div></div></div>"},"87248":{"type":"graphic_picture","displayName":"Dorsal diabetic foot wound","title":"Dorsal diabetic foot wound","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">Dorsal diabetic foot wound</div><div class=\"cntnt\"><img style=\"width:567px; height:756px;\" src=\"images/SURG/87248_Dorsal_diabetic_foot_wound.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dorsal diabetic foot wound following debridement of necrotizing streptococcal infection with exposed tendon and joint capsule.</div><div id=\"graphicVersion\">Graphic 87248 Version 1.0</div></div></div>"},"87250":{"type":"graphic_diagnosticimage","displayName":"Radiograph nondisplaced talar neck fracture","title":"Radiograph of nondisplaced talar neck fracture","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Radiograph of nondisplaced talar neck fracture</div><div class=\"cntnt\"><img style=\"width:598px; height:339px;\" src=\"images/RADIOL/87250_Xray_talus_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A lateral (A) and magnified lateral (B) view of the foot&nbsp;reveal a nondisplaced fracture (arrow) through the neck of the talus (Hawkins type I). To determine the full extent of this fracture, CT imaging is necessary.</div><div class=\"graphic_reference\">Courtesy of Gregory Waryasz, MD.</div><div id=\"graphicVersion\">Graphic 87250 Version 6.0</div></div></div>"},"87251":{"type":"graphic_diagnosticimage","displayName":"CT talar neck and body fractures","title":"CT of talar neck and body fractures","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">CT of talar neck and body fractures</div><div class=\"cntnt\"><img style=\"width:597px; height:336px;\" src=\"images/RADIOL/87251_CT_talus_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CT images using sagittal (A) and coronal (B) reconstructions show a fracture through the neck of the talus (arrowhead) with a comminuted component through the medial, posterior, and inferior aspects of the body of the talus, affecting the posterior calcaneal articulating surface (dashed arrow). A transverse fracture of the distal fibula is also present (arrow). The fracture components are in near anatomic alignment.&nbsp;Surgical referral is indicated because there are multiple fractures and an increased risk of complications.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Gregory Waryasz, MD.</div><div id=\"graphicVersion\">Graphic 87251 Version 4.0</div></div></div>"},"87252":{"type":"graphic_diagnosticimage","displayName":"Type II talar neck fracture","title":"Type II talar neck fracture","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Type II talar neck fracture</div><div class=\"cntnt\"><img style=\"width:540px; height:512px;\" src=\"images/RADIOL/87252_Type_II_talar_neck_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The magnified view of the foot in the lateral projection reveals a displaced fracture (arrow) through the neck of the talus (Hawkins type II).</div><div class=\"graphic_reference\">Reproduced with permission from: Bucholz RW, Heckman JD. Rockwood &amp; Green's Fractures in Adults, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87252 Version 2.0</div></div></div>"},"87253":{"type":"graphic_diagnosticimage","displayName":"Type IV talar neck fracture","title":"Type IV talar neck fracture","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Type IV talar neck fracture</div><div class=\"cntnt\"><img style=\"width:576px; height:478px;\" src=\"images/RADIOL/87253_Type_IV_talar_neck_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A displaced&nbsp;talar neck fracture (arrow)&nbsp;is depicted in this radiograph&nbsp;(Type IV talar neck fracture). Note in addition the displacement of the talar body with subluxation of the subtalar joint. The talonavicular joint is also dislocated.</div><div class=\"graphic_reference\">Reproduced with permission from: Bucholz RW, Heckman JD. Rockwood &amp; Green's Fractures in Adults, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87253 Version 2.0</div></div></div>"},"87254":{"type":"graphic_diagnosticimage","displayName":"Radiograph and CT lateral process talus fracture","title":"Radiograph and CT lateral process talus fracture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiograph and CT lateral process talus fracture</div><div class=\"cntnt\"><img style=\"width:362px; height:598px;\" src=\"images/RADIOL/87254_Xray_CT_lat_proces_talus_fx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiograph and CT scan of the left ankle of an 85-year-old female following a fall. The radiograph is shown in the AP projection and reveals an obvious fracture of the distal tibia (A, arrow) and a more subtle fracture of the lateral process of the talus magnified in B (arrowhead). The CT is shown in a reconstructed coronal projection (C) and in axial projection (D). The images confirm the fracture of the distal tibia (arrows) and the more subtle fracture of the lateral process of the talus (arrowheads).</div><div class=\"graphic_footnotes\">CT: computed tomography; AP: anterior posterior.</div><div class=\"graphic_reference\">Courtesy of Gregory Waryasz, MD.</div><div id=\"graphicVersion\">Graphic 87254 Version 3.0</div></div></div>"},"87255":{"type":"graphic_diagnosticimage","displayName":"Radiograph talar posterior process (lateral tubercle) fracture","title":"RadiographÂ of talar posterior process (lateral tubercle) fractureÂ ","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Radiograph&nbsp;of talar posterior process (lateral tubercle) fracture&nbsp;</div><div class=\"cntnt\"><img style=\"width:576px; height:492px;\" src=\"images/RADIOL/87255_Xray_frac_lat_tub_post_pro.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral radiograph of the ankle showing an acute fracture of the lateral tubercle of the posterior process of the talus (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Bucholz RW, Heckman JD. Rockwood &amp; Green's Fractures in Adults, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87255 Version 3.0</div></div></div>"},"87256":{"type":"graphic_diagnosticimage","displayName":"Radiograph talar posterior process (medial tubercle) fracture","title":"RadiographÂ of talarÂ posterior processÂ (medial tubercle)Â fracture","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Radiograph&nbsp;of talar&nbsp;posterior process&nbsp;(medial tubercle)&nbsp;fracture</div><div class=\"cntnt\"><img style=\"width:595px; height:403px;\" src=\"images/RADIOL/87256_Xray_frac_med_tuber_talus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anterior posterior (A) and lateral (B) radiographs of an acute fracture of the medial tubercle of the posterior process of the talus. The arrows identify the fracture line.</div><div class=\"graphic_reference\">Reproduced with permission from: Bucholz RW, Heckman JD. Rockwood &amp; Green's Fractures in Adults, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87256 Version 5.0</div></div></div>"},"87257":{"type":"graphic_diagnosticimage","displayName":"CT of fracture of the medial process of the talus","title":"CT of fracture of the medial process of the talus","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">CT of fracture of the medial process of the talus</div><div class=\"cntnt\"><img style=\"width:598px; height:328px;\" src=\"images/RADIOL/87257_CT_fracture_medial_talus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal computed tomography (CT) scan (A) and CT reconstruction (B) demonstrating a&nbsp;medial process fracture of the talus.</div><div class=\"graphic_reference\">Reproduced with permission from: Bucholz RW, Heckman JD. Rockwood &amp; Green's Fractures in Adults, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87257 Version 1.0</div></div></div>"},"87258":{"type":"graphic_diagnosticimage","displayName":"X-ray hamstring avulsion fracture of the ischial tuberosity","title":"X-ray hamstring avulsion fracture of the ischial tuberosity","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">X-ray hamstring avulsion fracture of the ischial tuberosity</div><div class=\"cntnt\"><img style=\"width:576px; height:454px;\" src=\"images/RADIOL/87258_Xray_avul_frac_ischial_tub.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An AP radiograph of the pelvis of the left hip demonstrates an avulsion fracture of the left ischial tuberosity (arrow). A well corticated bone fragment is seen (arrowhead) adjacent to the left femoral neck presumably relating to a chronic hamstring complex avulsion.</div><div class=\"graphic_reference\">Courtesy of Joseph Farnam, MD.</div><div id=\"graphicVersion\">Graphic 87258 Version 1.0</div></div></div>"},"87259":{"type":"graphic_diagnosticimage","displayName":"MRI hamstring avulsion fracture ischial tuberosity","title":"MRI hamstring avulsion fracture ischial tuberosity","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">MRI hamstring avulsion fracture ischial tuberosity</div><div class=\"cntnt\"><img style=\"width:598px; height:292px;\" src=\"images/RADIOL/87259_MRI_avul_frac_ischial_tuber.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left hip MRI demonstrates a focal cortical defect of the left ischial tuberosity with margins of the defect demonstrating low signal on T1-weighted coronal (arrow in image A), and T2-weighted coronal sequence (image B).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Joseph Farnam, MD.</div><div id=\"graphicVersion\">Graphic 87259 Version 2.0</div></div></div>"},"87260":{"type":"graphic_diagnosticimage","displayName":"CT avulsion fracture ischial tuberosity","title":"CT avulsion fracture ischial tuberosity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">CT avulsion fracture ischial tuberosity</div><div class=\"cntnt\"><img style=\"width:414px; height:611px;\" src=\"images/RADIOL/87260_CT_avul_frac_ischial_tuber.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan in axial projection (A) and the coronally reformatted image (B) reveals a focal defect in the ischial tuberosity (arrow)&nbsp;with surrounding sclerosis indicating a chronic injury.</div><div class=\"graphic_reference\">Courtesy of Joseph Farnam, MD.</div><div id=\"graphicVersion\">Graphic 87260 Version 1.0</div></div></div>"},"87261":{"type":"graphic_table","displayName":"Selection of double lumen tube size based on sex and height","title":"Selection of double lumen tube size based on sex and height","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selection of double lumen tube size based on sex and height</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Sex</td> <td class=\"subtitle1\">Height (cm)</td> <td class=\"subtitle1\">DLT size (Fr)</td> </tr> <tr> <td rowspan=\"3\">Male</td> <td class=\"centered\">&#62;170</td> <td class=\"centered\">41</td> </tr> <tr> <td class=\"centered\">160-170</td> <td class=\"centered\">39</td> </tr> <tr> <td class=\"centered\">&#60;160</td> <td class=\"centered\">37 or 39</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Female</td> <td class=\"centered\">&#62;160</td> <td class=\"centered\">37</td> </tr> <tr> <td class=\"centered\">150-160</td> <td class=\"centered\">35</td> </tr> <tr> <td class=\"centered\">&#60;160</td> <td class=\"centered\">32 or 35</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DLT: double lumen tube; Fr: french.</div><div id=\"graphicVersion\">Graphic 87261 Version 2.0</div></div></div>"},"87262":{"type":"graphic_table","displayName":"Selection of double lumen tube size based on bronchial diameter","title":"Selection of double lumen tube size based on bronchial diameter","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selection of double lumen tube size based on bronchial diameter</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Measured bronchial diameter (mm)</td> <td class=\"subtitle1\" rowspan=\"2\">DLT size (Fr)</td> <td class=\"subtitle1\" colspan=\"4\">Left bronchial lumen outer diameters from four manufacturers (mm)</td> </tr> <tr> <td class=\"subtitle2\">Mallinckrodt<br /> (St. Louis, MO)</td> <td class=\"subtitle2\">Rusch<br /> (Duluth, GA)</td> <td class=\"subtitle2\">Sheridan<br /> (Argyle, NY)</td> <td class=\"subtitle2\">Portex<br /> (Keene, NH)</td> </tr> <tr> <td class=\"centered\">&#8805;12</td> <td class=\"centered\">41</td> <td class=\"centered\">10.6</td> <td class=\"centered\">11.5</td> <td class=\"centered\">10.7</td> <td class=\"centered\">12.0</td> </tr> <tr> <td class=\"centered\">12</td> <td class=\"centered\">39</td> <td class=\"centered\">10.1</td> <td class=\"centered\">10.8</td> <td class=\"centered\">9.9</td> <td class=\"centered\">11.2</td> </tr> <tr> <td class=\"centered\">11</td> <td class=\"centered\">37</td> <td class=\"centered\">10.0</td> <td class=\"centered\">10.1</td> <td class=\"centered\">9.9</td> <td class=\"centered\">10.2</td> </tr> <tr> <td class=\"centered\">10</td> <td class=\"centered\">35</td> <td class=\"centered\">9.5</td> <td class=\"centered\">9.4</td> <td class=\"centered\">9.3</td> <td class=\"centered\">9.7</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Based on measured bronchial diameter.</div><div class=\"graphic_footnotes\">DLT: double lumen tube; Fr: french.</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Benumof JL, Partridge BL, Salvatierra C, Keating J. Margin of safety in positioning modern double-lumen endotracheal tubes. Anesthesiology 1987; 67:729.</LI>&#xD;&#xA;<LI>Hannallah MS, Benumof JL, Ruttimann UE. The relationship between left mainstem bronchial diameter and patient size. J Cardiothorac Vasc Anesth 1995; 9:119.</LI>&#xD;&#xA;<LI>Campos JH. Lung separation techniques. In: Thoracic Anesthesia, 3rd ed, Kaplan AH, Slinger PD (Eds), Elsevier Science, Philadelphia 2003. p.159.</LI></OL></div><div id=\"graphicVersion\">Graphic 87262 Version 2.0</div></div></div>"},"87263":{"type":"graphic_algorithm","displayName":"Confirming left double-lumen tube placement by auscultation","title":"Confirming left double-lumen tube placement by auscultation","html":"<div class=\"graphic\"><div style=\"width: 543px\" class=\"figure\"><div class=\"ttl\">Confirming left double-lumen tube placement by auscultation</div><div class=\"cntnt\"><img style=\"width:523px; height:711px;\" src=\"images/ANEST/87263_Confleftdoublumauscult.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">LMS: left main stem; RMS: right main stem; DLT: double-lumen tube.</div><div id=\"graphicVersion\">Graphic 87263 Version 3.0</div></div></div>"},"87264":{"type":"graphic_table","displayName":"Characteristics of bronchial blockers","title":"Characteristics of bronchial blockers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of bronchial blockers</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Cohen blocker</td> <td class=\"subtitle1\">Arndt blocker</td> <td class=\"subtitle1\">Fuji uniblocker</td> <td class=\"subtitle1\">EZ blocker</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Size</strong></td> <td class=\"centered\">9 Fr</td> <td class=\"centered\">5 Fr, 7 Fr, and 9 Fr</td> <td class=\"centered\">9 Fr</td> <td class=\"centered\">7 Fr</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Balloon shape</strong></td> <td class=\"centered\">Spherical</td> <td class=\"centered\">Spherical or elliptical</td> <td class=\"centered\">Spherical</td> <td class=\"centered\">Spherical</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Guidance mechanism</strong></td> <td class=\"centered\">Wheel device to deflect the tip</td> <td class=\"centered\">Nylon wire loop that is coupled with the fiberoptic bronchoscope</td> <td class=\"centered\">None, preshaped tip</td> <td class=\"centered\">None, \"Y\"-shaped tip</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Smallest recommended ETT for coaxial use</strong></td> <td class=\"centered\">9 Fr (8.0 ETT)</td> <td class=\"centered\">5 Fr (4.5 ETT), 7 Fr (7.0 ETT), 9 Fr (8.0 ETT)</td> <td class=\"centered\">9 Fr (8.0 ETT)</td> <td class=\"centered\">8.0 ETT</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Murphy eye</strong></td> <td class=\"centered\">Present</td> <td class=\"centered\">Present in 9 Fr</td> <td class=\"centered\">Not present</td> <td class=\"centered\">Not present</td> </tr> <tr> <td><strong>Center channel</strong></td> <td class=\"centered\">1.6 mm internal diameter</td> <td class=\"centered\">1.4 mm internal diameter</td> <td class=\"centered\">2.0 mm internal diameter</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ETT: single endotracheal tube; Fr: french.</div><div class=\"graphic_reference\">Modified with permission from: Campos JH. Which device should be considered the best for lung isolation: double-lumen endotracheal tube versus bronchial blockers. Curr Opin Anaesthesiol 2007; 20:27. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87264 Version 6.0</div></div></div>"},"87265":{"type":"graphic_algorithm","displayName":"Establishing lung isolation in difficult airways","title":"Establishing lung isolation in patients with difficult airways","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Establishing lung isolation in patients with difficult airways</div><div class=\"cntnt\"><img style=\"width:275px; height:350px;\" src=\"images/ANEST/87265_Estlungisoltndiffairwys.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SLT: single-lumen tube; DLT: double-lumen tube.</div><div id=\"graphicVersion\">Graphic 87265 Version 3.0</div></div></div>"},"87266":{"type":"graphic_diagnosticimage","displayName":"X-ray and CT of carpal boss","title":"X-ray and CT of carpal boss","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">X-ray and CT of carpal boss</div><div class=\"cntnt\"><img style=\"width:597px; height:294px;\" src=\"images/RADIOL/87266_Xray_CT_carpal_boss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lateral x-ray and CT examination reveal a carpal boss. This 40-year-old male presented with pain following trauma. A lateral radiograph (A) demonstrates a bony protuberance at the dorsal aspect of the capitate-3rd metacarpal joint (arrow). A multiplanar CT examination (B and C) was subsequently performed to evaluate for a radiographically occult fracture which more clearly demonstrates this finding, consistent with a carpal boss.</div><div class=\"graphic_reference\">Courtesy of Joseph Farnam, MD.</div><div id=\"graphicVersion\">Graphic 87266 Version 1.0</div></div></div>"},"87267":{"type":"graphic_diagnosticimage","displayName":"Radiograph osteochondral lesion of the dome of the talus","title":"RadiographÂ osteochondral lesion of the dome of the talus","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Radiograph&nbsp;osteochondral lesion of the dome of the talus</div><div class=\"cntnt\"><img style=\"width:597px; height:295px;\" src=\"images/RADIOL/87267_Xray_osteoch_les_dome_talus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Oblique view of the right ankle in a 35-year-old male with right ankle pain shows an osteochondral lesion in the medial and superior aspect of the left talus (arrow in A, magnified and highlighted in B).</div><div id=\"graphicVersion\">Graphic 87267 Version 2.0</div></div></div>"},"87268":{"type":"graphic_diagnosticimage","displayName":"MRI osteochondral defects of the talus","title":"MRI osteochondral defects of the talus","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">MRI osteochondral defects of the talus</div><div class=\"cntnt\"><img style=\"width:595px; height:433px;\" src=\"images/RADIOL/87268_MRI_osteochon_defects_talus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ankle MRI with intra-articular dilute gadolinium showing both medial and lateral osteochondral lesions. Panel A (fat saturated proton density sequence) and panel B (fat saturated T1 sequence) are in the coronal plane and the arrows identify the lesions. In panel B, the medial lesion is more distinct than the lateral lesion. There is no evidence of an unstable osteochondral fragment.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 87268 Version 2.0</div></div></div>"},"87269":{"type":"graphic_figure","displayName":"Differences between clinical and pathological staging","title":"Correlation of clinical and pathological staging in pleural mesothelioma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Correlation of clinical and pathological staging in pleural mesothelioma</div><div class=\"cntnt\"><img style=\"width:332px; height:434px;\" src=\"images/ONC/87269_Diff_clin_path_staging.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Rusch VW, Giroux D, Kennedy C, et al. Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database. J Thorac Oncol 2012; 7:1631. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87269 Version 4.0</div></div></div>"},"87270":{"type":"graphic_figure","displayName":"Survival for all patients","title":"Survival following surgery for pleural mesothelioma","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Survival following surgery for pleural mesothelioma</div><div class=\"cntnt\"><img style=\"width:550px; height:276px;\" src=\"images/ONC/87270_Survival_all_patients.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Staging was based upon most accurate available clinical and/or pathologic data.</div><div class=\"graphic_reference\">Reproduced with permission from: Rusch VW, Giroux D, Kennedy C, et al. Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database. J Thorac Oncol 2012; 7:1631. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87270 Version 4.0</div></div></div>"},"87271":{"type":"graphic_figure","displayName":"Relationship between histological subtype and survival","title":"Pleural mesothelioma survival based upon histology","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Pleural mesothelioma survival based upon histology</div><div class=\"cntnt\"><img style=\"width:526px; height:280px;\" src=\"images/ONC/87271_Relation_histo_sub_surviv.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Rusch VW, Giroux D, Kennedy C, et al. Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database. J Thorac Oncol 2012; 7:1631. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87271 Version 4.0</div></div></div>"},"87272":{"type":"graphic_picture","displayName":"Maternal airway pre- and post-labor","title":"Maternal airway pre- and post-labor","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Maternal airway pre- and post-labor</div><div class=\"cntnt\"><img style=\"width:515px; height:201px;\" src=\"images/ANEST/87272_Matern_air_pre_post_lab.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Airway picture pre-labor (Samsoon modification of Mallampati class 1 airway).<br />(B) Airway picture post-labor (Samsoon modification of Mallampati class 3 airway).</div><div class=\"graphic_reference\">Reproduced with permission from: Kodali BS, Chandrasekhar S, Bulich LN, Topulos GP, Datta S. Airway changes during labor and delivery. Anesthesiology 2008; 108:357. Copyright Â© 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87272 Version 4.0</div></div></div>"},"87276":{"type":"graphic_diagnosticimage","displayName":"Avascular necrosis of femoral heads in sickle cell disease","title":"X-ray and MRI avascular necrosis of femoral heads in sickle cell disease","html":"<div class=\"graphic\"><div style=\"width: 650px\" class=\"figure\"><div class=\"ttl\">X-ray and MRI avascular necrosis of femoral heads in sickle cell disease</div><div class=\"cntnt\"><img style=\"width:630px; height:352px;\" src=\"images/RADIOL/87276_Xray_avas_necr_femor_sickle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The images in the top series (A-D) show a patient with sickle cell disease and bilateral avascular necrosis of the hips. Images E-H show a normal patient. In image A an arrow points to two arcs of alternating densities. This finding is magnified in image B, revealing a superior subchondral lucent arc (arrowhead) adjacent to a more inferior sclerotic and denser arc of sclerotic bone (arrow). The subarticular lucent arc reflects resorbed bone and is known as the crescent sign. The sclerotic arc represents the reparative process. Image C is an MRI&nbsp;STIR sequence and reflects edema (arrowhead) in the superior subchondral arc. It is seen bilaterally but is more prominent on the right. Image D is a T1 weighted MRI image showing abnormal heterogeneous signal in both femoral heads. The dark signal in the femoral bones reflects increased hematopoiesis relative to normal. Images E and F reveal normal femoral heads&nbsp;that are less dense than the abnormal hips. On the MRI STIR image (G) there is no edema and no crescents are present. Image H is a normal T1 weighted MRI sequence and shows normal signal in the femoral&nbsp;heads bilaterally compared to the heterogeneous appearance in image D. The bright signal in the femoral epiphyses in H&nbsp;reflects a greater amount of fat compared to the femoral neck which contains hematopoietic bone marrow.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance image<BR>STIR: short tau inversion recovery.</div><div id=\"graphicVersion\">Graphic 87276 Version 1.0</div></div></div>"},"87279":{"type":"graphic_table","displayName":"Management of hypoxemia during one lung ventilation","title":"Management of hypoxemia during one lung ventilation<SUP>[1] </SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of hypoxemia during one lung ventilation<SUP>[1] </SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Gradual desaturation:</td> </tr> <tr> <td>Ensure F<sub>i</sub>O<sub>2</sub> = 1.0</td> </tr> <tr> <td>Check DLT/BB placement with fiberoptic bronchoscopy</td> </tr> <tr> <td>Suction airway as needed</td> </tr> <tr> <td>Optimize cardiac output</td> </tr> <tr> <td>Recruit ventilated lung</td> </tr> <tr> <td>Apply PEEP 5 cm to ventilated lung (except COPD)</td> </tr> <tr> <td>Apply CPAP 5 to 10 cm non-ventilated lung (after recruitment)</td> </tr> <tr> <td>Intermittently ventilate both lungs</td> </tr> <tr> <td class=\"sublist_other_start\">Partial ventilation of operative lung:</td> </tr> <tr> <td class=\"indent1\">i) Selective lobar collapse</td> </tr> <tr> <td class=\"indent1\">ii) O<sub>2</sub> insufflation to non-operative lobes</td> </tr> <tr> <td>Mechanical restriction of pulmonary blood flow to non-ventilated lung </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">If hypoxemia is acute and severe (O<SUB>2</SUB> saturation &lt;90 percent), two lung ventilation should be resumed until oxygenation is felt to be clinically adequate. The patient should be assessed after each maneuver; proceed to the next maneuver if hypoxemia persists.&nbsp;When&nbsp;oxygenation is adequate&nbsp;during one lung ventilation, subsequent steps are not necessary.<br /></div><div class=\"graphic_footnotes\">F<SUB>i</SUB>O<SUB>2</SUB>: fractional inspired concentration of oxygen; DLT: double-lumen tube; BB: bronchial blocker; PEEP: positive end expiratory pressure; COPD: chronic obstructive pulmonary disease; CPAP: continuous positive airway pressure; O<SUB>2</SUB>: oxygen.</div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Lohser J, Slinger P. Lung Injury After One-Lung Ventilation: A Review of the Pathophysiologic Mechanisms Affecting the Ventilated and the Collapsed Lung. Anesth Analg 2015; 121:302.</LI></OL></div><div id=\"graphicVersion\">Graphic 87279 Version 3.0</div></div></div>"},"87280":{"type":"graphic_movie","displayName":"Doppler ultrasound of the umbilical artery","title":"Doppler ultrasound of the umbilical artery","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Doppler ultrasound of the umbilical artery</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/OBGYN/87280_DopplUSumbilarteryvideo.mp4\" style=\"width:496px;height:384px\"></div><img style=\"width:296px; height:380px;\" src=\"images/OBGYN/87280_DopplUSumbilarteryimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Upper panel) Color flow depiction of umbilical blood flow in a normal pregnancy. The cursor line representing the Doppler ultrasound beam path can be seen aligned with the vascular flow axis. The two short horizontal lines indicate the Doppler interrogation site in the umbilical arterial flow.<br />(Lower panel) Doppler waveforms: the vertical axis shows the scale of the flow velocity. Note the low wall filter (40 Hz) depicted in small print in the upper right area of the image panel. The waveforms show prominent end-diastolic flow reflecting low impedance in the fetoplacental arterial circulation downstream from the measurement point.</div><div class=\"graphic_reference\">Courtesy of Dev Maulik, MD, PhD.</div><div id=\"graphicVersion\">Graphic 87280 Version 1.0</div></div></div>"},"87284":{"type":"graphic_figure","displayName":"Strongyloides life cycle","title":"<EM>Strongyloides </EM>life cycle","html":"<div class=\"graphic\"><div style=\"width: 611px\" class=\"figure\"><div class=\"ttl\"><EM>Strongyloides </EM>life cycle</div><div class=\"cntnt\"><img style=\"width:591px; height:480px;\" src=\"images/ID/87284_Strongyloides_life_cycle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><STRONG>Causal agent:</STRONG> The nematode (roundworm) <EM>Strongyloides stercoralis</EM>. Other <EM>Strongyloides</EM> include <EM>S. fÃ¼lleborni</EM>, which infects chimpanzees and baboons and may produce limited infections in humans.<BR><STRONG>Life cycle:</STRONG> The <EM>Strongyloides</EM> life cycle is more complex than that of most nematodes with its alternation between free-living and parasitic cycles, and its potential for autoinfection and multiplication within the host. Two types of cycles exist:<BR><STRONG>Free-living cycle:</STRONG> The rhabditiform larvae passed in the stool <STRONG>(1)</STRONG> (see \"Parasitic cycle\" below) can either molt twice and become infective filariform larvae (direct development) <STRONG>(6)</STRONG>, or molt four times and become free living adult males and females <STRONG>(2)</STRONG> that mate and produce eggs <STRONG>(3)</STRONG> from which rhabditiform larvae hatch <STRONG>(4)</STRONG>. The latter in turn can either develop <STRONG>(5)</STRONG> into a new generation of free-living adults (as represented in <STRONG>[2]</STRONG>), or into infective filariform larvae <STRONG>(6)</STRONG>. The filariform larvae penetrate the human host skin to initiate the parasitic cycle (see below) <STRONG>(6)</STRONG>.<BR><STRONG>Parasitic cycle:</STRONG> Filariform larvae in contaminated soil penetrate the human skin <STRONG>(6)</STRONG>, and are transported to the lungs where they penetrate the alveolar spaces; they are carried through the bronchial tree to the pharynx, are swallowed, and then reach the small intestine <STRONG>(7)</STRONG>. In the small intestine they molt twice and become adult female worms <STRONG>(8)</STRONG>. The females live threaded in the epithelium of the small intestine and by parthenogenesis produce eggs <STRONG>(9)</STRONG>, which yield rhabditiform larvae. The rhabditiform larvae can either be passed in the stool <STRONG>(1)</STRONG> (see \"Free-living cycle\" above), or can cause autoinfection <STRONG>(10)</STRONG>. In autoinfection, the rhabditiform larvae become infective filariform larvae, which can penetrate either the intestinal mucosa (internal autoinfection) or the skin of the perianal area (external autoinfection); in either case, the filariform larvae may follow the previously described route, being carried successively to the lungs, the bronchial tree, the pharynx, and the small intestine where they mature into adults; or they may disseminate widely in the body. To date, occurrence of autoinfection in humans with helminthic infections is recognized only in <EM>Strongyloides stercoralis</EM> and <EM>Capillaria philippinensis</EM> infections. In the case of <EM>Strongyloides</EM>, autoinfection may explain the possibility of persistent infections for many years in persons who have not been in an endemic area and of hyperinfections in immunodepressed individuals.<BR><STRONG>Geographic distribution:</STRONG> Tropical and subtropical areas, but cases also occur in temperate areas (including the South of the United States). More frequently found in rural areas, institutional settings, and lower socioeconomic groups.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. DPDx: Strongyloidiasis. Available at: <A href=\"http://www.cdc.gov/dpdx/strongyloidiasis/index.html\">http://www.cdc.gov/dpdx/strongyloidiasis/index.html</A>.</div><div id=\"graphicVersion\">Graphic 87284 Version 3.0</div></div></div>"},"87287":{"type":"graphic_table","displayName":"Discussing hospice care","title":"Guide to discussing hospice care with patients","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guide to discussing hospice care with patients</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td><strong>Identify other decision makers</strong></td> <td> <p>\"Is there anyone you rely on to help you make important decisions?\"</p> \"Who in the family should be there with us when we discuss the results?\"</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Assess understanding of prognosis</strong></td> <td> <p>\"What have your other doctors told you about your condition?\"</p> <p>\"Have they talked to you about what this latest problem might mean for you?\"</p> \"From what you know, do you think that over the next month your cancer will get better, worse, or stay the same?\"</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Define the patient's goals for care</strong></td> <td> <p>\"What do you hope for most in the next few months?\"</p> \"Is there anything that you're afraid of?\"</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Reframe goals</strong></td> <td>\"I wish we could guarantee that we could keep you alive until your daughter's graduation, but unfortunately we can't. Perhaps we can work together on a letter for her to read on that day, so she will know you are there in spirit in case you cannot be there.\"</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Identify needs for care</strong></td> <td> <p>\"It can be very difficult to care for a family member at home, and no one can do it alone. Have you thought about what kinds of help you might need?\"</p> <p>\"Would it help if we could find a way to deliver your medications to you?\"</p> \"Would it reassure you if we could send a nurse out to your home to check on you?\"</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Summarize and link goals with care needs</strong></td> <td>\"So I think I understand that your main goal is to stay at home and spend time with your family. To do that, we will need to help you in several ways, for instance, by sending a nurse out to your home and giving you both some help around the house. Is that right?\"</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Introduce hospice</strong></td> <td> <p>\"One of the best ways to give you the help that you will need to stay at home with your family is a program called hospice. Have you heard of hospice?\"</p> <p>\"Hospice is able to provide more services and support at home than most other home care programs.\"</p> \"The hospice team has a lot of experience caring for seriously ill patients at home.\"</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\"><strong>Respond to emotions elicited and provide closure</strong></td> </tr> <tr> <td class=\"indent1\">Acknowledge response</td> <td> <p>\"You seemed surprised to learn how sick you are.\"</p> \"I can see it's not easy for you to talk about hospice.\"</td> </tr> <tr> <td class=\"indent1\">Legitimize reaction</td> <td>\"Many people are understandably upset when they learn how ill their loved one is and that hospice is a possibility.\"</td> </tr> <tr> <td class=\"indent1\">Empathize</td> <td>\"I can imagine how hard this is for both of you; you care about each other so much.\"</td> </tr> <tr> <td class=\"indent1\">Explore concerns</td> <td>\"Tell me what's upsetting you the most.\"</td> </tr> <tr> <td class=\"indent1\">Explain hospice goals</td> <td> <p>\"Hospice doesn't help people die sooner. Hospice helps people die naturally, in their own time.\"</p> \"Hospice helps people live as well as they can for as long as they can.\"</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Reassure</td> <td> <p>\"Hospice's goal is to improve your quality of life as much as possible for whatever time you have left.\"</p> \"Hospice can help you and your family make the most of the time you have left.\"</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Reinforce commitment to care</strong></td> <td>\"Let's think this over for a day or two; you know I will continue to care for you whatever decision you make.\"</td> </tr> <tr> <td><strong>Recommend hospice</strong></td> <td> <p>\"I think that hospice would be your best choice right now, but of course, the final decision is yours.\"</p> \"Hospice could be very helpful to you in the ways that we've talked about, but I realize it's a big decision. I'd like to arrange for a hospice nurse to visit you so you can decide for yourself whether hospice is right for you.\"</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Casarett DJ, Quill TE. \"I'm Not Ready for Hospice\": Strategies for Timely and Effective Hospice Discussions. Ann Intern Med 2007; 146:443. Copyright &copy; 2007 American College of Physicians.</div><div id=\"graphicVersion\">Graphic 87287 Version 6.0</div></div></div>"},"87288":{"type":"graphic_picture","displayName":"Large plaque parapsoriasis 1","title":"Large plaque parapsoriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Large plaque parapsoriasis</div><div class=\"cntnt\"><img style=\"width:365px; height:498px;\" src=\"images/DERM/87288_Lg_plaque_parapsoriasis_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large, irregular, erythematous patches on the back of a patient with large plaque parapsoriasis.</div><div id=\"graphicVersion\">Graphic 87288 Version 2.0</div></div></div>"},"87289":{"type":"graphic_picture","displayName":"Large plaque parapsoriasis 2","title":"Large plaque parapsoriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Large plaque parapsoriasis</div><div class=\"cntnt\"><img style=\"width:438px; height:396px;\" src=\"images/DERM/87289_Large_plaque_parapsoriasi_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Irregularly shaped, erythematous patches, some larger than 10 cm in diameter, are characteristic of large plaque parapsoriasis.</div><div id=\"graphicVersion\">Graphic 87289 Version 4.0</div></div></div>"},"87290":{"type":"graphic_picture","displayName":"Digitate dermatosis","title":"Digitate dermatosis (small plaque parapsoriasis)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Digitate dermatosis (small plaque parapsoriasis)</div><div class=\"cntnt\"><img style=\"width:432px; height:576px;\" src=\"images/DERM/87290_Digitate_dermatosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Characteristic finger-shaped, erythematous patches with an atrophic, cigarette-paper surface are present on the flanks of this patient with digitate dermatosis, a variant of small plaque parapsoriasis. Note the distribution of the lesions along the skin cleavage lines.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87290 Version 3.0</div></div></div>"},"87291":{"type":"graphic_picture","displayName":"Small plaque parapsoriasis","title":"Small plaque parapsoriasis","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Small plaque parapsoriasis</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87291_Small_plaque_parapsoriasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small erythematous patches with fine scaling are characteristic of small plaque parapsoriasis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87291 Version 3.0</div></div></div>"},"87292":{"type":"graphic_picture","displayName":"Small plaque parapsoriasis 2","title":"Small plaque parapsoriasis","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Small plaque parapsoriasis</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87292_Small_plque_parapsoriasis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small, slightly erythematous or brown/yellowish patches and thin plaques with little scaling in a patient with small plaque parapsoriasis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87292 Version 3.0</div></div></div>"},"87308":{"type":"graphic_picture","displayName":"Bullous pemphigoid tense bullae 2 PI","title":"Bullous pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Bullous pemphigoid</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/PI/87308_Bull_pemph_tense_bullae2_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photo shows many blisters on the skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87308 Version 3.0</div></div></div>"},"87309":{"type":"graphic_picture","displayName":"Bullous pemphigoid on urticarial plaque PI","title":"Bullous pemphigoid","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Bullous pemphigoid</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/PI/87309_Bull_pemph_urticar_plaq_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photo shows blisters on red, raised areas of skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87309 Version 3.0</div></div></div>"},"87312":{"type":"graphic_diagnosticimage","displayName":"Chronic traumatic disruption of the left hemidiaphragm","title":"Chronic traumatic disruption of the left hemidiaphragm","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Chronic traumatic disruption of the left hemidiaphragm</div><div class=\"cntnt\"><img style=\"width:598px; height:371px;\" src=\"images/RADIOL/87312_Chron_traum_disrup_hemidiap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CT scan&nbsp;shows a&nbsp;chronic diphragmatic hernia due to trauma. The axial view (A) using lung windows&nbsp;shows&nbsp;a portion of the colon (white arrowhead) at the apex of the hernia sac at the level of the aortic arch (black arrow). The reconstructed coronal view (B) shows the defect in the diaphragm (between the two white arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 87312 Version 1.0</div></div></div>"},"87313":{"type":"graphic_table","displayName":"Cisplatin FU RT for EGJ cancer","title":"Trimodality therapy with cisplatin plus fluorouracil chemotherapy with concurrent radiotherapy followed by surgery for esophageal and esophagogastric junction cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Trimodality therapy with cisplatin plus fluorouracil chemotherapy with concurrent radiotherapy followed by surgery for esophageal and esophagogastric junction cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> Two courses of cisplatin and fluorouracil are administered starting on days 1 and 29 of the 5.5 week course of radiotherapy.</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Cisplatin</td> <td>100 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL normal saline (NS) and administer over 30 minutes. Do not administer with aluminum needles or sets.</td> <td>Days 1 and 29</td> </tr> <tr> <td>Fluorouracil</td> <td>1000 mg/m<sup>2</sup> per day IV</td> <td> <p>Dilute each day's dose in 500 to 1000 mL 5% dextrose in water (D5W) and administer as a continuous infusion over 24 hours per day for four days (96 hours). Begin each course after completion of cisplatin.</p> To accommodate an ambulatory pump for outpatient treatment, can be administered undiluted (50 mg/mL) or the total dose can be diluted in 100 to 150 mL NS.</td> <td>Days 1 through 4, and days 29 through 32</td> </tr> <tr class=\"divider_bottom\"> <td>Radiotherapy (50.4 Gy)</td> <td>1.8 Gy for five days a week (final 5.4 Gy is given as a boost)</td> <td>Begin within 24 hours of the administration of chemotherapy.</td> <td>Days 1 through 5; 8 through 12; 15 through 19; 22 through 26; 29 through 33; and 36 through 38</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Hydration</strong></td> <td colspan=\"3\"> <ul> <li>IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. </li> <li>Alternative: Pretreatment hydration with 1 to 2 L of IV fluid infused for 8 to 12 hours prior to each dose of cisplatin.<sup>[2]</sup> </li> <li>Refer to UpToDate topic on \"Cisplatin nephrotoxicity\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>HIGH on days 1 and 29, with substantial risk for delayed emesis on days 2 through 4 and 30 through 32. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> <li>Radiation therapy may induce clinically significant nausea and vomiting. </li> <li>Refer to UpToDate topic on \"Radiotherapy-induced nausea and vomiting: Prophylaxis and treatment\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Routine prophylaxis is not indicated. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Cisplatin is an irritant but can cause significant tissue damage; avoid extravasation. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF not warranted; the use of G-CSF with concurrent chemotherapy and radiotherapy should be avoided.<sup>[3]</sup> </li> <li>Refer to UpToDate topics on \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\", section on \"Granulocyte colony-stimulating factor\", and \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>The optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. Patients with a creatinine clearance &#60;50 mL/min were excluded from the original trial.<sup>[1]</sup> </li> <li>Refer to UpToDate topic on \"Chemotherapy nephrotoxicity and dose modification in patients with renal insufficiency: Conventional cytotoxic agents\".</li> <li>A lower starting dose of FU may be needed for patients with liver impairment. </li> <li>Refer to UpToDate topic on \"Chemotherapy hepatoxicity and dose modification in patients with liver disease\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential prior to each chemotherapy course. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes and liver and renal function prior to each chemotherapy course. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for hearing loss prior to each dose of cisplatin; audiometry as clinically indicated. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess change in neurologic function prior to each chemotherapy course. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for diarrhea, stomatitis, and cutaneous toxicity during therapy (palmar-plantar erythrodysesthesias). </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for significant nausea and vomiting. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Diarrhea</strong></td> <td colspan=\"3\"> <ul> <li>Hold FU for grade 2 or greater diarrhea, and restart at a lower dose after resolution. </li> <li><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after FU should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. </li> <li>Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>In the original protocol, radiotherapy, cisplatin, and FU were held for ANC &#60;1000 cells/microL and platelet count &#60;75,000/microL on day 1 of cycle 2.<sup>[4]</sup> Therapy was resumed when counts recovered to above these values, and FU was restarted at 80% of original dose (800 mg/m<sup>2</sup> per day). Chemotherapy was discontinued if counts did not recover after a seven-day period. For a nadir ANC &#60;500 cells/microL or platelet count &#60;50,000/microL, the FU dose was reduced to 800 mg/m<sup>2</sup> per day for the next cycle of therapy. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Nephrotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Hold cisplatin until serum creatinine is &#60;1.5 mg/dL and/or blood urea nitrogen is &#60;25 mg/dL. For grade &#8805;2 nephrotoxicity during treatment (creatinine &#62;1.5 times normal value despite adequate hydration), creatinine clearance should be determined prior to next cycle. In the original protocol, for a calculated creatinine clearance 30 to 49 mL/min, the dose of cisplatin was reduced by 50% and cisplatin was discontinued for creatinine clearance &#60;30 mL/min.<sup>[4]</sup> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Stomatitis/esophagitis and palmar-plantar erythrodysesthesia</strong></td> <td colspan=\"3\"> <ul> <li>In the original protocol, all therapy was held for grade 3 or 4 stomatitis, esophagitis, or dermatologic/skin reaction until resolution of toxicity to &#8804;grade 2 and the FU dose was decreased to 800 mg/m<sup>2</sup> per day for the subsequent cycle.<sup>[4]</sup> If chemotherapy could not be resumed within seven days, FU was discontinued.<sup>[5]</sup> </li> <li>Refer to UpToDate topics on \"Oral toxicity associated with chemotherapy\" and \"Cutaneous complications of conventional chemotherapy agents\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; Gy: gray; G-CSF: granulocyte colony-stimulating factors; CBC: complete blood count; FU: fluorouracil; ANC: absolute neutrophil count.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Tepper J, et al. J Clin Oncol 2008; 26:1086.</LI>&#xD;&#xA;<LI>Cisplatin injection, powder, lyophilized, for solution. United States Prescribing Information. US National Library of Medicine. (Available online at http://dailymed.nlm.nih.gov, accessed May 16, 2012).</LI>&#xD;&#xA;<LI>Neupogen (filgrastim) injection. United States Prescribing Information. US National Library of Medicine. (Available online at http://dailymed.nlm.nih.gov, accessed May 16, 2012).</LI>&#xD;&#xA;<LI>Dose modification instructions provided in the original protocol of Cancer and Leukemia Group B [CALGB] trial 9781, available online for members at the CALGB website (www.calgb.org).</LI>&#xD;&#xA;<LI>Fluorouracil injection. United States Prescribing Information. US National Library of Medicine. (Available online at http://dailymed.nlm.nih.gov, accessed May 16, 2012).</LI></OL></div><div id=\"graphicVersion\">Graphic 87313 Version 9.0</div></div></div>"},"87317":{"type":"graphic_table","displayName":"Drugs administered rectally in palliative care","title":"Drugs useful in palliative care that can be administered rectally","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs useful in palliative care that can be administered rectally</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Opioid analgesics</td> <td class=\"subtitle1\">Corticosteroids</td> <td class=\"subtitle1\">NSAIDs</td> <td class=\"subtitle1\">Anxiolytics</td> <td class=\"subtitle1\">Laxatives</td> <td class=\"subtitle1\">Anti-emetics</td> <td class=\"subtitle1\">Anti-epileptics</td> </tr> <tr> <td class=\"centered\">Morphine*</td> <td class=\"centered\">Hydrocortisone</td> <td class=\"centered\">Acetaminophen*</td> <td class=\"centered\">Diazepam*</td> <td class=\"centered\">Glycerin*</td> <td class=\"centered\">Prochlorperazine*</td> <td class=\"centered\">Phenobarbital</td> </tr> <tr> <td class=\"centered\">Hydromorphone*</td> <td class=\"centered\">Prednisolone</td> <td class=\"centered\">Diclofenac</td> <td class=\"centered\">Lorazepam</td> <td class=\"centered\">Sodium phosphates*</td> <td class=\"centered\">Promethazine*</td> <td class=\"centered\">Pentobarbital</td> </tr> <tr> <td class=\"centered\">Methadone</td> <td class=\"centered\">Dexamethasone</td> <td class=\"centered\">Indomethacin*</td> <td class=\"centered\">Midazolam</td> <td class=\"centered\">Mineral oil*</td> <td class=\"centered\">Chlorpromazine</td> <td class=\"centered\">Phenytoin</td> </tr> <tr> <td class=\"centered\">Oxycodone</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Ibuprofen</td> <td class=\"centered\">Clonazepam</td> <td class=\"centered\">Bisacodyl*</td> <td class=\"centered\">Metoclopramide</td> <td class=\"centered\">Carbamazepine</td> </tr> <tr> <td class=\"centered\">Codeine</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Naproxen</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Docusate*</td> <td class=\"centered\">Ondansetron</td> <td class=\"centered\">Valproic acid</td> </tr> <tr> <td class=\"centered\">Tramadol</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Aspirin</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Lamotrigine</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Commercially available as a suppository or enema in the United States.</div><div class=\"graphic_reference\">Reproduced with permission from: Samala RV, Davis MP. Use of Rectal Meds for Palliative Care Patients. Fast Facts and Concepts. September 2012; 257. Available at: <A spellcheck=true href=\"https://www.capc.org/fast-facts/257-palliative-care-rectum/\" target=_blank>https://www.capc.org/fast-facts/257-palliative-care-rectum/</A>. Copyright Â© 2012 EPERC.</div><div id=\"graphicVersion\">Graphic 87317 Version 4.0</div></div></div>"},"87321":{"type":"graphic_table","displayName":"Non-disease-specific baseline guidelines for hospice","title":"Medical guidelines for determining appropriateness of hospice referral: Non-disease-specific baseline guidelines plus comorbidities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medical guidelines for determining appropriateness of hospice referral: Non-disease-specific baseline guidelines plus comorbidities</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td> <p>A patient will be considered to have a life expectancy of six months or less if he/she meets the non-disease-specific <strong>\"Decline in clinical status\"</strong> guidelines described in Part I. Alternatively, the baseline non-disease-specific guidelines described in Part II plus the applicable disease-specific guidelines (listed in a separate table) will establish the necessary expectancy. </p> <p>A patient will be considered to have a life expectancy of six months or less if there is documented evidence of decline in clinical status that is not considered to be reversible based on the guidelines below.</p> </td> </tr> <tr> <td class=\"subtitle1_single\">I. Decline in clinical status guidelines</td> </tr> <tr> <td class=\"indent1\">A. Progression of disease as documented by worsening clinical status, symptoms, signs, and laboratory results.</td> </tr> <tr> <td class=\"indent2\">Clinical status:</td> </tr> <tr> <td class=\"indent3\">a. Recurrent or intractable serious infections, such as pneumonia, sepsis, or pyelonephritis.</td> </tr> <tr> <td class=\"indent3\">b. Progressive inanition as documented by:</td> </tr> <tr> <td class=\"indent4\"> <ol> <li>Weight loss of at least 10% body weight in the prior six months, not due to reversible causes (eg, depression, use of diuretics). </li> <li>Decreasing anthropomorphic measurements (mid-arm circumference, abdominal girth), not due to reversible causes (eg, depression or use of diuretics). </li> <li>Observation of ill-fitting clothes, decrease in skin turgor, increasing skin folds, or other observation of weight loss in a patient without a documented weight. </li> <li>Decreasing serum albumin or cholesterol. </li> <li>Dysphagia leading to recurrent aspiration and/or inadequate oral intake documented by decreasing food portion consumption. </li> </ol> </td> </tr> <tr> <td class=\"indent2\">Symptoms:</td> </tr> <tr> <td class=\"indent3\">a. Dyspnea with increasing respiratory rate.</td> </tr> <tr> <td class=\"indent3\">b. Cough, intractable.</td> </tr> <tr> <td class=\"indent3\">c. Nausea/vomiting poorly responsive to treatment.</td> </tr> <tr> <td class=\"indent3\">d. Diarrhea, intractable.</td> </tr> <tr> <td class=\"indent3\">e. Pain requiring increasing doses of major analgesics more than briefly.</td> </tr> <tr> <td class=\"indent2\">Signs:</td> </tr> <tr> <td class=\"indent3\">a. Decline in systolic blood pressure to below 90 or progressive postural hypotension.</td> </tr> <tr> <td class=\"indent3\">b. Ascites.</td> </tr> <tr> <td class=\"indent3\">c. Venous, arterial, or lymphatic obstruction due to local progression or metastatic disease.</td> </tr> <tr> <td class=\"indent3\">d. Edema.</td> </tr> <tr> <td class=\"indent3\">e. Pleural/pericardial effusion.</td> </tr> <tr> <td class=\"indent3\">f. Weakness.</td> </tr> <tr> <td class=\"indent3\">g. Change in level of consciousness.</td> </tr> <tr> <td class=\"indent2\">Laboratory (when available; lab testing is not required to establish hospice eligibility):</td> </tr> <tr> <td class=\"indent3\">a. Increasing pCO2 or decreasing pO2 or decreasing SaO2.</td> </tr> <tr> <td class=\"indent3\">b. Increasing calcium, creatinine, or liver function studies.</td> </tr> <tr> <td class=\"indent3\">c. Increasing tumor markers (eg, CEA, PSA).</td> </tr> <tr> <td class=\"indent3\">d. Progressively decreasing or increasing serum sodium or increasing serum potassium.</td> </tr> <tr> <td class=\"indent1\">B. Decline in Karnofsky Performance Status (KPS) or Palliative Performance Score (PPS) due to progression of disease.</td> </tr> <tr> <td class=\"indent1\">C. Progressive decline in Functional Assessment Staging (FAST) for dementia (from 7A on the FAST).</td> </tr> <tr> <td class=\"indent1\">D. Progression to dependence on assistance with additional activities of daily living (refer to&nbsp;part II, below).</td> </tr> <tr> <td class=\"indent1\">E. Progressive stage 3-4 pressure ulcers in spite of optimal care.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">F. History of increasing&nbsp;emergency room&nbsp;visits, hospitalizations, or physician visits related to the hospice primary diagnosis prior to election of the hospice benefit.</td> </tr> <tr> <td class=\"subtitle1_single\">II. Non-disease-specific baseline guidelines (both A and B should be met) </td> </tr> <tr> <td class=\"indent1\">A. Physiologic impairment of functional status as demonstrated by KPS or PPS &#60;70 percent. Note that two of the disease-specific guidelines (HIV and stroke/coma) establish a lower qualifying KPS or PPS.</td> </tr> <tr> <td class=\"indent1\">B. Dependence on assistance for two or more activities of daily living:</td> </tr> <tr> <td class=\"indent2\"> <ol> <li>Feeding. </li> <li>Ambulation. </li> <li>Continence. </li> <li>Transfer. </li> <li>Bathing. </li> <li>Dressing. </li> </ol> </td> </tr> <tr> <td class=\"indent1\"><strong>Comorbidities</strong></td> </tr> <tr> <td class=\"indent2\">Although not the primary hospice diagnosis, the presence of comorbid disease&nbsp;that is likely to contribute to a life expectancy of six months or less should be considered for hospice eligibility. Comorbid diseases may include:</td> </tr> <tr> <td class=\"indent3\"> <ol> <li>Chronic obstructive pulmonary disease. </li> <li>Congestive heart failure. </li> <li>Ischemic heart disease. </li> <li>Diabetes mellitus. </li> <li>Neurologic disease (CVA, ALS, MS, Parkinson). </li> <li>Renal failure. </li> <li>Liver disease. </li> <li>Neoplasia. </li> <li>Acquired immune deficiency syndrome/HIV. </li> <li>Dementia. </li> <li>Refractory severe autoimmune disease (eg, Lupus or rheumatoid arthritis). </li> </ol> </td> </tr> <tr> <td class=\"indent1\">A patient will be considered to have a life expectancy of six months and be eligible for hospice services if he/she meets criteria for BOTH the above non-disease-specific baseline guidelines AND disease-specific guidelines (shown on a separate table).</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These baseline guidelines do not independently qualify a patient for hospice coverage. Refer to separate table for disease-specific guidelines to be used with these guidelines.</div><div class=\"graphic_footnotes\">pCO2: partial pressure of carbon dioxide; pO2: partial pressure of oxygen; SaO2: arterial oxygen saturation; CEA: carcinoembryonic antigen; PSA: prostate-specific antigen; HIV: human immunodeficiency virus; CVA: cerebrovascular accident or stroke; ALS: amyotrophic lateral sclerosis; MS: multiple sclerosis.</div><div class=\"graphic_reference\">Source: Centers for Medicare &amp; Medicaid Services. <A href=\"https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=33393&amp;ContrId=272&amp;ver=2&amp;ContrVer=1&amp;CntrctrSelected=272*1&amp;Cntrctr=272&amp;name=National+Government+Services%2c+Inc.+(06004%2c+HHH+MAC)&amp;DocType=All&amp;s=56&amp;bc=AggAAAIAAAAAAA%3d%3d&amp;amp;\" target=_blank>Local Coverage Determination (LCD) for Hospice Determining Terminal Status (L33393)</A>. (Accessed on January 18, 2016).</div><div id=\"graphicVersion\">Graphic 87321 Version 8.0</div></div></div>"},"87322":{"type":"graphic_table","displayName":"Features of ruptured abdominal aortic aneurysm on CT","title":"Features of ruptured abdominal aortic aneurysm on CT","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Features of ruptured abdominal aortic aneurysm on CT</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Abdominal aortic rupture</td> </tr> <tr> <td class=\"indent1\">Retroperitoneal hematoma</td> </tr> <tr> <td class=\"indent1\">Indistinct aortic wall</td> </tr> <tr> <td class=\"indent1\">Retroperitoneal stranding</td> </tr> <tr> <td class=\"indent1\">Loss of fat plane between the aorta and surrounding tissue</td> </tr> <tr> <td class=\"indent1\">Extravasation of contrast</td> </tr> <tr> <td class=\"subtitle1_single\">\"Impending\" rupture</td> </tr> <tr> <td class=\"indent1\">Crescent sign - layering hematoma</td> </tr> <tr> <td class=\"indent1\">Aortic blebs</td> </tr> <tr> <td class=\"indent1\">Draping of the aorta over a vertebral body</td> </tr> <tr> <td class=\"indent1\">Irregular aortic wall</td> </tr> <tr> <td class=\"indent1\">Breaks in calcification of the aortic wall</td> </tr> <tr> <td class=\"indent1\"><span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">Localized areas of higher attenuation within mural thrombus </span></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Source: Chien DK, Chang WH, Yeh YH. Radiographic findings of a ruptured abdominal aortic aneurysm. Circulation 2010; 122:1880.</div><div id=\"graphicVersion\">Graphic 87322 Version 4.0</div></div></div>"},"87324":{"type":"graphic_diagnosticimage","displayName":"Abdominal aortic aneurysm with crescent sign","title":"Abdominal aortic aneurysm with crescent sign","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Abdominal aortic aneurysm with crescent sign</div><div class=\"cntnt\"><img style=\"width:572px; height:495px;\" src=\"images/RADIOL/87324_Abd_aortic_aneur_cresc_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These images&nbsp;show a&nbsp;large infrarenal aortic aneurysm in a 77-year-old male.&nbsp;The lumen of the aorta can be appreciated&nbsp;in panel A&nbsp;(arrow) and is surrounded by mural thrombus. A hyperdense crescent can be seen within the thrombus in panel B (arrowhead) suggesting acute hemorrhage within the thrombus. This finding suggests an unstable AAA with impending rupture. Narrow windows (C and D) are used to accentuate the high density crescent sign (arrowhead in D).</div><div class=\"graphic_footnotes\">AAA: abdominal aortic aneurysm.</div><div id=\"graphicVersion\">Graphic 87324 Version 1.0</div></div></div>"},"87326":{"type":"graphic_diagnosticimage","displayName":"Abdominal aortic aneurysm with bleb","title":"Abdominal aortic aneurysm with bleb","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Abdominal aortic aneurysm with bleb</div><div class=\"cntnt\"><img style=\"width:590px; height:394px;\" src=\"images/RADIOL/87326_Abdom_aortic_aneurysm_bleb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An unstable large infrarenal aortic aneurysm in this 90-year-old female shows a focal bulge in the left lateral wall of the aneurysm (white arrow) suggesting an impending rupture.</div><div id=\"graphicVersion\">Graphic 87326 Version 1.0</div></div></div>"},"87327":{"type":"graphic_diagnosticimage","displayName":"Symptomatic abdominal aortic aneurysm with rapid expansion","title":"Symptomatic abdominal aortic aneurysm with rapid expansion","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Symptomatic abdominal aortic aneurysm with rapid expansion</div><div class=\"cntnt\"><img style=\"width:598px; height:468px;\" src=\"images/RADIOL/87327_Symptom_abd_AA_rapid_expans.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An infrarenal AAA is shown over a 17-month period. The earliest axial CT (A) shows&nbsp; the AAA measuring 5 cm. Ten months later, the AAA is marginally larger and measures 5.2 cm in diameter. Seven months later, the patient presented with left lower quadrant pain and a tender aneurysm now measuring 6 cm on CT scan (C). A new deformity in the anterior abdominal wall is identified anterior to the aorta (arrow) caused by the rapidly expanding aneurysm, which has an increased&nbsp;risk for rupture.</div><div class=\"graphic_footnotes\">AAA: abdominal aortic aneurysm; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 87327 Version 1.0</div></div></div>"},"87328":{"type":"graphic_diagnosticimage","displayName":"Aortoduodenal fistula","title":"Aortoduodenal fistula","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Aortoduodenal fistula</div><div class=\"cntnt\"><img style=\"width:597px; height:229px;\" src=\"images/RADIOL/87328_Aortoduodenalfistula.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CT scan comes from a 75-year-old patient with a history of AAA repair who presented with massive lower gastrointestinal bleeding and hypotension. An aortoduodenal fistula is demonstrated by a CT scan, which shows a break in the wall of the aorta (arrow) and high-density hematoma (arrowhead). In (B), air can be seen tracking between the duodenum and the aorta (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography; AAA: abdominal aortic aneurysm.</div><div id=\"graphicVersion\">Graphic 87328 Version 2.0</div></div></div>"},"87329":{"type":"graphic_diagnosticimage","displayName":"Aortogram normal aorta and infrarenal aortic aneurysm","title":"Aortogram normal aorta and infrarenal aortic aneurysm","html":"<div class=\"graphic\"><div style=\"width: 615px\" class=\"figure\"><div class=\"ttl\">Aortogram normal aorta and infrarenal aortic aneurysm</div><div class=\"cntnt\"><img style=\"width:595px; height:248px;\" src=\"images/RADIOL/87329_Aorto_norm_infra_aortic_ane.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal aortogram (A) is contrasted with the aortogram of a patient with a large infrarenal abdominal aortic aneurysm. The arrows point to the right renal artery in both images.</div><div id=\"graphicVersion\">Graphic 87329 Version 1.0</div></div></div>"},"87330":{"type":"graphic_diagnosticimage","displayName":"Ultrasound of normal abdominal aorta and aortic aneurysm","title":"Ultrasound of normal abdominal aorta and aortic aneurysm","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Ultrasound of normal abdominal aorta and aortic aneurysm</div><div class=\"cntnt\"><img style=\"width:597px; height:228px;\" src=\"images/RADIOL/87330_US_norm_abd_aorta_aneurysm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound in longitudinal view shows a normal abdominal aorta (A), which is contrasted with a similar view of an aorta in a patient with a 7.7 cm infrarenal abdominal aortic aneurysm (B).</div><div id=\"graphicVersion\">Graphic 87330 Version 1.0</div></div></div>"},"87331":{"type":"graphic_diagnosticimage","displayName":"CT scan infrarenal aortic aneurysm with thrombus","title":"CT scan infrarenal aortic aneurysm with thrombus","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">CT scan infrarenal aortic aneurysm with thrombus</div><div class=\"cntnt\"><img style=\"width:597px; height:401px;\" src=\"images/RADIOL/87331_CT_infra_aort_aneu_thrombus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 4 cm infrarenal AAA is shown on the axial CT images prior to (A) and following administration of intravenous contrast (B). Luminal thrombus (arrowhead) is seen&nbsp;surrounding the flow channel. The coronal CT reconstruction (C) shows the low density circumferential thrombus (arrows) surrounding the contrast-filled lumen.</div><div class=\"graphic_footnotes\">CT: computed tomography; AAA: abdominal aortic aneurysm.</div><div id=\"graphicVersion\">Graphic 87331 Version 1.0</div></div></div>"},"87332":{"type":"graphic_diagnosticimage","displayName":"CT scan infrarenal aortic aneurysm with eccentric thrombus","title":"CT scan infrarenal aortic aneurysm with eccentric thrombus","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">CT scan infrarenal aortic aneurysm with eccentric thrombus</div><div class=\"cntnt\"><img style=\"width:538px; height:343px;\" src=\"images/RADIOL/87332_CT_infra_aort_ane_ecc_throm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The axial CT image shows an infrarenal abdominal aortic aneurysm, which measures 3.2 cm. Eccentric mural thrombus is seen adjacent the contrast-enhanced lumen (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 87332 Version 2.0</div></div></div>"},"87333":{"type":"graphic_diagnosticimage","displayName":"Abdominal aortic aneurysm on three-dimensional imaging","title":"Abdominal aortic aneurysm on three-dimensional imaging","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Abdominal aortic aneurysm on three-dimensional imaging</div><div class=\"cntnt\"><img style=\"width:598px; height:314px;\" src=\"images/RADIOL/87333_3D_CT_infra_abd_aortic_aneu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;three-dimensional&nbsp;rendered CT images show a 5.2 cm infrarenal abdominal aortic aneurysm (between white arrows). The aneurysm originates 2.3 cm below the renal arteries and terminates 1.9 cm above the iliac bifurcation.</div><div class=\"graphic_footnotes\">CT: computed tomography.<BR></div><div id=\"graphicVersion\">Graphic 87333 Version 1.0</div></div></div>"},"87334":{"type":"graphic_diagnosticimage","displayName":"Abdominal aortic aneurysm extending to the iliac bifurcation","title":"Abdominal aortic aneurysm extending to the iliac bifurcation","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Abdominal aortic aneurysm extending to the iliac bifurcation</div><div class=\"cntnt\"><img style=\"width:598px; height:400px;\" src=\"images/RADIOL/87334_CT_infra_abd_aneu_ext_iliac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;axial contrast-enhanced CT shows that the abdominal aortic diameter&nbsp;is normal at the level of the renal arteries&nbsp;(A, arrow), and well below the renal arteries (B). A fusiform&nbsp;dilation (C) begins at the level or&nbsp;the third lumbar vertebra and&nbsp;extends to the iliac bifurcation (D) but does not extend into the common&nbsp;iliac arteries. The sagittal view (E)&nbsp;shows the distal fusiform aneurysm with luminal&nbsp;thrombus.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 87334 Version 1.0</div></div></div>"},"87335":{"type":"graphic_diagnosticimage","displayName":"Aortogram and CT scan of infrarenal abdominal aortic aneurysm","title":"Aortogram and CT scan of infrarenal abdominal aortic aneurysm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortogram and CT scan of infrarenal abdominal aortic aneurysm</div><div class=\"cntnt\"><img style=\"width:382px; height:598px;\" src=\"images/RADIOL/87335_Aortogr_CT_infra_abd_aortic.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The digital subtraction aortogram (A) shows a fusiform AAA (arrow). The contrast column shows the luminal diameter and not the true diameter of the aneurysm. Aortic diameter is best evaluated on cross-sectional CT, which shows the outside margin of the aortic wall (B). Note that there is a large amount of eccentric, mural thrombus within the aorta (arrow) on the CT scan. Also,&nbsp;a horseshoe kidney&nbsp;is quite obvious on the CT scan (arrowhead) but is only vaguely outlined&nbsp;on the arteriogram (black arrows in panel A). The presence of a horseshoe kidney&nbsp;may alter the&nbsp;approach to AAA repair.</div><div class=\"graphic_footnotes\">AAA: abdominal aortic aneurysm.<BR>CT: computed tomography.<BR></div><div id=\"graphicVersion\">Graphic 87335 Version 1.0</div></div></div>"},"87336":{"type":"graphic_diagnosticimage","displayName":"Infrarenal abdominal aortic aneurysm on MRI and CT scan","title":"Infrarenal abdominal aortic aneurysm on MRI and CT scan","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Infrarenal abdominal aortic aneurysm on MRI and CT scan</div><div class=\"cntnt\"><img style=\"width:597px; height:197px;\" src=\"images/RADIOL/87336_MRI_CT_infrarenl_abd_aortic.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The T1 weighted MRI sequence (A) shows a 4 cm infrarenal AAA. The same aneurysm is also shown on a contrast enhanced CT scan (B). CT is highly sensitive for even small amounts of calcium (arrow), whereas the lack of sensitivity of MRI for calcification limits accurate measurement and characterization of changes in the aortic wall.</div><div class=\"graphic_footnotes\">AAA: abdominal aortic aneurysm; CT: computed tomography; MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 87336 Version 2.0</div></div></div>"},"87337":{"type":"graphic_diagnosticimage","displayName":"Rapid expansion of abdominal aortic aneurysm on ultrasound","title":"Rapid expansion of abdominal aortic aneurysm on ultrasound","html":"<div class=\"graphic\"><div style=\"width: 597px\" class=\"figure\"><div class=\"ttl\">Rapid expansion of abdominal aortic aneurysm on ultrasound</div><div class=\"cntnt\"><img style=\"width:577px; height:502px;\" src=\"images/RADIOL/87337_US_rapid_growth_AAA_hydr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound images were performed six months apart and show rapid (&gt;0.5 cm)&nbsp;expansion of an abdominal aortic aneurysm (AAA) (A to B)&nbsp;and advancing hydronephrosis (white arrow) (C to D).&nbsp;Perianeurysmal fibrosis with secondary progressive ureteral obstruction, as would be seen with an inflammatory aneurysm,&nbsp;could explain these findings.</div><div id=\"graphicVersion\">Graphic 87337 Version 1.0</div></div></div>"},"87338":{"type":"graphic_diagnosticimage","displayName":"Abdominal aortic aneurysm with aortocaval fistula","title":"Abdominal aortic aneurysm with aortocaval fistula","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Abdominal aortic aneurysm with aortocaval fistula</div><div class=\"cntnt\"><img style=\"width:505px; height:598px;\" src=\"images/RADIOL/87338_AAA_with_aortocaval_fistula.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The aortograms (A, C red overlay) show a saccular infrarenal aortic aneurysm. Premature filling of the inferior vena cava (B, D blue overlay) is consistent with an aortocaval fistula, which is due to AAA rupture.</div><div class=\"graphic_footnotes\">AAA: abdominal aortic aneurysm.</div><div id=\"graphicVersion\">Graphic 87338 Version 2.0</div></div></div>"},"87339":{"type":"graphic_diagnosticimage","displayName":"Arteriomegaly and aneurysmal disease","title":"Arteriomegaly and aneurysmal disease","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Arteriomegaly and aneurysmal disease</div><div class=\"cntnt\"><img style=\"width:597px; height:432px;\" src=\"images/RADIOL/87339_Arteria_magna_aneurysmal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The predisposition to multicentric aneurysmal disease in the aorta and peripheral arteries suggests a diagnosis of arteriomegaly. The CT scan through the lower abdomen (A) shows an abdominal aortic aneurysm (AAA) (arrow). In the pelvis (B), aneurysms of the common iliac arteries can be seen, larger on the right (arrow) than the left. In the lower extremities (C and D), ectatic femoral arteries (bilateral arrows, C), and bilateral popliteal aneurysms (bilateral arrows, D) are seen. The right popliteal aneurysm is lobulated (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 87339 Version 2.0</div></div></div>"},"87340":{"type":"graphic_diagnosticimage","displayName":"Bilateral grade III GMH-IVH in preterm infant","title":"Bilateral grade III germinal matrix hemorrhage-intraventricular hemorrhage in a preterm infant","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Bilateral grade III germinal matrix hemorrhage-intraventricular hemorrhage in a preterm infant</div><div class=\"cntnt\"><img style=\"width:764px; height:345px;\" src=\"images/RADIOL/87340_Bilatgr3GMHIVHprtrminf.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cranial ultrasound images of a preterm infant born at 29 weeks gestation&nbsp;with a bilateral grade III germinal matrix hemorrhage-intraventricular hemorrhage (arrows) with acute dilatation due to a large clot in both ventricles. Coronal view angling backwards (A) and parasagittal view (B).</div><div class=\"graphic_reference\"><P class=MsoNormal style=\"MARGIN: 0in 0in 0pt\"><I><FONT size=3 face=Calibri>Courtesy of Linda S de Vries, MD, PhD and Lara M Leijser, MD, PhD, MSc. </FONT><?xml:namespace prefix = \"o\" ns = \"urn:schemas-microsoft-com:office:office\" /><o:p></o:p></I></div><div id=\"graphicVersion\">Graphic 87340 Version 3.0</div></div></div>"},"87341":{"type":"graphic_diagnosticimage","displayName":"Posthemorrhagic hydrocephalus Grade III IVH","title":"Magnetic resonance imaging (MRI) of posthemorrhagic hydrocephalus in a patient with grade III IVH","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance imaging (MRI) of posthemorrhagic hydrocephalus in a patient with grade III IVH</div><div class=\"cntnt\"><img style=\"width:303px; height:655px;\" src=\"images/RADIOL/87341_Posthem_hydroceph_grIII_IVH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a followup MRI obtained 1 year following initial presentation, axial FLAIR images (A, B, C, D) demonstrate marked bilateral hydrocephalus with colpocephalic features, hypoplasia/atrophy of the cerebellum (arrowhead), and dysmorphia of the pons (short arrow). Coronal CISS image (E) demonstrates disproportionate dilation of the atrium and occipital horn of the lateral ventricle (dashed arrow) reflecting the colpocephalic features.</div><div class=\"graphic_footnotes\">FLAIR: fluid attenuated inversion recovery; CISS: constructive interference in steady state (a gradient-echo MRI sequence); MRI: magnetic resonance imaging; IVH: intraventricular hemorrhage.</div><div class=\"graphic_reference\">Courtesy of Joseph Farnam, MD.</div><div id=\"graphicVersion\">Graphic 87341 Version 2.0</div></div></div>"},"87343":{"type":"graphic_picture","displayName":"Scalp psoriasis","title":"Psoriasis vulgaris","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Psoriasis vulgaris</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87343_Scalp_psoriasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Well-demarcated, erythematous, scaly plaques are present on the neck and scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87343 Version 3.0</div></div></div>"},"87344":{"type":"graphic_table","displayName":"Exploratory questions for advanced care planning","title":"Helpful exploratory questions that can be used in palliative care for the advanced care planning process","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Helpful exploratory questions that can be used in palliative care for the advanced care planning process</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Have you had someone close to you/had your own experience with serious illness or death? If you were in that situation (again), what would you hope for?</td> </tr> <tr> <td>Can you think of circumstances in which living longer might be more burdensome than dying?</td> </tr> <tr> <td>When you think of becoming critically ill, what worries you the most?</td> </tr> <tr> <td>If you were to become critically ill and unable to speak on your own behalf, is there anyone you trust to make medical decisions for you? Are your preferences documented/in writing?</td> </tr> <tr> <td>Have you given any thought to whether you'd like cardiopulmonary resuscitation if you were to die suddenly? May I explain what CPR entails in your circumstances and what are your estimated chances of benefiting from it?</td> </tr> <tr> <td>What kind of treatments would you want, and which ones might you decline if you were to become critically ill and unable to speak for yourself?</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 87344 Version 1.0</div></div></div>"},"87346":{"type":"graphic_table","displayName":"MAP osteosarcoma young adults and children","title":"Cisplatin, doxorubicin, and methotrexate for non-metastatic high-grade osteosarcoma in young adults and children<sup>[1]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cisplatin, doxorubicin, and methotrexate for non-metastatic high-grade osteosarcoma in young adults and children<sup>[1]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"5\">Cycle length: 5 weeks (cycles 1 through 4), 4 weeks (cycle 5 and 6).<br /> Duration of therapy: 6 cycles.</td> </tr> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Week of treatment</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td><strong>Cisplatin*</strong></td> <td>60 mg/m<sup>2</sup> per day IV (total dose = 120 mg/m<sup>2</sup> per cycle)</td> <td>Dilute in 250 mL normal saline (NS) and administer over four hours. Do not administer with aluminum needles or sets.</td> <td> <p>Preoperative: Weeks 1 and 6</p> Postoperative: Weeks 12 and 17</td> <td>Days 1 and 2</td> </tr> <tr> <td><strong>Doxorubicin*</strong></td> <td>37.5 mg/m<sup>2</sup> per day IV (total dose = 75 mg/m<sup>2</sup> per cycle)</td> <td> <p>Dilute in 1000 mL NS<sup>&#916;</sup> and administer as a continuous IV infusion over 24 hours daily.</p> Alternative: dilute with NS to a final concentration of 2 mg/mL and administer as an IV bolus over three to five minutes into a free flowing IV infusion of NS or 5 percent dextrose in water (D5W). Final solution should be protected from light.</td> <td> <p>Preoperative: Weeks 1 and 6</p> Postoperative: Weeks 12, 17, 22, and 26</td> <td>Days 1 through 2</td> </tr> <tr> <td><strong>Methotrexate*</strong></td> <td>12 g/m<sup>2</sup> IV<sup>&#9674;</sup></td> <td>Dilute in 500 mL D5W and administer over four hours. Final solution should be protected from light.</td> <td> <p>Preoperative: Week 4, 5, 9, and 10</p> Postoperative: Week 15, 16, 20, 21, 24, 25, 28, and 29</td> <td>Day 1</td> </tr> <tr> <td><strong>Leucovorin</strong></td> <td>15 mg orally, IV, or IM every six hours (adjust dose according to serum methotrexate concentrations<sup>&#165;</sup>)</td> <td>Begin 24 hours after start of methotrexate infusion and continue until serum methotrexate concentration is less than 0.1 micromol/L<sup>[1]</sup>.</td> <td> <p>Preoperative: Week 4, 5, 9, and 10</p> Postoperative: Week 15, 16, 20, 21, 24, 25, 28, and 29</td> <td>Begin 24 hours after start of methotrexate infusion and continue until serum methotrexate concentration is less than 0.1 micromol/L<sup>[1]</sup></td> </tr> <tr> <td><strong>Surgery</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Week 11</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"5\">Pretreatment considerations:</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"5\">&#8226; <strong>Hydration:</strong></td> </tr> <tr> <td class=\"sublist2\" colspan=\"5\">- Cisplatin: Normal saline-based IV fluid to establish a urine flow of at least 100 mL/hour for at least two hours prior to and two hours after cisplatin administration. Alternative: pretreatment hydration with 1 to 2 L of normal saline-based fluid infused for 8 to 12 hours prior to each dose of cisplatin<sup>[2]</sup>. Refer to UpToDate topic on \"Cisplatin nephrotoxicity\".</td> </tr> <tr> <td class=\"sublist2\" colspan=\"5\">- Methotrexate: Adequate IV fluid (approximately 125 to 150 mL/hour) with electrolytes and bicarbonate must be given to maintain adequate urine output and alkalinization for methotrexate clearance. A urine pH &#62;7 must be achieved before starting the methotrexate infusion and maintained until the methotrexate serum level is &#60;0.1 micromol/L. Refer to UpToDate topic on \"Therapeutic use and toxicity of high-dose methotrexate\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">&#8226; <strong>Emesis risk:</strong> Cisplatin plus doxorubicin: HIGH. Methotrexate: LOW. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">&#8226; <strong>Prophylaxis for infusion reactions:</strong> There is no standard premedication regimen for cisplatin, doxorubicin, or methotrexate. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">&#8226; <strong>Vesicant/irritant properties:</strong> Cisplatin is an irritant but can cause significant tissue damage with a large volume, concentrated extravasation; avoid extravasation. Doxorubicin is a vesicant; avoid extravasation. Administer infusions of doxorubicin through a central venous line. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">&#8226; <strong>Infection prophylaxis:</strong> The AOST 0331/EURAMOS-1 protocol recommended secondary prophylaxis with G-CSF after doxorubicin/cisplatin cycles if prior doxorubicin/cisplatin cycles were complicated by fever and neutropenia with non-catheter-related sepsis or prolonged hospitalization (&#62;7 days). However, many centers give G-CSF with each cycle of doxorubicin/cisplatin. If given, begin growth factor support at least 24 hours after completion of chemotherapy; if given daily, continue until WBC &#8805;5000 cells/mm<sup>3</sup> after the nadir, and discontinue at least two days prior to next course of chemotherapy. Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">&#8226; <strong>Dose adjustment for baseline liver or renal dysfunction and third-space fluid collections:</strong> A lower starting dose of cisplatin and methotrexate may be needed for patients with renal impairment, although the optimal approach to cisplatin therapy in patients with preexisting renal impairment is unknown. Many clinicians would decrease the initial dose of cisplatin for a creatinine clearance &#60;50 mL/min. A lower starting dose of doxorubicin and methotrexate may be needed for patients with liver impairment. In the AOST0331 protocol: for total bilirubin greater than or equal to 1.25 mg/dL and less than 2.1 mg/dL, doxorubicin doses were reduced by 25 percent; for total bilirubin greater than or equal to 2.1 mg/dL and less than 3.06 mg/dL, doxorubicin doses were reduced by 50 percent; for total bilirubin greater than or equal to 3.06 mg/dL and less than 5 mg/dL, doxorubicin doses were reduced by 75 percent; and for total bilirubin greater than or equal to 5 mg/dL, doxorubicin was omitted<sup>[1]</sup>. For patients with third space fluid collections (eg, ascites, pleural effusion), await resolution or perform drainage before initiating methotrexate. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", and \"Therapeutic use and toxicity of high-dose methotrexate\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">&#8226; <strong>Cardiac issues:</strong> Doxorubicin is associated with dose-dependent cardiomyopathy; the incidence is related to cumulative dose. The risk of developing congestive heart failure increases rapidly with increasing total cumulative doses of doxorubicin in excess of 400 mg/m<sup>2</sup>. Cardiac toxicity may occur at lower cumulative doses whether or not cardiac risk factors are present. Assess baseline LVEF prior to initiating therapy. Doxorubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmias, or prior treatment with maximum cumulative doses of anthracyclines<sup>[2]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">&#8226; <strong>Prevention of high dose methotrexate toxicity:</strong> Maintaining urine output, alkalinization of the urine, monitoring methotrexate concentrations, providing leucovorin rescue, identifying and avoiding drug-drug interactions (eg, use with penicillins, cephalosporins, nonsteroidal anti-inflammatory agents, proton-pump inhibitors, etc), and monitoring electrolytes and renal function are important in the prevention of methotrexate toxicity. Refer to UpToDate topic on \"Therapeutic use and toxicity of high-dose methotrexate\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"5\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">&#8226; CBC with differential prior to treatment.</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">&#8226; Assess electrolytes and liver and renal function prior to treatment and daily during treatment.</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">&#8226; Baseline audiometry, monitor for hearing loss prior to each dose of cisplatin; repeat audiometry as clinically indicated.</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">&#8226; Assess change in neurologic function prior to each treatment.</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">&#8226; Assess patient for third-space fluid collection prior to treatment.</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">&#8226; Monitor for diarrhea, stomatitis, and cutaneous toxicity.</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">&#8226; Monitor for clinically significant nausea and vomiting.</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">&#8226; Monitor serum methotrexate concentration daily starting 24 hours after the start of the methotrexate infusion and continue until serum methotrexate level is &#60;0.1 micromol/L (microM). If toxic concentrations of methotrexate with reduced clearance occur in the setting of renal insufficiency, consider emergent use of glucarpidase. Refer to UpToDate topic on \"Therapeutic use and toxicity of high-dose methotrexate\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">&#8226; Monitor daily fluid balance (intake and output), weight, CBC with differential, platelets, blood pressure, LFTs (AST, ALT, total bilirubin), and serum creatinine daily during and after methotrexate therapy until the methotrexate serum level is &#60;0.1 micromol/L (microM).</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">&#8226; Monitor cumulative doxorubicin dose. Reassess LVEF periodically during doxorubicin therapy as clinically indicated. Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"5\">Suggested dose alterations for toxicity:</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"5\">&#8226; <strong>Myelotoxicity:</strong></td> </tr> <tr> <td class=\"sublist2\" colspan=\"5\">- For cycles of cisplatin plus doxorubicin, hold treatment until ANC &#8805;750 cells/microL and platelet count is &#8805;75,000/microL. If ANC and platelets recovery is &#8804;7 days, no dose adjustment is required. If recovery is delayed &#62;7 days or if there is febrile neutropenia with prolonged hospitalization, decrease the cisplatin dose by 25 percent<sup>[1]</sup>.</td> </tr> <tr> <td class=\"sublist2\" colspan=\"5\">- For high dose methotrexate, if the ANC &#60;250 cells/microL or platelets &#60;50,000/microL, hold methotrexate until adequate hematologic recovery occurs<sup>[1]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">&#8226; <strong>Audiology:</strong> For any hearing loss with a threshold greater than 30 dB at less than or equal to 2 kHz, discontinue cisplatin<sup>[1]</sup>. Refer to UpToDate topic on \"<span style=\"font-size: 11pt; font-family: calibri,sans-serif;\">Overview of neurologic complications of platinum-based chemotherapy</span>\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">&#8226; <strong>Cardiotoxicity:</strong> For LVEF less than 50 percent or shortening fraction less than 28 percent, repeat MUGA or ECHO in one week. If the MUGA or ECHO is within normal limits, then proceed with chemotherapy. If LVEF does not normalize after one week, omit all further doxorubicin<sup>[1]</sup>. There are no prospective data on the use of the cardioprotective agent dexrazoxane in osteosarcoma therapy, particularly in children. Dexrazoxane may be used if a 10 percent decrease in LVEF or similar decrease within the normal range of shortening fraction (ECHO) occurs. Some clinicians add dexrazoxane once cumulative doxorubicin dose reaches 225 to 300 mg/m<sup>2</sup>. If cardioprotection is used, doxorubicin should be administered daily over 15 minutes immediately following dexrazoxane.</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"5\">&#8226; <strong>Hepatotoxicity:</strong></td> </tr> <tr> <td class=\"sublist2\" colspan=\"5\">- For elevated LFTs that are not methotrexate induced, delay methotrexate treatment for one week and administer methotrexate if ALT is less than 10 times normal.</td> </tr> <tr> <td class=\"sublist2\" colspan=\"5\">- For elevated LFTs that are probably methotrexate induced (ie, up to three weeks after methotrexate), it is expected that patients receiving high dose methotrexate will develop hypertransaminasemia and occasionally hyperbilirubinemia. These elevations can last up to two weeks following the methotrexate infusion and should not be considered toxicity requiring dose reduction or discontinuation of the drug. However, for total bilirubin greater than 1.5 times normal for longer than three weeks, discontinue methotrexate<sup>[1]</sup>. Refer to UpToDate topic on \"Therapeutic use and toxicity of high-dose methotrexate\".</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"5\">&#8226; <strong>Mucositis, severe abdominal pain, diarrhea, and typhlitis:</strong></td> </tr> <tr> <td class=\"sublist2\" colspan=\"5\">- For grade 4 mucositis or typhlitis or repeated grade 3 mucositis, hold cisplatin and doxorubicin until toxicity has resolved and then decrease subsequent doxorubicin total dose to 60 mg/m<sup>2</sup> per cycle<sup>[1]</sup>.</td> </tr> <tr> <td class=\"sublist2\" colspan=\"5\">- For grade 3 or 4 mucositis or diarrhea after methotrexate, consider leucovorin rescue dose adjustment<sup>&#165;[1]</sup>. Also, maximize measures for methotrexate elimination. Refer to UpToDate topic on \"Therapeutic use and toxicity of high-dose methotrexate\".</td> </tr> <tr> <td class=\"sublist2\" colspan=\"5\">- If grade 3 or 4 mucositis or diarrhea after methotrexate in week 4 (cycle 1) and it persists for greater than one week, omit week 5 methotrexate and proceed to week 6 of preoperative chemotherapy (or surgery)<sup>[1]</sup>.</td> </tr> <tr> <td class=\"sublist2_start\" colspan=\"5\">&#8226; <strong>Nephrotoxicity:</strong></td> </tr> <tr> <td class=\"sublist2\" colspan=\"5\">- Hold cisplatin if serum creatinine is greater than twice baseline or if GFR &#60;70 mL/min/1.73 m<sup>2</sup>. If renal function does not improve, omit cisplatin and administer doxorubicin alone. Cisplatin can be restarted in future courses if GFR improves to &#8805;70 mL/min/1.73 m<sup>2</sup>.</td> </tr> <tr> <td class=\"sublist2\" colspan=\"5\">- Hold methotrexate treatment if GFR &#60;70 mL/min/1.73 m<sup>2</sup> until GFR is &#8805;70 mL/min/1.73 m<sup>2</sup>. If renal function does not improve within one week, then omit methotrexate and proceed to the next possible cycle. If renal function subsequently improves, resume methotrexate<sup>[1]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"5\">&#8226; <strong>Peripheral neurotoxicity:</strong> Neuropathy is usually seen with cumulative doses of cisplatin greater than 400 mg/m<sup>2</sup>, although there is marked interindividual variation. Patients with mild neuropathy can continue to receive full cisplatin doses. However, if the neuropathy interferes with function, the risk of potentially disabling neurotoxicity must be weighed against the benefit of continued treatment. As per the original protocol, for grade 2 peripheral neurotoxicity, reduce cisplatin dose by 25 percent for all future courses; for &#8805;grade 3 peripheral neurotoxicity, omit cisplatin for all future cycles<sup>[1]</sup>. Refer to UpToDate topic on \"<span style=\"font-size: 11pt; font-family: calibri,sans-serif;\">Overview of neurologic complications of platinum-based chemotherapy</span>\".</td> </tr> <tr> <td colspan=\"5\"><strong>If there is a change in body weight of at least 10 percent (except for cases of limb loss during surgery), doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician who is trained in the use of this specific type of chemotherapy regimen. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; IM: intramuscular; ECHO: echocardiogram; G-CSF: granulocyte colony-stimulating factors; CBC: complete blood count; AST: aspartate aminotransferase; LVEF: ventricular ejection fraction; ANC: absolute neutrophil count; MUGA: multigated acquisition scan; LFTs: liver function tests; ALT: alanine aminotransferase; GFR: glomerular filtration rate.<br />* Chemotherapy doses should be calculated according to presurgery body surface area (using actual body weight) with no adjustment for postoperative limb loss<SUP>[1]</SUP>.<br />Î Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br /><FONT class=lozenge>â</FONT> Some pediatric centers limit the methotrexate dose to 20 grams<SUP>[3]</SUP>, regardless of the body surface area.<br />Â¥ The reversal of methotrexate action by leucovorin is competitive. Therefore, proportionately higher leucovorin concentrations are required to achieve rescue in the presence of high methotrexate levels. Specific dose modification schemas for leucovorin vary widely among protocols and institutions, but most schemas utilized are derived from Bleyer WA<SUP>[4,5]</SUP>. Refer to UpToDate topic on \"Therapeutic use and toxicity of high-dose methotrexate\" for further information on leucovorin rescue and UpToDate table titled \"Recommendations for dose adjustment of leucovorin (d,l-racemic mixture) for prolonged methotrexate excretion\" as an example of leucovorin dose adjustment.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Children's Oncology Group - Protocol AOST0331 (EURAMOS1): A phase III intergroup study; a randomized trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy (http://www.clinicaltrials.gov/ct2/show/NCT00134030?term=AOST0331&amp;rank=1, accessed December 17, 2012).</LI>&#xD;&#xA;<LI>Cisplatin injection, powder, lyophilized, for solution.&nbsp;United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed November 20, 2012).</LI>&#xD;&#xA;<LI>Meyers PA, et al. J Clin Oncol 2005; 23:2004.</LI>&#xD;&#xA;<LI>Bleyer WA. Cancer Treat Rev 1977; 4:87.</LI>&#xD;&#xA;<LI>Bleyer WA. Cancer 1978; 41:36.</LI></OL></div><div id=\"graphicVersion\">Graphic 87346 Version 9.0</div></div></div>"},"87347":{"type":"graphic_table","displayName":"NCI CTCAE v5 hypertension","title":"NCI CTCAE v5.0 hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 hypertension</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Hypertension</td> <td> <p>Adult: Systolic BP 120 to 139 mmHg or diastolic BP 80 to 89 mmHg</p> <hr /> <p>Pediatric: Systolic/diastolic BP &#62;90<sup>th</sup> percentile but &#60;95<sup>th</sup> percentile</p> <hr /> Adolescent: BP &#8805;120/80 even if &#60;95<sup>th</sup> percentile</td> <td> <p>Adult: Systolic BP 140 to 159 mmHg or diastolic BP 90 to 99 mmHg if previously WNL; change in baseline medical intervention indicated; recurrent or persistent (&#8805;24 hours); symptomatic increase by &#62;20 mmHg (diastolic) or to &#62;140/90 mmHg; monotherapy indicated or initiated</p> <hr /> <p>Pediatric and adolescent: Recurrent or persistent (&#8805;24 hours) BP &#62;ULN; monotherapy indicated; systolic and/or diastolic BP between the 95<sup>th</sup> percentile and 5 mmHg above the 99<sup>th</sup> percentile</p> <hr /> Adolescent: Systolic between 130 to 139 or diastolic between 80 to 89 even if &#60;95<sup>th</sup> percentile</td> <td> <p>Adult: Systolic BP &#8805;160 mmHg or diastolic BP &#8805;100 mmHg; medical intervention indicated; more than one drug or more intensive therapy than previously used indicated</p> <hr /> Pediatric and adolescent: Systolic and/or diastolic &#62;5 mmHg above the 99<sup>th</sup> percentile</td> <td>Adult and pediatric: Life-threatening consequences (eg, malignant hypertension, transient or permanent neurologic deficit, hypertensive crisis); urgent intervention indicated</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Hypertension is characterized by a pathological increase in blood pressure.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events; BP: blood pressure; WNL: within normal limits; ULN: upper limit of normal.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 87347 Version 7.0</div></div></div>"},"87348":{"type":"graphic_picture","displayName":"Alopecia areata 1","title":"Alopecia areata","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Alopecia areata</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/DERM/87348_Alopecia_areata_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This discrete area of hair loss is characteristic of alopecia areata.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87348 Version 3.0</div></div></div>"},"87350":{"type":"graphic_picture","displayName":"Drug rash PI","title":"Rash caused by drug allergy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rash caused by drug allergy</div><div class=\"cntnt\"><img style=\"width:334px; height:504px;\" src=\"images/PI/87350_Drug_rash_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This man's rash was caused by a drug he took.</div><div id=\"graphicVersion\">Graphic 87350 Version 1.0</div></div></div>"},"87355":{"type":"graphic_figure","displayName":"Desmosome in skin and mucous membranes","title":"The desmosome in skin and mucous membranes","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">The desmosome in skin and mucous membranes</div><div class=\"cntnt\"><img style=\"width:533px; height:604px;\" src=\"images/DERM/87355_Desmosome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The desmosome is a critical junction for cell to cell adhesion in&nbsp;the skin and mucous membranes. The major desmosomal proteins are&nbsp;desmogleins, desmocollins, plakoglobin, plakophilins, and&nbsp;desmoplakin. Desmogleins and desmocollins are transmembrane&nbsp;glycoproteins of the cadherin (calcium-dependent cell adhesion&nbsp;molecule) family. Plakoglobin and plakophilins are components of&nbsp;the desmosomal plaque. Desmoplakin binds to plakoglobin and links&nbsp;the desmosomal plaque to keratin filaments of the cytoskeleton.&nbsp;Envoplakin and periplakin are additional desmosomoal proteins found&nbsp;in the desmosomal plaque.</div><div id=\"graphicVersion\">Graphic 87355 Version 2.0</div></div></div>"},"87356":{"type":"graphic_figure","displayName":"Desmoglein compensation theory","title":"Desmoglein compensation theory","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Desmoglein compensation theory</div><div class=\"cntnt\"><img style=\"width:515px; height:669px;\" src=\"images/DERM/87356_Desmoglein_compensation_theory.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Graphic depiction of the desmoglein compensation theory. The&nbsp;desmoglein compensation theory is a proposed explanation for the&nbsp;correlation between the clinical features of pemphigus vulgaris and&nbsp; pemphigus foliaceus and the autoantibody profiles of these&nbsp;disorders. In the skin, desmoglein 1 (Dsg1) is expressed mostly in&nbsp;the upper portions of the epidermis, while desmoglein 3 (Dsg3) is&nbsp;expressed mostly in the basal and suprabasal layers of the&nbsp;epithelium. In the mucous membranes, Dsg3 is present in abundance&nbsp;throughout the epithelium, while Dsg1 is expressed to a much lower&nbsp;degree. Mucosal dominant pemphigus vulgaris (A) is characterized by&nbsp;autoantibodies against Dsg 3 and results in only mucosal lesions&nbsp;because Dsg1 compensates for the loss of Dsg3 in the skin. In the&nbsp;mucous membranes, Dsg1 cannot compensate resulting in&nbsp;intraepithelial blistering. In mucocutaneous pemphigus vulgaris&nbsp;(B), autoantibodies against both Dsg1 and Dsg3 are present. Thus, compensation occurs neither in the skin nor the mucous membranes,&nbsp;and blistering occurs in both locations. Pemphigus foliaceus (C) is&nbsp;characterized by autoantibodies against only Dsg1. This results in&nbsp;very superficial blisters in the skin. The mucous membranes are&nbsp;spared due to high levels of Dsg3 expression throughout the&nbsp;epithelium and low levels of Dsg1 expression.</div><div id=\"graphicVersion\">Graphic 87356 Version 1.0</div></div></div>"},"87383":{"type":"graphic_table","displayName":"NCI CTCAE v5 thromboembolic event","title":"NCI CTCAE v5.0 thromboembolic event","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">NCI CTCAE v5.0 thromboembolic event</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Adverse event</td> <td class=\"subtitle1\">Grade 1</td> <td class=\"subtitle1\">Grade 2</td> <td class=\"subtitle1\">Grade 3</td> <td class=\"subtitle1\">Grade 4</td> <td class=\"subtitle1\">Grade 5</td> </tr> <tr> <td>Thromboembolic event</td> <td>Medical intervention not indicated (eg, superficial thrombosis)</td> <td>Medical intervention indicated</td> <td>Urgent medical intervention indicated (eg, pulmonary embolism or intracardiac thrombus)</td> <td>Life-threatening consequences with hemodynamic or neurologic instability</td> <td>Death</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A thromboembolic event is characterized by occlusion of a vessel by a thrombus and/or embolism to another vessel. Refer to table on arterial thromboembolism for arterial thrombi.</div><div class=\"graphic_footnotes\">NCI CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events.</div><div class=\"graphic_reference\">Reproduced from: Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: <a href=\"https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf\" target=\"_blank\">https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf</a> (Accessed March 27, 2018).</div><div id=\"graphicVersion\">Graphic 87383 Version 7.0</div></div></div>"},"87390":{"type":"graphic_table","displayName":"Gender nonconformity transition plan","title":"Examples of ways that youth, providers, and caretakers can assist gender-nonconforming youth create a transition plan according to youth, family/parent, and provider priorities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of ways that youth, providers, and caretakers can assist gender-nonconforming youth create a transition plan according to youth, family/parent, and provider priorities</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Goal<br /> (examples)</td> <td class=\"subtitle1\" colspan=\"3\">Specific action(s)</td> </tr> <tr> <td class=\"subtitle2\">Youth</td> <td class=\"subtitle2\">Family/parent</td> <td class=\"subtitle2\">Therapist/other child health professionals</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Youth priorities</td> </tr> <tr> <td class=\"indent1\">Be allowed to dress in the gender they assert</td> <td>Pick out clothes that express asserted gender and are school and age appropriate</td> <td> <p>Assist the youth with in-store, online shopping</p> Allow the youth to cut hair in style she/he wants</td> <td>Reassure parents that allowing a youth to express himself/herself is generally desirable for self-esteem and identity development</td> </tr> <tr> <td class=\"indent1\">Be called by asserted name and pronoun</td> <td>Tell friends that you would like them to use your asserted name and desired pronoun</td> <td> <p>Make using asserted name a priority for self and family members; apologize and try again when mistakes are made</p> Engage with school, peers and parents, and other family and social settings to introduce and find ways to maintain change in name and pronoun</td> <td>Impress upon parents and others that use of the asserted name and pronoun is very important to the youth; it sends the youth a message that her/his identity is acknowledged and that her/his needs are important</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Family/parent priorities</td> </tr> <tr> <td class=\"indent1\">Help the youth disclose at a time and in a manner that allows parents to prepare important support persons</td> <td> <p>May need to delay full social transition until parents have talked to and prepared other support persons</p> <p>Can fully social transition at home with support of parents</p> Consider and tell parent if there are any persons who might make transition unsafe</td> <td> <p>Work with teachers, guidance office, and principal to create plan for disclosure to peers</p> Have plan for supporting the youth when there are negative reactions to disclosure</td> <td> <p>Work with schools to increase their knowledge of gender nonconforming youth and needs specific to this youth and family</p> Engage agencies that may help parents by taking the role of advocate so that parents can maintain role of caregiver</td> </tr> <tr> <td class=\"indent1\">Maintain plans for safety with potential for bullying and assault</td> <td> <p>Be alert to persons or situations that present as negative or threatening regarding their gender expression</p> Immediately report to teacher and parent(s) if persons are bullying or threatening</td> <td> <p>Discuss with principal and school zero tolerance policies on bullying and assault</p> Consider which past and present persons and settings may be negative or harmful to the youth's transition goals</td> <td>Work with youth and parents regarding healthy ways to express self, react to negative social interactions, and maintain safety with persons who are not supportive or intolerant</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Mental health provider priorities</td> </tr> <tr> <td class=\"indent1\">Prevent self-harm and suicide</td> <td>Agree to safety plan with therapist</td> <td>Know safety plan and be one of the responsible adults to whom the youth can report suicidal or self-harm thoughts</td> <td>Encourage total honesty and disclosure when discussing self-harm, suicidality, and suicide attempts; review and revise safety plan as needed</td> </tr> <tr> <td class=\"indent1\">Family/parent acceptance</td> <td>Understand that parents and other families may \"transition\" and accept their identity in a somewhat different time frame than theirs</td> <td>Be open to individual, couples, or family therapy to learn how to adapt to the youth's asserted identity and cope with their own feelings</td> <td>Assist parents, siblings, and additional significant caregivers with their own thoughts and feelings with the transition plan</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Michelle Forcier, MD, MPH, and Johanna Olson-Kennedy, MD.</div><div id=\"graphicVersion\">Graphic 87390 Version 5.0</div></div></div>"},"87391":{"type":"graphic_table","displayName":"Obstructed labor injuries","title":"Obstructed labor injury complex","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Obstructed labor injury complex</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Urologic injury</td> </tr> <tr> <td>Vesicovaginal fistula</td> </tr> <tr> <td>Urethrovaginal fistula</td> </tr> <tr> <td>Ureterovaginal fistula</td> </tr> <tr> <td>Uterovesical fistula</td> </tr> <tr> <td>Complete urethral loss</td> </tr> <tr> <td>Stress urinary incontinence</td> </tr> <tr> <td>Secondary hydroureteronephrosis</td> </tr> <tr> <td>Renal failure</td> </tr> <tr> <td class=\"subtitle1_single\">Gynecologic injury</td> </tr> <tr> <td>Amenorrhea</td> </tr> <tr> <td>Vaginal stenosis</td> </tr> <tr> <td>Cervical damage or complete cervical destruction</td> </tr> <tr> <td>Secondary pelvic inflammatory disease</td> </tr> <tr> <td>Secondary infertility</td> </tr> <tr> <td class=\"subtitle1_single\">Gastrointestinal injury</td> </tr> <tr> <td>Rectovaginal fistula</td> </tr> <tr> <td>Acquired rectal atresia</td> </tr> <tr> <td>Anal sphincter incompetence</td> </tr> <tr> <td class=\"subtitle1_single\">Musculoskeletal injury</td> </tr> <tr> <td>Osteitis pubis</td> </tr> <tr> <td class=\"subtitle1_single\">Neurologic injury</td> </tr> <tr> <td>Foot-drop</td> </tr> <tr> <td>Complex neuropathic bladder dysfunction</td> </tr> <tr> <td class=\"subtitle1_single\">Dermatologic injury</td> </tr> <tr> <td>Chronic excoriation of skin from maceration in urine</td> </tr> <tr> <td class=\"subtitle1_single\">Fetal injury</td> </tr> <tr> <td>93 percent case fatality in prolonged obstructed labor</td> </tr> <tr> <td class=\"subtitle1_single\">Social injury</td> </tr> <tr> <td>Social isolation</td> </tr> <tr> <td>Divorce</td> </tr> <tr> <td>Worsening poverty</td> </tr> <tr> <td>Malnutrition</td> </tr> <tr> <td>Suicide</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Spectrum of trauma occurring in the obstructed labor injury complex.</div><div class=\"graphic_reference\">Reproduced with permission from: Arrowsmith S, Hamlin EC, Wall LL. Obstructed labor injury complex: obstetric fistula formation and the multifaceted morbidity of maternal birth trauma in the developing world. Obstet Gynecol Surv 1996; 51:568. Copyright Â© 2012 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87391 Version 4.0</div></div></div>"},"87392":{"type":"graphic_picture","displayName":"Kaposi sarcoma of gastric mucosa","title":"Kaposi sarcoma of gastric mucosa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Kaposi sarcoma of gastric mucosa</div><div class=\"cntnt\"><img style=\"width:310px; height:377px;\" src=\"images/PULM/87392_Kaposi_sarc_gast_mucosa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gastric lesions of Kaposi sarcoma in an HIV-positive patient who presented with an upper gastrointestinal bleed, endobronchial and skin lesions of Kaposi sarcoma, and a hemorrhagic pleural effusion.</div><div id=\"graphicVersion\">Graphic 87392 Version 1.0</div></div></div>"},"87393":{"type":"graphic_picture","displayName":"Endobronchial lesion of Kaposi sarcoma","title":"Endobronchial lesion of Kaposi sarcoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Endobronchial lesion of Kaposi sarcoma</div><div class=\"cntnt\"><img style=\"width:317px; height:384px;\" src=\"images/PULM/87393_Endobr_les_Kapo_sarcom.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous plaques of Kaposi sarcoma seen on bronchoscopy just proximal to the main carina in a patient who presented with an upper gastrointestinal bleed, gastric mucosal and skin lesions of Kaposi sarcoma, and a hemorrhagic pleural effusion.</div><div id=\"graphicVersion\">Graphic 87393 Version 1.0</div></div></div>"},"87394":{"type":"graphic_picture","displayName":"Eosinophilic cellulitis","title":"Skin appearance in eosinophilic cellulitis (Wells syndrome)","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Skin appearance in eosinophilic cellulitis (Wells syndrome)</div><div class=\"cntnt\"><img style=\"width:517px; height:391px;\" src=\"images/HEME/87394_Eosinophilic_cellulitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Eosinophilic cellulitis (Wells syndrome) is characterized by areas of single or multiple cellulitic plaques, often on the extremities, which typically resolve in two to eight weeks. Unlike bacterial cellulitis, the involved skin is not warm. Blood eosinophilia is found in approximately one-half of cases.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87394 Version 4.0</div></div></div>"},"87395":{"type":"graphic_diagnosticimage","displayName":"Hemorrhagic pleural effusion in Kaposi sarcoma","title":"Chest imaging of hemorrhagic pleural effusions in Kaposi sarcoma","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Chest imaging of hemorrhagic pleural effusions in Kaposi sarcoma</div><div class=\"cntnt\"><img style=\"width:513px; height:202px;\" src=\"images/PULM/87395_Hem_pleu_eff_Kap_sarc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph (A) and chest computed tomography (B) showing bilateral pleural effusions in a patient with AIDS-related cutaneous, endobronchial, and gastric involvement with Kaposi sarcoma.</div><div id=\"graphicVersion\">Graphic 87395 Version 2.0</div></div></div>"},"87396":{"type":"graphic_algorithm","displayName":"Obstet fistula low resource setting","title":"Pathway to obstetric fistulas in low-resource settings","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Pathway to obstetric fistulas in low-resource settings</div><div class=\"cntnt\"><img style=\"width:538px; height:608px;\" src=\"images/OBGYN/87396_Obstet_fistula_low_setting.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: The Worldwide Fistula Fund. Copyright &copy; 2012.</div><div id=\"graphicVersion\">Graphic 87396 Version 1.0</div></div></div>"},"87397":{"type":"graphic_picture","displayName":"Aeroneb Go mesh nebulizer","title":"Aeroneb Go mesh nebulizer","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Aeroneb Go mesh nebulizer</div><div class=\"cntnt\"><img style=\"width:504px; height:296px;\" src=\"images/PULM/87397_Aeroneb_Go_mesh_neb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Aeroneb Go (Aerogen) is a type of mesh nebulizer that is portable, battery-operated, and has a small residual medication volume.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2012 Aerogen. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87397 Version 1.0</div></div></div>"},"87415":{"type":"graphic_table","displayName":"Simple complicated obstetric fistulas","title":"Obstetric urogenital fistulas: Simple versus complicated","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Obstetric urogenital fistulas: Simple versus complicated</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Defining criteria</td> <td class=\"subtitle1\">Good prognosis/simple</td> <td class=\"subtitle1\">Complicated/uncertain</td> </tr> <tr> <td>Number of fistula</td> <td>Single</td> <td>Multiple</td> </tr> <tr> <td>Site</td> <td>Vesicovaginal (VVF)</td> <td>Rectovaginal (RVF) mixed VVF/RVF involvement of cervix</td> </tr> <tr> <td>Size (diameter)</td> <td>&#60;4 cm</td> <td>&#62;4 cm</td> </tr> <tr> <td>Involvement of the urethra/continence mechanism</td> <td>Absent</td> <td>Present</td> </tr> <tr> <td>Scarring of vaginal tissue</td> <td>Absent</td> <td>Present</td> </tr> <tr> <td>Presence of circumferential defect*</td> <td>Absent</td> <td>Present</td> </tr> <tr> <td>Degree of tissue loss</td> <td>Minimal</td> <td>Extensive</td> </tr> <tr> <td>Ureter/bladder involvement</td> <td>Ureters are inside the bladder, not draining into the vagina</td> <td>Ureters are draining into the vagina, bladder may have stones</td> </tr> <tr> <td>Number of attempts at repair</td> <td>No previous attempt</td> <td>Failed previous attempts of repair</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Criteria based on the degree of anticipated difficulty of the repair.</div><div class=\"graphic_footnotes\">* The complete separation of the urethra from the bladder.</div><div class=\"graphic_reference\">Modified from: Lewis G, de Bernis L (Eds). Obstetric Fistula: Guiding principles for clinical management and programme development. World Health Organization, Geneva, 2006.</div><div id=\"graphicVersion\">Graphic 87415 Version 1.0</div></div></div>"},"87416":{"type":"graphic_table","displayName":"Classification progestins in combined OC pills","title":"Classification of progestins used in combined oral contraceptive pills","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of progestins used in combined oral contraceptive pills</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">First generation</td> </tr> <tr> <td> <ul> <li>Norethindrone acetate</li> <li>Ethynodiol diacetate</li> <li>Lynestrenol</li> <li>Norethynodrel</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Second generation</td> </tr> <tr> <td> <ul> <li>dl-Norgestrel</li> <li>Levonorgestrel</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Third generation</td> </tr> <tr> <td> <ul> <li>Desogestrel</li> <li>Gestodene</li> <li>Norgestimate</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Unclassified</td> </tr> <tr> <td> <ul> <li>Drospirenone</li> <li>Cyproterone acetate</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Reust CE, Espinoza SA, Ruplinger J, Swofford S. What is the approach to intermenstrual bleeding in a woman taking a combined oral contraceptive? Evidence-Based Practice 2012; 15:29. Copyright &copy; 2013 Family Physicians Inquiries Network.</div><div id=\"graphicVersion\">Graphic 87416 Version 1.0</div></div></div>"},"87420":{"type":"graphic_diagnosticimage","displayName":"Thoracoabdominal aortic aneurysm on axial CT","title":"Thoracoabdominal aortic aneurysm on axial CT","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Thoracoabdominal aortic aneurysm on axial CT</div><div class=\"cntnt\"><img style=\"width:597px; height:480px;\" src=\"images/RADIOL/87420_Suprarenal_AAA_axial_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The series of axial CT images shows a distal thoracoabdominal aortic aneurysm. The aneurysmal segment of the suprarenal aorta (arrows) contrasts to the normal-diameter infrarenal aorta (arrowhead, C).</div><div class=\"graphic_footnotes\">AAA: abdominal aortic aneurysm; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 87420 Version 1.0</div></div></div>"},"87421":{"type":"graphic_picture","displayName":"Plantar neuropathic diabetic foot wound","title":"Plantar neuropathic diabetic foot wound","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plantar neuropathic diabetic foot wound</div><div class=\"cntnt\"><img style=\"width:354px; height:472px;\" src=\"images/SURG/87421_Plantar_neuropathic_diabet.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Plantar neuropathic diabetic foot wound following deroofing of bulla with exposed tendon.</div><div id=\"graphicVersion\">Graphic 87421 Version 1.0</div></div></div>"},"87426":{"type":"graphic_picture","displayName":"Dermatitis herpetiformis knees PI","title":"Dermatitis herpetiformis","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Dermatitis herpetiformis</div><div class=\"cntnt\"><img style=\"width:576px; height:377px;\" src=\"images/PI/87426_Dermatit_herpetifor_knee_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The rash of dermatitis herpetiformis often appears on the knees, elbows, forearms or buttocks. The bumps or blisters are itchy.</div><div id=\"graphicVersion\">Graphic 87426 Version 1.0</div></div></div>"},"87435":{"type":"graphic_table","displayName":"Warfarin maintenance dose adjustment","title":"Adjustment of maintenance warfarin dosing based on the RE-LY trial","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Adjustment of maintenance warfarin dosing based on the RE-LY trial</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">INR</td> <td class=\"subtitle1\">Adjustment in total mg of warfarin per week</td> </tr> <tr> <td>&#8804;1.5</td> <td>Increase 15 percent per week</td> </tr> <tr> <td>1.51 to 1.99</td> <td>Increase 10 percent per week*</td> </tr> <tr> <td>2 to 3</td> <td>No change</td> </tr> <tr> <td>3.01 to 4</td> <td>Decrease 10 percent per week</td> </tr> <tr> <td>4.01 to 4.99</td> <td>Hold one dose; restart with dose decreased by 10 percent per week</td> </tr> <tr> <td>5 to 8.99</td> <td>Hold until INR is 2 to 3; restart with dose decreased by 15 percent per week</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The table provides an algorithm for monitoring and adjustment of maintenance warfarin dosing with a goal of maintaining the INR between 2 and 3. The maintenance dose algorithm requires that INR measurements are made at a maximum interval of every four weeks, with at least weekly monitoring for out of range INRs (&lt;2 or &gt;3).&nbsp;All percent changes in warfarin dosage are adjusted based on the current INR value and calculated based upon the sum of the previous seven days of warfarin doses (also known as mg of warfarin per week). The increase or decrease in warfarin dose per week is distributed over the following week, preferably as evenly as possible to avoid large fluctuations. <br />This algorithm is not applicable to selecting a warfarin starting dose or for adjusting the starting dose during the first week of treatment. Refer to UpToDate&nbsp;content on the use of warfarin for details.</div><div class=\"graphic_footnotes\">RE-LY: Randomized Evaluation of Long-term anticoagulation therapY; INR: international normalized ratio. <br />* As an example, a&nbsp;patient taking 30 mg of warfarin per week with an INR of 1.8 would increase the dose by 10 percent (increase by 3 mg to 33 mg per week). The new weekly dose (33 mg) could be distributed as 5 mg daily on six&nbsp;days of the week and 3 mg on the remaining day. Several alternate means of distributing the dose could also be used (eg, 5 mg daily on&nbsp;five days of the week and 4 mg daily on the remaining&nbsp;two days).</div><div class=\"graphic_reference\">Data from: Van Spall HG, Wallentin L, Yusuf S, et al. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation (RE-LY) trial. Circulation 2012; 126:2309.</div><div id=\"graphicVersion\">Graphic 87435 Version 5.0</div></div></div>"},"87440":{"type":"graphic_picture","displayName":"Chronic allergic contact dermatitis","title":"Allergic contact dermatitis","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Allergic contact dermatitis</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87440_Chronic_ACD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A well-demarcated patch of chronic allergic contact dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87440 Version 4.0</div></div></div>"},"87441":{"type":"graphic_picture","displayName":"Plaque psoriasis 2","title":"Plaque psoriasis","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Plaque psoriasis</div><div class=\"cntnt\"><img style=\"width:576px; height:433px;\" src=\"images/DERM/87441_Plaque_psoriasis_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large, infiltrated, erythematous plaque with well-demarcated margins in a patient with plaque psoriasis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" style=\"font-style: italic;\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87441 Version 6.0</div></div></div>"},"87442":{"type":"graphic_picture","displayName":"Plaque psoriasis 1","title":"Plaque psoriasis","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Plaque psoriasis</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87442_Plaque_psoriasis_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Elevated red plaques with a sharply defined margin and symmetric distribution in a patient with chronic plaque psoriasis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87442 Version 4.0</div></div></div>"},"87443":{"type":"graphic_picture","displayName":"Plaque psoriasis 3","title":"Plaque psoriasis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plaque psoriasis</div><div class=\"cntnt\"><img style=\"width:432px; height:576px;\" src=\"images/DERM/87443_Plaque_psoriasis_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Well-demarcated, raised, erythematous plaques with a silvery-white scaly surface are characteristic of plaque psoriasis.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87443 Version 4.0</div></div></div>"},"87445":{"type":"graphic_table","displayName":"Clinical decisions and prognosis","title":"Impact of prognosis on selected clinical decisions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Impact of prognosis on selected clinical decisions</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Prognosis</td> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Clinical decision to be considered</td> </tr> <tr class=\"divider_bottom\"> <td>&#60;4 to 6 weeks</td> <td>Depression at end of life</td> <td>Use methylphenidate to treat depression instead of&nbsp;a selective serotonin reuptake inhibitor as SSRIs&nbsp;require four to six weeks to take effect<sup>[1]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>&#60;3 months</td> <td>Hyperlipidemia</td> <td>Discontinuation of statins<sup>[2,3]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>&#62;3 months</td> <td>Spinal metastases</td> <td>Surgery for spinal cord compression due to metastatic cancer<sup>[4]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>&#60;6 months</td> <td>Hospice</td> <td>Referral to hospice</td> </tr> <tr class=\"divider_bottom\"> <td>&#60;1 to 2 years</td> <td>Asymptomatic abdominal aortic aneurysm</td> <td>Non-operative management of asymptomatic abdominal aortic aneurysm<sup>[5-8]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>&#60;2 to 3 years</td> <td>Prevention macrovascular complications in diabetes mellitus</td> <td>Blood pressure/lipid control in diabetes mellitus unlikely to prevent macrovascular complications<sup>[9]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>&#60;2 to 3 years</td> <td>Hypertension</td> <td>Lowering blood pressure &#60;140/80 unlikely to improve cardiovascular outcomes<sup>[2,10]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>&#60;5 years</td> <td>Screening for breast cancer</td> <td>Discontinuation of breast cancer screening<sup>[11-14]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>&#60;5 years</td> <td>Heart valve replacement</td> <td>Stented bioprosthetic heart valve may be preferable to a metallic valve<sup>[15]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>&#60;5 years</td> <td>Glycemic control in diabetes</td> <td>Limited benefit to lowering target for A1C to &#60;8 percent<sup>[2,9]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>&#60;7 years</td> <td>Screening for colorectal cancer</td> <td>Discontinuation of colorectal cancer screening<sup>[11,16-18]</sup></td> </tr> <tr> <td>&#60;8 years</td> <td>Prevention microvascular complications in diabetes</td> <td>Tight glycemic control in diabetes mellitus is unlikely to prevent microvascular complications<sup>[2,9,19,20]</sup></td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Block SD. Perspectives on care at the close of life. Psychological considerations, growth, and transcendence at the end of life: the art of the possible. JAMA 2001; 285:2898.</li>&#xD;&#xA;    <li>Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsidering medication appropriateness for patients late in life. Arch Intern Med 2006; 166:605.</li>&#xD;&#xA;    <li>Vollrath AM, Sinclair C, Hallenbeck J. Discontinuing cardiovascular medications at the end of life: lipid-lowering agents. J Palliat Med 2005; 8:876.</li>&#xD;&#xA;    <li>Abrahm JL, Banffy MB, Harris MB. Spinal cord compression in patients with advanced metastatic cancer: \"all I care about is walking and living my life\". JAMA 2008; 299:937.</li>&#xD;&#xA;    <li>Fillinger M. Who should we operate on and how do we decide: predicting rupture and survival in patients with aortic aneurysm. Semin Vasc Surg 2007; 20:121.</li>&#xD;&#xA;    <li>Conway KP, Byrne J, Townsend M, Lane IF. Prognosis of patients turned down for conventional abdominal aortic aneurysm repair in the endovascular and sonographic era: Szilagyi revisited? J Vasc Surg 2001; 33:752.</li>&#xD;&#xA;    <li>Lederle FA, Johnson GR, Wilson SE, et al. Rupture rate of large abdominal aortic aneurysms in patients refusing or unfit for elective repair. JAMA 2002; 287:2968.</li>&#xD;&#xA;    <li>Mohan IV, Harris PL. When not to operate for abdominal aortic aneurysms. Semin Interv Cardiol 2000; 5:15.</li>&#xD;&#xA;    <li>Brown AF, Mangione CM, Saliba D, Sarkisian CA. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 2003; 51:S265.</li>&#xD;&#xA;    <li>Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358:1887.</li>&#xD;&#xA;    <li>Walter LC, Lewis CL, Barton MB. Screening for colorectal, breast, and cervical cancer in the elderly: a review of the evidence. Am J Med 2005; 118:1078.</li>&#xD;&#xA;    <li>Warner E. Clinical practice. Breast-cancer screening. N Engl J Med 2011; 365:1025.</li>&#xD;&#xA;    <li>Breast cancer screening in older women. American Geriatrics Society Clinical Practice Committee. J Am Geriatr Soc 2000; 48:842.</li>&#xD;&#xA;    <li>U.S. Preventive Services Task Force: Screening for Breast Cancer. U.S. Preventive Services Task Force 2009.</li>&#xD;&#xA;    <li>Rahimtoola SH. Choice of prosthetic heart valve in adults an update. J Am Coll Cardiol 2010; 55:2413.</li>&#xD;&#xA;    <li>Walter LC, Lindquist K, Nugent S, et al. Impact of age and comorbidity on colorectal cancer screening among older veterans. Ann Intern Med 2009; 150:465.</li>&#xD;&#xA;    <li>Colon cancer screening (USPSTF recommendation). U.S. Preventive Services Task Force. J Am Geriatr Soc 2000; 48:333.</li>&#xD;&#xA;    <li>U.S. Preventive Services Task Force: Screening for Colorectal Cancer. U.S. Preventive Services Task Force 2008.</li>&#xD;&#xA;    <li>Huang ES, Zhang Q, Gandra N, et al. The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: a decision analysis. Ann Intern Med 2008; 149:11.</li>&#xD;&#xA;    <li>Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009; 53:298.</li>&#xD;&#xA;</ol>&#xD;&#xA;Modified with permission from: Yourman LC, Lee SJ, Schonberg MA, et al. Prognostic indices for older adults. A systematic review. JAMA 2012; 307:182. Copyright &copy; 2012 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87445 Version 4.0</div></div></div>"},"87446":{"type":"graphic_picture","displayName":"Laminaria","title":"Laminaria","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Laminaria</div><div class=\"cntnt\"><img style=\"width:586px; height:329px;\" src=\"images/OBGYN/87446_Laminaria.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Seaweed laminaria japonica. Used for cervical dilation.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2014 MedGyn Products, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87446 Version 2.0</div></div></div>"},"87447":{"type":"graphic_picture","displayName":"Dilapan","title":"Osmotic cervical dilator","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Osmotic cervical dilator</div><div class=\"cntnt\"><img style=\"width:590px; height:393px;\" src=\"images/OBGYN/87447_Dilapan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dilapan-S.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2014 MEDICEM.</div><div id=\"graphicVersion\">Graphic 87447 Version 1.0</div></div></div>"},"87448":{"type":"graphic_picture","displayName":"Sopher uterine forceps","title":"Sopher uterine forceps","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Sopher uterine forceps</div><div class=\"cntnt\"><img style=\"width:586px; height:426px;\" src=\"images/OBGYN/87448_Sopher_uterine_forceps.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2014 MedGyn Products, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87448 Version 1.0</div></div></div>"},"87449":{"type":"graphic_picture","displayName":"Bierer uterine forceps","title":"Bierer uterine forceps","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Bierer uterine forceps</div><div class=\"cntnt\"><img style=\"width:586px; height:487px;\" src=\"images/OBGYN/87449_Bierer_uterine_forceps.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2014 MedGyn Products, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87449 Version 1.0</div></div></div>"},"87450":{"type":"graphic_table","displayName":"Treatment of acute episodes of HAE in adults and children","title":"Treatment of acute episodes of hereditary angioedema (HAE) in adults and children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of acute episodes of hereditary angioedema (HAE) in adults and children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Availability</td> <td class=\"subtitle1\">Dosing</td> <td class=\"subtitle1\">Precautions</td> </tr> <tr class=\"divider_bottom\"> <td> <p>C1 inhibitor concentrate (plasma-derived)</p> (Berinert, Berinert P, Cinryze)</td> <td>In United States: <ul class=\"decimal_heading\"> <li>Berinert </li> <li>Cinryze </li> </ul> Other countries: <ul class=\"decimal_heading\"> <li>Berinert or Berinert P </li> <li>Cinryze </li> </ul> </td> <td>20 units per kg body weight given IV over 10 minutes. Symptoms usually stabilize in 30 minutes. Second dose uncommonly needed but may be given 30 minutes to&nbsp;2 hours after first.</td> <td>Do not shake solution because protein will denature. Cinryze not FDA-approved for acute attacks, but has efficacy.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Recombinant C1 inhibitor</p> Conestat alfa (Ruconest, Rhucin)</td> <td>Europe, United States, some other countries.</td> <td>50 units per kg body weight for patients &#60;84 kg. 4200 units (2 vials) for those &#8805;84 kg. Second dose rarely needed.</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Bradykinin B<sub>2</sub> receptor antagonist</p> Icatibant (Firazyr)</td> <td> <p>United States and many other countries.</p> Approved in the United States for individuals over the age of 18 years.</td> <td>30 mg slow subcutaneous infusion (because of volume) in abdominal area. Second dose needed in about 10% of patients and can be given&nbsp;6 hours after first. Max of three doses in 25 hours.</td> <td>Caution in patients with unstable angina. Mild injection site reactions are common.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Kallikrein inhibitor</p> Ecallantide (Kalbitor)</td> <td> <p>United States only.</p> Approved in the United States for individuals over the age of 12 years.</td> <td>30 mg (3 doses of 10 mg each) given at three separate sites, subcutaneously in abdomen, upper arm, or thigh and away from site of angioedema. May be repeated in 1 hour.</td> <td>Rare allergy reaction reported usually in &#60;1 hour. Should be administered by a clinician or nurse in a medical facility equipped to treat anaphylaxis.</td> </tr> <tr> <td>Plasma</td> <td> <ul> <li>Solvent detergent treated plasma (S/D plasma) (preferred) </li> <li>Fresh frozen plasma (FFP) </li> </ul> </td> <td>2 units initially. Can be repeated every&nbsp;2 to&nbsp;4 hours if needed.</td> <td>Monitor for volume overload in patients with underlying conditions predisposing to volume overload. Theoretical risk of transmission of blood-borne pathogens.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenously; FDA: US Food and Drug Administration; IgE: immunoglobulin E.</div><div id=\"graphicVersion\">Graphic 87450 Version 18.0</div></div></div>"},"87451":{"type":"graphic_figure","displayName":"Pathways involved in kinin-mediated angioedema/actions of drugs","title":"Pathways involved in kinin-mediated angioedema and actions of drugs","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Pathways involved in kinin-mediated angioedema and actions of drugs</div><div class=\"cntnt\"><img style=\"width:592px; height:523px;\" src=\"images/ALLRG/87451_HAE_pathways.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">C4: complement component 4; C1INH: C1 inhibitor.<br />* In the disorder hereditary angioedema (HAE) with factor XII mutations, factor XII may&nbsp;be prone to excessive activation.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Morgan PB. Hereditary angioedema&mdash;therapies old and new. N Engl J Med 2010; 363:581.</li>&#xD;&#xA;    <li>Longhurst H, Cicardi M. Hereditary angio-oedema. Lancet 2012; 379:474.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 87451 Version 8.0</div></div></div>"},"87452":{"type":"graphic_table","displayName":"Cancer presentations with a median survival of 6 months or less","title":"Clinical characteristics of patients with a variety of tumor types and a median survival of 6 months or less","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical characteristics of patients with a variety of tumor types and a median survival of 6 months or less</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Solid cancer by site</td> <td class=\"subtitle1\">Clinical factors</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Breast cancer</td> </tr> <tr> <td class=\"indent1\">Any metastatic breast carcinoma with one or more of the following presentations:</td> <td> <p>KPS &#60;60 (ECOG performance status &#62;2)</p> <p>Serum calcium &#62;11.2 mg/dL</p> <p>Epidural spinal cord compression with decreased ability to walk</p> <p>Serum C-reactive protein &#62;10 mg/L and serum albumin &#60;3.5 g/dL</p> Peritoneal or leptomeningeal metastases</td> </tr> <tr> <td class=\"indent1\">Any metastatic breast carcinoma with three or more of the following presentations:</td> <td> <p>KPS &#60;80 (ECOG performance status &#8805;2)</p> <p>Serum lactate dehydrogenase (LDH)&nbsp;&#62;500 IU/L</p> <p>Any liver metastasis</p> <p>At least 2 sites of metastases</p> <p>Disease-free interval from initial presentation to metastatic disease of &#60;24 months</p> <p>Recurrent or refractory disease after initial chemotherapy</p> Estrogen receptor-negative/progesterone receptor-negative tumor</td> </tr> <tr> <td class=\"indent1\">Metastatic breast carcinoma with brain metastases and one or more of the following presentations:</td> <td> <p>KPS &#60;80 (ECOG performance status &#8805;2)</p> <p>&#8805;2 brain metastases plus extracranial metastases</p> Tumor both estrogen receptor and progesterone receptor-negative </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Primary brain cancer</td> </tr> <tr> <td class=\"indent1\">Glioblastoma with one or more of the following presentations:</td> <td> <p>KPS &#60;70 (ECOG performance status &#8805;2)</p> <p>Suboptimal surgical resection or unresectable disease</p> Progressive or refractory disease despite initial treatment (unresponsive to treatment)</td> </tr> <tr> <td class=\"indent1\">Glioblastoma with two or more of the following presentations:</td> <td> <p>KPS &#60;90 (ECOG performance status &#8805;1)</p> <p>Age &#62;55 years</p> <p>Recurrent disease after initial treatment</p> <p>Lesion in critical hemispheric brain region</p> <p>Tumor volume &#62;50 cm<sup>3</sup> prior to resection</p> <p>Hemoglobin &#60;12 g/dL</p> Platelet count &#62; upper limit normal</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Digestive system neoplasms</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Colorectal cancer</td> </tr> <tr> <td class=\"indent1\">Metastatic colorectal cancer with one or more of the following presentations:</td> <td> <p>KPS &#60;70 (ECOG performance status &#8805;2)</p> <p>Age &#62;75 years</p> Brain metastases with KPS &#60;80, age &#62;70 years, extracranial metastases, or &#8805;2 brain lesions</td> </tr> <tr> <td class=\"indent1\">Metastatic colorectal carcinoma with two or more of the following presentations:</td> <td> <p>KPS &#60;90 (ECOG performance status &#8805;1)</p> <p>Peritoneal carcinomatosis</p> <p>&#62;2 metastatic sites</p> <p>Malignant ascites</p> Chemotherapy - refractory disease </td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Esophageal and gastric cancers</td> </tr> <tr> <td class=\"indent1\">Locally advanced or metastatic esophageal or gastric cancer with one or more of the following presentations:</td> <td> <p>KPS &#60;80 (ECOG performance status &#62;1)</p> Recurrent or refractory disease, with disease-free interval &#60;6 months</td> </tr> <tr> <td class=\"indent1\">Locally advanced or metastatic esophageal or gastric cancer with two or more of the following presentations:</td> <td> <p>KPS &#60;90 (ECOG performance status &#8805;1)</p> <p>Liver metastases</p> <p>Peritoneal metastases</p> <p>Serum alkaline phosphatase &#62;100 U/L</p> <p>Serum&nbsp;LDH &#62;200 IU/L</p> Serum hemoglobin &#60;11 g/dL</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Hepatobiliary and pancreatic cancers</td> </tr> <tr> <td class=\"indent1\">Locally advanced or metastatic cholangiocarcinoma, gallbladder carcinoma, or pancreatic cancer with one or more of the following presentations:</td> <td> <p>KPS &#60;90 (ECOG performance status &#8805; 1)</p> <p>Biliary obstruction with jaundice</p> <p>Recurrent or refractory disease after initial chemotherapy</p> <p>Liver, peritoneal, or distant metastases</p> <p>Portal vein thrombosis or other vascular invasion</p> <p>Gross residual disease (visible cancer) after resection</p> <p>Poorly differentiated or infiltrating disease</p> <p>Serum albumin &#60;3.5 g/dL or &#62;10% weight loss</p> <p>Serum LDH &#62;500 IU/L</p> <p>Episode of extremity venous thromboembolism or pulmonary embolization</p> Malignant ascites</td> </tr> <tr> <td class=\"indent1\">Any hepatocellular carcinoma with one or more of the following presentations:</td> <td> <p>KPS &#60;60 (ECOG performance status &#62;2)</p> <p>End-stage cirrhosis</p> <p>Large tumor size (maximum tumor diameter &#62;10 cm or tumor volume &#62;70% liver volume)</p> Any brain metastasis</td> </tr> <tr> <td class=\"indent1\">Unresectable locally advanced or metastatic hepatocellular carcinoma with two or more of the following presentations:</td> <td> <p>KPS &#60;90 (ECOG performance status &#8805;1)</p> <p>Extrahepatic metastases</p> <p>Moderate to severe symptomatic cirrhosis (eg, jaundice, ascites, fatigue, or bleeding)</p> <p>Alpha-fetoprotein level &#8805;400 ng/mL</p> Portal vein thrombosis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Head and neck neoplasms</td> </tr> <tr> <td class=\"indent1\">Recurrent, refractory, or metastatic head and neck squamous cell carcinoma with one or more of the following presentations:</td> <td> <p>KPS &#60;90 (ECOG performance status &#8805;1)</p> <p>Recurrence of disease with any metastases &#62;10% weight loss</p> <p>Muscle invasion or residual tumor at primary site</p> <p>Pretreatment hemoglobin &#60;11 g/dL</p> Serum calcium &#62;11.2 mg/dL</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Melanoma</td> </tr> <tr> <td class=\"indent1\">Advanced or metastatic melanoma with one or more of the following presentations:</td> <td> <p>KPS &#60;80 (ECOG performance status &#8805;2)</p> <p>Serum LDH &#62;2 x the upper limit of normal</p> <p>Serum calcium &#62;11.2 mg/dL</p> <p>Metastasis to the brain or spine</p> Metastases to liver and one other site</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Non-small cell lung cancer</td> </tr> <tr> <td class=\"indent1\">Any locally advanced or metastatic non-small cell lung cancer with one or more of the following presentations:</td> <td> <p>KPS &#60;70 (ECOG performance status &#62;2)</p> <p>Weight loss of &#62;5% or serum albumin &#60;3 g/dL</p> <p>Liver metastases</p> <p>Bone or bone marrow metastases</p> <p>Brain metastases with neurological symptoms, KPS &#60;70, age &#62;65 years, or extracranial metastases</p> <p>Pericardial effusion</p> <p>Pleural effusion with evidence of distant metastases</p> <p>Serum hemoglobin &#60;12 g/dL</p> <p>Serum calcium &#62;11.2 mg/dL</p> Age &#62;70 years with pleural effusion, hypoalbuminemia, elevated serum lactate dehydrogenase, or hyponatremia (levels outside the normal range)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Urogenital neoplasms</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Female genital neoplasms</td> </tr> <tr> <td class=\"indent1\">Locally advanced or metastatic ovarian, uterine endometrial, or uterine cervical cancer with regional or distant spread, and one or more of the following presentations:</td> <td> <p>KPS &#60;60 (ECOG performance status &#62;2)</p> <p>Serum calcium &#62;11.2 mg/dL</p> <p>Brain metastases plus extracranial lesion or KPS &#60;70 or &#8805;2 brain metastases</p> <p>Intestinal obstruction without successful repair, or urinary tract obstruction with stent placement</p> Unresectable disease due to location of disease or comorbid illness</td> </tr> <tr> <td class=\"indent1\">Locally advanced or metastatic ovarian, uterine endometrial or uterine cervical cancer with regional or distant spread, and two or more of the following presentations:</td> <td> <p>KPS &#60;80 (ECOG performance status &#62;1)</p> <p>Recurrent or refractory disease (unresponsive to treatment)</p> <p>Disease-free interval from diagnosis to disease recurrence or persistence of &#60;6 months</p> <p>Suboptimal resection with bulky residual disease</p> <p>Significant weight loss (&#62;5%)</p> Extra-abdominal metastases</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Prostate cancer</td> </tr> <tr> <td class=\"indent1\">Hormone-refractory metastatic prostate cancer with one or more of the following presentations:</td> <td> <p>KPS &#60;60 (ECOG performance status &#62;2)</p> <p>KPS &#60;80 (ECOG performance status &#62;1) or significant fatigue, plus hemoglobin &#60;12 g/dL</p> <p>Hemoglobin &#60;10 g/dL</p> Spinal cord compression with decreased ambulation</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Bladder and renal cell carcinoma</td> </tr> <tr> <td class=\"indent1\">Locally advanced or metastatic bladder or renal cell carcinoma with one or more of the following presentations:</td> <td> <p>KPS &#60;70 (ECOG performance status &#62;2)</p> <p>Brain metastases with &#8805;2 metastases, or extracranial metastases</p> Serum calcium &#62;11.2 mg/dL</td> </tr> <tr> <td class=\"indent1\">Locally advanced or metastatic bladder or renal cell carcinoma with three or more of the following presentations:</td> <td> <p>KPS &#60;80 (ECOG performance status &#8805;2)</p> <p>Hemoglobin &#60;11.5 g/dL</p> <p>Serum LDH &#62;300 IU/L or alkaline phosphatase &#62;220 U/L</p> <p>Disease-free interval from initial presentation to metastatic disease or disease progression &#8804;1 year</p> Visceral metastases</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Presentations associated with a median survival of six months or less.</div><div class=\"graphic_footnotes\">KPS: Karnofsky Performance Status; ECOG: Eastern Cooperative Oncology Group.</div><div class=\"graphic_reference\">Modified with permission from: Salpeter SR, Malter DS, Luo EJ, et al. Systematic review of cancer presentations with a median survival of six months or less. J Palliat Med 2012; 15:175. Copyright &copy; 2012 Mary Ann Liebert, Inc.</div><div id=\"graphicVersion\">Graphic 87452 Version 5.0</div></div></div>"},"87458":{"type":"graphic_figure","displayName":"Meckels diverticulum age distribution in children","title":"Meckels diverticulum age distribution in children","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Meckels diverticulum age distribution in children</div><div class=\"cntnt\"><img style=\"width:454px; height:610px;\" src=\"images/SURG/87458_Meck_divert_age_dist_child.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The age distribution in children (lower graph)&nbsp;includes all pathologic presentations of Meckels diverticulum including the more common presentations, such as bleeding or diverticulitis,&nbsp;as well&nbsp;as a variety of other presentations, such as persistent omphalomesenteric ducts that result in chronic umbilical drainage, intussusception, and volvulus around a Meckelâs band.<BR></div><div class=\"graphic_reference\">Reproduced with permission from: Park JJ, Wolff BG, Tollefson MK, et al. Meckel diverticulum: the Mayo Clinic experience with 1476 patients (1950-2002). Ann Surg 2005; 241:529. Copyright Â© 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87458 Version 3.0</div></div></div>"},"87459":{"type":"graphic_diagnosticimage","displayName":"Ultrasound cyst classification","title":"Ultrasonographic classification of cysts due to cystic echinococcosis","html":"<div class=\"graphic\"><div style=\"width: 749px\" class=\"figure\"><div class=\"ttl\">Ultrasonographic classification of cysts due to cystic echinococcosis</div><div class=\"cntnt\"><img style=\"width:729px; height:334px;\" src=\"images/ID/87459_US_cyst_classification.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel CL) Consists of unilocular, cystic lesion(s) (CL) with uniform anechoic content. The cyst wall is not clearly visible; lesions are usually round but may be oval. If these lesions are caused by cystic echinococcosis at an early stage of development, they are usually not fertile. Definitive diagnosis cannot be made by ultrasound findings alone.<br />(Panel CE1) Consists of unilocular, simple cyst with uniform anechoic content. The cyst wall is visible; lesions are round or oval. Cyst may exhibit fine echoes due to shifting of brood capsules called hydatid sand (\"snow flake sign\").<br />(Panel CE2) Consists of multivesicular, multiseptated cysts. The cyst wall is normally visible; lesions are round or oval. Septations produce \"wheel-like\" structures. The presence of daughter cysts is indicated by rosette-like or honeycomb-like structures. Daughter cysts may partly or completely fill the unilocular mother cyst.<br />(Panel CE3) Consists of a unilocular cyst which may contain daughter cysts. Anechoic content with detachment of laminated membrane from the cyst wall may be visible as floating membrane or as \"water-lily sign\" which is indicative of wavy membranes floating on top of remaining cyst fluid. The cyst form may be less round because of decreased intracystic pressure. The cyst which may degenerate further or may give rise to daughter cysts.<br />(Panel CE4) Consists of heterogenous hypoechoic or hyperechoic degenerative contents; no daughter cysts are present. A \"ball of wool\" sign may be seen, which is indicative of degenerating membranes. Most cysts of this type are not fertile. Definitive diagnosis cannot be made by ultrasound findings alone.<br />(Panel CE5) Cysts characterized by a thick calcified wall that is arch shaped, producing a cone shaped shadow. The degree of calcification varies from partial to complete. These cysts are not fertile in most case. Definitive diagnosis cannot be made by ultrasound findings alone.</div><div class=\"graphic_reference\">World Health Organization Informal Working Group on Echinococcosis (WHO-IWGE) standardized classification of Echinococcal cysts. PAIR: Puncture, Aspiration, Injection, Re-Aspiration: An option for the treatment of Cystic Echinococcosis. WHO/CDS/CSR/APH/2001.6. World Health Organization 2001. Copyright &copy; 2001.</div><div id=\"graphicVersion\">Graphic 87459 Version 2.0</div></div></div>"},"87460":{"type":"graphic_figure","displayName":"Structure of the echinococcal cyst","title":"Structure of the echinococcal cyst","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Structure of the echinococcal cyst</div><div class=\"cntnt\"><img style=\"width:534px; height:524px;\" src=\"images/ID/87460_Structure_of_the_echinococcal_cyst.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 87460 Version 2.0</div></div></div>"},"87461":{"type":"graphic_table","displayName":"Features of Meckels diverticulum on imaging studies","title":"Features of Meckel's diverticulum on imaging studies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Features of Meckel's diverticulum on imaging studies</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Modality</td> <td class=\"subtitle1\">Features and caveats</td> </tr> <tr class=\"divider_bottom\"> <td>Plain abdominal film</td> <td> <ul> <li>May demonstrate nonspecific signs of intestinal obstruction </li> <li>An enterolith may be seen in the lower abdomen, but cannot be definitively localized to the Meckel's as opposed to the appendix </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Ultrasonography</td> <td> <ul> <li>An obstructed Meckel's diverticulum may be identified as a fluid-filled pouch off the distal small intestine </li> <li>Ultrasound findings are nonspecific and are easily confused with appendicitis </li> <li>Intussusception can be diagnosed with ultrasound, but attributing the lead point to be a Meckel's diverticulum cannot be determined with any certainty </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Computed tomography</td> <td> <ul> <li>Asymptomatic or bleeding diverticula are rarely or infrequently identified with computed tomography </li> <li>A distinction between a Meckel's diverticulum and normal small intestinal loops is virtually impossible in the absence of associated inflammation </li> <li>Acutely inflamed diverticula can be identified as a blind pouch off the distal small intestine, and is typically with associated bowel wall thickening of the peri-diverticular fat </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Upper gastrointestinal series</td> <td> <ul> <li>Small bowel series have demonstrated Meckel's diverticulum, but are unreliable even using enteroclysis in experienced hands </li> <li> <p>False negative rates are high due to:</p> <p>- Rapid emptying of contrast from the diverticulum</p> <p>- Obscured visualization of the diverticulum due to overlying contrast-filled small bowel loops</p> - Poor filling of the diverticulum (occlusion or narrowing of the entrance) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Mesenteric arteriorgraphy</td> <td> <ul> <li>A diagnosis of Meckel's is based upon the finding of an anomalous superior mesenteric artery branch feeding the diverticulum; active contrast extravasation may be seen in patients with ongoing hemorrhage </li> </ul> </td> </tr> <tr> <td>Meckel's scan</td> <td> <ul> <li>Identifies areas of ectopic gastric mucosa, if present </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 87461 Version 2.0</div></div></div>"},"87467":{"type":"graphic_picture","displayName":"Gingival tray","title":"Gingival tray","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Gingival tray</div><div class=\"cntnt\"><img style=\"width:481px; height:288px;\" src=\"images/DERM/87467_Gingival_tray.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A gingival tray can facilitate application of topical corticosteroids to the oral mucosa.</div><div id=\"graphicVersion\">Graphic 87467 Version 1.0</div></div></div>"},"87471":{"type":"graphic_picture","displayName":"Temporal triangular alopecia","title":"Temporal triangular alopecia","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Temporal triangular alopecia</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87471_Temp_triangul_alopecia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A triangular patch with a paucity of terminal hair is present on the temporal scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87471 Version 3.0</div></div></div>"},"87472":{"type":"graphic_picture","displayName":"Loose anagen syndrome","title":"Loose anagen syndrome","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Loose anagen syndrome</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87472_Loose_anagen_synd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse hair thinning is present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87472 Version 3.0</div></div></div>"},"87473":{"type":"graphic_picture","displayName":"Trichorrhexis nodosa","title":"Trichorrhexis nodosa","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Trichorrhexis nodosa</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87473_Trichorrhexis_nodosa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Broom-like fraying of the hair shaft is seen in trichorrhexis nodosa.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87473 Version 3.0</div></div></div>"},"87474":{"type":"graphic_picture","displayName":"Trichothiodystrophy","title":"Trichothiodystrophy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trichothiodystrophy</div><div class=\"cntnt\"><img style=\"width:432px; height:576px;\" src=\"images/DERM/87474_Trichothiodystrophy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Short, brittle hair is characteristic of trichothiodystrophy.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87474 Version 3.0</div></div></div>"},"87475":{"type":"graphic_picture","displayName":"Trichoschisis","title":"Trichoschisis","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Trichoschisis</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87475_Trichoschisis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse fractures are evident in several hair shafts in this hair specimen from a patient with trichothiodystrophy.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87475 Version 3.0</div></div></div>"},"87477":{"type":"graphic_picture","displayName":"Menkes disease","title":"Menkes disease (Menkes kinky hair syndrome)","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Menkes disease (Menkes kinky hair syndrome)</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87477_Menkes_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hair with a steel wool or kinky quality develops in patients with Menkes disease.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87477 Version 3.0</div></div></div>"},"87478":{"type":"graphic_picture","displayName":"Pili torti","title":"Pili torti","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Pili torti</div><div class=\"cntnt\"><img style=\"width:576px; height:433px;\" src=\"images/DERM/87478_Pili_torti.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This flattened, twisted hair shaft was taken from a patient with Menkes disease.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87478 Version 3.0</div></div></div>"},"87479":{"type":"graphic_picture","displayName":"Monilethrix","title":"Monilethrix","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Monilethrix</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87479_Monilethrix.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Short brittle hair is present in this patient with monilethrix.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87479 Version 3.0</div></div></div>"},"87480":{"type":"graphic_picture","displayName":"Monilethrix hair shaft","title":"Monilethrix","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Monilethrix</div><div class=\"cntnt\"><img style=\"width:576px; height:433px;\" src=\"images/DERM/87480_Monilethrix_hair_shaft.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Elliptical nodes are visible in these hair shafts from a patient with monilethrix.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87480 Version 3.0</div></div></div>"},"87481":{"type":"graphic_picture","displayName":"Netherton syndrome","title":"Netherton syndrome","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Netherton syndrome</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87481_Netherton_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Short, sparse hair is present in this patient with Netherton syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87481 Version 3.0</div></div></div>"},"87482":{"type":"graphic_picture","displayName":"Ichthyosis linearis circumflexa in Netherton syndrome","title":"Ichthyosis linearis circumflexa in Netherton syndrome","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Ichthyosis linearis circumflexa in Netherton syndrome</div><div class=\"cntnt\"><img style=\"width:576px; height:433px;\" src=\"images/DERM/87482_Ichthy_circ_Netherton_synd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Serpiginous, erythematous, pruritic plaques with double-edged peripheral scale develop in patients with Netherton syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87482 Version 3.0</div></div></div>"},"87483":{"type":"graphic_picture","displayName":"Trichorrhexis invaginata","title":"Trichorrhexis invaginata","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Trichorrhexis invaginata</div><div class=\"cntnt\"><img style=\"width:576px; height:433px;\" src=\"images/DERM/87483_Trichorrhexis_invaginata.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Trichorrhexis invaginata is a ball-and-socket-like deformity of the hair shaft that is seen in patients with Netherton syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87483 Version 4.0</div></div></div>"},"87484":{"type":"graphic_picture","displayName":"Uncombable hair syndrome","title":"Uncombable hair syndrome","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Uncombable hair syndrome</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87484_Uncombable_hair_synd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spun glass-like, silvery-blond, unruly hair is characteristic of uncombable hair syndrome. Pili trianguli et canaliculi is visible on electron microscopy of the hair shaft. Uncombable hair syndrome does not cause fragile hair.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87484 Version 3.0</div></div></div>"},"87485":{"type":"graphic_picture","displayName":"Alopecia mucinosa","title":"Alopecia mucinosa (follicular mucinosis)","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Alopecia mucinosa (follicular mucinosis)</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87485_Alopecia_mucinosa.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An erythematous plaque accompanied by hair loss within the eyebrow&nbsp;is present in this patient with alopecia mucinosa.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87485 Version 3.0</div></div></div>"},"87486":{"type":"graphic_picture","displayName":"Keratosis follicularis spinulosa decalvans","title":"Keratosis follicularis spinulosa decalvans","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Keratosis follicularis spinulosa decalvans</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87486_Kerat_follic_spin_decalv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cicatricial alopecia and follicular keratotic papules are features of keratosis follicularis spinulosa decalvans.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87486 Version 3.0</div></div></div>"},"87487":{"type":"graphic_picture","displayName":"Keratosis follicularis spinulosa decalvans face","title":"Keratosis follicularis spinulosa decalvans","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Keratosis follicularis spinulosa decalvans</div><div class=\"cntnt\"><img style=\"width:432px; height:576px;\" src=\"images/DERM/87487_Kerat_follic_spin_dec_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous small keratotic follicular papules and cicatricial (scarring) alopecia involving the eyebrow are present.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87487 Version 4.0</div></div></div>"},"87488":{"type":"graphic_picture","displayName":"Folliculitis decalvans","title":"Folliculitis decalvans","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Folliculitis decalvans</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87488_Folliculitis_decalvans.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Numerous inflammatory papules and pustules are present on the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87488 Version 4.0</div></div></div>"},"87489":{"type":"graphic_picture","displayName":"Tufted folliculitis in folliculitis decalvans","title":"Folliculitis decalvans","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Folliculitis decalvans</div><div class=\"cntnt\"><img style=\"width:576px; height:433px;\" src=\"images/DERM/87489_Tufted_follic_follic_ dec.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tufted folliculitis (multiple hairs emerging from a single inflamed follicular orifice) is evident at the periphery of scarring in this patient with folliculitis decalvans.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87489 Version 3.0</div></div></div>"},"87490":{"type":"graphic_picture","displayName":"Acne keloidalis nuchae on posterior scalp","title":"Acne keloidalis nuchae","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Acne keloidalis nuchae</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87490_Acne_keloi_nuch_post_scalp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dome-shaped, firm papules are present on the posterior scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87490 Version 3.0</div></div></div>"},"87491":{"type":"graphic_picture","displayName":"Erosive pustular dermatosis of the scalp","title":"Erosive pustular dermatosis of the scalp","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Erosive pustular dermatosis of the scalp</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87491_Erosive_pust_derma_scalp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Crusted plaques and erosions are present on the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87491 Version 3.0</div></div></div>"},"87492":{"type":"graphic_figure","displayName":"Spectrum of broad band and narrow band UVB lamps","title":"Spectrum of broad band and narrow band UVB lamps","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Spectrum of broad band and narrow band UVB lamps</div><div class=\"cntnt\"><img style=\"width:500px; height:354px;\" src=\"images/DERM/87492_Spect_broad_nar_band_UVB.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of James Ferguson, Dundee, Scotland.</div><div id=\"graphicVersion\">Graphic 87492 Version 1.0</div></div></div>"},"87493":{"type":"graphic_table","displayName":"Broadband or narrowband UVB MED","title":"Determination of the minimal erythema dose (MED) with broadband or narrowband UVB sources","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Determination of the minimal erythema dose (MED) with broadband or narrowband UVB sources</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"6\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Exposure doses (mJ/cm<sup>2</sup>)</td> </tr> <tr> <td class=\"indent1\">Broadband UVB</td> <td>20</td> <td>40</td> <td>60</td> <td>80</td> <td>100</td> <td>120</td> </tr> <tr> <td class=\"indent1\">Narrowband UVB</td> <td>200</td> <td>400</td> <td>600</td> <td>800</td> <td>1000</td> <td>1200</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 87493 Version 1.0</div></div></div>"},"87494":{"type":"graphic_table","displayName":"UVB phototherapy indications","title":"Clinical indications for UVB phototherapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical indications for UVB phototherapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Indication</td> <td class=\"subtitle1\">Broadband</td> <td class=\"subtitle1\">Narrowband</td> </tr> <tr> <td>Psoriasis</td> <td class=\"centered\">+</td> <td class=\"centered\">++</td> </tr> <tr> <td>Atopic dermatitis</td> <td class=\"centered\">+</td> <td class=\"centered\">++</td> </tr> <tr> <td>Pruritus, prurigo</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td>Parapsoriasis en plaques</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td>Mycosis fungoides (patch stage)</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td>Polymorphous light eruption (prophylaxis)</td> <td class=\"centered\">+</td> <td class=\"centered\">++</td> </tr> <tr> <td>Vitiligo</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">++</td> </tr> <tr> <td>Pityriasis lichenoides</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td>Lymphomatoid papulosis</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td>Seborrheic dermatitis</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td>HIV-associated pruritic eruptions</td> <td class=\"centered\">+</td> <td class=\"centered\">X</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">+: recommendable; ++: superior; &ndash;: low efficacy; X: no experience.</div><div id=\"graphicVersion\">Graphic 87494 Version 1.0</div></div></div>"},"87495":{"type":"graphic_picture","displayName":"Pemphigus herpetiformis","title":"Pemphigus herpetiformis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Pemphigus herpetiformis</div><div class=\"cntnt\"><img style=\"width:504px; height:371px;\" src=\"images/DERM/87495_Pemphigus_herpetiformis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Annular and arcuate erythematous plaques with erosions and occasional vesicles were present in this patient with pemphigus herpetiformis.</div><div class=\"graphic_reference\">Reproduced with permission from: Kleker BM, Ramirez-Fort MK, Puchalsky D, et al. A generalized annular eruption with occasional vesicles. Arch Dermatol 2012; 148:531. Copyright Â© 2012 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87495 Version 3.0</div></div></div>"},"87496":{"type":"graphic_table","displayName":"UVB therapy adverse effects","title":"Short-term and long-term adverse effects of UVB phototherapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Short-term and long-term adverse effects of UVB phototherapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Acute</td> </tr> <tr> <td class=\"indent1\">Sunburn or phototoxic reaction if overdosed </td> <td class=\"centered\">++</td> </tr> <tr> <td class=\"indent1\">Phototoxic reaction from accidental intake of a photosensitizer</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td class=\"indent1\">Conjunctivitis, keratitis (if no eye shielding is used)</td> <td class=\"centered\">++</td> </tr> <tr> <td class=\"indent1\">Provocation of photodermatoses (eg, polymorphous light eruption)</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Chronic</td> </tr> <tr> <td class=\"indent1\">Lentigines</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Photoaging</td> <td class=\"centered\">++</td> </tr> <tr> <td class=\"indent1\">Actinic keratosis, nonmelanoma skin cancer</td> <td class=\"centered\">+/&#177;</td> </tr> <tr> <td class=\"indent1\">Melanoma</td> <td class=\"centered\">?</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">&ndash;: no risk; ++: high risk; +: medium risk; &plusmn;: low risk; ?: possible, insufficient data.</div><div class=\"graphic_footnotes\">Most photosensitizing substances absorb in the UVA range. Thus, exposure to UVB after the accidental ingestion of a photosensitizer does not induce a phototoxic reaction.</div><div id=\"graphicVersion\">Graphic 87496 Version 2.0</div></div></div>"},"87501":{"type":"graphic_figure","displayName":"Sinus endoscopy PI","title":"Sinus endoscopy","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sinus endoscopy</div><div class=\"cntnt\"><img style=\"width:443px; height:427px;\" src=\"images/ALLRG/87501_Endoscopic_sinus_surg_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This&nbsp;figure shows sinus endoscopy. This procedure allows doctors to see inside the sinuses and take samples of mucus from the sinuses.</div><div id=\"graphicVersion\">Graphic 87501 Version 3.0</div></div></div>"},"87502":{"type":"graphic_figure","displayName":"Rise and fall of AAA incidence and smoking","title":"Rise and fall of AAA incidence and smoking","html":"<div class=\"graphic\"><div style=\"width: 642px\" class=\"figure\"><div class=\"ttl\">Rise and fall of AAA incidence and smoking</div><div class=\"cntnt\"><img style=\"width:622px; height:358px;\" src=\"images/SURG/87502_Rise_fall_AAA_inc_smoking.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">US annual adult per capita cigarette consumption and US age-adjusted AAA mortality per 100,000 white men by year<SUP>[1,2]</SUP>. For 1951 to 1978, rates are standardized to the US 1960 population as calculated by Lilienfeld et al<SUP>[3]</SUP>, and from 1979 onward to the US 1970 population from CDC Wonder<SUP>[4]</SUP>. Rates include abdominal, thoracoabdominal, and unspecified aortic aneurysm, both ruptured and nonruptured, but exclude thoracic aneurysm and dissection. Because all non-syphilitic aortic aneurysms and dissections were combined before 1968, and 1967 to 1968 data indicate that thoracic aneurysm and dissection accounted for 20 percent of total, pre-1968 values.</div><div class=\"graphic_footnotes\">US: United States; AAA: abdominal aortic aneurysm; CDC: Centers for Disease Control (United States).</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Centers for Disease Control and Prevention. Surveillance for selected tobacco-use behaviors - United States, 1900-1994. MMWR 1994; 43:1.</li>&#xD;&#xA;    <li>Economic Research Service, US Department of Agriculture (USDA). Tobacco Outlook October 24, 2007, TBS-263. Available at: http://usda. mannlib.cornell.edu/MannUsda/viewDocumentInfo.do?documentID1389. Accessed July 2011.</li>&#xD;&#xA;    <li>Lilienfeld DE, Gunderson PD, Sprafka JM, Vargas C. Epidemiology of aortic aneurysms, I: mortality trends in the United States, 1951 to 1981. Arteriosclerosis 1987; 7:637.</li>&#xD;&#xA;    <li>Centers for Disease Control and Prevention. Compressed Mortality File 1979-1998 and 1999-2007. CDC WONDER On-line Database. Available at: http://wonder.cdc.gov. Accessed July 2011.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: Lederle FA. The rise and fall of abdominal aortic aneurysm. Circulation 2011; 124:1097. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87502 Version 4.0</div></div></div>"},"87503":{"type":"graphic_algorithm","displayName":"Rx in the setting of loss of response to anti-TNF agents","title":"Proposed treatment algorithm in the setting of loss of response to anti-TNF agents","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Proposed treatment algorithm in the setting of loss of response to anti-TNF agents</div><div class=\"cntnt\"><img style=\"width:543px; height:319px;\" src=\"images/GAST/87503_RxstgrspnTNFantgntagnt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Additional information is required about the optimal cut-off values for ADL and CZP.</div><div class=\"graphic_footnotes\">TNF: tumor necrosis factor; ADA: antidrug antibody; IFX: infliximab; ADL: adalimumab; CZP: certolizumab.<br />* [IFX], &lt;5 microg/mL; [ADL], &lt;7.5 microg/mL; [CZP], &lt;20 microg/mL.<br />Â¶ [IFX],&nbsp;â¥5 microg/mL; [ADL], â¥7.5 microg/mL; [CZP], â¥20 microg/mL.<br /></div><div class=\"graphic_reference\">Original figure modified for this publication. Ord&aacute;s I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012; 10:1079. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87503 Version 8.0</div></div></div>"},"87504":{"type":"graphic_table","displayName":"ASA Physical Status Classification System","title":"American Society of Anesthesiologists (ASA) Physical Status Classification System","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American Society of Anesthesiologists (ASA) Physical Status Classification System</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">ASA PS classification</td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Examples, including, but not limited to:</td> </tr> <tr> <td class=\"centered\">ASA I</td> <td>A normal healthy patient.</td> <td>Healthy, non-smoking, no or minimal alcohol use.</td> </tr> <tr> <td class=\"centered\">ASA II</td> <td>A patient with mild systemic disease.</td> <td>Mild diseases only without substantive functional limitations. Current smoker, social alcohol drinker, pregnancy, obesity (30&#60;BMI&#60;40), well-controlled DM/HTN, mild lung disease.</td> </tr> <tr> <td class=\"centered\">ASA III</td> <td>A patient with severe systemic disease.</td> <td>Substantive functional limitations; one or more moderate to severe diseases. Poorly controlled DM or HTN, COPD, morbid obesity (BMI &#8805;40), active hepatitis, alcohol dependence or abuse, implanted pacemaker, moderate reduction of ejection fraction, ESRD undergoing regularly scheduled dialysis, premature infant PCA&#60;60 weeks, history (&#62;3 months) of MI, CVA, TIA, or CAD/stents.</td> </tr> <tr> <td class=\"centered\">ASA IV</td> <td>A patient with severe systemic disease that is a constant threat to life.</td> <td>Recent (&#60;3 months) MI, CVA, TIA, or CAD/stents, ongoing cardiac ischemia or severe valve dysfunction, severe reduction of ejection fraction, sepsis, DIC, ARDS, or ESRD not undergoing regularly scheduled dialysis.</td> </tr> <tr> <td class=\"centered\">ASA V</td> <td>A moribund patient who is not expected to survive without the operation.</td> <td>Ruptured abdominal/thoracic aneurysm, massive trauma, intracranial bleed with mass effect, ischemic bowel in the face of significant cardiac pathology or multiple organ/system dysfunction.</td> </tr> <tr> <td class=\"centered\">ASA VI</td> <td>A declared brain-dead patient whose organs are being removed for donor purposes.</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The addition of \"E\" to the numerical status (eg, IE, IIE, etc.) denotes Emergency surgery (an emergency is defined as existing when delay in treatment of the patient would lead to a significant increase in the threat to life or body part).</div><div class=\"graphic_footnotes\">BMI: body mass index; DM: diabetes mellitus; HTN: hypertension; COPD: chronic obstructive pulmonary disease; ESRD: end-stage renal disease; PCA: post conceptual age; MI: myocardial infarction; CVA: cerebrovascular accident; TIA: transient ischemic attack; CAD: coronary artery disease; DIC: disseminated intravascular coagulation; ARDS: acute respiratory distress syndrome.</div><div class=\"graphic_reference\">ASA Physical Status Classification System (Copyright Â© 2014) is reprinted with permission of the American Society of Anesthesiologists, 1061 American Lane, Schaumburg, Illinois 60173-4973.</div><div id=\"graphicVersion\">Graphic 87504 Version 8.0</div></div></div>"},"87505":{"type":"graphic_table","displayName":"Classification of pityriasis rubra pilaris","title":"Classification of pityriasis rubra pilaris","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of pityriasis rubra pilaris</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">PRP type</td> <td class=\"subtitle1\">Clinical characteristics</td> <td class=\"subtitle1\">Prognosis</td> </tr> <tr> <td>I (classic adult)*</td> <td>Wide distribution of follicular papules and plaques with cephalocaudal progression and sparing islands of normal-appearing skin</td> <td>Favorable - 80 percent of patients resolve spontaneously within three years</td> </tr> <tr> <td>II (atypical adult)</td> <td>Ichthyosiform dermatitis, palmoplantar hyperkeratosis, chronic course</td> <td>Chronic course</td> </tr> <tr> <td>III (classic juvenile)</td> <td>Wide distribution of follicular papules and plaques with cephalocaudal progression and spared islands of normal-appearing skin</td> <td>Often remission after one year</td> </tr> <tr> <td>IV (circumscribed juvenile)</td> <td>Circumscribed lesions restricted to the elbows and knees and frequent palmoplantar hyperkeratosis</td> <td>Unclear</td> </tr> <tr> <td>V (atypical juvenile)</td> <td>Ichthyosiform dermatitis, palmoplantar hyperkeratosis</td> <td>Chronic course</td> </tr> <tr> <td>VI (HIV-associated)</td> <td>Similar to type I</td> <td>Variable</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Most common form of PRP.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Griffiths WA, Ozluer S. [Pityriasis rubra pilaris]. Ann Dermatol Venereol 2001; 128:931.</li>&#xD;&#xA;    <li>Griffiths WA. Pityriasis rubra pilaris. Clin Exp Dermatol 1980; 5:105.</li>&#xD;&#xA;    <li>Klein A, Landthaler M, Karrer S. Pityriasis rubra pilaris: a review of diagnosis and treatment. Am J Clin Dermatol 2010; 11:157.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 87505 Version 2.0</div></div></div>"},"87507":{"type":"graphic_table","displayName":"Predicted body weight and tidal volume for men","title":"Predicted body weight and tidal volume for men","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Predicted body weight and tidal volume for men</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">Height</td> <td class=\"subtitle1\">PBW</td> <td class=\"subtitle1\" colspan=\"5\">Tidal volume</td> </tr> <tr> <td class=\"subtitle2\">Feet/inches</td> <td class=\"subtitle2\">Inches</td> <td class=\"subtitle2\">Centimeters</td> <td class=\"subtitle2\">kg</td> <td class=\"subtitle2\">4 mL/kg</td> <td class=\"subtitle2\">5 mL/kg</td> <td class=\"subtitle2\">6 mL/kg</td> <td class=\"subtitle2\">7 mL/kg</td> <td class=\"subtitle2\">8 mL/kg</td> </tr> <tr> <td class=\"centered\">4' 0\"</td> <td class=\"centered\">48</td> <td class=\"centered\">122</td> <td class=\"centered\">22.4</td> <td class=\"centered\">90</td> <td class=\"centered\">112</td> <td class=\"centered\">134</td> <td class=\"centered\">157</td> <td class=\"centered\">179</td> </tr> <tr> <td class=\"centered\">4' 1\"</td> <td class=\"centered\">49</td> <td class=\"centered\">124</td> <td class=\"centered\">24.7</td> <td class=\"centered\">99</td> <td class=\"centered\">124</td> <td class=\"centered\">148</td> <td class=\"centered\">173</td> <td class=\"centered\">198</td> </tr> <tr> <td class=\"centered\">4' 2\"</td> <td class=\"centered\">50</td> <td class=\"centered\">127</td> <td class=\"centered\">27</td> <td class=\"centered\">108</td> <td class=\"centered\">135</td> <td class=\"centered\">162</td> <td class=\"centered\">189</td> <td class=\"centered\">216</td> </tr> <tr> <td class=\"centered\">4' 3\"</td> <td class=\"centered\">51</td> <td class=\"centered\">130</td> <td class=\"centered\">29.3</td> <td class=\"centered\">117</td> <td class=\"centered\">147</td> <td class=\"centered\">176</td> <td class=\"centered\">205</td> <td class=\"centered\">234</td> </tr> <tr> <td class=\"centered\">4' 4\"</td> <td class=\"centered\">52</td> <td class=\"centered\">132</td> <td class=\"centered\">31.6</td> <td class=\"centered\">126</td> <td class=\"centered\">158</td> <td class=\"centered\">190</td> <td class=\"centered\">221</td> <td class=\"centered\">253</td> </tr> <tr> <td class=\"centered\">4' 5\"</td> <td class=\"centered\">53</td> <td class=\"centered\">135</td> <td class=\"centered\">33.9</td> <td class=\"centered\">136</td> <td class=\"centered\">170</td> <td class=\"centered\">203</td> <td class=\"centered\">237</td> <td class=\"centered\">271</td> </tr> <tr> <td class=\"centered\">4' 6\"</td> <td class=\"centered\">54</td> <td class=\"centered\">137</td> <td class=\"centered\">36.2</td> <td class=\"centered\">145</td> <td class=\"centered\">181</td> <td class=\"centered\">217</td> <td class=\"centered\">253</td> <td class=\"centered\">290</td> </tr> <tr> <td class=\"centered\">4' 7\"</td> <td class=\"centered\">55</td> <td class=\"centered\">140</td> <td class=\"centered\">38.5</td> <td class=\"centered\">154</td> <td class=\"centered\">193</td> <td class=\"centered\">231</td> <td class=\"centered\">270</td> <td class=\"centered\">308</td> </tr> <tr> <td class=\"centered\">4' 8\"</td> <td class=\"centered\">56</td> <td class=\"centered\">142</td> <td class=\"centered\">40.8</td> <td class=\"centered\">163</td> <td class=\"centered\">204</td> <td class=\"centered\">245</td> <td class=\"centered\">286</td> <td class=\"centered\">326</td> </tr> <tr> <td class=\"centered\">4' 9\"</td> <td class=\"centered\">57</td> <td class=\"centered\">145</td> <td class=\"centered\">43.1</td> <td class=\"centered\">172</td> <td class=\"centered\">216</td> <td class=\"centered\">259</td> <td class=\"centered\">302</td> <td class=\"centered\">345</td> </tr> <tr> <td class=\"centered\">4' 10\"</td> <td class=\"centered\">58</td> <td class=\"centered\">147</td> <td class=\"centered\">45.4</td> <td class=\"centered\">182</td> <td class=\"centered\">227</td> <td class=\"centered\">272</td> <td class=\"centered\">318</td> <td class=\"centered\">363</td> </tr> <tr> <td class=\"centered\">4' 11\"</td> <td class=\"centered\">59</td> <td class=\"centered\">150</td> <td class=\"centered\">47.7</td> <td class=\"centered\">191</td> <td class=\"centered\">239</td> <td class=\"centered\">286</td> <td class=\"centered\">334</td> <td class=\"centered\">382</td> </tr> <tr> <td class=\"centered\">5' 0\"</td> <td class=\"centered\">60</td> <td class=\"centered\">152</td> <td class=\"centered\">50</td> <td class=\"centered\">200</td> <td class=\"centered\">250</td> <td class=\"centered\">300</td> <td class=\"centered\">350</td> <td class=\"centered\">400</td> </tr> <tr> <td class=\"centered\">5' 1\"</td> <td class=\"centered\">61</td> <td class=\"centered\">155</td> <td class=\"centered\">52.3</td> <td class=\"centered\">209</td> <td class=\"centered\">262</td> <td class=\"centered\">314</td> <td class=\"centered\">366</td> <td class=\"centered\">418</td> </tr> <tr> <td class=\"centered\">5' 2\"</td> <td class=\"centered\">62</td> <td class=\"centered\">157</td> <td class=\"centered\">54.6</td> <td class=\"centered\">218</td> <td class=\"centered\">273</td> <td class=\"centered\">328</td> <td class=\"centered\">382</td> <td class=\"centered\">437</td> </tr> <tr> <td class=\"centered\">5' 3\"</td> <td class=\"centered\">63</td> <td class=\"centered\">160</td> <td class=\"centered\">56.9</td> <td class=\"centered\">228</td> <td class=\"centered\">285</td> <td class=\"centered\">341</td> <td class=\"centered\">398</td> <td class=\"centered\">455</td> </tr> <tr> <td class=\"centered\">5' 4\"</td> <td class=\"centered\">64</td> <td class=\"centered\">163</td> <td class=\"centered\">59.2</td> <td class=\"centered\">237</td> <td class=\"centered\">296</td> <td class=\"centered\">355</td> <td class=\"centered\">414</td> <td class=\"centered\">474</td> </tr> <tr> <td class=\"centered\">5' 5\"</td> <td class=\"centered\">65</td> <td class=\"centered\">165</td> <td class=\"centered\">61.5</td> <td class=\"centered\">246</td> <td class=\"centered\">308</td> <td class=\"centered\">369</td> <td class=\"centered\">431</td> <td class=\"centered\">492</td> </tr> <tr> <td class=\"centered\">5' 6\"</td> <td class=\"centered\">66</td> <td class=\"centered\">168</td> <td class=\"centered\">63.8</td> <td class=\"centered\">255</td> <td class=\"centered\">319</td> <td class=\"centered\">383</td> <td class=\"centered\">447</td> <td class=\"centered\">510</td> </tr> <tr> <td class=\"centered\">5' 7\"</td> <td class=\"centered\">67</td> <td class=\"centered\">170</td> <td class=\"centered\">66.1</td> <td class=\"centered\">264</td> <td class=\"centered\">331</td> <td class=\"centered\">397</td> <td class=\"centered\">463</td> <td class=\"centered\">529</td> </tr> <tr> <td class=\"centered\">5' 8\"</td> <td class=\"centered\">68</td> <td class=\"centered\">173</td> <td class=\"centered\">68.4</td> <td class=\"centered\">274</td> <td class=\"centered\">342</td> <td class=\"centered\">410</td> <td class=\"centered\">479</td> <td class=\"centered\">547</td> </tr> <tr> <td class=\"centered\">5' 9\"</td> <td class=\"centered\">69</td> <td class=\"centered\">175</td> <td class=\"centered\">70.7</td> <td class=\"centered\">283</td> <td class=\"centered\">354</td> <td class=\"centered\">424</td> <td class=\"centered\">495</td> <td class=\"centered\">566</td> </tr> <tr> <td class=\"centered\">5' 10\"</td> <td class=\"centered\">70</td> <td class=\"centered\">178</td> <td class=\"centered\">73</td> <td class=\"centered\">292</td> <td class=\"centered\">365</td> <td class=\"centered\">438</td> <td class=\"centered\">511</td> <td class=\"centered\">584</td> </tr> <tr> <td class=\"centered\">5' 11\"</td> <td class=\"centered\">71</td> <td class=\"centered\">180</td> <td class=\"centered\">75.3</td> <td class=\"centered\">301</td> <td class=\"centered\">377</td> <td class=\"centered\">452</td> <td class=\"centered\">527</td> <td class=\"centered\">602</td> </tr> <tr> <td class=\"centered\">6' 0\"</td> <td class=\"centered\">72</td> <td class=\"centered\">183</td> <td class=\"centered\">77.6</td> <td class=\"centered\">310</td> <td class=\"centered\">388</td> <td class=\"centered\">466</td> <td class=\"centered\">543</td> <td class=\"centered\">621</td> </tr> <tr> <td class=\"centered\">6' 1\"</td> <td class=\"centered\">73</td> <td class=\"centered\">185</td> <td class=\"centered\">79.9</td> <td class=\"centered\">320</td> <td class=\"centered\">400</td> <td class=\"centered\">479</td> <td class=\"centered\">559</td> <td class=\"centered\">639</td> </tr> <tr> <td class=\"centered\">6' 2\"</td> <td class=\"centered\">74</td> <td class=\"centered\">188</td> <td class=\"centered\">82.2</td> <td class=\"centered\">329</td> <td class=\"centered\">411</td> <td class=\"centered\">493</td> <td class=\"centered\">575</td> <td class=\"centered\">658</td> </tr> <tr> <td class=\"centered\">6' 3\"</td> <td class=\"centered\">75</td> <td class=\"centered\">190</td> <td class=\"centered\">84.5</td> <td class=\"centered\">338</td> <td class=\"centered\">423</td> <td class=\"centered\">507</td> <td class=\"centered\">592</td> <td class=\"centered\">676</td> </tr> <tr> <td class=\"centered\">6' 4\"</td> <td class=\"centered\">76</td> <td class=\"centered\">193</td> <td class=\"centered\">86.8</td> <td class=\"centered\">347</td> <td class=\"centered\">434</td> <td class=\"centered\">521</td> <td class=\"centered\">608</td> <td class=\"centered\">694</td> </tr> <tr> <td class=\"centered\">6' 5\"</td> <td class=\"centered\">77</td> <td class=\"centered\">196</td> <td class=\"centered\">89.1</td> <td class=\"centered\">356</td> <td class=\"centered\">446</td> <td class=\"centered\">535</td> <td class=\"centered\">624</td> <td class=\"centered\">713</td> </tr> <tr> <td class=\"centered\">6' 6\"</td> <td class=\"centered\">78</td> <td class=\"centered\">198</td> <td class=\"centered\">91.4</td> <td class=\"centered\">366</td> <td class=\"centered\">457</td> <td class=\"centered\">548</td> <td class=\"centered\">640</td> <td class=\"centered\">731</td> </tr> <tr> <td class=\"centered\">6' 7\"</td> <td class=\"centered\">79</td> <td class=\"centered\">201</td> <td class=\"centered\">93.7</td> <td class=\"centered\">375</td> <td class=\"centered\">469</td> <td class=\"centered\">562</td> <td class=\"centered\">656</td> <td class=\"centered\">750</td> </tr> <tr> <td class=\"centered\">6' 8\"</td> <td class=\"centered\">80</td> <td class=\"centered\">203</td> <td class=\"centered\">96</td> <td class=\"centered\">384</td> <td class=\"centered\">480</td> <td class=\"centered\">576</td> <td class=\"centered\">672</td> <td class=\"centered\">768</td> </tr> <tr> <td class=\"centered\">6' 9\"</td> <td class=\"centered\">81</td> <td class=\"centered\">206</td> <td class=\"centered\">98.3</td> <td class=\"centered\">393</td> <td class=\"centered\">492</td> <td class=\"centered\">590</td> <td class=\"centered\">688</td> <td class=\"centered\">786</td> </tr> <tr> <td class=\"centered\">6' 10\"</td> <td class=\"centered\">82</td> <td class=\"centered\">208</td> <td class=\"centered\">100.6</td> <td class=\"centered\">402</td> <td class=\"centered\">503</td> <td class=\"centered\">604</td> <td class=\"centered\">704</td> <td class=\"centered\">805</td> </tr> <tr> <td class=\"centered\">6' 11\"</td> <td class=\"centered\">83</td> <td class=\"centered\">211</td> <td class=\"centered\">102.9</td> <td class=\"centered\">412</td> <td class=\"centered\">515</td> <td class=\"centered\">617</td> <td class=\"centered\">720</td> <td class=\"centered\">823</td> </tr> <tr> <td class=\"centered\">7' 0\"</td> <td class=\"centered\">84</td> <td class=\"centered\">213</td> <td class=\"centered\">105.2</td> <td class=\"centered\">421</td> <td class=\"centered\">526</td> <td class=\"centered\">631</td> <td class=\"centered\">736</td> <td class=\"centered\">842</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PBW: predicted body weight.</div><div class=\"graphic_reference\">Reproduced with permission from: NHLBI ARDS Network.&nbsp;Available at: <A spellcheck=true href=\"http://www.ardsnet.org/\" target=_blank>http://www.ardsnet.org/</A>&nbsp;(Accessed on November 20, 2012). Copyright Â© 2012.</div><div id=\"graphicVersion\">Graphic 87507 Version 5.0</div></div></div>"},"87511":{"type":"graphic_picture","displayName":"Erythroplakia","title":"Erythroplakia","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Erythroplakia</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87511_Erythroplakia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A red patch is present on the tongue.</div><div class=\"graphic_reference\">Image created by Carl Allen, DDS, MSD. Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87511 Version 3.0</div></div></div>"},"87514":{"type":"graphic_picture","displayName":"Normal anagen hair and loose anagen syndrome hair","title":"Normal anagen hair and loose anagen syndrome hair","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Normal anagen hair and loose anagen syndrome hair</div><div class=\"cntnt\"><img style=\"width:205px; height:512px;\" src=\"images/DERM/87514_Norm_ana_hair_loose.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal anagen hairs have pigmented, distorted bulbs and an attached root sheath (left). Hairs shed from the scalp in patients with loose anagen syndrome have a ruffled cuticle and lack an attached root sheath (right).</div><div class=\"graphic_reference\">Reproduced with permission from: Wolff K, Goldsmith LA, Katz S, et al. Fitzpatrick's Dermatology in General Medicine, 7th ed, McGraw-Hill Professional 2008. Copyright &copy; 2008 The McGraw-Hill Companies, Inc.</div><div id=\"graphicVersion\">Graphic 87514 Version 4.0</div></div></div>"},"87553":{"type":"graphic_table","displayName":"Emergent management of anaphylaxis in pregnant women","title":"Rapid overview: Emergent management of anaphylaxis in pregnant women","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Rapid overview: Emergent management of anaphylaxis in pregnant women</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Diagnosis is made clinically:</td> </tr> <tr> <td>The most common signs and symptoms are cutaneous (eg, sudden onset of generalized urticaria, angioedema, flushing, pruritus). However, 10 to 20% of patients have no skin findings.</td> </tr> <tr> <td><strong><span style=\"color: #ff0000;\">Danger signs: Rapid progression of symptoms, respiratory distress (eg, stridor, wheezing, dyspnea, increased work of breathing, persistent cough, cyanosis), hypotension, dysrhythmia, chest pain, collapse.</span></strong></td> </tr> <tr> <td class=\"subtitle1_single\">Acute management:</td> </tr> <tr> <td>The first and most important therapy in anaphylaxis is epinephrine. There are <strong>NO absolute contraindications</strong> <strong>to epinephrine </strong>in the setting of anaphylaxis.</td> </tr> <tr> <td><strong>Airway:</strong> Immediate intubation if evidence of impending airway obstruction from angioedema. Delay may lead to complete obstruction. Intubation can be difficult and should be performed by the most experienced clinician available. Cricothyrotomy may be necessary.</td> </tr> <tr> <td>Call for help. This might involve a multispecialty resuscitation team (anesthesiologist, obstetrician, neonatologist) in a hospital setting or emergency medical services in a community setting.</td> </tr> <tr> <td class=\"subtitle2_left\">Promptly and simultaneously, give:</td> </tr> <tr> <td class=\"indent1\"><strong>IM epinephrine (1 mg/mL preparation):</strong> Give epinephrine 0.3 to 0.5 mg intramuscularly, preferably in the mid-anterolateral thigh. Can repeat every 5 to 15 minutes, as needed. If symptoms are not responding to epinephrine injections, prepare IV epinephrine for infusion (see below).</td> </tr> <tr> <td class=\"indent1\"><strong>Oxygen:</strong> Give 6 to 8 liters per minute via facemask or up to 100% oxygen, as needed.</td> </tr> <tr> <td class=\"indent1\">Place the woman on her left side (or in a position of comfort if there is respiratory distress and/or vomiting), and elevate her lower extremities. Manual displacement of the gravid uterus to the left might be necessary. Positioning on the back might lead to inferior vena caval compression and reduced venous return to the heart. Fatality can occur within seconds if she stands or sits suddenly.</td> </tr> <tr> <td class=\"indent1\"><strong>Normal saline rapid bolus:</strong> Treat hypotension with rapid infusion of 1 to 2 liters IV. Repeat ,as needed. Massive fluid shifts with severe loss of intravascular volume can occur.</td> </tr> <tr> <td>Start continuous electronic monitoring of maternal blood pressure, cardiac rate and function, respiratory status, and oxygenation, and start continuous electronic fetal monitoring. If continuous electronic monitoring is not available, monitor maternal vital signs and fetal heart rate every&nbsp;five minutes or more frequently. Maintain a minimum maternal systolic blood pressure of 90 mmHg.</td> </tr> <tr> <td class=\"subtitle2_left\">Consider administration of:</td> </tr> <tr> <td class=\"indent1\"><strong>Albuterol <span style=\"color: #ff0000;\"></span></strong><strong>(salbutamol):</strong> For bronchospasm resistant to IM epinephrine, give 2.5 to 5 mg in 3 mL saline via nebulizer. Repeat, as needed.</td> </tr> <tr> <td class=\"indent1\"><strong>H1 antihistamine*:</strong> Consider giving diphenhydramine 25 to 50 mg IV (for relief of urticaria and itching only).</td> </tr> <tr> <td class=\"indent1\"><strong>H2 antihistamine*:</strong> Consider giving ranitidine 50 mg IV.</td> </tr> <tr> <td class=\"indent1\"><strong>Glucocorticoid*:</strong> Consider giving methylprednisolone 125 mg IV.</td> </tr> <tr> <td>When indicated at any time, perform emergency cesarean delivery for anaphylaxis refractory to medical management as outlined above or for fetal distress.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\"><FONT color=black>IM: intramuscular; IV: intravenous.<br />*These medications should not be used as initial or sole treatment.</FONT></div><div class=\"graphic_reference\">Adapted from: Simons FER, Schatz M. Anaphylaxis during pregnancy. J Allergy Clin Immunol 2012; 130:597.</div><div id=\"graphicVersion\">Graphic 87553 Version 3.0</div></div></div>"},"87554":{"type":"graphic_table","displayName":"Medications that may cause depression","title":"Medications that may cause depression","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications that may cause depression</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>ACTH (Corticotropin)</td> </tr> <tr> <td>Acutane</td> </tr> <tr> <td>Alpha-methyldopa</td> </tr> <tr> <td>Anabolic steroids</td> </tr> <tr> <td>Baclofen</td> </tr> <tr> <td>Benzodiazepines</td> </tr> <tr> <td>Caffeine</td> </tr> <tr> <td>Cimetadine</td> </tr> <tr> <td>Clonidine</td> </tr> <tr> <td>Cycloserine</td> </tr> <tr> <td>Glucocorticoids</td> </tr> <tr> <td>Guanethidine</td> </tr> <tr> <td>Interferons</td> </tr> <tr> <td>L-dopa</td> </tr> <tr> <td>Metaclopramide</td> </tr> <tr> <td>Oral contraceptives</td> </tr> <tr> <td>Phenothiazines</td> </tr> <tr> <td>Propranolol</td> </tr> <tr> <td>Pseudoephedrine</td> </tr> <tr> <td>Ranitidine</td> </tr> <tr> <td>Reserpine</td> </tr> <tr> <td>Sulfonamides</td> </tr> <tr> <td>Varenicline</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Agency for Health Care Policy and Research. Depression Associated with Medications. In: Depression in Primary Care: Detection and Diagnosis. AHCPR Publication No. 93-0550. US Department of Health and Human Services, Washington, DC, 1993. Vol 1, p.67.</div><div id=\"graphicVersion\">Graphic 87554 Version 1.0</div></div></div>"},"87555":{"type":"graphic_table","displayName":"Clinical features of FPIES","title":"Clinical features of food protein-induced enterocolitis syndrome (FPIES)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of food protein-induced enterocolitis syndrome (FPIES)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Chronic</td> <td class=\"subtitle1\">Acute</td> </tr> <tr> <td class=\"centered\" colspan=\"2\"><strong>Signs and symptoms</strong></td> </tr> <tr class=\"divider_bottom\"> <td> <p>Intermittent, chronic vomiting</p> <p>Chronic, watery diarrhea with blood/mucus</p> <p>Lethargy</p> <p>Pallor</p> <p>Dehydration</p> <p>Abdominal distension</p> <p>Weight loss</p> Failure to thrive</td> <td> <p>Repetitive vomiting every 10 to 15 minutes, onset one to three hours after ingestion (&#62;90%)</p> <p>Diarrhea, onset&nbsp;approximately five hours after ingestion (&#60;50%)</p> <p>Lethargy (70%)</p> <p>Pallor (70%)</p> <p>Dehydration</p> <p>Hypotension (15%)</p> <p>Hypothermia (25%)</p> Abdominal distension</td> </tr> <tr> <td class=\"centered\" colspan=\"2\"><strong>Laboratory findings</strong></td> </tr> <tr class=\"divider_bottom\"> <td> <p>Anemia</p> <p>Hypoalbuminemia</p> <p>Elevated white count:<br /> - Left shift<br /> - Eosinophilia</p> <p>Metabolic acidosis</p> <p>Methemoglobinemia</p> <p>Stool-reducing substances</p> Negative IgE test to the trigger food in most cases</td> <td> <p>Elevated neutrophil count</p> <p>Thrombocytosis</p> <p>Metabolic acidosis</p> <p>Methemoglobinemia</p> <p>Fecal leukocytes and eosinophils</p> <p>Frank or occult fecal blood</p> <p>Increased carbohydrate content in stool</p> <p>Elevated gastric juice leukocytes</p> Negative IgE test to the trigger food in most cases</td> </tr> <tr> <td class=\"centered\" colspan=\"2\"><strong>Radiologic features*</strong></td> </tr> <tr> <td>Air-fluid levels</td> <td>Air-fluid levels</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgE: immunoglobulin E.<br />* Radiologic studies are not recommended for the diagnosis&nbsp;of FPIES, since there is no radiographic finding that is pathognomonic for FPIES. A few older studies, involving infants with possible FPIES symptoms including chronic diarrhea, rectal bleeding,&nbsp;and/or&nbsp;failure to thrive, reported air-fluid levels, nonspecific narrowing and thumb printing of the rectum and sigmoid, and thickening of the plicae circulares in the duodenum and jejunum with excess luminal fluid. Intramural gas has also been rarely documented, potentially leading to a misdiagnosis of necrotizing enterocolitis (NEC).</div><div id=\"graphicVersion\">Graphic 87555 Version 7.0</div></div></div>"},"87565":{"type":"graphic_table","displayName":"Differential diagnosis of FPIES","title":"Differential diagnosis of food protein-induced enterocolitis syndrome (FPIES)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of food protein-induced enterocolitis syndrome (FPIES)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Allergic</td> </tr> <tr> <td>Food protein-induced proctocolitis</td> </tr> <tr> <td>Food protein-induced enteropathy</td> </tr> <tr> <td>Eosinophilic gastroenteropathies</td> </tr> <tr> <td>Anaphylaxis</td> </tr> <tr> <td class=\"subtitle1_single\">Nonallergic</td> </tr> <tr> <td class=\"subtitle2_single\">Infectious</td> </tr> <tr> <td class=\"indent1\">Sepsis</td> </tr> <tr> <td class=\"indent1\">Viral gastroenteritis</td> </tr> <tr> <td class=\"indent1\">Bacterial enteritis (<em>Salmonella</em>, <em>Shigella</em>, <em>Campylobacter</em>, <em>Yersinia</em>)</td> </tr> <tr> <td class=\"indent1\">Parasites</td> </tr> <tr> <td class=\"subtitle2_single\">Gastrointestinal disorders</td> </tr> <tr> <td class=\"indent1\">Hirschsprung disease</td> </tr> <tr> <td class=\"indent1\">Intussusception</td> </tr> <tr> <td class=\"indent1\">Volvulus</td> </tr> <tr> <td class=\"indent1\">Gastroesophageal reflux disease</td> </tr> <tr> <td class=\"indent1\">Pyloric stenosis</td> </tr> <tr> <td class=\"subtitle2_single\">Other</td> </tr> <tr> <td class=\"indent1\">Metabolic disorders</td> </tr> <tr> <td class=\"indent1\">Neurologic disorders</td> </tr> <tr> <td class=\"indent1\">Heart defects</td> </tr> <tr> <td class=\"indent1\">Necrotizing enterocolitis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 87565 Version 1.0</div></div></div>"},"87566":{"type":"graphic_table","displayName":"FPIES oral food challenge","title":"Food protein-induced enterocolitis syndrome (FPIES) oral food challenge","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Food protein-induced enterocolitis syndrome (FPIES) oral food challenge</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Protocol</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Basic requirements:&nbsp;Clinician supervision, secure intravenous (IV) access, immediate availability of fluid resuscitation. </li> <li>Baseline vital signs and complete blood count with differential to determine the baseline peripheral blood neutrophil count. </li> <li>Administration of food protein 0.06 to 0.6 g/kg body weight in three equal doses over 45 minutes generally not to exceed total 3 g protein or 10 g of total food (100 mL of liquid) for an initial feeding. A lower dose is used in patients with a history of severe reactions. </li> <li>If no reaction occurs within two to three hours of administration of the final dose, feed the patient an age appropriate serving of the food followed by four hours of observation. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Criteria for a positive challenge</td> </tr> <tr> <td class=\"indent1 \"><strong>Symptoms</strong> <ul> <li>Emesis (onset&nbsp;1 to&nbsp;3 hours) </li> <li>Lethargy (onset 1&nbsp;to&nbsp;3 hours) </li> <li>Diarrhea (onset&nbsp;2 to&nbsp;10 hours, mean&nbsp;5 hours) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Laboratory</strong> <ul> <li>Elevated neutrophil count (&#62;3500 cells/mL, peaks at six hours). This is evaluated by obtaining a complete blood count with differential approximately six hours after the start of a challenge if the patient becomes symptomatic. </li> <li>Fecal leukocytes, red blood cells, and/or eosinophils. This study is only performed if the patient develops diarrhea. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Treatment for a positive challenge*</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>First-line therapy: Fluid resuscitation with 20 mL/kg IV boluses of normal saline (0.9 percent sodium chloride). </li> <li>Therapy for hypotension/shock: Intramuscular (IM) epinephrine 0.01 mg/kg per dose using 1 mg/mL solution (also labeled 1:1000); maximum single dose 0.5 mL (0.5 mg); may repeat after 5 to 15 minutes if needed. </li> <li>Additional therapy for severe reactions: Glucocorticoids (eg, methylprednisolone 1 mg/kg IV, maximum <strong>daily</strong> dose 80 mg) or ondansetron 0.1 to 0.15 mg/kg IV, maximum <strong>single</strong> dose 16 mg. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Treatment is initiated in patients with severe, repetitive emesis; significant tachycardia; hypotension; and/or dusky appearance.</div><div id=\"graphicVersion\">Graphic 87566 Version 8.0</div></div></div>"},"87567":{"type":"graphic_diagnosticimage","displayName":"Pararenal abdominal aortic aneurysm","title":"Pararenal abdominal aortic aneurysm","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Pararenal abdominal aortic aneurysm</div><div class=\"cntnt\"><img style=\"width:598px; height:358px;\" src=\"images/RADIOL/87567_Pararen_abd_aort_aneur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large 6 by 5.4 cm pararenal AAA can be&nbsp;seen in the coronal CT&nbsp;reconstruction (A) encroaching on the&nbsp;right renal artery (arrow). In the cross sectional images, the right renal artery (arrow in B) and&nbsp;the left renal artery (arrow in C) can be seen.</div><div class=\"graphic_footnotes\">AAA: abdominal aortic aneurysm; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 87567 Version 1.0</div></div></div>"},"87568":{"type":"graphic_table","displayName":"Comparison of pneumococcal vaccines","title":"Comparison of properties of the pneumococcal polysaccharide and conjugate vaccines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of properties of the pneumococcal polysaccharide and conjugate vaccines</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Polysaccharide vaccine</td> <td class=\"subtitle1\">Conjugate polysaccharide vaccine</td> </tr> <tr> <td><strong>Stimulates antibodies in infants and toddlers</strong></td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> </tr> <tr> <td><strong>Stimulates antibodies in healthy adults</strong></td> <td class=\"centered\">Yes</td> <td class=\"centered\">Yes</td> </tr> <tr> <td><strong>Stimulates antibodies in immunocompromised adults</strong></td> <td class=\"centered\">+/-</td> <td class=\"centered\">+/- </td> </tr> <tr> <td><strong>Antibodies are long-lasting</strong></td> <td class=\"centered\">+/-</td> <td class=\"centered\">+/-</td> </tr> <tr> <td><strong>Primes immunologically for enhanced responses</strong></td> <td class=\"centered\">No</td> <td class=\"centered\">Possibly</td> </tr> <tr> <td><strong>Stimulates mucosal immunity, resulting in decreased colonization</strong></td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> </tr> <tr> <td><strong>Exhibits herd effect (secondary protection of unvaccinated individuals)</strong></td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> </tr> <tr> <td><strong>Use is associated with replacement strains</strong></td> <td class=\"centered\">No</td> <td class=\"centered\">Yes</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 87568 Version 1.0</div></div></div>"},"87570":{"type":"graphic_table","displayName":"ARR cutoff values","title":"ARR cutoff values, depending on assay and based on whether PAC, PRA, and DRC are measured in conventional or SI units","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ARR cutoff values, depending on assay and based on whether PAC, PRA, and DRC are measured in conventional or SI units</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">PRA<br /> (ng/mL x hour)</td> <td class=\"subtitle1\">PRA<br /> (pmol/L x minute)</td> <td class=\"subtitle1\">DRC*<br /> (mU/L)</td> <td class=\"subtitle1\">DRC*<br /> (ng/L)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>PAC</strong> (ng/dL)</td> <td class=\"centered\">20</td> <td class=\"centered\">1.6</td> <td class=\"centered\">2.4</td> <td class=\"centered\">3.8</td> </tr> <tr> <td class=\"centered\"><strong>30<sup>&#182;</sup></strong></td> <td class=\"centered\">2.5</td> <td class=\"centered\">3.7</td> <td class=\"centered\">5.7</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">40</td> <td class=\"centered\">3.1</td> <td class=\"centered\">4.9</td> <td class=\"centered\">7.7</td> </tr> <tr> <td rowspan=\"2\"><strong>PAC</strong> (pmol/L)</td> <td class=\"centered\"><strong>750<sup>&#182;</sup></strong></td> <td class=\"centered\">60</td> <td class=\"centered\">91</td> <td class=\"centered\">144</td> </tr> <tr> <td class=\"centered\">1000</td> <td class=\"centered\">80</td> <td class=\"centered\">122</td> <td class=\"centered\">192</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ARR: aldosterone-renin ratio; DRC: direct renin concentration; PAC: plasma aldosterone concentration; PRA: plasma renin activity; SI: Systeme International.<br />* Values shown are on the basis of a conversion factor of PRA (ng/mL/hour) to DRC (mU/liter) of 8.2. DRC assays are still in evolution, and in a recently introduced and already commonly used automated DRC assay, the conversion factor is 12. It should be noted that there is poor correlation between DRC and PRA in the range where PRA is &lt;1 ng/mL/h, the domain of major interest in primary aldosterone screening.<br />Â¶ The most commonly adopted cutoff values are shown in bold: 30 for PAC and PRA in conventional units (equivalent to 830 when PAC is in SI units) and 750 when PAC is expressed in SI units (equivalent to 27 in conventional units).</div><div class=\"graphic_reference\">Republished with permission of The Endocrine Society, from Funder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101:1889. Copyright Â© 2016; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 87570 Version 5.0</div></div></div>"},"87572":{"type":"graphic_table","displayName":"STOP-Bang questionnaire","title":"STOP-Bang questionnaire","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">STOP-Bang questionnaire</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"10%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td><span class=\"primarybox_left\">&nbsp;</span> Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span> No</td> <td> <p><strong>Snoring?</strong></p> <p>Do you <strong>snore loudly</strong> (loud enough to be heard through closed doors, or your bed partner elbows you for snoring at night)?</p> </td> </tr> <tr class=\"divider_bottom\"> <td><span class=\"primarybox_left\">&nbsp;</span> Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span> No</td> <td> <p><strong>Tired?</strong></p> <p>Do you often feel <strong>tired, fatigued, or sleepy </strong>during the daytime (such as falling asleep during driving)?</p> </td> </tr> <tr class=\"divider_bottom\"> <td><span class=\"primarybox_left\">&nbsp;</span> Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span> No</td> <td> <p><strong>Observed?</strong></p> <p>Has anyone <strong>observed </strong>you <strong>stop breathing</strong> or <strong>choking/gasping </strong>during your sleep?</p> </td> </tr> <tr class=\"divider_bottom\"> <td><span class=\"primarybox_left\">&nbsp;</span> Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span> No</td> <td> <p><strong>Pressure?</strong></p> <p>Do you have or are being treated for <strong>high blood pressure</strong>?</p> </td> </tr> <tr class=\"divider_bottom\"> <td><span class=\"primarybox_left\">&nbsp;</span> Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span> No</td> <td> <p><strong>Body mass index more than 35 kg/m<sup>2</sup>?</strong></p> </td> </tr> <tr class=\"divider_bottom\"> <td><span class=\"primarybox_left\">&nbsp;</span> Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span> No</td> <td> <p><strong>Age older than 50 years old?</strong></p> </td> </tr> <tr class=\"divider_bottom\"> <td><span class=\"primarybox_left\">&nbsp;</span> Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span> No</td> <td> <p><strong>Neck size large? (measured around Adam's apple)</strong></p> <p>For male, is your shirt collar 17 inches or larger?</p> <p>For female, is your shirt collar 16 inches or larger?</p> </td> </tr> <tr class=\"divider_bottom\"> <td><span class=\"primarybox_left\">&nbsp;</span> Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span> No</td> <td> <p><strong>Gender = Male?</strong></p> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Scoring criteria:*</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\"><strong>For general population</strong></td> </tr> <tr> <td class=\"indent2\" colspan=\"3\"><strong>Low risk of OSA:</strong> Yes to 0 to 2 questions</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\"><strong>Intermediate risk of OSA:</strong> Yes to 3 to 4 questions</td> </tr> <tr> <td class=\"indent2\" colspan=\"3\"><strong>High risk of OSA:</strong> Yes to 5 to 8 questions</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OSA: obstructive sleep apnea<br />* For validated scoring criteria in obese patients, please refer to UpToDate topic on surgical risk and the preoperative evaluation and management of adults with obstructive sleep apnea.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Chung F, Yegneswaran B, Liao P, et al. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. Anesthesiology 2008; 108:812.</li>&#xD;&#xA;    <li>Chung F, Subramanyam R, Liao P, et al. High STOP-Bang score indicates a high probability of obstructive sleep apnoea. Br J Anaesth 2012; 108:768.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 87572 Version 6.0</div></div></div>"},"87573":{"type":"graphic_figure","displayName":"Supraperiosteal infiltration","title":"Supraperiosteal infiltration","html":"<div class=\"graphic\"><div style=\"width: 650px\" class=\"figure\"><div class=\"ttl\">Supraperiosteal infiltration</div><div class=\"cntnt\"><img style=\"width:630px; height:415px;\" src=\"images/EM/87573_Supraperiostealinfiltrat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Nerve supply of the maxillary teeth.<br />(B) Needle insertion at the mucobuccal fold allows deposition of anesthesia close to the tooth apex.<br />(C) Minimal depth of needle insertion (about 2 mm) is required for the anterior primary maxillary teeth.</div><div class=\"graphic_reference\">Reproduced with permission from: Kassuto Z. Orofacial anesthesia techniques. In: Textbook of Pediatric Emergency Procedures, 2nd ed, King C, Henretig FM (Ed), Lippincott Williams &amp; Wilkins, Philadelphia, 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87573 Version 5.0</div></div></div>"},"87574":{"type":"graphic_figure","displayName":"Gingival avulsion repair","title":"Gingival avulsion repair","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Gingival avulsion repair</div><div class=\"cntnt\"><img style=\"width:538px; height:652px;\" src=\"images/EM/87574_Gingival_avulsion_repair.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Pass suture through tip of flap on the facial portion of the gum and pass needle through the teeth to the palatal portion of the gum. If the teeth are too close together to permit passage of the needle floss the suture between the teeth and then take a bite through the palatal portion of the gums (inset). <BR>(B) Pass the needle circumferentially around the tooth to the facial side of the gum so that it comes out through the flap and tie. If the teeth are too close to permit passage of the needle, floss the suture between the teeth to the facial portion of the gums, take a bite of tissue, and then tie (inset). For edentulous patients be sure that the suture knots and loops are not located in regions of contact with the bridge.</div><div id=\"graphicVersion\">Graphic 87574 Version 1.0</div></div></div>"},"87582":{"type":"graphic_figure","displayName":"Extrafollicular penetration in pseudofolliculitis barbae","title":"Extrafollicular penetration in pseudofolliculitis barbae","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Extrafollicular penetration in pseudofolliculitis barbae</div><div class=\"cntnt\"><img style=\"width:503px; height:287px;\" src=\"images/DERM/87582_Extrafollicular_PFB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reentry of the hair&nbsp;into the skin occurs after the hair has exited the follicle.</div><div id=\"graphicVersion\">Graphic 87582 Version 1.0</div></div></div>"},"87583":{"type":"graphic_figure","displayName":"Transfollicular penetration in pseudofolliculitis barbae","title":"Transfollicular penetration in pseudofolliculitis barbae","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Transfollicular penetration in pseudofolliculitis barbae</div><div class=\"cntnt\"><img style=\"width:503px; height:263px;\" src=\"images/DERM/87583_Transfollicular_PFB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Entry of the hair into the interfollicular skin occurs prior to exiting of the hair from the follicle.</div><div id=\"graphicVersion\">Graphic 87583 Version 1.0</div></div></div>"},"87584":{"type":"graphic_diagnosticimage","displayName":"CT scout small bowel obstruction ","title":"Small bowel obstruction on the scout film of a CT scan","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Small bowel obstruction on the scout film of a CT scan</div><div class=\"cntnt\"><img style=\"width:380px; height:512px;\" src=\"images/RADIOL/87584_CT_scout_bowel_obstruct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A supine examination of the abdomen shows a fluid-filled stomach (arrow) and a dilated loop of air-filled small bowel in the left upper quadrant (arrowhead). The colon is barely visualized, implying that it is decompressed and there is no air in the rectum.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 87584 Version 1.0</div></div></div>"},"87585":{"type":"graphic_diagnosticimage","displayName":"CT SBO and small bowel feces sign ","title":"Small bowel obstruction with small bowel feces sign on CT scan","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Small bowel obstruction with small bowel feces sign on CT scan</div><div class=\"cntnt\"><img style=\"width:598px; height:373px;\" src=\"images/RADIOL/87585_CT_SBO_small_bow_feces.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan of the abdomen (A) shows a zone of transition at the site of a small bowel obstruction (arrowhead). A small bowel feces sign is present in the small bowel adjacent to the obstruction (arrow) and the remaining upstream small bowel is dilated (dashed arrow).<br />Image B is a coronal reconstruction of the CT and shows a fluid-filled and distended stomach (arrow) despite the presence of a nasogastric tube. Both the ascending colon and descending colon are decompressed (arrowheads).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 87585 Version 3.0</div></div></div>"},"87586":{"type":"graphic_diagnosticimage","displayName":"CT small bowel obstruction ovarian carcinoma","title":"Small bowel obstruction caused by metastatic ovarian carcinoma on CT scan","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Small bowel obstruction caused by metastatic ovarian carcinoma on CT scan</div><div class=\"cntnt\"><img style=\"width:598px; height:385px;\" src=\"images/RADIOL/87586_CT_sm_bow_obst_ov_carc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A CT scan of the abdomen (A) shows dilated upstream small bowel (arrowhead). The downstream small bowel is decompressed (arrow). Image B is a coronal reconstruction of the CT and shows dilated upstream small bowel (arrowhead). The downstream small bowel is decompressed (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 87586 Version 1.0</div></div></div>"},"87587":{"type":"graphic_table","displayName":"Categories of risk for foot complications","title":"Categories of risk for foot complications","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Categories of risk for foot complications</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk category</td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Treatment recommendations</td> <td class=\"subtitle1\">Suggested follow-up</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">0</td> <td>No LOPS, no PAD, no deformity</td> <td> <ul> <li>Patient education including advice on appropriate footwear. </li> </ul> </td> <td>Annually (by generalist and/or specialist)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">1</td> <td>LOPS &#177; deformity</td> <td> <ul> <li>Consider prescriptive or accommodative footwear. </li> <li>Consider prophylactic surgery if deformity is not able to be safely accommodated in shoes. Continue patient education. </li> </ul> </td> <td>Every three to six months (by generalist or specialist)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">2</td> <td>PAD &#177; LOPS</td> <td> <ul> <li>Consider prescriptive or accommodative footwear. </li> <li>Consider vascular consultation for combined follow-up. </li> </ul> </td> <td>Every two to three months (by specialist)</td> </tr> <tr> <td class=\"centered\">3</td> <td>History of ulcer or amputation</td> <td> <ul> <li>Same as category 1. </li> <li>Consider vascular consultation for combined follow-up if PAD present. </li> </ul> </td> <td>Every one to two months (by specialist)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LOPS: loss of protective sensation; PAD: peripheral artery disease.</div><div class=\"graphic_reference\">From: Boulton AJM, Armstrong DG, Albert SF, et al. Comprehensive foot examination and risk assessment. Diabetes Care 2008; 31:1679. American Diabetes Association, Diabetes Care. American Diabetes Association, 2008. Copyright and all rights reserved. Material from this publication has been used with the permission of American Diabetes Association.</div><div id=\"graphicVersion\">Graphic 87587 Version 2.0</div></div></div>"},"87588":{"type":"graphic_figure","displayName":"Abdominal hernias PI","title":"Abdominal wall hernias","html":"<div class=\"graphic\"><div style=\"width: 503px\" class=\"figure\"><div class=\"ttl\">Abdominal wall hernias</div><div class=\"cntnt\"><img style=\"width:483px; height:615px;\" src=\"images/PI/87588_Abdominal_hernias_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Abdominal wall hernias can happen in different parts of the torso:<br /><ul>&#xD;&#xA;    <li>Incisional hernias happen along incisions from surgery </li>&#xD;&#xA;    <li>Umbical hernias happen at the belly button </li>&#xD;&#xA;    <li>Epigastric hernias happen in the midline above the belly button</li>&#xD;&#xA;    <li>Spigelian hernias happen to the left or right of midline, where 2 layers of muscle meet</li>&#xD;&#xA;    <li>Lumbar hernias (not shown) happen at the back</li>&#xD;&#xA;    <li>Inguinal hernias happen in the groin region</li>&#xD;&#xA;    <li>Femoral hernias happen where the thigh joins the torso</li>&#xD;&#xA;</ul></div><div id=\"graphicVersion\">Graphic 87588 Version 2.0</div></div></div>"},"87589":{"type":"graphic_table","displayName":"Microbiology of prosthetic valve endocarditis","title":"Microbiology of prosthetic valve endocarditis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Microbiology of prosthetic valve endocarditis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"3\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">Organism</td> <td class=\"subtitle1\" colspan=\"3\">Number of cases (percent)</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"3\">Time of onset after valve surgery</td> </tr> <tr> <td class=\"subtitle3\">&#60;2 months<br /> n = 250</td> <td class=\"subtitle3\">2 to 12 months<br /> n = 47</td> <td class=\"subtitle3\">&#62;12 months<br /> n = 282</td> </tr> <tr> <td>Streptococci*</td> <td class=\"centered\">6&nbsp;(2)</td> <td class=\"centered\">6 (13)</td> <td class=\"centered\">84 (30)</td> </tr> <tr> <td>Pneumococci</td> <td class=\"centered\">&#8212;</td> <td class=\"centered\">&#8212;</td> <td class=\"centered\">&#60;1 percent</td> </tr> <tr> <td>Enterococci</td> <td class=\"centered\">20&nbsp;(8)</td> <td class=\"centered\">5 (11)</td> <td class=\"centered\">31 (11)</td> </tr> <tr> <td><em>Staphylococcus aureus</em></td> <td class=\"centered\">75&nbsp;(30)</td> <td class=\"centered\">6 (13)</td> <td class=\"centered\">62 (22)</td> </tr> <tr> <td>Coagulase-negative staphylococci</td> <td class=\"centered\">69 (28)</td> <td class=\"centered\">17 (36)</td> <td class=\"centered\">34 (12)</td> </tr> <tr> <td>HACEK group<sup>&#182;</sup></td> <td class=\"centered\">&#8212;</td> <td class=\"centered\">&#8212;</td> <td class=\"centered\">11 (4)</td> </tr> <tr> <td>Gram-negative bacilli</td> <td class=\"centered\">26 (10)</td> <td class=\"centered\">2 (4)</td> <td class=\"centered\">13 (5)</td> </tr> <tr> <td>Fungi (<em>Candida</em> species)</td> <td class=\"centered\">22 (9)</td> <td class=\"centered\">4 (8)</td> <td class=\"centered\">3 (1)</td> </tr> <tr> <td>Polymicrobial/miscellaneous</td> <td class=\"centered\">7 (3)</td> <td class=\"centered\">4 (8)</td> <td class=\"centered\">12 (4)</td> </tr> <tr> <td>Diphtheroids</td> <td class=\"centered\">9 (4)</td> <td class=\"centered\">&#8212;</td> <td class=\"centered\">5 (2)</td> </tr> <tr> <td>Culture negative</td> <td class=\"centered\">16&nbsp;(6)</td> <td class=\"centered\">3 (6)</td> <td class=\"centered\">27 (10)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Includes viridans streptococci, <EM>S. gallolyticus</EM> (previously <EM>S. bovis</EM> biotype 1), other nongroupable and groupable streptococci.<br />Â¶&nbsp;Includes <EM>Hemophilus</EM> species, <EM>Aggregatibacter aphrophilus</EM>, <EM>Aggregatibacter actinomycetemcomitans</EM>, <EM>Cardiobacterium hominis</EM>, <EM>Eikenella</EM> species, and <EM>Kingella kingae</EM>.</div><div class=\"graphic_reference\">References:<br /><OL>&#xD;&#xA;<LI>Rivas P, Alonso J, Moya J, et al. The impact of hospital-acquired infections on the microbial etiology and prognosis of late-onset prosthetic valve endocarditis. Chest 2005; 128:764.</LI>&#xD;&#xA;<LI>Karchmer AW, Longworth DL. Infections of intracardiac devices. Infect Dis Clin North Amer 2002; 16:477.</LI>&#xD;&#xA;<LI>Hill EE, Herregods MC, Vanderschueren S, et al. Management of prosthetic valve infective endocarditis. Am J Cardiol 2008; 101:1174.</LI>&#xD;&#xA;<LI>Lee JH, Burner JD, Fealey ME, et al. Prosthetic valve endocarditis: Clinicopathological correlates in 122 surgical specimens from 116 patients (1985-2004). Cardiovasc Pathol 2011; 20:26.</LI>&#xD;&#xA;<LI>Wang A, Athan E, Pappas PA, et al. Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA 2007; 297:1354.</LI></OL></div><div id=\"graphicVersion\">Graphic 87589 Version 3.0</div></div></div>"},"87590":{"type":"graphic_picture","displayName":"Lichen spinulosus","title":"Lichen spinulosus","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Lichen spinulosus</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87590_Lichen_spinulosus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Circumscribed plaque with hyperkeratotic follicular papules on the abdomen of a child.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87590 Version 3.0</div></div></div>"},"87609":{"type":"graphic_figure","displayName":"Radiofrequency vein ablation PI","title":"Radiofrequency vein ablation","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Radiofrequency vein ablation</div><div class=\"cntnt\"><img style=\"width:466px; height:652px;\" src=\"images/PI/87609_RF_vein_ablation_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During radiofrequency vein ablation, the doctor inserts a special wire into the diseased vein. The wire heats up the vein from the inside and seals it closed. Laser vein ablation works in a very similar way.</div><div id=\"graphicVersion\">Graphic 87609 Version 1.0</div></div></div>"},"87611":{"type":"graphic_diagnosticimage","displayName":"Multiple pulmonary nodules in primary amyloid","title":"Primary amyloid of the lung: Multiple, confluent calcified and ossified pulmonary nodules","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Primary amyloid of the lung: Multiple, confluent calcified and ossified pulmonary nodules</div><div class=\"cntnt\"><img style=\"width:576px; height:534px;\" src=\"images/PULM/87611_Multpl_plmnry_ndls_prm_amld.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph shows multiple, confluent calcified and ossified pulmonary nodules in a patient with primary amyloidosis of the lungs.</div><div id=\"graphicVersion\">Graphic 87611 Version 2.0</div></div></div>"},"87612":{"type":"graphic_picture","displayName":"Magrina-Bookwalter vaginal retractor","title":"Magrina-Bookwalter vaginal retractor","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Magrina-Bookwalter vaginal retractor</div><div class=\"cntnt\"><img style=\"width:504px; height:378px;\" src=\"images/OBGYN/87612_Magrina_book_vag_ret.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magrina-Bookwalter vaginal retractor system is attached to the operating table. Self-retaining retractors are attached to the ring, which avoids the need for bedside assistants and provides maximum exposure.</div><div class=\"graphic_reference\">Courtesy of Rosanne M Kho, MD.</div><div id=\"graphicVersion\">Graphic 87612 Version 1.0</div></div></div>"},"87614":{"type":"graphic_diagnosticimage","displayName":"X-ray abdomen small bowel obstruction","title":"Small bowel obstruction on x-ray of the abdomen","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Small bowel obstruction on x-ray of the abdomen</div><div class=\"cntnt\"><img style=\"width:598px; height:327px;\" src=\"images/RADIOL/87614_X_abd_sma_bow_obstruct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A supine examination of the abdomen (A) shows a dilated loop of small bowel in the left upper quadrant (arrow). The descending colon is not visualized and implies that it is decompressed, and there is no air in the rectum. The stomach is distended with fluid, and the upright examination (B) shows a small air fluid level in the stomach (arrow) and more obvious air fluid levels in the small bowel (arrowheads).</div><div id=\"graphicVersion\">Graphic 87614 Version 1.0</div></div></div>"},"87620":{"type":"graphic_picture","displayName":"Patient position for laparoscopic or robotic trachelectomy","title":"Patient position for laparoscopic or robotic trachelectomy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Patient position for laparoscopic or robotic trachelectomy</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/OBGYN/87620_Pat_pos_abdomin_trach.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient lies directly on an anti-skid material that is taped securely to the operating table. No straps or blocks are utilized to minimize risk of neuropathies. The arms are tucked on the patient's sides using blankets.</div><div class=\"graphic_reference\">Courtesy of Rosanne M Kho, MD.</div><div id=\"graphicVersion\">Graphic 87620 Version 1.0</div></div></div>"},"87621":{"type":"graphic_figure","displayName":"Trocar positions for robotic pelvic surgery","title":"Trocar positions for robotic pelvic surgery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trocar positions for robotic pelvic surgery</div><div class=\"cntnt\"><img style=\"width:421px; height:373px;\" src=\"images/OBGYN/87621_Trocar_positions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Robotic &nbsp;trocar positions. A: umbilical incision for the robotic camera; B, C and D: lateral 8 mm ports for robotic trocars; E: 10 mm accessory port for the bedside assistant.</div><div id=\"graphicVersion\">Graphic 87621 Version 1.0</div></div></div>"},"87625":{"type":"graphic_table","displayName":"Common causes nausea and vomiting in palliative care pts","title":"Common causes of nausea and vomiting in palliative care","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common causes of nausea and vomiting in palliative care</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Toxic/metabolic</td> </tr> <tr> <td class=\"indent1\"><strong>Drugs</strong></td> </tr> <tr> <td class=\"indent2\">Cytotoxic chemotherapy</td> </tr> <tr> <td class=\"indent2\">Opioids, tramadol</td> </tr> <tr> <td class=\"indent2\">NSAIDs, aspirin</td> </tr> <tr> <td class=\"indent2\">Digitalis</td> </tr> <tr> <td class=\"indent2\">Iron</td> </tr> <tr> <td class=\"indent2\">Antibiotics</td> </tr> <tr> <td class=\"indent2\">Theophylline</td> </tr> <tr> <td class=\"indent2\">SSRIs and bupropion</td> </tr> <tr> <td class=\"indent2\">Anticonvulsants</td> </tr> <tr> <td class=\"indent2\">Many other drugs</td> </tr> <tr> <td class=\"indent1\"><strong>Organ failure</strong></td> </tr> <tr> <td class=\"indent2\">Liver, renal</td> </tr> <tr> <td class=\"indent1\"><strong>Metabolic</strong></td> </tr> <tr> <td class=\"indent2\">Hypercalcemia</td> </tr> <tr> <td class=\"indent2\">Hyponatremia</td> </tr> <tr> <td class=\"indent2\">Ketoacidosis</td> </tr> <tr> <td class=\"indent1\"><strong>Poisoning, substance abuse</strong></td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Disorders of viscera</td> </tr> <tr> <td class=\"indent1\"><strong>Obstruction</strong></td> </tr> <tr> <td class=\"indent2\">Gastric outlet</td> </tr> <tr> <td class=\"indent2\">Small bowel</td> </tr> <tr> <td class=\"indent2\">Biliary/pancreatic duct</td> </tr> <tr> <td class=\"indent1\"><strong>Hepatomegaly</strong></td> </tr> <tr> <td class=\"indent1\"><strong>Severe constipation</strong></td> </tr> <tr> <td class=\"indent1\"><strong>Gastroparesis</strong></td> </tr> <tr> <td class=\"indent1\"><strong>Inflammation/irritation</strong></td> </tr> <tr> <td class=\"indent2\">NSAID</td> </tr> <tr> <td class=\"indent2\">Chemotherapy: (direct GI effects)</td> </tr> <tr> <td class=\"indent2\">Radiation</td> </tr> <tr> <td class=\"indent2\">Gastritis</td> </tr> <tr> <td class=\"indent2\">Gastroenteritis</td> </tr> <tr> <td class=\"indent2\">Hepatitis</td> </tr> <tr> <td class=\"indent2\">Cholecystitis</td> </tr> <tr> <td class=\"indent2\">Pancreatitis</td> </tr> <tr> <td class=\"indent1\"><strong>Tumors of the gastrointestinal tract and thorax</strong></td> </tr> <tr> <td class=\"indent1\"><strong>Ascites</strong></td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">CNS causes</td> </tr> <tr> <td class=\"indent1\"><strong>Increased intracranial pressure</strong></td> </tr> <tr> <td class=\"indent2\">Malignancy</td> </tr> <tr> <td class=\"indent2\">Hemorrhage</td> </tr> <tr> <td class=\"indent2\">Cranial irradiation</td> </tr> <tr> <td class=\"indent2\">Abscess</td> </tr> <tr> <td class=\"indent1\"><strong>Meningeal infiltration</strong></td> </tr> <tr> <td class=\"indent1\"><strong>Vestibular</strong></td> </tr> <tr> <td class=\"indent2\">Drug effects</td> </tr> <tr> <td class=\"indent2\">Labyrinthitis</td> </tr> <tr> <td class=\"indent1\"><strong>Anxiety</strong></td> </tr> <tr> <td class=\"indent2\">Anticipatory nausea and vomiting</td> </tr> <tr> <td class=\"indent1\"><strong>Pain</strong></td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SSRI: selective serotonin reuptake inhibitor.</div><div id=\"graphicVersion\">Graphic 87625 Version 5.0</div></div></div>"},"87626":{"type":"graphic_picture","displayName":"Callus 1","title":"Callus","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Callus</div><div class=\"cntnt\"><img style=\"width:576px; height:433px;\" src=\"images/DERM/87626_Callus_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large, hyperkeratotic area localized at the base of the third toe.</div><div class=\"graphic_reference\">Reproduced with permission from <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87626 Version 3.0</div></div></div>"},"87627":{"type":"graphic_picture","displayName":"Atrophie blanche lipodermatosclerosis 1","title":"Atrophie blanche","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Atrophie blanche</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87627_Atrophie_blanche_lipoderm_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atrophie blanche in a patient with lipodermatosclerosis: characteristic ivory-white, stellate fibrotic scars.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87627 Version 3.0</div></div></div>"},"87628":{"type":"graphic_diagnosticimage","displayName":"Autoimmune pancreatitis","title":"Autoimmune pancreatitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Autoimmune pancreatitis</div><div class=\"cntnt\"><img style=\"width:370px; height:256px;\" src=\"images/GAST/87628_Autoimmune_pancreatitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial portal phase computed tomography (CT) image shows diffuse sausage-like swelling of pancreas with loss of pancreatic clefts and thin, symmetric capsule-like rim of low attenuation surrounding pancreas (arrows).</div><div class=\"graphic_reference\">From: Kim JH, Byun JH, Lee SS, et al. Atypical manifestations of IgG4-related sclerosing disease in the abdomen: Imaging findings and pathologic correlations. AJR Am J Roentgenol 2013; 200:102. Reprinted with permission from the American Journal of Roentgenology. Copyright Â© 2013 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 87628 Version 1.0</div></div></div>"},"87629":{"type":"graphic_figure","displayName":"Posterior urethral valves","title":"Posterior urethral valves","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Posterior urethral valves</div><div class=\"cntnt\"><img style=\"width:532px; height:357px;\" src=\"images/PEDS/87629_Posterior_urethral_valves.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An oblique membrane associated with the verumontanum, the congenital obstructive posterior urethral membrane (COPUM), appears to be the cause of posterior urethral valves.</div><div id=\"graphicVersion\">Graphic 87629 Version 2.0</div></div></div>"},"87630":{"type":"graphic_table","displayName":"Examples of drugs that may cause pruritus","title":"Examples of drugs that may cause pruritus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of drugs that may cause pruritus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Group of drugs</td> <td class=\"subtitle1\">Examples</td> <td class=\"subtitle1\">Possible mechanism of pruritus</td> <td class=\"subtitle1\">Frequency of pruritus</td> </tr> <tr> <td>Anti-arrhythmic drugs</td> <td>Amiodarone</td> <td>Cholestatic liver injury</td> <td>Case reports</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"15\">Antibiotics</td> <td>Penicillins</td> <td>Secondary to skin lesions or cholestatic liver injury</td> <td>2 to 20%</td> </tr> <tr> <td>Cephalosporins</td> <td>Unknown or secondary to skin lesions</td> <td>&#60;2%</td> </tr> <tr> <td>Macrolides</td> <td>Secondary to skin lesions or cholestatic liver injury</td> <td>&#60;0.3%</td> </tr> <tr> <td>Carbapenemes</td> <td>Cholestatic liver injury</td> <td>Rare</td> </tr> <tr> <td>Monobactams</td> <td>Secondary to skin lesions</td> <td>Rare</td> </tr> <tr> <td>Quinolones</td> <td>Unknown or secondary to skin lesions</td> <td>1 to 4%</td> </tr> <tr> <td>Tetracyclines</td> <td>Unknown or cholestatic liver injury</td> <td>1 to 2%</td> </tr> <tr> <td>Lincosamides</td> <td>Secondary to skin lesions or cholestatic liver injury</td> <td>Rare</td> </tr> <tr> <td>Streptogramins</td> <td>Secondary to skin lesions</td> <td>2.5%</td> </tr> <tr> <td>Metronidazole</td> <td>Unknown or secondary to skin lesions</td> <td>&#60;5%</td> </tr> <tr> <td>Rifampin</td> <td>Unknown</td> <td>Case report</td> </tr> <tr> <td>Tiamphenicol</td> <td>Unknown</td> <td>&#60;0.1%</td> </tr> <tr> <td rowspan=\"2\">Trimethoprim/sulphamethoxazole</td> <td>Secondary to skin lesions</td> <td>2 to 10%</td> </tr> <tr> <td>Cholestatic liver injury</td> <td>Rare</td> </tr> <tr> <td>Antimalarials</td> <td>Unknown, but genetic background is important; release of histamine or activation of mu-receptors were postulated</td> <td>Up to 60 to 70% of Black Africans, uncommon in Caucasians or Asians</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Anticoagulants</td> <td>Ticlopidine</td> <td>Cholestatic liver injury</td> <td>Case reports</td> </tr> <tr> <td>Fractionated heparins</td> <td>Urticarial reaction</td> <td>Case reports</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"2\">Anti-diabetic drugs</td> <td>Biguanides</td> <td>Cholestatic liver injury</td> <td>Case reports</td> </tr> <tr> <td>Sulphonylurea derivates</td> <td>Unknown</td> <td>&#60;5%</td> </tr> <tr class=\"divider_top\"> <td>Anti-epileptics</td> <td>Carbamazepine, fosphenytoin, oxcarbazepine, phenytoin, topiramate</td> <td>Secondary to skin lesions, allergic reaction</td> <td>Rare</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"8\">Antihypertensive drugs</td> <td>Angiotensin-converting enzyme inhibitors</td> <td>Increase of bradykinin level or cholestatic liver injury or secondary to skin lesions</td> <td>1 to 15%</td> </tr> <tr> <td>Angiotensin II antagonists (sartans)</td> <td>Cholestatic liver injury</td> <td>Case reports</td> </tr> <tr> <td rowspan=\"2\">Beta-adrenergic blockers</td> <td>Secondary to skin lesions</td> <td>Frequent, if administered transdermally</td> </tr> <tr> <td>Cholestatic liver injury</td> <td>Rare</td> </tr> <tr> <td rowspan=\"2\">Calcium channel blockers</td> <td>Secondary to skin lesions or unknown</td> <td>&#60;2%</td> </tr> <tr> <td>Cholestatic liver injury</td> <td>Case reports</td> </tr> <tr> <td>Methyldopa</td> <td>Unknown or secondary to skin lesions</td> <td>&#60;2%</td> </tr> <tr> <td>Sildenafil</td> <td>Cholestatic liver injury</td> <td>Case report</td> </tr> <tr class=\"divider_top\"> <td>BRAF inhibitors</td> <td>Vemurafenib</td> <td>Unknown</td> <td>19%</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"4\">Cytokines, growth factors and monoclonal antibodies</td> <td>Granulocyte-macrophage colony-stimulating factor</td> <td>Unknown</td> <td>Common</td> </tr> <tr> <td>Interleukin 2</td> <td>Direct pruritogenic effect of interleukin 2</td> <td>Very common</td> </tr> <tr> <td>Matuzumab</td> <td>Unknown</td> <td>&#60;10%</td> </tr> <tr> <td>Lapatinib</td> <td>Unknown or urticarial reaction</td> <td>3%</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Cytostatics</td> <td>Chlorambucil</td> <td>Secondary to skin lesions</td> <td>Case reports</td> </tr> <tr> <td>Paclitaxel</td> <td>Unknown or secondary to skin lesions</td> <td>10 to 14%</td> </tr> <tr> <td>Tamoxifen</td> <td>Sebostasis/xerosis</td> <td>3 to 5%</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Epidermal growth factor inhibitors</td> <td>Cetuximab</td> <td>Unknown</td> <td>22%</td> </tr> <tr> <td>Erlotinib</td> <td>Unknown</td> <td>18%</td> </tr> <tr> <td>Panitumumab</td> <td>Unknown</td> <td>58%</td> </tr> <tr class=\"divider_top\"> <td>Hypolipaemic drugs</td> <td>Statins</td> <td>Unknown or secondary to skin lesions</td> <td>16%</td> </tr> <tr class=\"divider_top\"> <td>Monoclonal antibody to CTLA-4</td> <td>Ipilimumab</td> <td>Unknown</td> <td>31%</td> </tr> <tr class=\"divider_top\"> <td>Plasma volume expanders</td> <td>Hydroxyethyl starch (HES)</td> <td>Deposition of HES in small peripheral nerves or in Schwann's cells of cutaneous nerves</td> <td>12.6 to 54%</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"3\">Psychotropic drugs</td> <td>Tricyclic antidepressants</td> <td>Cholestatic liver injury</td> <td>Rare</td> </tr> <tr> <td>Selective serotonin re-uptake inhibitors</td> <td>Activation of peripheral serotonin receptors or secondary to skin lesions</td> <td>Rare</td> </tr> <tr> <td>Neuroleptics</td> <td>Cholestatic liver injury</td> <td>Rare</td> </tr> <tr class=\"divider_top\"> <td rowspan=\"7\">Others</td> <td>Anti-thyroid agents</td> <td>Cholestatic liver injury</td> <td>Rare</td> </tr> <tr> <td rowspan=\"2\">Nonsteroidal antiinflammatory drugs</td> <td>Increased synthesis of leukotrienes</td> <td>1 to 7%</td> </tr> <tr> <td>Cholestatic liver injury</td> <td>Rare</td> </tr> <tr> <td>Corticosteroids</td> <td>Cholestatic liver injury</td> <td>Very rare</td> </tr> <tr> <td>Sex hormones</td> <td>Cholestatic liver injury</td> <td>Rare</td> </tr> <tr> <td>Opioids</td> <td>Centrally mediated process via mu-opioid receptor</td> <td>2 to 100%</td> </tr> <tr> <td>Inhibitors of xanthine oxidase</td> <td>Secondary to skin lesions</td> <td>0.8 to 2.1%</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CTLA-4: cytotoxic T-lymphocyte associated protein 4.</div><div class=\"graphic_reference\">Reference:<br /><ol>&#xD;&#xA;    <li>Fischer A, Rosen AC, Ensslin CJ, et al. Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4. Dermatol Ther 2013; 26:135.</li>&#xD;&#xA;</ol>&#xD;&#xA;<br />Reproduced with permission from: Reich A, St&auml;nder S, Szepietowski JC. Drug-induced pruritus: A review. Acta Derm Venereol 2009; 89:236.</div><div id=\"graphicVersion\">Graphic 87630 Version 3.0</div></div></div>"},"87631":{"type":"graphic_figure","displayName":"A childs drawing and description of RLS","title":"A drawing and description of restless legs syndrome by a 10-year-old girl","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">A drawing and description of restless legs syndrome by a 10-year-old girl</div><div class=\"cntnt\"><img style=\"width:471px; height:504px;\" src=\"images/PEDS/87631_ChilddrawdescriptRLS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The child described the symptoms as follows: \"What I drew was saying that my top part of my body is relaxed and calm, but the bottom wants to run really bad.\"</div><div class=\"graphic_reference\">Reproduced with permission from: the RLS Foundation Youth Initiative Drawing Contest, 2010. More information available at <A style=\"FONT-STYLE: italic\" href=\"http://www.rls.org/\" target=_blank>www.rls.org</A>.</div><div id=\"graphicVersion\">Graphic 87631 Version 2.0</div></div></div>"},"87632":{"type":"graphic_figure","displayName":"Overview of uropathogen virulence factors","title":"Overview of uropathogen virulence factors","html":"<div class=\"graphic\"><div style=\"width: 636px\" class=\"figure\"><div class=\"ttl\">Overview of uropathogen virulence factors</div><div class=\"cntnt\"><img style=\"width:616px; height:720px;\" src=\"images/ID/87632_Overview_uropath_virul_fact.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The left hand side of this schematic bacterial cell represents uropathogenic Escherichia coli, and the right hand side represents Proteus mirabilis. Proteins that contribute to each mechanism of pathogenesis&mdash;immune evasion, toxin production, iron acquisition, adherence, and motility&mdash;are highlighted for each pathogen. Some strains of uropathogenic <em>E. coli</em> strains encode the proteins SisA and SisB, which suppress the host inflammatory response during early stages of infection. <em>P. mirabilis</em> produces urease, which plays a role in the formation of urinary stones.</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd: Nature Reviews Urology. Nielubowicz GR, Mobley HL. Host-pathogen interactions in urinary tract infection. Nat Rev Urol 2010; 7:430. Copyright &copy; 2010. <a href=\"http://www.nature.com/nrurol/index.html\" target=\"_blank\">http://www.nature.com/nrurol/index.html</a>.</div><div id=\"graphicVersion\">Graphic 87632 Version 1.0</div></div></div>"},"87633":{"type":"graphic_picture","displayName":"Scalp laceration through the galea","title":"Scalp laceration through the galea","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Scalp laceration through the galea</div><div class=\"cntnt\"><img style=\"width:586px; height:386px;\" src=\"images/EM/87633_Scalp_lacertion_thrgh_galea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) This patient has a scalp laceration that extends through the galea aponeurosis (white arrows).<br />(B) Computed tomography of the head shows an associated skull fracture.</div><div class=\"graphic_reference\">Reproduced with permission from: Edward Dickinson, MD.</div><div id=\"graphicVersion\">Graphic 87633 Version 1.0</div></div></div>"},"87634":{"type":"graphic_picture","displayName":"Bone marrow findings in myeloproliferative variants of HES","title":"Bone marrow findings in myeloproliferative variants of hypereosinophilic syndrome (HES)","html":"<div class=\"graphic\"><div style=\"width: 633px\" class=\"figure\"><div class=\"ttl\">Bone marrow findings in myeloproliferative variants of hypereosinophilic syndrome (HES)</div><div class=\"cntnt\"><img style=\"width:613px; height:361px;\" src=\"images/ALLRG/87634_BM_findings_myeloprolif_HES.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The bone marrow biopsy sections presented are from two representative patients with hypereosinophilic syndrome&nbsp;with (A to C) and without (D to F) elevated serum tryptase levels stained with hematoxylin and eosin (A, D), antitryptase antibody (B, E), and antireticulin antibody (C, F). Although the bone marrow biopsy specimens from both patients show a dramatic increase in eosinophils and myeloid precursors (A, D), only the specimen from the patient with elevated serum tryptase shows marked hypercellularity (A), atypical spindle-shaped mast cells (B), and reticulin fibrosis (C).</div><div class=\"graphic_reference\">This research was originally published in Blood. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101:4660. Copyright &copy; 2003 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 87634 Version 4.0</div></div></div>"},"87655":{"type":"graphic_diagnosticimage","displayName":"Apical 5-chamber MV SAM in HCM","title":"Apical 5-chamber echocardiogram showing systolic anterior motion (SAM) of the mitral valve (MV) in a patient with hypertrophic cardiomyopathy (HCM)","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Apical 5-chamber echocardiogram showing systolic anterior motion (SAM) of the mitral valve (MV) in a patient with hypertrophic cardiomyopathy (HCM)</div><div class=\"cntnt\"><img style=\"width:515px; height:252px;\" src=\"images/CARD/87655_Apic_5_cham_MV_SAM_HCM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Apical five-chamber transthoracic echocardiogram showing minimal systolic anterior motion (SAM) of the mitral valve under basal resting conditions (panel A) which is markedly worsening during exercise (panel B) resulting in mitral-septal contact and obstruction in the left ventricular outflow tract.</div><div class=\"graphic_reference\">Reproduced with permission from: Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006; 114:2232. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87655 Version 4.0</div></div></div>"},"87656":{"type":"graphic_diagnosticimage","displayName":"CMR septal LVH in HCM","title":"Four-chamber cardiac magnetic resonance (CMR) showing massive septal hypertrophy in a patient with hypertrophic cardiomyopathy (HCM)","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Four-chamber cardiac magnetic resonance (CMR) showing massive septal hypertrophy in a patient with hypertrophic cardiomyopathy (HCM)</div><div class=\"cntnt\"><img style=\"width:576px; height:487px;\" src=\"images/CARD/87656_CMR_septal_LVH_in_HCM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four-chamber cardiac magnetic resonance (CMR) image showing massive septal hypertrophy in a patient with hypertrophic cardiomyopathy (HCM).</div><div class=\"graphic_reference\">Courtesy of Martin Maron, M.D.</div><div id=\"graphicVersion\">Graphic 87656 Version 2.0</div></div></div>"},"87657":{"type":"graphic_diagnosticimage","displayName":"Echo vs CMR LVH in HCM","title":"Echo vs CMR LVH in HCM","html":"<div class=\"graphic\"><div style=\"width: 531px\" class=\"figure\"><div class=\"ttl\">Echo vs CMR LVH in HCM</div><div class=\"cntnt\"><img style=\"width:511px; height:265px;\" src=\"images/CARD/87657_Echo_CMR_LVH_HCM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two-dimensional stop-frame echocardiogram (A) and comparative cardiac magnetic resonance (CMR, panel B) images acquired in short axis plane in end diastole at mitral valve level. In panel A, the echocardiogram shows normal thickness in all LV wall segments, including ventricular septum and contiguous portion of anterolateral free wall (*). In panel B, CMR image showing segmental area of hypertrophy confined to anterolateral LV free wall (20 mm) and small portion of contiguous anterior septum (*), which was identified only with CMR, in the same cross-sectional plane as echocardiogram shown in panel A.</div><div class=\"graphic_footnotes\">HCM: hypertrophic cardiomyopathy; RV: right ventricle; AVS: anterior ventricular septum; LV: left ventricle.</div><div class=\"graphic_reference\">Reproduced with permission from: Rickers C, Wilke NM, Jerosch-Herold M, et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 2005; 112:855. Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87657 Version 5.0</div></div></div>"},"87658":{"type":"graphic_figure","displayName":"Pathologic LVH vs Physiologic LVH","title":"Pathologic LVH vs Physiologic LVH","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathologic LVH vs Physiologic LVH</div><div class=\"cntnt\"><img style=\"width:336px; height:506px;\" src=\"images/CARD/87658_Pathol_LVH_vs_Physiol_LVH.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Comparison of features which can be useful in distinguishing Pathologic LVH from Physiologic LVH.</div><div class=\"graphic_footnotes\">LA: left atrium; LV: left ventricle; LVH: left ventricular hypertrophy; ECG: electrocardiogram; HCM: hypertrophic cardiomyopathy.</div><div class=\"graphic_reference\">Additional updated information from:<br /><OL>&#xD;&#xA;<LI>Maron BJ, Maron MS. Hypertrophic cardiomyopathy. Lancet 2012.</LI>&#xD;&#xA;<LI>Maron BJ, Pelliccia A. The heart of trained athletes: cardiac remodeling and the risks of sports, including sudden death. Circulation 2006; 114:1633.</LI></OL>Reproduced with permission from: Maron BJ, Pelliccia A, Spirito P. Cardiac disease in young trained athletes. Insights into methods for distinguishing athlete's heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy. Circulation 1995; 91:1596.</div><div id=\"graphicVersion\">Graphic 87658 Version 3.0</div></div></div>"},"87660":{"type":"graphic_figure","displayName":"Chemical relationship among ketone bodies","title":"Ketone bodies","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Ketone bodies</div><div class=\"cntnt\"><img style=\"width:536px; height:348px;\" src=\"images/NEPH/87660_Ketone_bodies.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 87660 Version 1.0</div></div></div>"},"87662":{"type":"graphic_waveform","displayName":"ECG with TCA poisoning - Initial presentation","title":"ECG with TCA poisoning: Initial presentation","html":"<div class=\"graphic\"><div style=\"width: 621px\" class=\"figure\"><div class=\"ttl\">ECG with TCA poisoning: Initial presentation</div><div class=\"cntnt\"><img style=\"width:601px; height:524px;\" src=\"images/EM/87662_ECG_changes_TCA_poisoning.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These are a series of electrocardiograms (ECGs) obtained from a patient with tricyclic antidepressant overdose.&nbsp;The first&nbsp;(above) shows the initial ECG demonstrating QRS interval prolongation and characteristic changes in AVR.&nbsp;The second (Severe cardiac toxicity)&nbsp;shows worsening changes consistent with progression of cardiac toxicity. Note the increases in the QRS interval and the R wave in AVR.&nbsp;The third (After treatment)&nbsp;shows narrowing of the QRS complex but persistent right axis deviation of the terminal 40 milliseconds following the initiation of treatment.&nbsp;The final ECG (Resolution)&nbsp;shows complete resolution of interval changes related to toxicity.</div><div class=\"graphic_reference\">Courtesy of Steven Sahalnick, MD.</div><div id=\"graphicVersion\">Graphic 87662 Version 2.0</div></div></div>"},"87665":{"type":"graphic_diagnosticimage","displayName":"Ruptured abdominal aortic aneurysm","title":"Ruptured abdominal aortic aneurysm","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Ruptured abdominal aortic aneurysm</div><div class=\"cntnt\"><img style=\"width:598px; height:508px;\" src=\"images/RADIOL/87665_Rupt_abd_aort_aneurysm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The CT scan of the abdomen shows an acute rupture of a 5 cm infrarenal abdominal aortic aneurysm. The high density acute blood obliterates the periaortic fat plane (arrow in A). The blood dissects into the retroperitoneum and obliterates the fat plane around the IVC (arrowhead) and the right psoas muscle in the posterior pararenal space (dashed arrow). The high density acute blood is better appreciated with narrowed windows (arrow in B). The full extent of the bleed is demonstrated by the maroon overlay in image C. The aneurysm is overlaid in bright red and the compressed IVC in blue.</div><div class=\"graphic_footnotes\">CT: computed tomography; IVC: inferior vena cava.</div><div id=\"graphicVersion\">Graphic 87665 Version 2.0</div></div></div>"},"87666":{"type":"graphic_diagnosticimage","displayName":"Large ruptured abdominal aortic aneurysm","title":"Large ruptured abdominal aortic aneurysm","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Large ruptured abdominal aortic aneurysm</div><div class=\"cntnt\"><img style=\"width:599px; height:240px;\" src=\"images/RADIOL/87666_Lge_rupt_abd_aor_aneu.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A ruptured 9.6 cm infrarenal abdominal aneurysm of a 70-year-old male with pain and hypotension is shown in the axial CT image. Blood dissects into the left-sided posterior pararenal space, perirenal space, and into Gerota's fascia (arrow in A). The site of rupture (arrow in B) is noted more inferiorly.</div><div class=\"graphic_footnotes\">CT: Computed tomography.</div><div id=\"graphicVersion\">Graphic 87666 Version 1.0</div></div></div>"},"87667":{"type":"graphic_diagnosticimage","displayName":"Ruptured abdominal aortic aneurysm with contrast extravasation ","title":"Ruptured abdominal aortic aneurysm with contrast extravasation ","html":"<div class=\"graphic\"><div style=\"width: 610px\" class=\"figure\"><div class=\"ttl\">Ruptured abdominal aortic aneurysm with contrast extravasation </div><div class=\"cntnt\"><img style=\"width:590px; height:445px;\" src=\"images/RADIOL/87667_Rupt_abdom_aneu_extra.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A ruptured infrarenal aortic aneurysm is identified with acute extravasation of contrast between the layers of chronic laminated thrombus. Extravasated blood can be seen in the posterior pararenal space (arrow), perirenal space (arrowhead), and in the anterior pararenal space (dashed arrow). The right kidney is displaced posteriorly.</div><div id=\"graphicVersion\">Graphic 87667 Version 1.0</div></div></div>"},"87673":{"type":"graphic_table","displayName":"Time to test positivity","title":"Time to positivity of HIV diagnostic tests","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Time to positivity of HIV diagnostic tests</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Target of detection</td> <td class=\"subtitle1\">Approximate time to positivity (days)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Enzyme-linked immunoassay</td> </tr> <tr> <td class=\"indent1\">First generation</td> <td class=\"centered\">IgG antibody</td> <td class=\"centered\">35 to 45</td> </tr> <tr> <td class=\"indent1\">Second generation</td> <td class=\"centered\">IgG antibody</td> <td class=\"centered\">25 to 35</td> </tr> <tr> <td class=\"indent1\">Third generation</td> <td class=\"centered\">IgM and IgG antibody</td> <td class=\"centered\">20 to 30</td> </tr> <tr> <td class=\"indent1\">Fourth generation</td> <td class=\"centered\">IgM and IgG antibody and p24 antigen</td> <td class=\"centered\">15 to 20</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Western blot</td> </tr> <tr> <td rowspan=\"2\">&nbsp;</td> <td class=\"centered\" rowspan=\"2\">IgM and IgG antibody</td> <td class=\"centered\">35 to 50 (indeterminate)</td> </tr> <tr> <td class=\"centered\">45 to 60 (positive)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">HIV viral load test</td> </tr> <tr> <td class=\"indent1\">Sensitivity cutoff 50 copies/mL</td> <td class=\"centered\">RNA</td> <td class=\"centered\">10 to 15</td> </tr> <tr> <td class=\"indent1\">Ultrasensitive cutoff 1 to 5 copies/mL</td> <td class=\"centered\">RNA</td> <td class=\"centered\">5</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table demonstrates the approximate time to positivity following infection for various diagnostic tests for HIV.</div><div class=\"graphic_footnotes\">IgG: immunoglobulin G; IgM: immunoglobulin M.</div><div class=\"graphic_reference\">References:<br /><ol>&#xD;&#xA;    <li>Branson BM, Stekler JD. Detection of acute HIV infection: We can't close the window. J Infect Dis 2012; 205:521.</li>&#xD;&#xA;    <li>Owen SM. Testing for acute HIV infection: implications for treatment as prevention. Curr Opin HIV AIDS 2012; 7:125.</li>&#xD;&#xA;    <li>Cohen MS, Gay CL, Busch MP, et al. The detection of acute HIV infection. J Infect Dis 2010; 202:S270.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 87673 Version 3.0</div></div></div>"},"87676":{"type":"graphic_table","displayName":"Treatment of invasive candidiasis","title":"Treatment of candidemia and invasive candidiasis in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of candidemia and invasive candidiasis in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Condition or treatment group</td> <td class=\"subtitle1\" colspan=\"3\">Therapy</td> </tr> <tr> <td class=\"subtitle2\">Primary</td> <td class=\"subtitle2\">Step-down</td> <td class=\"subtitle2\">Comments</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Candidemia</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Nonneutropenic adults</td> <td> <p>An echinocandin (caspofungin 70 mg IV loading dose, then 50 mg IV daily; micafungin 100 mg IV daily; anidulafungin 200 mg IV loading dose, then 100 mg IV daily) is recommended as initial therapy.</p> <p>An alternative for patients who are not critically ill and who are considered unlikely to have fluconazole-resistant <em>Candida </em>spp* is fluconazole 800 mg (12 mg/kg) oral loading dose, then 400 mg (6 mg/kg) orally<sup>&#182;</sup> daily.</p> <p>A lipid formulation of&nbsp;amphotericin B&nbsp;(3 to 5 mg/kg IV daily) is an alternative if there is intolerance, limited availability, or resistance to other antifungal agents.</p> </td> <td> <p>For patients who are clinically stable, have isolates that are susceptible to fluconazole, and have negative repeat blood cultures following initiation of antifungal therapy, transition from an echinocandin or lipid formulation amphotericin B to fluconazole is appropriate (usually within five to&nbsp;seven days).</p> <p>For <em>C. glabrata </em>infection, transition to higher-dose fluconazole 800 mg (12 mg/kg) orally daily or voriconazole<sup>&#916;</sup> 200 to 300 mg (3 to 4 mg/kg) orally twice daily should only be considered for patients with fluconazole-susceptible or voriconazole-susceptible isolates.</p> </td> <td>When the source is presumed to be the CVC, remove it as early as possible. For candidemia without obvious metastatic complications, treat for 14 days after first negative blood culture result and resolution of signs and symptoms associated with candidemia. Dilated funduscopic examination within a week of diagnosis is recommended for all patients.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Neutropenic patients</td> <td> <p>An echinocandin (caspofungin 70 mg IV loading dose, then 50 mg IV daily; micafungin 100 mg IV daily; anidulafungin 200 mg IV loading dose, then 100 mg IV daily) is recommended as initial therapy.</p> <p>A lipid formulation of amphotericin B (3 to 5 mg/kg IV daily) is a less attractive alternative because of the potential for toxicity.</p> <p>For patients who are not critically ill and who have had no prior azole exposure, an alternative is fluconazole 800 mg (12 mg/kg) oral loading dose, then 400 mg (6 mg/kg) orally<sup>&#182;</sup> daily.</p> <p>In situations in which additional mold coverage is desired, voriconazole<sup>&#916;</sup> 400 mg orally (or 6 mg/kg IV) twice daily for two doses then 200 to 300 mg orally (or 3 to 4 mg/kg IV) twice daily can be used.</p> </td> <td> <p>Fluconazole 400 mg (6 mg/kg) orally<sup>&#182;</sup> daily can be used for step-down therapy during persistent neutropenia in clinically stable patients who have fluconazole-susceptible isolates and documented bloodstream clearance.</p> <p>Voriconazole<sup>&#916; </sup>200 to 300 mg (3 to 4 mg/kg) orally twice daily can be used as step-down therapy during neutropenia in clinically stable patients who have voriconazole-susceptible isolates and documented bloodstream clearance.</p> </td> <td>For candidemia without obvious metastatic complications, recommended minimum duration of therapy is&nbsp;14 days&nbsp;after documented clearance of <em>Candida</em> from the bloodstream, provided neutropenia and signs and symptoms attributable to candidemia have resolved. Dilated funduscopic examination is recommended for all patients; examination should be repeated within 7 days after recovery from neutropenia. CVC removal should be considered on a case-by-case basis. G-CSF-mobilized granulocyte transfusions can be considered in cases of persistent candidemia with anticipated protracted neutropenia.&nbsp; </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The doses above are intended for patients with normal organ function. The&nbsp;fluconazole dose requires adjustment in the setting of renal insufficiency; the caspofungin and voriconazole doses may require adjustment in hepatic insufficiency. Refer to the Lexicomp monographs included within UpToDate for additional information including specific dose adjustment recommendations.</div><div class=\"graphic_footnotes\">IV: intravenous; CVC: central venous catheter; G-CSF: granulocyte colony-stimulating factor.<br />*&nbsp;Fluconazole should be considered a first-line option only in patients who are stable, have no previous exposure to azoles, and are not at high risk for C. glabrata infection (eg, older adults, underlying malignancy, diabetic); refer to accompanying text.<br />Â¶&nbsp;Since fluconazole is highly bioavailable, oral therapy is appropriate for most patients. IV therapy (at the same dose) should be given to patients who are unable to take oral medications, who are not expected to have good gastrointestinal absorption, or who are severely ill.<br />â Therapeutic drug monitoring should be considered due to widely variable pharmacokinetics; refer to the UpToDate topic review on pharmacology of azoles for details.</div><div class=\"graphic_reference\">Data from: Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</div><div id=\"graphicVersion\">Graphic 87676 Version 7.0</div></div></div>"},"87677":{"type":"graphic_table","displayName":"Treatment of Candida UTIs","title":"Treatment of <EM>Candida</EM> infections of the bladder and kidneys in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of <EM>Candida</EM> infections of the bladder and kidneys in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Condition or treatment group</td> <td class=\"subtitle1\" colspan=\"3\">Therapy</td> </tr> <tr> <td class=\"subtitle2\">Primary</td> <td class=\"subtitle2\">Alternative</td> <td class=\"subtitle2\">Comments</td> </tr> <tr> <td>Asymptomatic candiduria</td> <td> <p>Therapy is&nbsp;<strong>not</strong> usually indicated, unless patients are at high risk for dissemination (neutropenic patients, very low birthweight infants [&#60;1500 g], patients undergoing urologic procedures).</p> <p>Neutropenic patients and very low birthweight infants should be treated with similar regimens as patients with candidemia.*</p> <p>Patients undergoing a urologic procedure: oral fluconazole 400 mg or amphotericin B deoxycholate<sup>&#182;</sup> 0.3 to 0.6 mg/kg IV daily for several days before and after the procedure.</p> </td> <td>&nbsp;N/A</td> <td>Elimination of predisposing factors is recommended.</td> </tr> <tr> <td>Cystitis</td> <td>For fluconazole-susceptible isolates: fluconazole 200 mg orally daily for two weeks</td> <td> <p>For fluconazole-resistant <em>C. glabrata</em>: amphotericin B deoxycholate<sup>&#182;</sup>&nbsp;0.3 to 0.6 mg/kg IV daily for 1 to 7 days or flucytosine 25 mg/kg orally four times daily for 7 to 10 days</p> <p>For <em>C. krusei</em>: amphotericin B deoxycholate<sup>&#182;</sup> 0.3 to 0.6 mg/kg IV for 1 to 7 days</p> </td> <td>Indwelling bladder catheters should be removed, if feasible. Amphotericin B deoxycholate bladder irrigation 50 mg/L sterile water daily for 5 days can be used&nbsp;for patients with fluconazole-resistant organisms, such as<em> C. krusei</em> and <em>C. glabrata</em>. </td> </tr> <tr> <td>Pyelonephritis</td> <td>Fluconazole 200 to 400 mg orally daily for two weeks</td> <td> <p>For fluconazole-resistant <em>C. glabrata</em>: amphotericin B deoxycholate<sup>&#182;</sup> 0.3 to 0.6 mg/kg IV daily with or without flucytosine 25 mg/kg orally four times daily for 1 to 7 days or flucytosine alone for two weeks</p> <p>For <em>C. krusei</em>: amphotericin B deoxycholate<sup>&#182;</sup> 0.3 to 0.6 mg/kg IV for 1 to 7 days</p> </td> <td>Elimination of urinary tract obstruction is strongly recommended. For patients with nephrostomy tubes or stents, consider removal or replacement, if feasible. </td> </tr> <tr> <td>Urinary fungus balls</td> <td> <p>Surgical removal is strongly recommended.</p> <p>Antifungal therapy should be given according to the recommendations for pyelonephritis; therapy should be continued until a procedure to remove the fungus ball has been performed and symptoms have resolved.</p> </td> <td>&nbsp;N/A</td> <td>If nephrostomy tubes are present, irrigate with amphotericin B deoxycholate 25 to 50 mg in 200 to 500 mL sterile water as an adjunct to systemic antifungal therapy.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The doses above are intended for patients with normal renal function. The doses of most of these agents must be adjusted in the setting of renal insufficiency. Refer to the Lexicomp drug-specific monographs for additional information, including specific renal dose adjustments.</div><div class=\"graphic_footnotes\">IV: intravenously.<br />* For specific recommendations, refer to separate UpToDate topic reviews of treatment of candidemia and invasive candidiasis in adults and treatment of <EM>Candida</EM> infection in neonates.&nbsp;<br />Â¶ Lipid formulations of amphotericin B do not achieve adequate urine concentrations and should not be substituted for amphotericin B deoxycholate.</div><div class=\"graphic_reference\">Data from: Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</div><div id=\"graphicVersion\">Graphic 87677 Version 9.0</div></div></div>"},"87678":{"type":"graphic_table","displayName":"Treatment of chronic disseminated candidiasis","title":"Treatment of chronic disseminated candidiasis (hepatosplenic candidiasis) in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of chronic disseminated candidiasis (hepatosplenic candidiasis) in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">Therapy</td> </tr> <tr> <td class=\"subtitle2\">Initial therapy</td> <td class=\"subtitle2\">Step-down therapy</td> <td class=\"subtitle2\">Comments</td> </tr> <tr> <td>A lipid formulation of amphotericin B 3 to 5 mg/kg IV daily <strong>OR</strong> an echinocandin (caspofungin 70 mg IV loading dose, then 50 mg IV daily; micafungin 100 mg IV daily; anidulafungin 200 mg IV loading dose, then 100 mg IV daily) for several weeks.</td> <td> <p>For most patients, initial therapy should be followed by step-down therapy with oral fluconazole (400 mg [6 mg/kg] daily).</p> <p>For patients who have been shown to have a fluconazole-resistant isolate, such as patients who had a preceding candidemia with <em>C. glabrata</em> or <em>C. krusei</em>, we give step-down therapy with voriconazole or posaconazole. However, there is minimal experience using these agents for this form of candidiasis, and they should only be used if the organism has been shown to be susceptible. </p> </td> <td>Step-down therapy should continue until lesions have resolved on imaging (eg, contrast-enhanced computed tomography), which usually takes months, and should continue through periods of immunosuppression (eg, chemotherapy and hematopoietic cell transplantation).</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The doses above are intended for patients with normal organ function. The fluconazole dose requires adjustment in the setting of renal insufficiency; the caspofungin dose requires adjustment in the setting of moderate or severe hepatic insufficiency. Refer to the Lexicomp monographs included within UpToDate for additional information including specific dose adjustment recommendations.</div><div class=\"graphic_footnotes\">IV: intravenously.</div><div class=\"graphic_reference\">Data from: Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</div><div id=\"graphicVersion\">Graphic 87678 Version 5.0</div></div></div>"},"87679":{"type":"graphic_table","displayName":"Treatment of Candida osteoarticular infections","title":"Treatment of <EM>Candida</EM> osteoarticular infections in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of <EM>Candida</EM> osteoarticular infections in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Condition or treatment group</td> <td class=\"subtitle1\" colspan=\"3\">Therapy</td> </tr> <tr> <td class=\"subtitle2\">Primary</td> <td class=\"subtitle2\">Alternative</td> <td class=\"subtitle2\">Comments</td> </tr> <tr> <td>Osteomyelitis</td> <td>Fluconazole 400 mg (6 mg/kg) orally daily for 6 to 12 months<strong>&nbsp;OR </strong>an echinocandin (caspofungin 50 to 70 mg IV daily, micafungin 100 mg IV daily, anidulafungin 100 mg IV daily) for at least 2 weeks, then fluconazole 400 mg (6 mg/kg) orally daily for 6 to 12 months</td> <td>Lipid formulation of amphotericin B 3 to 5 mg/kg IV daily for at least two weeks, followed by fluconazole 400 mg (6 mg/kg) orally&nbsp;daily for 6 to 12 months is a less attractive alternative</td> <td>Duration of therapy is prolonged (6 to 12 months). Surgical debridement is frequently necessary.</td> </tr> <tr> <td>Septic arthritis</td> <td>Fluconazole 400 mg (6 mg/kg) orally daily for&nbsp;6 weeks<strong> OR </strong>an echinocandin (caspofungin 50 to 70 mg IV daily, micafungin 100 mg IV daily, anidulafungin 100 mg IV daily) for 2 weeks, then fluconazole 400 mg (6 mg/kg) orally daily for at least 4 weeks</td> <td>Lipid formulation of amphotericin B 3 to 5 mg/kg IV daily for at least 2 weeks, followed by fluconazole 400 mg (6 mg/kg) orally&nbsp;daily for at least 4 weeks is a less attractive alternative</td> <td>Duration of therapy is usually for at least 6 weeks, but few data are available. Surgical&nbsp;drainage is recommended for all cases. For infected prosthetic joints, removal is recommended for most cases. If the prosthetic device cannot be removed, chronic suppression with fluconazole 400 mg (6 mg/kg) orally daily should be given if the isolate is susceptible.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The fluconazole dose requires adjustment in renal insufficiency (CrCl â¤50 mL/minute); the caspofungin dose requires adjustment in moderate or severe hepatic impairment. Refer to the Lexicomp monographs included within UpToDate for additional information including specific dose adjustment recommendations.</div><div class=\"graphic_footnotes\">IV: intravenously.</div><div class=\"graphic_reference\">Data from: Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</div><div id=\"graphicVersion\">Graphic 87679 Version 5.0</div></div></div>"},"87680":{"type":"graphic_table","displayName":"Treatment of Candida CNS infections","title":"Treatment of <EM>Candida</EM> infections of the central nervous system in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of <EM>Candida</EM> infections of the central nervous system in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"3\">Therapy</td> </tr> <tr> <td class=\"subtitle2\">Initial therapy</td> <td class=\"subtitle2\">Step-down therapy</td> <td class=\"subtitle2\">Comments</td> </tr> <tr> <td>Liposomal amphotericin B 5 mg/kg IV daily with or without flucytosine* 25 mg/kg orally four times daily for several weeks, followed by step-down therapy with fluconazole once the patient has responded to initial therapy.</td> <td>Fluconazole 400 to 800 mg (6 to 12 mg/kg) orally<sup>&#182; </sup>daily</td> <td>Treat until all signs and symptoms, cerebrospinal fluid abnormalities, and radiographic abnormalities have resolved. Removal of intraventricular devices and other CNS devices is recommended.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The doses above are intended for patients with normal renal function. The doses of fluconazole and flucytosine must be adjusted in the setting of renal insufficiency. Refer to the Lexicomp monographs included within UpToDate for additional information including specific dose adjustment recommendations.</div><div class=\"graphic_footnotes\">IV: intravenously; CNS: central nervous system.<br />* Toxic effects on bone marrow and liver require careful monitoring, preferably with frequent serum flucytosine levels.<br />Â¶&nbsp;Since fluconazole is highly bioavailable, oral therapy is appropriate for most patients.&nbsp;Intravenous therapy (at the same dose) should be given to patients who are unable to take oral medications, who are not expected to have good gastrointestinal absorption, or who are severely ill.</div><div class=\"graphic_reference\">Data from: Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.</div><div id=\"graphicVersion\">Graphic 87680 Version 5.0</div></div></div>"},"87681":{"type":"graphic_table","displayName":"Treatment of Candida cardiovascular infections","title":"Treatment of <em>Candida</em> endocarditis and suppurative thrombophlebitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Treatment of <em>Candida</em> endocarditis and suppurative thrombophlebitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"19%\"></colgroup><colgroup span=\"3\" width=\"27%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Condition or treatment group</td> <td class=\"subtitle1\" colspan=\"3\">Therapy</td> </tr> <tr> <td class=\"subtitle2\">Primary</td> <td class=\"subtitle2\">Step-down</td> <td class=\"subtitle2\">Comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\"><em>Candida</em> endocarditis</td> </tr> <tr> <td class=\"indent1\">Native valve endocarditis</td> <td> <ul> <li> <p>A lipid formulation of amphotericin B (3 to 5 mg/kg IV daily) with or without flucytosine* (25 mg/kg orally four times daily);</p> </li> </ul> <p class=\"indent2\">OR</p> <ul> <li>High-dose echinocandin (caspofungin 150 mg IV daily, micafungin 150 mg IV daily, or anidulafungin 200 mg IV daily). </li> </ul> </td> <td> <ul> <li>For patients who are clinically stable, have isolates that are susceptible to fluconazole, and have negative repeat blood cultures following initiation of a lipid formulation of amphotericin B or high-dose echinocandin therapy, transition to oral fluconazole<sup>&#182;</sup> 400 to 800 mg (6 to 12 mg/kg) daily is appropriate. </li> <li>Oral voriconazole<sup>&#916;</sup> 200 to 300 mg (3 to 4 mg/kg) twice daily or delayed-release posaconazole tablets<sup><span style=\"font-size: 13px;\">&#916;</span></sup> 300 mg daily can be used for step-down therapy in clinically stable patients who have isolates susceptible to these agents but not susceptible to fluconazole. </li> </ul> </td> <td> <ul> <li>Valve replacement is recommended; treatment should continue for at least 6 weeks after surgery. </li> <li>For patients who cannot undergo valve replacement, long-term suppression with an oral azole (fluconazole<sup>&#182;</sup> 400 to 800 mg [6 to 12 mg/kg] daily if the isolate is susceptible<sup>&#9674;</sup>) is recommended following initial antifungal therapy. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Prosthetic valve endocarditis</td> <td> <ul> <li> <p>A lipid formulation of amphotericin B (3 to 5 mg/kg IV daily) with or without flucytosine* (25 mg/kg orally four times daily);</p> </li> </ul> <p class=\"indent2\">OR</p> <ul> <li>High-dose echinocandin (caspofungin 150 mg IV daily, micafungin 150 mg IV daily, or anidulafungin 200 mg IV daily). </li> </ul> </td> <td> <ul> <li>For patients who are clinically stable, have isolates that are susceptible to fluconazole, and have negative repeat blood cultures following initiation of a lipid formulation of amphotericin B or high-dose echinocandin therapy, transition to oral fluconazole<sup>&#182;</sup> 400 to 800 mg (6 to 12 mg/kg) daily is appropriate. </li> <li>Oral voriconazole<sup>&#916;</sup> 200 to 300 mg (3 to 4 mg/kg) twice daily or delayed-release posaconazole tablets<sup><span style=\"font-size: 13px;\">&#916;</span></sup> 300 mg daily can be used for step-down therapy in clinically stable patients who have isolates susceptible to these agents but not susceptible to fluconazole. </li> </ul> </td> <td> <ul> <li>Valve replacement is recommended. </li> <li>Lifelong suppression with an oral azole (fluconazole<sup>&#182;</sup> 400 to 800 mg [6 to 12 mg/kg] daily if the isolate is susceptible<sup>&#9674;</sup>) is recommended to prevent recurrence following initial antifungal therapy in all patients. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\"><em>Candida</em> suppurative thrombophlebitis</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td> <ul> <li> <p>A lipid formulation of amphotericin B (3 to 5 mg/kg IV daily);</p> </li> </ul> <p class=\"indent2\">OR</p> <ul> <li> <p>Fluconazole<sup>&#182;</sup> 400 to 800 mg (6 to 12 mg/kg) IV or orally daily;</p> </li> </ul> <p class=\"indent2\">OR</p> <ul> <li>High-dose echinocandin (caspofungin 150 mg IV daily, micafungin 150 mg IV daily, or anidulafungin 200 mg IV daily). </li> </ul> </td> <td> <ul> <li>For patients who are clinically stable, have isolates that are susceptible to fluconazole, and have negative repeat blood cultures following initiation of amphotericin B or high-dose echinocandin therapy, transition to oral fluconazole<sup>&#182;</sup> 400 to 800 mg (6 to 12 mg/kg) daily is appropriate. </li> </ul> </td> <td> <ul> <li>Catheter removal and incision and drainage or resection of the vein is recommended if feasible. </li> <li>Treat with one of the options for primary therapy for at least two weeks after candidemia has cleared, before transitioning to step-down therapy. </li> <li>Resolution of thrombus can be used as evidence to discontinue antifungal therapy if clinical and culture data are supportive. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The doses above are intended for patients with normal organ function. The dose of fluconazole and flucytosine must be adjusted in the setting of renal insufficiency; the caspofungin and voriconazole dose may require adjustment in hepatic insufficiency. Refer to the Lexicomp drug-specific monographs for additional information including specific dose adjustment recommendations.</div><div class=\"graphic_footnotes\">IV: intravenously.<br />* Toxic effects on bone marrow and liver require careful monitoring preferably with frequent serum flucytosine levels; refer to accompanying text for discussion of benefits and risks of combined flucytosine and amphotericin B therapy.<br />&para; Since fluconazole is highly bioavailable, oral therapy is appropriate for most patients. IV therapy (at the same dose) should be given to patients who are unable to take oral medications, who are not expected to have good gastrointestinal absorption, or who are severely ill.<br />&Delta; Therapeutic drug monitoring should be considered due to widely variable pharmacokinetics; refer to the topic review on pharmacology of azoles for detail.<br /><span class=\"lozenge\">&loz;</span> In patients with endocarditis caused by a <em>Candida</em> species that is not susceptible to fluconazole, oral voriconazole (200 or 300 mg [3 to 4 mg/kg] twice daily) or delayed-release posaconazole tablets (300 mg daily) should be used for chronic suppressive therapy if the organism is susceptible.</div><div class=\"graphic_reference\">Data from: Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 2015; 62:e1.</div><div id=\"graphicVersion\">Graphic 87681 Version 4.0</div></div></div>"},"87682":{"type":"graphic_table","displayName":"Clinical manifestations of acute HIV","title":"Clinical manifestations of acute HIV infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations of acute HIV infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Features<br /> (percent)</td> <td class=\"subtitle1\">Overall<br /> (n = 378)</td> <td class=\"subtitle1\">Male<br /> (n = 355)</td> <td class=\"subtitle1\">Female<br /> (n = 23)</td> <td class=\"subtitle1\">Sexual*<br /> (n = 324)</td> <td class=\"subtitle1\">IVDU<sup>&#182;</sup><br /> (n = 34)</td> </tr> <tr> <td>Fever</td> <td class=\"centered\">75</td> <td class=\"centered\">74</td> <td class=\"centered\">83</td> <td class=\"centered\">77</td> <td class=\"centered\">50</td> </tr> <tr> <td>Fatigue</td> <td class=\"centered\">68</td> <td class=\"centered\">67</td> <td class=\"centered\">78</td> <td class=\"centered\">71</td> <td class=\"centered\">50</td> </tr> <tr> <td>Myalgia</td> <td class=\"centered\">49</td> <td class=\"centered\">50</td> <td class=\"centered\">26</td> <td class=\"centered\">52</td> <td class=\"centered\">29</td> </tr> <tr> <td>Skin rash</td> <td class=\"centered\">48</td> <td class=\"centered\">48</td> <td class=\"centered\">48</td> <td class=\"centered\">51</td> <td class=\"centered\">21</td> </tr> <tr> <td>Headache</td> <td class=\"centered\">45</td> <td class=\"centered\">45</td> <td class=\"centered\">44</td> <td class=\"centered\">47</td> <td class=\"centered\">30</td> </tr> <tr> <td>Pharyngitis</td> <td class=\"centered\">40</td> <td class=\"centered\">40</td> <td class=\"centered\">48</td> <td class=\"centered\">43</td> <td class=\"centered\">18</td> </tr> <tr> <td>Cervical adenopathy</td> <td class=\"centered\">39</td> <td class=\"centered\">39</td> <td class=\"centered\">39</td> <td class=\"centered\">41</td> <td class=\"centered\">27</td> </tr> <tr> <td>Arthralgia</td> <td class=\"centered\">30</td> <td class=\"centered\">30</td> <td class=\"centered\">26</td> <td class=\"centered\">28</td> <td class=\"centered\">26</td> </tr> <tr> <td>Night sweats</td> <td class=\"centered\">28</td> <td class=\"centered\">28</td> <td class=\"centered\">22</td> <td class=\"centered\">30</td> <td class=\"centered\">27</td> </tr> <tr> <td>Diarrhea</td> <td class=\"centered\">27</td> <td class=\"centered\">27</td> <td class=\"centered\">21</td> <td class=\"centered\">28</td> <td class=\"centered\">23</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table lists the most frequent clinical findings reported among patients with acute HIV infection from five prospective cohorts.</div><div class=\"graphic_footnotes\">* Homosexual or heterosexual route of transmission.<br />&para; IVDU, intravenous drug use as route of transmission.</div><div class=\"graphic_reference\">Reproduced with permission from: Daar ES, Pilcher CD, Hecht FM. Clinical presentation and diagnosis of primary HIV-1 infection. Curr Opin HIV AIDS 2008; 3:10. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87682 Version 3.0</div></div></div>"},"87683":{"type":"graphic_table","displayName":"Revised definitions of morphological features of AP","title":"Revised definitions of morphological features of acute pancreatitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Revised definitions of morphological features of acute pancreatitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">1. Interstitial edematous pancreatitis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Acute inflammation of the pancreatic parenchyma and peripancreatic tissues, but without recognizable tissue necrosis<br /> <em>Contrast-enhanced computed tomography criteria:</em> <ul> <li>Pancreatic parenchyma enhancement by intravenous contrast agent </li> <li>No findings of peripancreatic necrosis </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">2. Necrotizing pancreatitis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Inflammation associated with pancreatic parenchymal necrosis and/or peripancreatic necrosis<br /> <em>Contrast-enhanced computed tomography criteria:</em> <ul> <li>Lack of pancreatic parenchymal enhancement by intravenous contrast agent, and/or </li> <li>Presence of findings of peripancreatic necrosis (see below&#8212;acute peripancreatic fluid collection and walled off necrosis) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">3. Acute peripancreatic fluid collection (APFC)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Peripancreatic fluid associated with interstitial edematous pancreatitis with no associated peripancreatic necrosis. This term applies only to areas of peripancreatic fluid seen within the first four weeks after onset of interstitial edematous pancreatitis and without the features of a pseudocyst.<br /> <em>Contrast-enhanced computed tomography criteria:</em> <ul> <li>Occurs in the setting of interstitial edematous pancreatitis </li> <li>Homogeneous collection with fluid density </li> <li>Confined by normal peripancreatic fascial planes </li> <li>No definable wall encapsulating the collection </li> <li>Adjacent to pancreas (no intrapancreatic extension) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">4. Pancreatic pseudocyst</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">An encapsulated collection of fluid with a well defined inflammatory wall usually outside the pancreas with minimal or no necrosis. This entity usually occurs more than four weeks after onset of interstitial edematous pancreatitis to mature.<br /> <em>Contrast-enhanced computed tomography criteria:</em> <ul> <li>Well circumscribed, usually round or oval </li> <li>Homogeneous fluid density </li> <li>No non-liquid component </li> <li>Well defined wall (ie, completely encapsulated) </li> <li>Maturation usually requires &#62;4 weeks after onset of acute pancreatitis; occurs after interstitial edematous pancreatitis </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">5. Acute necrotic collection (ANC)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">A collection containing variable amounts of both fluid and necrosis associated with necrotizing pancreatitis; the necrosis can involve the pancreatic parenchyma and/or the peripancreatic tissues<br /> <em>Contrast-enhanced computed tomography criteria:</em> <ul> <li>Occurs only in the setting of acute necrotizing pancreatitis </li> <li>Heterogeneous and non-liquid density of varying degrees in different locations (some appear homogeneous early in their course) </li> <li>No definable wall encapsulating the collection </li> <li>Location&#8212;intrapancreatic and/or extrapancreatic </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">6. Walled-off necrosis (WON)</td> </tr> <tr> <td class=\"indent1\">A mature, encapsulated collection of pancreatic and/or peripancreatic necrosis that has developed a well defined inflammatory wall. WON usually occurs &#62;4 weeks after onset of necrotizing pancreatitis.<br /> <em>Contrast-enhanced computed tomography criteria:</em> <ul> <li>Heterogeneous with liquid and non-liquid density with varying degrees of loculations (some may appear homogeneous) </li> <li>Well defined wall, that is, completely encapsulated </li> <li>Location&#8212;intrapancreatic and/or extrapancreatic </li> <li>Maturation usually requires four weeks after onset of acute necrotizing pancreatitis </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis - 2012: revisions of the Atlanta classification and definitions by international consensus. Gut 2013; 62:102. BMJ Publishing Group Ltd. Copyright &copy; 2013.</div><div id=\"graphicVersion\">Graphic 87683 Version 2.0</div></div></div>"},"87687":{"type":"graphic_table","displayName":"ID screening international adoptees","title":"Infectious disease screening for internationally adopted children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infectious disease screening for internationally adopted children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Infectious disease</td> <td class=\"subtitle1\">Test</td> </tr> <tr> <td>Hepatitis A virus (acute infection)</td> <td>Hepatitis A IgM antibody</td> </tr> <tr> <td>Hepatitis B virus</td> <td>Hepatitis B surface antigen, surface antibody, core antibody</td> </tr> <tr> <td>Hepatitis C virus</td> <td>Hepatitis C antibody</td> </tr> <tr> <td>Syphilis</td> <td> <p>Nontreponemal (RPR or VDRL)</p> <p><strong>and</strong></p> Treponemal tests (TPPA or FTA-ABS)</td> </tr> <tr> <td>HIV</td> <td>Combined antigen/antibody HIV test*</td> </tr> <tr> <td>Tuberculosis</td> <td> <p>Tuberculin skin test (TST)<sup>&#182;</sup></p> <p><strong>or</strong> </p> Interferon-gamma release assay&nbsp;(&#8805;5 years of age)</td> </tr> <tr> <td>Intestinal parasites</td> <td> <p>Stool ova and parasites examination (3 specimens)</p> <p><strong>and</strong></p> <em>Giardia intestinalis</em> and <em>Cryptosporidium</em> antigen (1 specimen)</td> </tr> <tr> <td>Bacterial enteric infection (children with bloody diarrhea or diarrhea and fever)</td> <td>Bacterial stool culture</td> </tr> <tr> <td>Tissue parasites&nbsp;(for adopted children from endemic areas)<sup>&#916;</sup></td> <td> <p><em>Strongyloides</em> serologic testing</p> <em>Schistosoma</em> serologic testing</td> </tr> <tr> <td>Lymphatic filariasis (for children &#62;2 years&nbsp;of age&nbsp;adopted from endemic areas)<sup>&#916;</sup></td> <td>Filarial serologic testing (&#8805;2 years of age)</td> </tr> <tr> <td>Chagas (endemic areas)</td> <td><em>Trypanosoma cruzi</em> serologic testing</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RPR: rapid plasma reagin; VDRL: Venereal Disease Research Laboratory; TPPA: treponema pallidum particle agglutination; FTA-ABS: fluorescent treponemal antibody absorption; HIV: human immunodeficiency virus.<br />* Some experts suggest reassessing six months after arrival.<br />Â¶ Repeat TST testing â¥3 months after the initial test is suggested if the initial TST is negative.<br />Î Some experts perform serologic testing only if absolute eosinophil count is â¥450 cell/microL and stool ova and parasite examination is negative.</div><div id=\"graphicVersion\">Graphic 87687 Version 3.0</div></div></div>"},"87688":{"type":"graphic_table","displayName":"Prevalence of infections in international adoptees","title":"Prevalence of infectious diseases in newly arrived internationally adopted children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prevalence of infectious diseases in newly arrived internationally adopted children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"5\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Condition</td> <td class=\"subtitle1\" colspan=\"5\">Country or region</td> </tr> <tr> <td class=\"subtitle2\">Russia</td> <td class=\"subtitle2\">China</td> <td class=\"subtitle2\">Guatemala</td> <td class=\"subtitle2\">Korea</td> <td class=\"subtitle2\">Africa</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"6\">Hepatitis A</td> </tr> <tr> <td class=\"indent1\">- Acute</td> <td class=\"centered\">&#60;1 percent</td> <td class=\"centered\">0 percent</td> <td class=\"centered\">0 percent</td> <td class=\"centered\">0 percent</td> <td class=\"centered\">2 percent</td> </tr> <tr> <td class=\"indent1\">- Past</td> <td class=\"centered\">18 percent</td> <td class=\"centered\">9 percent</td> <td class=\"centered\">32 percent</td> <td class=\"centered\">0 percent</td> <td class=\"centered\">68 percent</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"6\">Hepatitis B</td> </tr> <tr> <td class=\"indent1\">- Chronic</td> <td class=\"centered\">&#60;1 percent</td> <td class=\"centered\">2 percent</td> <td class=\"centered\">0 percent</td> <td class=\"centered\">0 percent</td> <td class=\"centered\">3 percent</td> </tr> <tr> <td class=\"indent1\">- Past recovered</td> <td class=\"centered\">2 percent</td> <td class=\"centered\">6 percent</td> <td class=\"centered\">2 percent</td> <td class=\"centered\">6 percent</td> <td class=\"centered\">9 percent</td> </tr> <tr> <td>Hepatitis C</td> <td class=\"centered\">&#60;1 percent</td> <td class=\"centered\">0 percent</td> <td class=\"centered\">0 percent</td> <td class=\"centered\">0 percent</td> <td class=\"centered\">0 percent</td> </tr> <tr> <td>Syphilis</td> <td class=\"centered\">&#60;1 percent</td> <td class=\"centered\">&#60;1 percent</td> <td class=\"centered\">&#60;1 percent</td> <td class=\"centered\">0 percent</td> <td class=\"centered\">5 percent</td> </tr> <tr> <td>HIV</td> <td class=\"centered\">0 percent</td> <td class=\"centered\">0 percent</td> <td class=\"centered\">0 percent</td> <td class=\"centered\">0 percent</td> <td class=\"centered\">2 percent</td> </tr> <tr> <td>Latent tuberculosis</td> <td class=\"centered\">22 percent</td> <td class=\"centered\">18 percent</td> <td class=\"centered\">32 percent</td> <td class=\"centered\">6 percent</td> <td class=\"centered\">27 percent</td> </tr> <tr> <td class=\"sublist1_start\">Intestinal parasites (pathogen)</td> <td class=\"centered\">44 percent</td> <td class=\"centered\">14 percent</td> <td class=\"centered\">10 percent</td> <td class=\"centered\">0 percent</td> <td class=\"centered\">49 percent</td> </tr> <tr> <td class=\"indent1\">- <em>Giardia intestinalis</em></td> <td class=\"centered\">30 percent</td> <td class=\"centered\">11 percent</td> <td class=\"centered\">6 percent</td> <td class=\"centered\">0 percent</td> <td class=\"centered\">32 percent</td> </tr> <tr> <td class=\"indent1\">- Helminths</td> <td class=\"centered\">&#60;1 percent</td> <td class=\"centered\">&#60;1 percent</td> <td class=\"centered\">&#60;1 percent</td> <td class=\"centered\">&#60;1 percent</td> <td class=\"centered\">15 percent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Abdulla RY, Rice MA, Donauer S, et al. Hepatitis A in internationally adopted children: screening for acute and previous infection. Pediatrics 2010 Nov; 126:e1039.</li>&#xD;&#xA;    <li>Stadler LP, Mezoff AG, Staat MA. Hepatitis B virus screening for internationally adopted children. Pediatrics 2008; 122:1223.</li>&#xD;&#xA;    <li>Trehan I, Meinzen-Derr JK, Jamison L, Staat MA. Tuberculosis screening in internationally adopted children: the need for initial and repeat testing. Pediatrics 2008; 122:e7.</li>&#xD;&#xA;    <li>Staat MA, Rice M, Donauer S, et al. Intestinal parasite screening in internationally adopted children: importance of testing multiple stool specimens. Pediatrics 2011; 128:e613.</li>&#xD;&#xA;    <li>Staat MA, Rice M, Leach K, Rawlings A. Medical Conditions in Internationally Adopted Children from Africa [abstract]. Pediatric Academy Societies Annual Meeting: Boston Massachusetts, 2012.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 87688 Version 3.0</div></div></div>"},"87689":{"type":"graphic_table","displayName":"Serologic testing in international adoptees","title":"Serologic testing for verifying immunization or past infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Serologic testing for verifying immunization or past infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup span=\"2\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Protective level</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Children &#8805;5 months of age</td> </tr> <tr> <td class=\"indent1\">Diphtheria antibody (IgG)</td> <td class=\"centered\">ELISA</td> <td class=\"centered\">&#62;0.10 IU/mL</td> </tr> <tr> <td class=\"indent1\">Tetanus antibody (IgG)</td> <td class=\"centered\">ELISA</td> <td class=\"centered\">&#62;0.10 IU/mL</td> </tr> <tr> <td class=\"indent1\">Hepatitis B surface antibody (IgG)</td> <td class=\"centered\">ELISA</td> <td class=\"centered\">&#8805;10 mIU/mL</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><em>Haemophilus influenzae</em> type b polyribosylribitol phosphate antibody (IgG)*</td> <td class=\"centered\">ELISA</td> <td class=\"centered\">&#8805;1.0 IU/mL</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Children &#8805;12 months of age</td> </tr> <tr> <td class=\"indent1\">Rubeola (measles) antibody (IgG)</td> <td class=\"centered\">IFA or ELISA</td> <td class=\"centered\">&#182;</td> </tr> <tr> <td class=\"indent1\">Mumps antibody (IgG)</td> <td class=\"centered\">IFA or ELISA</td> <td class=\"centered\">&#182;</td> </tr> <tr> <td class=\"indent1\">Rubella antibody (IgG)</td> <td class=\"centered\">ELISA</td> <td class=\"centered\">&#182;</td> </tr> <tr> <td class=\"indent1\">Varicella antibody (IgG)</td> <td class=\"centered\">ELISA</td> <td class=\"centered\">&#182;</td> </tr> <tr> <td class=\"indent1\">Hepatitis A antibody (total or IgG)</td> <td class=\"centered\">EIA</td> <td class=\"centered\">&#182;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IgG: immunoglobulin G; ELISA: enzyme-linked immunosorbent assay; IU: international unit; IFA: immunofluorescence assay; EIA: enzyme immunoassay.<br />*&nbsp;Serologic testing for protective antibody to <EM>H. influenzae</EM> type b in international adoptees is not as well established as that for the other antibodies listed above.<br />Â¶&nbsp;Value for positive result varies by test and laboratory.</div><div id=\"graphicVersion\">Graphic 87689 Version 6.0</div></div></div>"},"87691":{"type":"graphic_picture","displayName":"Cauliflower ear after auricular hematoma","title":"Cauliflower ear after auricular hematoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cauliflower ear after auricular hematoma</div><div class=\"cntnt\"><img style=\"width:437px; height:540px;\" src=\"images/EM/87691_Cauliflower_ear_auric_hemat.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Berg D, Worzala K. Atlas of Adult Physical Diagnosis. Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87691 Version 1.0</div></div></div>"},"87692":{"type":"graphic_picture","displayName":"Relapsing polychondritis with ear involvement","title":"Relapsing polychondritis with ear involvement","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Relapsing polychondritis with ear involvement</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/EM/87692_Relap_polychon_ear_involv.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87692 Version 3.0</div></div></div>"},"87693":{"type":"graphic_diagnosticimage","displayName":"MRI large sellar mass","title":"MRI images of a large sellar mass after administration of gadolinium","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">MRI images of a large sellar mass after administration of gadolinium</div><div class=\"cntnt\"><img style=\"width:513px; height:186px;\" src=\"images/ENDO/87693_MRI_lrg_sellar_mass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) MRI image, taken after the administration of gadolinium, depicting a coronal view of a large sellar mass that was a gonadotroph adenoma. The arrow points to the mass. The arrowhead points to the optic chiasm elevated by the mass.<br />(B) MRI image, taken after the administration of gadolinium, depicting a sagittal view of the same large sellar mass that was a gonadotroph adenoma. The arrow points to the mass.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 87693 Version 3.0</div></div></div>"},"87694":{"type":"graphic_figure","displayName":"An adolescents drawing and description of RLS","title":"A drawing and description of restless legs syndrome by a 17-year-old adolescent","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">A drawing and description of restless legs syndrome by a 17-year-old adolescent</div><div class=\"cntnt\"><img style=\"width:362px; height:504px;\" src=\"images/PEDS/87694_Adoles_draw_descript_RLS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The adolescent described the symptoms as follows: \"My restless legs pain feels like the bones deep in my legs are being hit with a hammer. They only feel better if I move them constantly. It keeps me awake at night.\"</div><div class=\"graphic_reference\">Courtesy of Daniel L Picchietti, MD.</div><div id=\"graphicVersion\">Graphic 87694 Version 2.0</div></div></div>"},"87697":{"type":"graphic_picture","displayName":"Junctional EB Herlitz 6","title":"Junctional epidermolysis bullosa (JEB), generalized severe","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Junctional epidermolysis bullosa (JEB), generalized severe</div><div class=\"cntnt\"><img style=\"width:504px; height:337px;\" src=\"images/DERM/87697_Junctional_EB_Herlitz_6.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two-year-old girl with generalized severe JEB. Note the characteristic exuberant granulation tissue.</div><div class=\"graphic_reference\">Reproduced with permission of: Informa Healthcare, from Mallory SB, Bree AF, Chern P. Bullous diseases. In: Illustrated Manual of Pediatric Dermatology: Diagnosis and Management, Taylor &amp; Francis, United Kingdom 2005; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 87697 Version 3.0</div></div></div>"},"87698":{"type":"graphic_table","displayName":"ITP treatment response times","title":"Time to platelet count response for different immune thrombocytopenia (ITP) treatments","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Time to platelet count response for different immune thrombocytopenia (ITP) treatments</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Treatment</td> <td class=\"subtitle1\">Initial response* (days)</td> <td class=\"subtitle1\">Peak response<sup>&#182;</sup> (days)</td> </tr> <tr> <td>IVIG</td> <td class=\"centered\">1 to 3</td> <td class=\"centered\">2 to 7</td> </tr> <tr> <td>Anti-D</td> <td class=\"centered\">1 to 3</td> <td class=\"centered\">3 to 7</td> </tr> <tr> <td>Splenectomy</td> <td class=\"centered\">1 to 56</td> <td class=\"centered\">7 to 56</td> </tr> <tr> <td>Dexamethasone</td> <td class=\"centered\">2 to 14</td> <td class=\"centered\">4 to 28</td> </tr> <tr> <td>Prednisone</td> <td class=\"centered\">4 to 14</td> <td class=\"centered\">7 to 28</td> </tr> <tr> <td>Romiplostim</td> <td class=\"centered\">7&nbsp;to 14<sup>&#916;</sup></td> <td class=\"centered\">14 to 60</td> </tr> <tr> <td>Rituximab</td> <td class=\"centered\">7 to 56</td> <td class=\"centered\">14 to 180</td> </tr> <tr> <td>Eltrombopag</td> <td class=\"centered\">7 to 14<sup>&#916;</sup></td> <td class=\"centered\">14 to 90</td> </tr> <tr> <td>Vinblastine</td> <td class=\"centered\">7 to 14</td> <td class=\"centered\">7 to 42</td> </tr> <tr> <td>Vincristine</td> <td class=\"centered\">7 to 14</td> <td class=\"centered\">7 to 42</td> </tr> <tr> <td>Danazol</td> <td class=\"centered\">14 to 90</td> <td class=\"centered\">28 to 180</td> </tr> <tr> <td>Azathioprine</td> <td class=\"centered\">30 to 90</td> <td class=\"centered\">30 to 180</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The expected time to initial response and peak response with various ITP treatments are listed. Treatments are listed in order of approximate rapidity of the expected initial response. Peak response reflects the time after which response becomes less likely at typically used doses. These data do not address the quality of the response (ie, absolute platelet count reached or percent increase from baseline) or the likelihood of a response for any given treatment. Refer to UpToDate topic on the treatment of ITP for details of our approach to the initial and subsequent treatment of ITP and the overall efficacy of these treatments. Refer to UpToDate topic on chronic refractory ITP for our approach to the treatment of patients for whom initial treatment is ineffective.</div><div class=\"graphic_footnotes\">IVIG: intravenous immune globulin.<br />* Initial response is the first time that a response could be reasonably expected.<br />Â¶ Peak response is the time after which a response becomes less likely at typically used doses.<br />Î Thrombopoietin receptor agonist dose should be titrated upward until an adequate platelet count is achieved or maximum dose is reached.</div><div class=\"graphic_reference\">Updated information from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117:4190.</LI></OL>This table was adapted from research originally published in Blood. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113:2386. Copyright Â© 2009 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 87698 Version 4.0</div></div></div>"},"87701":{"type":"graphic_waveform","displayName":"Recordings of periodic limb movements of sleep ","title":"Variable periodicity of periodic limb movements of sleep (PLMS) in children","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Variable periodicity of periodic limb movements of sleep (PLMS) in children</div><div class=\"cntnt\"><img style=\"width:526px; height:674px;\" src=\"images/PEDS/87701_Rec_per_limb_mov_sleep.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Recordings of leg activity in a 10-year-old male with periodic limb movement disorder and a strong family history of restless legs syndrome. Each polysomnographic segment is 3.5 minutes long. Top panel: an example of high-periodicity leg movement activity, with consecutive intervals in the approximate range of 20-40 seconds. Bottom panel: an example of low-periodicity leg movement activity in the same child.</div><div class=\"graphic_footnotes\">L: left; R: right; EEG: electroencephalogram; EOG: electrooculogram; EMG: electromyogram; PTAF: pressure transducer airflow sensor; Therm: thermocouple (measures temperature); Chest: chest inductance plethysmography; Abdomen: abdomen inductance plethysmography.</div><div class=\"graphic_reference\">Courtesty of Daniel L. Picchietti, MD</div><div id=\"graphicVersion\">Graphic 87701 Version 1.0</div></div></div>"},"87702":{"type":"graphic_figure","displayName":"Energy requirements of infants","title":"Energy requirements of infants, FAO/WHO/UNU","html":"<div class=\"graphic\"><div style=\"width: 575px\" class=\"figure\"><div class=\"ttl\">Energy requirements of infants, FAO/WHO/UNU</div><div class=\"cntnt\"><img style=\"width:555px; height:386px;\" src=\"images/PEDS/87702_Energy_require_infants.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Energy requirements of healthy infants 0 to 12 months of age as estimated by the joint FAO/WHO/UNU Expert Consultation on Energy in Human Nutrition in 2001 (closed symbols), combining data for breastfed and formula-fed infants. The 1985 FAO/WHO/UNU estimates are shown for comparison (open symbol).</div><div class=\"graphic_footnotes\">FAO: Food and Agriculture Organization of the United Nations; WHO: World Health Organization; UNU: United Nations University.</div><div class=\"graphic_reference\">Food and Agriculture Organization of the United Nations, 2004, Human energy requirements: Report of a Joint FAO/WHO/UNU Expert Consultation. Food and Nutrition Technical Report Series 1, <a href=\"http://www.fao.org/docrep/007/y5686e/y5686e05.htm\" style=\"font-style: italic;\" target=\"_blank\">http://www.fao.org/docrep/007/y5686e/y5686e05.htm</a>.</div><div id=\"graphicVersion\">Graphic 87702 Version 1.0</div></div></div>"},"87703":{"type":"graphic_figure","displayName":"Pharmacologic mechanisms of crystal meth","title":"Pharmacologic mechanisms of crystal meth","html":"<div class=\"graphic\"><div style=\"width: 862px\" class=\"figure\"><div class=\"ttl\">Pharmacologic mechanisms of crystal meth</div><div class=\"cntnt\"><img style=\"width:842px; height:566px;\" src=\"images/PSYCH/87703_Pharma_mechan_crystal_meth.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic diagram of the human dopamine-rich striatum, which is made up of the caudate nucleus, putamen and ventral striatum (left), and a striatal dopamine nerve ending (right). This coronal slice is taken at the rostral tip of the anterior commissure. Methamphetamine causes dopamine release from the nerve endings. The areas of the brain responsible for methamphetamine-liking and craving are unknown but probably include the striatum and regions that provide input to the striatum. Normally, dopamine released into the synapse is taken back up into the nerve ending by the dopamine transporter and is transported into the synaptic vesicle by the vesicular monoamine transporter 2. Methamphetamine causes the release of striatal dopamine from the nerve ending into the synapse. This likely involves the translocation of dopamine from the synaptic vesicle to the neuronal cytoplasm via the vesicular monoamine transporter 2 and the reverse transport of dopamine from the cytoplasm into the synapse via the dopamine transporter.</div><div class=\"graphic_reference\">Reproduced with permission from: Kish SJ. Pharmacologic mechanisms of crystal meth. CMAJ 2008; 178:1679. Copyright &copy; 2008 Canadian Medical Association. This work is protected by copyright and the making of this copy was with the permission of Access Copyright. Any alteration of its content or further copying in any form whatsoever is strictly prohibited unless otherwise permitted by law.</div><div id=\"graphicVersion\">Graphic 87703 Version 1.0</div></div></div>"},"87705":{"type":"graphic_diagnosticimage","displayName":"Focal organizing pneumonia CT","title":"Focal organizing pneumonia CT","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Focal organizing pneumonia CT</div><div class=\"cntnt\"><img style=\"width:491px; height:367px;\" src=\"images/PULM/87705_Focal_organ_pneumon_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography image of focal organizing pneumonia manifest as a right upper lobe solitary spiculated mass with irregular margins, cavitation, and thickening of the adjacent pleura, but without air bronchogram or mediastinal lymphadenopathy.</div><div id=\"graphicVersion\">Graphic 87705 Version 1.0</div></div></div>"},"87707":{"type":"graphic_diagnosticimage","displayName":"Rib notching coarctation of the aorta ","title":"Rib notching coarctation of the aorta ","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Rib notching coarctation of the aorta </div><div class=\"cntnt\"><img style=\"width:599px; height:312px;\" src=\"images/RADIOL/87707_Rib_notch_coarct_aorta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This chest radiograph of an adult patient with coarctation of the aorta shows rib notching. Image A shows rib notching in the posterior and inferior aspects of the right sided ribs starting at the third rib and is most pronounced in ribs 7 and 8 (arrow). Image B is a magnified view of the notching of ribs 7 and 8.</div><div id=\"graphicVersion\">Graphic 87707 Version 1.0</div></div></div>"},"87708":{"type":"graphic_diagnosticimage","displayName":"Quantitative HIDA scan decreased ejection fraction","title":"Quantitative HIDA scan showing a decreased gallbladder ejection fraction","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Quantitative HIDA scan showing a decreased gallbladder ejection fraction</div><div class=\"cntnt\"><img style=\"width:516px; height:352px;\" src=\"images/RADIOL/87708_Quant_HIDA_scan_dec_ej_frac.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The quantitative HIDA scan shows early filling of the gallbladder at 25 minutes. At 57 minutes, infusion of CCK was initiated (broad white arrow). Mild reduction of gallbladder activity was demonstrated. The ejection fraction was 30 percent (normal 40 percent or greater).</div><div class=\"graphic_footnotes\">HIDA: hepatic iminodiacetic acid.</div><div id=\"graphicVersion\">Graphic 87708 Version 3.0</div></div></div>"},"87710":{"type":"graphic_table","displayName":"Conditions associated with the histopathology of OP","title":"Conditions associated with the histopathology of organizing pneumonia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with the histopathology of organizing pneumonia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li><strong>Cryptogenic organizing pneumonia (previously called bronchiolitis obliterans organizing pneumonia):</strong> May be focal, patchy, or diffuse </li> </ul> </td> </tr> <tr> <td> <ul> <li><strong>Drug toxicity</strong>* </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Amiodarone </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Beta blockers </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Bleomycin </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Carbamazepine </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Cocaine </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Cyclophosphamide </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Mesalamine </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Minocycline </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Penicillamine </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Phenytoin </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Trastuzumab </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <li><strong>Chronic heart or renal failure</strong> </li> </ul> </td> </tr> <tr> <td> <ul> <li><strong>Chronic thyroiditis</strong> </li> </ul> </td> </tr> <tr> <td> <ul> <li><strong>Rheumatic diseases</strong> </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Ankylosing spondylitis </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Beh&#231;et disease </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Granulomatosis with polyangiitis </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Polyarteritis nodosa </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Polymyositis/dermatomyositis </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Rheumatoid arthritis </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Systemic sclerosis </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Sj&#246;gren syndrome </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Systemic lupus erythematosus </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <li><strong>Mixed cryoglobulinemia</strong> </li> </ul> </td> </tr> <tr> <td> <ul> <li><strong>Hematologic malignancy (eg, diffuse large B-cell lymphoma, leukemia, non-Hodgkin lymphoma)</strong> </li> </ul> </td> </tr> <tr> <td> <ul> <li><strong>Hypersensitivity pneumonitis</strong> </li> </ul> </td> </tr> <tr> <td> <ul> <li><strong>Immunodeficiency syndromes</strong> </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Common variable immunodeficiency </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <li><strong>Infections (organizing)</strong> </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Bacterial (eg, <em>Chlamydia pneumoniae</em>, <em>Legionella pneumophila</em>, <em>Mycoplasma pneumoniae</em>, <em>Nocardia asteroides</em>) </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Fungal (<em>Aspergillus</em>, <em>Pneumocystis jirovecii</em>) </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Mycobacterial (<em>Mycobacterium avium</em> complex) </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Protozoa (<em>Plasmodium vivax</em>) </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Viral </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <li><strong>Inflammatory bowel disease</strong> </li> </ul> </td> </tr> <tr> <td> <ul> <li><strong>Inhalation injury (eg, aspiration of gastric contents, sulfur dioxide)</strong> </li> </ul> </td> </tr> <tr> <td> <ul> <li><strong>Irradiation injury (eg, breast cancer)</strong> </li> </ul> </td> </tr> <tr> <td> <ul> <li><strong>Reaction around other lung processes</strong> </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Abscess </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Diffuse alveolar hemorrhage </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Lung tumor or other airway obstruction </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <li><strong>Transplantation (eg, allogeneic hematopoietic cell, liver, lung)</strong> </li> </ul> </td> </tr> <tr> <td> <ul> <li><strong>Association with other interstitial pneumonias</strong> </li> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Chronic eosinophilic pneumonia </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Hypersensitivity pneumonitis </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Nonspecific interstitial pneumonia </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Organizing diffuse alveolar damage/acute respiratory distress syndrome (ARDS) </li> </ul> </ul> </td> </tr> <tr> <td> <ul> <ul> <li>Usual interstitial pneumonia (minor scattered foci) </li> </ul> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* List is not comprehensive. Refer to <a href=\"http://www.pneumotox.com/\" target=\"_blank\">www.pneumotox.com</a> for more complete list.</div><div class=\"graphic_reference\">Adapted from: King TE Jr. Organizing pneumonia, Table 33-1 (p. 982). In:<em> Interstitial Lung Disease</em>, 5th ed, King TE Jr, Schwarz MI (Eds), People's Medical Publishing House-USA, Shelton, CT 2011. p.982.</div><div id=\"graphicVersion\">Graphic 87710 Version 2.0</div></div></div>"},"87712":{"type":"graphic_table","displayName":"Causes and evaluation of bronchiectasis in children","title":"Causes and evaluation of bronchiectasis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes and evaluation of bronchiectasis in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Specific examples</td> <td class=\"subtitle1\">Diagnostic tools</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Congenital bronchiectasis</td> </tr> <tr> <td>&nbsp;</td> <td> <p>Cartilage deficiency (Williams-Campbell Syndrome)</p> Tracheobronchomegaly (Mounier-Kuhn Syndrome)</td> <td>Chest imaging</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Bronchial narrowing/obstruction</td> </tr> <tr> <td class=\"indent1\">Congenital abnormalities</td> <td> <p>Tracheomalacia, bronchomalacia, tracheal or bronchial stenosis, bronchogenic cyst, tracheal bronchus, vascular ring, pulmonary artery aneurysm, or dilation</p> <p>Bronchopulmonary sequestration (intralobar)</p> Congenital pulmonary airway (cystic adenomatoid) malformation (CPAM or CCAM)</td> <td> <p>Chest imaging (CT scan with angiogram) &ndash; to evaluate for sequestration, CPAM, vascular rings, or pulmonary artery abnormalities</p> Flexible bronchoscopy &ndash; to evaluate for bronchomalacia, ectopic bronchus, bronchial stenosis, or vascular compression</td> </tr> <tr> <td class=\"indent1\">Foreign body aspiration</td> <td>Peanuts, candy, small objects</td> <td>History (eg, of choking episode, even if remote, and/or recurrent pneumonia), physical exam, chest imaging, and rigid bronchoscopy</td> </tr> <tr> <td class=\"indent1\">Mucoid impaction</td> <td> <p>Mucus plug (post operative, asthma, middle lobe syndrome)</p> <p>Allergic bronchopulmonary aspergillosis (ABPA)</p> Bronchocentric granulomatosis (BG)</td> <td>Chest imaging, serology for Aspergillus, IgE, flexible bronchoscopy with BAL, and biopsy in case of BG</td> </tr> <tr> <td class=\"indent1\">Hilar adenopathy</td> <td> <p>Tuberculosis</p> <p>Histoplasmosis</p> Sarcoidosis</td> <td>Chest imaging, flexible bronchoscopy, serology, cultures, and biopsy if needed</td> </tr> <tr> <td class=\"indent1\">Tumors</td> <td>Airway adenoma, endobronchial teratoma</td> <td>Chest imaging, flexible bronchoscopy</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Immunodeficiency</td> </tr> <tr> <td class=\"indent1\">Immunoglobulin deficiencies</td> <td> <p>Congenital agammaglobulinemia (Bruton's disease)</p> <p>Selective IgG subclass deficiency (IgG2, IgG4)</p> <p>Common variable immunodeficiency</p> <p>IgA deficiency with ataxia-telangiectasia</p> Selective IgA deficiency (possible association)</td> <td>Quantitative immunoglobulin levels, immunoglobulin subclasses, humoral panel with specific antibody titers to childhood vaccines and pneumococcal vaccine</td> </tr> <tr> <td class=\"indent1\">Leukocyte dysfunction</td> <td>Chronic granulomatous disease (NADPH oxidase dysfunction)</td> <td>Dihydrorhodamine 123 (DHR) test; nitroblue tetrazolium test, genetic testing</td> </tr> <tr> <td class=\"indent1\">Combined immunodeficiencies</td> <td> <p>Severe combined immunodeficiency</p> <p>DiGeorge syndrome</p> <p>Bare lymphocyte syndrome (T cell receptor defect caused by major histocompatibility complex [MHC] deficiency)</p> <p>CXCR4 mutation (WHIM syndrome)</p> <p>CD40 deficiency or CD40 ligand deficiency (hypergammaglobulinemia M syndrome)</p> Others</td> <td>Chest x-ray, immunoglobulin levels, specific antibody titers, evaluation of lymphocyte subsets (T, B, and NK), and assessment of T cell function</td> </tr> <tr> <td class=\"indent1\">Complement deficiency</td> <td>Eg, C3 deficiency, Ficolin-3 deficiency</td> <td>Complement assays (C3, C4, and THC)</td> </tr> <tr> <td class=\"indent1\">Acquired immunodeficiencies</td> <td>Pharmacologic immunosuppression, HIV infection, malnutrition, malignancy, etc</td> <td>History, blood counts, quantitative immunoglobulins</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Abnormal secretion clearance (leading to chronic airway infection)</td> </tr> <tr> <td class=\"indent1\">Abnormal secretions</td> <td>Cystic fibrosis</td> <td>Sweat test, genetic testing</td> </tr> <tr> <td class=\"indent1\">Ciliary dysfunction</td> <td>Primary ciliary dyskinesia (known as Kartagener syndrome if situs inversus is present)</td> <td> <p>Nasal or bronchial ciliary biopsy with motility studies, and electron microscopy, genetic testing</p> Situs inversus in Kartagener syndrome</td> </tr> <tr> <td class=\"indent1\">Unknown mechanism</td> <td>Young syndrome (obstructive azoospermia and sinopulmonary disease)</td> <td>Sperm count</td> </tr> <tr> <td class=\"indent1\">Other causes</td> <td>CNS abnormalities, muscle weakness, and weak cough</td> <td>History and exam</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Infection</td> </tr> <tr> <td class=\"indent1\">Persistent bacterial bronchitis</td> <td>Varied organisms</td> <td>History of chronic wet cough, sputum culture</td> </tr> <tr> <td class=\"indent1\">Bacterial pneumonia</td> <td>Staphylococcus aureus, Streptococcus pneumonia, Klebsiella, Pseudomonas aeruginosa</td> <td>History and cultures</td> </tr> <tr> <td class=\"indent1\">Childhood infection</td> <td>Eg, pertussis, measles</td> <td>History of infection</td> </tr> <tr> <td class=\"indent1\">Viral infections</td> <td>Adenovirus (particularly types 7 and 21), influenza, herpes simplex</td> <td>History, viral studies (titers, PCR, culture)</td> </tr> <tr> <td class=\"indent1\">Other infections</td> <td> <p>Fungal (histoplasmosis)</p> <p>Mycobacterium tuberculosis, atypical mycobacterium</p> Possibly mycoplasma</td> <td>History, serology, cultures</td> </tr> <tr> <td class=\"indent1\">Recurrent aspiration</td> <td> <p>Neurological disorders</p> <p>Vocal cord paralysis</p> <p>Swallowing dysfunction</p> <p>Laryngeal clefts</p> <p>Tracheoesophageal fistula</p> Gastroesophageal reflux disease</td> <td> <p>History, chest imaging</p> <p>Swallowing studies and contrast esophagram</p> Direct laryngoscopy with probing for laryngeal cleft</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Miscellaneous disorders</td> </tr> <tr> <td class=\"indent1\">Bronchiolitis obliterans</td> <td> <p>Post infectious</p> <p>Post transplant with chronic rejection (bone marrow, lung transplant)</p> <p>Interstitial lung disease</p> Other causes</td> <td>History, PFTs, Chest CT scan</td> </tr> <tr> <td class=\"indent1\">Genetic disorders</td> <td>Yellow nail syndrome (MIM %153300): yellow nails, lymphedema, and respiratory tract disease with pleural effusions</td> <td>Physical examination, family history, possible genetic testing</td> </tr> <tr> <td class=\"indent1\">Autoimmune and connective tissue disease</td> <td> <p>Rheumatoid arthritis</p> <p>Scleroderma</p> <p>Relapsing polychondritis (RP)</p> <p>Tracheobronchial amyloidosis</p> Marfan syndrome</td> <td> <p>History, physical exam</p> <p>Rheumatological work up</p> <p>Cartilage biopsy for RP</p> Biopsy for amyloid</td> </tr> <tr> <td class=\"indent1\">Inhalation of toxic fumes and dusts</td> <td> <p>Ammonia</p> <p>Nitrogen dioxide</p> <p>Other irritant gases</p> <p>Smoke</p> <p>Talc</p> Silicate</td> <td> <p>Exposure history</p> Chest imaging</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computerized tomography; BAL: bronchoalveolar lavage; WHIM: warts, hypogammaglobulinemia, infections, and myelokathexis; THC: total hemolytic complement (CH50); CNS: central nervous system; PCR: polymerase chain reaction; PFTs: pulmonary function tests; MIM: Mendelian Inheritance in Man (also known as OMIM) database; %: percent.</div><div class=\"graphic_reference\">Courtesy of Khoulood Fakhoury, MD, and Adaobi Kanu, MD.</div><div id=\"graphicVersion\">Graphic 87712 Version 5.0</div></div></div>"},"87713":{"type":"graphic_table","displayName":"Pros and cons of buprenorphine substitution therapy in pregnancy","title":"Pros and cons of buprenorphine versus methadoneÂ substitution therapy in pregnancy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pros and cons of buprenorphine versus methadone&nbsp;substitution therapy in pregnancy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Pros</td> </tr> <tr> <td> <ul> <li>Lower risk of overdose </li> </ul> </td> </tr> <tr> <td> <ul> <li>Fewer drug interactions </li> </ul> </td> </tr> <tr> <td> <ul> <li>Ability to be treated on an outpatient basis without the need for daily visits to a licensed treatment program </li> </ul> </td> </tr> <tr> <td> <ul> <li>Dosing of buprenorphine is similar to that in nonpregnant women </li> </ul> </td> </tr> <tr> <td> <ul> <li>Evidence suggesting less severe neonatal withdrawal </li> </ul> </td> </tr> <tr> <td> <ul> <li>Insurance in the United States may cover buprenorphine prescribed by a private physician in an office setting, while not covering methadone dispensed in a licensed opioid treatment program </li> </ul> </td> </tr> <tr> <td> <ul> <li>Fewer side effects </li> </ul> </td> </tr> <tr> <td> <ul> <li>Low risk of adverse cardiovascular side effects (in contrast,&nbsp;methadone is associated with small increase in risk of arrhythmia) </li> </ul> </td> </tr> <tr> <td> <ul> <li><span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">For the newborn, in utero exposure to buprenorphine rather than methadone may result in a lower risk of preterm birth, higher birth weight, larger head circumference, and, potentially, a lower rate and severity of neonatal withdrawal.</span> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Cons</td> </tr> <tr> <td> <ul> <li>Only limited data are available on pregnancy outcomes after first trimester exposure </li> </ul> </td> </tr> <tr> <td> <ul> <li>Lack of long-term neurodevelopmental outcome data </li> </ul> </td> </tr> <tr> <td> <ul> <li>Clinically important patient dropout rate due to dissatisfaction with the drug </li> </ul> </td> </tr> <tr> <td> <ul> <li>More difficult induction protocol with the potential risk of precipitated withdrawal </li> </ul> </td> </tr> <tr> <td> <ul> <li>Increased risk of diversion* (especially the buprenorphine monotherapy formulation ) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Less stringent structure of some office-based treatment programs </li> </ul> </td> </tr> <tr> <td> <ul> <li>Reports of maternal hepatic dysfunction and elevated transaminases </li> </ul> </td> </tr> <tr> <td> <ul> <li>Effects of buprenorphine are only partially reversible by naloxone </li> </ul> </td> </tr> <tr> <td> <ul id=\"_telerik_insertedList_id\"> <li>The maximum daily dose of buprenorphine is 32 mg, due to a ceiling effect, which may not be sufficient in all women (usually those requiring more than 140 mg per day of methadone) </li> </ul> </td> </tr> <tr> <td> <ul id=\"_telerik_insertedList_id\"> <li>More expensive than methadone </li> </ul> </td> </tr> <tr> <td> <ul id=\"_telerik_insertedList_id\"> <li>Treatment with methadone may result in greater reduction in illicit opioid use </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The combination of buprenorphine and naloxone (Suboxone) is not used during pregnancy.</div><div class=\"graphic_reference\">Adapted from:<br /><OL>&#xD;&#xA;<LI>ACOG Committee on Health Care for Underserved Women, American Society of Addiction Medicine. ACOG Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol 2012; 119:1070.</LI>&#xD;&#xA;<LI>Young JL, Martin PR. Treatment of opioid dependence in the setting of pregnancy. Psychiatr Clin North Am 2012; 35:441.</LI>&#xD;&#xA;<LI>Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363:2320.</LI>&#xD;&#xA;<LI>Peddicord AN, Bush C, Cruze C. A comparison of suboxone and methadone in the treatment of opiate addiction. J Addict Res Ther 2015; 6:248.</LI></OL></div><div id=\"graphicVersion\">Graphic 87713 Version 6.0</div></div></div>"},"87714":{"type":"graphic_table","displayName":"Causes of erythroderma","title":"Causes of erythroderma (exfoliative dermatitis)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of erythroderma (exfoliative dermatitis)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Idiopathic erythroderma</td> </tr> <tr> <td class=\"subtitle1_single\">Inflammatory dermatoses</td> </tr> <tr> <td class=\"indent1\">Psoriasis</td> </tr> <tr> <td class=\"indent1\">Atopic dermatitis</td> </tr> <tr> <td class=\"indent1\">Dermatitis (other than atopic)</td> </tr> <tr> <td class=\"indent1\">Pityriasis rubra pilaris</td> </tr> <tr> <td class=\"indent1\">Lichen planus</td> </tr> <tr> <td class=\"indent1\">Chronic actinic dermatitis</td> </tr> <tr> <td class=\"indent1\">Papuloerythroderma of Ofuji</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> <tr> <td class=\"subtitle1_single\">Drug reactions</td> </tr> <tr> <td class=\"subtitle1_single\">Malignancies: hematologic</td> </tr> <tr> <td class=\"indent1\">Cutaneous T cell lymphoma, Sezary syndrome</td> </tr> <tr> <td class=\"indent1\">Other lymphomas (Hodgkin's, non-Hodgkin's)</td> </tr> <tr> <td class=\"indent1\">Leukemias</td> </tr> <tr> <td class=\"subtitle1_single\">Malignancies: solid organ</td> </tr> <tr> <td class=\"indent1\">Renal cell carcinoma</td> </tr> <tr> <td class=\"indent1\">Hepatocellular carcinoma</td> </tr> <tr> <td class=\"indent1\">Lung</td> </tr> <tr> <td class=\"indent1\">Colon</td> </tr> <tr> <td class=\"subtitle1_single\">Immunobullous disease</td> </tr> <tr> <td class=\"indent1\">Pemphigus foliaceus, vulgaris</td> </tr> <tr> <td class=\"indent1\">Bullous pemphigoid</td> </tr> <tr> <td class=\"indent1\">Paraneoplastic pemphigus</td> </tr> <tr> <td class=\"subtitle1_single\">Connective tissue disease</td> </tr> <tr> <td class=\"indent1\">Dermatomyositis</td> </tr> <tr> <td class=\"indent1\">Subacute lupus erythematosus</td> </tr> <tr> <td class=\"subtitle1_single\">Infections</td> </tr> <tr> <td class=\"indent1\">Scabies</td> </tr> <tr> <td class=\"indent1\">Dermatophytosis</td> </tr> <tr> <td class=\"indent1\">Congenital cutaneous candidiasis</td> </tr> <tr> <td class=\"indent1\">Staphylococcus scalded skin syndrome</td> </tr> <tr> <td class=\"indent1\">Beta-hemolytic streptococcal erythroderma syndrome</td> </tr> <tr> <td class=\"subtitle1_single\">Blood disorders</td> </tr> <tr> <td class=\"indent1\">Hypereosinophilic syndrome</td> </tr> <tr> <td class=\"indent1\">Mastocytosis</td> </tr> <tr> <td class=\"indent1\">Graft-versus-host disease (GVHD)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 87714 Version 5.0</div></div></div>"},"87715":{"type":"graphic_figure","displayName":"Clopidogrel nonresponsiveness and duration of therapy","title":"Clopidogrel nonresponsiveness varies according to duration of therapy","html":"<div class=\"graphic\"><div style=\"width: 666px\" class=\"figure\"><div class=\"ttl\">Clopidogrel nonresponsiveness varies according to duration of therapy</div><div class=\"cntnt\"><img style=\"width:646px; height:552px;\" src=\"images/CARD/87715_Clopidogral_non_dur_surger.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relationship between frequency of patients and absolute change in aggregation (Î Aggregation [percent]) in response to 5 Î¼mol/L ADP at 2 hours, 24 hours, 5 days, and 30 days after stenting. Î Aggregation (percent) is defined as baseline aggregation (percent) minus post-treatment aggregation (percent). Resistance, as defined herein, is Î Aggregation (percent) â¤10 percent. Resistance is present in those patients subtended by double-headed arrow. Curves represent normal distribution of data and were created by Statistica software.</div><div class=\"graphic_reference\">Reproduced with permission from: Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107:2908. Copyright Â© 2003 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 87715 Version 5.0</div></div></div>"},"87716":{"type":"graphic_figure","displayName":"Clopidogrel metabolism","title":"Clopidogrel metabolism","html":"<div class=\"graphic\"><div style=\"width: 612px\" class=\"figure\"><div class=\"ttl\">Clopidogrel metabolism</div><div class=\"cntnt\"><img style=\"width:592px; height:456px;\" src=\"images/CARD/87716_Clopidogrel_metabolism.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Central role of adenosine diphosphate P2Y12 receptor interaction in platelet activation and aggregation during the occurrence of ischemic events and stent thrombosis. After plaque rupture, tissue factor and collagen are exposed, leading to platelet activation. Three important pathways (thrombin-protease activated receptor-1, thromboxane [Tx] A2-thromboxane receptor, and ADP-P2Y12 receptor) amplify the response. The ADP-P2Y12 interaction plays a central role. PCI indicates percutaneous coronary intervention.</div><div class=\"graphic_reference\">Original figure modified for this publication. Bonello L, Tantry US, Marcucci R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010; 56:919. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87716 Version 1.0</div></div></div>"},"87718":{"type":"graphic_table","displayName":"Modified Marshall scoring system for organ dysfunction","title":"Modified Marshall scoring system for organ dysfunction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Modified Marshall scoring system for organ dysfunction</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"5\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Organ system</td> <td class=\"subtitle1\" colspan=\"5\">Score</td> </tr> <tr> <td class=\"subtitle2\">0</td> <td class=\"subtitle2\">1</td> <td class=\"subtitle2\">2</td> <td class=\"subtitle2\">3</td> <td class=\"subtitle2\">4</td> </tr> <tr> <td>Respiratory (PaO<sub>2</sub>/FiO<sub>2</sub>)</td> <td class=\"centered\">&#62;400</td> <td class=\"centered\">301-400</td> <td class=\"centered\">201-300</td> <td class=\"centered\">101-200</td> <td class=\"centered\">&#8804;101</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"6\">Renal*</td> </tr> <tr> <td class=\"indent1\">(serum creatinine, micromol/L)</td> <td class=\"centered\">&#8804;134</td> <td class=\"centered\">134-169</td> <td class=\"centered\">170-310</td> <td class=\"centered\">311-439</td> <td class=\"centered\">&#62;439</td> </tr> <tr> <td class=\"indent1\">(serum creatinine, mg/dL)</td> <td class=\"centered\">&#60;1.4</td> <td class=\"centered\">1.4-1.8</td> <td class=\"centered\">1.9-3.6</td> <td class=\"centered\">3.6-4.9</td> <td class=\"centered\">&#62;4.9</td> </tr> <tr class=\"divider_bottom\"> <td>Cardiovascular (systolic blood pressure, mmHg)<sup>&#182;</sup></td> <td class=\"centered\">&#62;90</td> <td class=\"centered\">&#60;90, fluid responsive</td> <td class=\"centered\">&#60;90, not fluid responsive</td> <td class=\"centered\">&#60;90, pH &#60;7.3</td> <td class=\"centered\">&#60;90, pH &#60;7.2</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"6\">For nonventilated patients, the FiO<sub>2</sub> can be estimated from below:</td> </tr> <tr> <td class=\"subtitle2_left\">Supplemental oxygen (L/min)</td> <td class=\"subtitle2_left\" colspan=\"5\">FiO<sub>2</sub> (percent)</td> </tr> <tr> <td class=\"indent1\">Room air</td> <td colspan=\"5\">21</td> </tr> <tr> <td class=\"indent1\">2</td> <td colspan=\"5\">25</td> </tr> <tr> <td class=\"indent1\">4</td> <td colspan=\"5\">30</td> </tr> <tr> <td class=\"indent1\">6-8</td> <td colspan=\"5\">40</td> </tr> <tr> <td class=\"indent1\">9-10</td> <td colspan=\"5\">50</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A score of 2 or more in any system defines the presence of organ failure.</div><div class=\"graphic_footnotes\">* A score for patients with pre-existing chronic renal failure depends on the extent of further deterioration of baseline renal function. No formal correction exists for a baseline serum creatinine â¥134 micromol/L or â¥1.4 mg/dL.<br />Â¶ Off inotropic support.</div><div class=\"graphic_reference\">Reproduced with permission from: Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis - 2012: revisions of the Atlanta classification and definitions by international consensus. Gut 2013; 62:102. BMJ Publishing Group Ltd. Copyright &copy; 2013.</div><div id=\"graphicVersion\">Graphic 87718 Version 2.0</div></div></div>"},"87721":{"type":"graphic_table","displayName":"Pain management strategies for buprenorphine maintained women","title":"Pain management strategies for postpartum women on buprenorphine substitution therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pain management strategies for postpartum women on buprenorphine substitution therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Preferred strategy</td> </tr> <tr> <td> <ul> <li>Give the maintenance dose of buprenorphine* plus full opioid agonists<sup>&#916;</sup> (eg, patient-controlled-analgesia; intravenous, transdermal, or intramuscular opioids; oral opioids plus acetaminophen) and non-steroidal anti-inflammatory drugs (NSAIDs) (eg, ibuprofen, ketorolac). Total daily doses required for opioid analgesia may be 30 to 100 percent higher than usual doses in opioid-na&#239;ve patients. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Alternative strategies</td> </tr> <tr> <td> <ul> <li>Give the maintenance dose of buprenorphine plus supplemental 2 to 4 mg doses of sublingual (SL) buprenorphine every 4 to 6 hours in addition to the patient's daily maintenance dose not to exceed 32 mg SL daily. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Give the maintenance dose of buprenorphine in 4 divided doses over 24 hours taking advantage of the analgesic effects of buprenorphine. Additional full agonist opioids can be given as necessary. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Stop buprenorphine prior to surgery and replace with short-acting full agonist opioids titrated to pain and withdrawal. High doses of full agonist opioids in divided doses every three to four hours are needed for the first 24 to 60 hours to compete with the presence of buprenorphine. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Ancillary measures</td> </tr> <tr> <td> <ul> <li>Provide intrapartum regional anesthesia, with or without continuation postpartum. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Instill local anesthesia (eg, cesarean incision, laceration repair, assisted delivery). </li> </ul> </td> </tr> <tr> <td> <ul> <li>Administer clonidine, especially when pain management is complicated by symptoms of withdrawal. Adjunctive clonidine 0.1 to 0.2 mg orally every two to four hours as needed may decrease withdrawal symptoms. Side effects include orthostatic hypotension, sedation, dry mouth and constipation. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Usual buprenorphine maintenance doses can be given in two to four divided doses if there is a concern for sedation or respiratory depression due to addition of opioids for analgesia.<br />&Delta; Mixed acting opioid agonists-antagonists such as nalbuphine or butorphanol can precipitate acute withdrawal symptoms and should therefore be avoided.</div><div id=\"graphicVersion\">Graphic 87721 Version 2.0</div></div></div>"},"87722":{"type":"graphic_table","displayName":"Estimates of energy requirements for children","title":"Estimates of energy requirements (kcal/day) for healthy children with moderate physical activity","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Estimates of energy requirements (kcal/day) for healthy children with moderate physical activity</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Age</td> <td class=\"subtitle1\" colspan=\"2\">WHO estimates* (kcal/kg/day)</td> <td class=\"subtitle1\" colspan=\"2\">IOM estimates<sup>&#182;</sup> (kcal/kg/day)</td> </tr> <tr> <td class=\"subtitle2\">Boys</td> <td class=\"subtitle2\">Girls</td> <td class=\"subtitle2\">Boys</td> <td class=\"subtitle2\">Girls</td> </tr> <tr> <td>12 months</td> <td class=\"centered\">82</td> <td class=\"centered\">80</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td>24 months</td> <td class=\"centered\">84</td> <td class=\"centered\">81</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>3 to 4 years</td> <td class=\"centered\">80</td> <td class=\"centered\">77</td> <td class=\"centered\">104</td> <td class=\"centered\">100</td> </tr> <tr> <td>4 to 5 years</td> <td class=\"centered\">77</td> <td class=\"centered\">74</td> <td class=\"centered\">97</td> <td class=\"centered\">93</td> </tr> <tr> <td>5 to 6 years</td> <td class=\"centered\">74</td> <td class=\"centered\">72</td> <td class=\"centered\">90</td> <td class=\"centered\">87</td> </tr> <tr> <td>6 to 7 years</td> <td class=\"centered\">73</td> <td class=\"centered\">69</td> <td class=\"centered\">84</td> <td class=\"centered\">81</td> </tr> <tr> <td>7 to 8 years</td> <td class=\"centered\">71</td> <td class=\"centered\">67</td> <td class=\"centered\">80</td> <td class=\"centered\">75</td> </tr> <tr> <td>8 to 9 years</td> <td class=\"centered\">69</td> <td class=\"centered\">64</td> <td class=\"centered\">75</td> <td class=\"centered\">71</td> </tr> <tr> <td>9 to 10 years</td> <td class=\"centered\">67</td> <td class=\"centered\">61</td> <td class=\"centered\">71</td> <td class=\"centered\">65</td> </tr> <tr> <td>10 to 11 years</td> <td class=\"centered\">65</td> <td class=\"centered\">58</td> <td class=\"centered\">67</td> <td class=\"centered\">60</td> </tr> <tr> <td>11 to 12 years</td> <td class=\"centered\">62</td> <td class=\"centered\">55</td> <td class=\"centered\">63</td> <td class=\"centered\">56</td> </tr> <tr> <td>12 to 13 years</td> <td class=\"centered\">60</td> <td class=\"centered\">52</td> <td class=\"centered\">60</td> <td class=\"centered\">52</td> </tr> <tr> <td>13 to 14 years</td> <td class=\"centered\">58</td> <td class=\"centered\">49</td> <td class=\"centered\">57</td> <td class=\"centered\">50</td> </tr> <tr> <td>14 to 15 years</td> <td class=\"centered\">56</td> <td class=\"centered\">47</td> <td class=\"centered\">55</td> <td class=\"centered\">47</td> </tr> <tr> <td>15 to 16 years</td> <td class=\"centered\">53</td> <td class=\"centered\">45</td> <td class=\"centered\">54</td> <td class=\"centered\">45</td> </tr> <tr> <td>16 to 17 years</td> <td class=\"centered\">52</td> <td class=\"centered\">44</td> <td class=\"centered\">52</td> <td class=\"centered\">44</td> </tr> <tr> <td>17 to 18 years</td> <td class=\"centered\">50</td> <td class=\"centered\">44</td> <td class=\"centered\">50</td> <td class=\"centered\">43</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">WHO: World Health Organization; IOM: Institute of Medicine.<br />* The WHO estimates are based on assumed physical activity levels of 1.45 to 1.85 mJ/day (boys, increasing with age), and 1.4 to 1.7 mJ/day (girls, increasing with age), considered \"moderate physical activity\" (rather than light or vigorous physical activity).<br />&para; The IOM estimates for children 3 to 18 years are based on assumed physical activity coefficients of 1.6 to 1.9 mJ/day, considered \"active\" (rather than sedentary, low active, or very active).</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>WHO estimates from: Food and Agriculture Organization of the United Nations (FAO), World Health Organization (WHO) and United Nations University (UNU): Human Energy Requirements.&nbsp;Available at:&nbsp;<A href=\"http://www.fao.org/docrep/007/y5686e/y5686e00.htm#Contents\">http://www.fao.org/docrep/007/y5686e/y5686e00.htm#Contents</A> (Accessed on May 16th, 2016).</LI>&#xD;&#xA;<LI>IOM estimates from: DIETARY REFERENCE INTAKES FOR ENERGY, Institute of Medicine, 2005. Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids (macronutrients), 2005, chapter 5. Available at: http://fnic.nal.usda.gov/dietary-guidance/dri-reports/energy-carbohydrate-fiber-fat-fatty-acids-cholesterol-protein-and-amino#overlay-context=dietary-guidance/dietary-reference-intakes/dri-reports (Accessed on January 21, 2013).</LI></OL></div><div id=\"graphicVersion\">Graphic 87722 Version 3.0</div></div></div>"},"87723":{"type":"graphic_figure","displayName":"Pathophysiologic pathways involved in emesis ","title":"Pathophysiologic pathways involved in emesis","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Pathophysiologic pathways involved in emesis</div><div class=\"cntnt\"><img style=\"width:487px; height:707px;\" src=\"images/PALC/87723_Emesis_pathways.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Emesis is mediated centrally by two separate âcentersâ. The chemoreceptor trigger zone (CTZ) is localized to the area postrema in the floor of the fourth ventricle where chemosensitive nerve cell projections are bathed by cerebrospinal fluid that is in equilibrium with blood in the fenestrated local capillaries. Neural pathways project from the CTZ to the nucleus tractus solitarius and the reticular formation of the medulla oblongata, which is the location of the vomiting center (VC). The VC is a diffuse, interconnecting neural network that integrates emetogenic stimuli with parasympathetic and motor efferent activity to produce the vomiting reflex. It receives afferents from the cerebral cortex and higher brainstem, thalamus and hypothalamus, the vestibular system, and via the vagus and splanchnic nerves, the pharynx, gastrointestinal tract, serosae, and other thoracoabdominal organs.</div><div id=\"graphicVersion\">Graphic 87723 Version 1.0</div></div></div>"},"87724":{"type":"graphic_table","displayName":"Erythroderma pathology features","title":"Histopathologic features of erythroderma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histopathologic features of erythroderma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Causes of erythroderma</td> <td class=\"subtitle1\">Key histopathologic features</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Idiopathic erythroderma</strong></td> <td class=\"sublist1_start\">Nonspecific features including hyperkeratosis, parakeratosis, acanthosis, and inflammatory infiltrate</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\"><strong>Inflammatory dermatoses</strong></td> </tr> <tr> <td class=\"indent1\">Psoriasis</td> <td>Epidermal acanthosis, parakeratosis, Munro microabscesses, dilated tortuous papillary blood vessels</td> </tr> <tr> <td class=\"indent1\">Atopic dermatitis</td> <td>Acanthosis, hyperkeratosis, spongiosis</td> </tr> <tr> <td class=\"indent1\">Dermatitis (other than atopic)</td> <td>Acanthosis, hyperkeratosis, spongiosis</td> </tr> <tr> <td class=\"indent1\">Pityriasis rubra pilaris</td> <td>Acanthosis, hyperkeratosis, alternating ortho- and parakeratosis (horizontal and vertical)</td> </tr> <tr> <td class=\"indent1\">Lichen planus</td> <td>Lymphohistiocytic infiltrate with band-like distribution upper dermis; obscures the dermoepidermal junction</td> </tr> <tr> <td class=\"indent1\">Chronic actinic dermatitis</td> <td>Acanthosis, hyperkeratosis, spongiosis, perivascular chronic inflammatory cell infiltrate, occasional atypical cerebriform lymphoid cells</td> </tr> <tr> <td class=\"indent1\">Papuloerythroderma of Ofuji</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> <td>Noncaseating epithelial cell-like granulomas in the deep dermis</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Drug reactions</strong></td> <td class=\"sublist1_start\"> <p>Histology varies according to the reaction pattern</p> <ul> <li>In exanthematous type, interface dermatitis, vacuolar changes, necrotic keratinocytes, inflammatory infiltrate with eosinophils&nbsp; </li> <li>In Stevens Johnson syndrome/toxic epidermal necrolysis, partial to full-thickness skin necrosis </li> </ul> </td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\"><strong>Malignancies: hematologic</strong></td> </tr> <tr> <td class=\"indent1\">Cutaneous T cell lymphoma, S&#233;zary syndrome</td> <td>Findings may be subtle and variable. S&#233;zary cells (highly convoluted cerebriform lymphocytes) along the basal layer, lichenoid infiltrate, epidermotropism, Pautrier microabscesses. Absence of spongiosis.</td> </tr> <tr> <td class=\"indent1\">Other lymphomas (Hodgkin's, non-Hodgkin's)</td> <td>Atypical lymphocytes in dermis and epidermis</td> </tr> <tr> <td class=\"indent1\">Leukemias</td> <td>Leukemic cells in dermis and epidermis</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Malignancies: solid organ</strong></td> <td>Nonspecific, variable findings</td> </tr> <tr> <td class=\"indent1\">Renal cell carcinoma</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Hepatocellular carcinoma</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Lung</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Colon</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\"><strong>Immunobullous disease</strong></td> </tr> <tr> <td class=\"indent1\">Pemphigus foliaceus, vulgaris</td> <td>Acantholysis</td> </tr> <tr> <td class=\"indent1\">Bullous pemphigoid</td> <td>Subepidermal separation</td> </tr> <tr> <td class=\"indent1\">Paraneoplastic pemphigus</td> <td>Acantholysis, lichenoid infiltrate, necrotic keratinocytes</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\"><strong>Connective tissue disease</strong></td> </tr> <tr> <td class=\"indent1\">Dermatomyositis</td> <td>Interface dermatitis</td> </tr> <tr> <td class=\"indent1\">Subacute lupus erythematosus</td> <td>Interface dermatitis</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\"><strong>Infections</strong></td> </tr> <tr> <td class=\"indent1\">Scabies</td> <td>Scabies mite at junction of epidermis and stratum corneum; spongiosis, dermal lymphocytic infiltrate</td> </tr> <tr> <td class=\"indent1\">Dermatophytosis</td> <td>Hyphae</td> </tr> <tr> <td class=\"indent1\">Congenital cutaneous candidiasis</td> <td>Hyphae and yeast-like forms</td> </tr> <tr> <td class=\"indent1\">Staphylococcus scalded skin syndrome</td> <td>Vesiculation at level of granular cell layer</td> </tr> <tr> <td class=\"indent1\">Beta-hemolytic streptococcal erythroderma syndrome</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\"><strong>Blood disorders</strong></td> </tr> <tr> <td class=\"indent1\">Hypereosinophilic syndrome</td> <td>Dermal eosinophilic infiltrates</td> </tr> <tr> <td class=\"indent1\">Mastocytosis</td> <td>Dermal mast cell infiltrates</td> </tr> <tr> <td class=\"indent1\">Graft-versus-host disease (GVHD)</td> <td>Interface dermatitis</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Erythroderma occurring in the first year of life (congenital/neonatal/infant): additional diagnoses to be considered</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\"><strong>Inherited ichthyoses</strong></td> </tr> <tr> <td class=\"indent1\">Epidermolytic hyperkeratosis (bullous congenital ichthyosiform erythroderma)</td> <td>Hyperkeratosis, acanthosis, superficial vacuolation, clumps of irregular eosinophilic granules in the granular layer</td> </tr> <tr> <td class=\"indent1\">Nonbullous congenital ichthyosiform erythroderma</td> <td>Acanthosis, hyperkeratosis, focal parakeratosis</td> </tr> <tr> <td class=\"indent1\">Netherton syndrome</td> <td>Epidermal psoriasiform hyperplasia</td> </tr> <tr> <td class=\"indent1\">Rare ichthyoses</td> <td>Hyperkeratosis</td> </tr> <tr> <td class=\"sublist1_start\"><strong>Primary immunodeficiencies</strong></td> <td class=\"sublist1_start\">Nonspecific features including hyperkeratosis, parakeratosis, acanthosis, and inflammatory infiltrate</td> </tr> <tr> <td class=\"indent1\">Severe combined immunodeficiency (SCID)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Severe combined immunodeficiency - Omenn syndrome (a form of SCID)</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">X-linked ectodermal dysplasia with immunodeficiency</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\"><strong>Ectodermal dysplasias</strong></td> </tr> <tr> <td class=\"indent1\">Ankyloblepharon-ectodermal defects-cleft lip/palate&nbsp;syndrome</td> <td>Nonspecific features including hyperkeratosis, parakeratosis, acanthosis, and inflammatory infiltrate</td> </tr> <tr> <td class=\"sublist1_start\" colspan=\"2\"><strong>Miscellaneous</strong></td> </tr> <tr> <td class=\"indent1\">Menkes disease</td> <td>&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 87724 Version 6.0</div></div></div>"},"87725":{"type":"graphic_algorithm","displayName":"Algorithm for acute weight loss in children and adolescents","title":"Diagnostic algorithm for acute weight loss in children and adolescents*","html":"<div class=\"graphic\"><div style=\"width: 680px\" class=\"figure\"><div class=\"ttl\">Diagnostic algorithm for acute weight loss in children and adolescents*</div><div class=\"cntnt\"><img style=\"width:660px; height:664px;\" src=\"images/EM/87725_Algrth_acte_wt_ls_chdn_adlc.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Weight loss occuring over approximately one week.<br />Â¶ Once fluid and physical exam status normalized, patients with dehydration should be evaluated as for patients who were NOT initially ill-appearing.</div><div id=\"graphicVersion\">Graphic 87725 Version 4.0</div></div></div>"},"87726":{"type":"graphic_algorithm","displayName":"Algorithm for chronic weight loss in children and adolescents","title":"Diagnostic algorithm for chronic weight loss in children and adolescents*","html":"<div class=\"graphic\"><div style=\"width: 1073px\" class=\"figure\"><div class=\"ttl\">Diagnostic algorithm for chronic weight loss in children and adolescents*</div><div class=\"cntnt\"><img style=\"width:1053px; height:941px;\" src=\"images/EM/87726_Chronwghtlsschldadlscnt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Chronic weight loss refers to decreased body weight over more than one to two weeks.<br />Â¶ Fever may <STRONG>not</STRONG> always be present in patients with weight loss caused by malignancy.<br />Î Several chronic infections may cause weight loss in association with prolonged fever and nonspecific and variable clinical findings such as lymphadenopathy, hepatitis, and myalgias including brucellosis, leptospirosis, tularemia, and Epstein-Barr virus. For more information refer to UpToDate topics on fever of unknown origin.</div><div id=\"graphicVersion\">Graphic 87726 Version 3.0</div></div></div>"},"87727":{"type":"graphic_table","displayName":"Causes of weight loss in children and adolescents","title":"Causes of weight loss in children and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of weight loss in children and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Causes of weight loss in infants over six months of age, children, and adolescents</td> </tr> <tr> <td class=\"subtitle2_single\">Life-threatening conditions</td> </tr> <tr> <td class=\"indent1\">Diabetes mellitus</td> </tr> <tr> <td class=\"indent1\">Adrenal insufficiency</td> </tr> <tr> <td class=\"indent1\">Eating disorders with complications (eg, anorexia nervosa, bulimia nervosa, fad diets)</td> </tr> <tr> <td class=\"indent1\">Dehydration</td> </tr> <tr> <td class=\"subtitle2_single\">Common conditions</td> </tr> <tr> <td class=\"indent1\">Viral gastroenteritis</td> </tr> <tr> <td class=\"indent1\">Depression</td> </tr> <tr> <td class=\"indent1\">Inflammatory bowel disease</td> </tr> <tr> <td class=\"indent1\">Acute infections</td> </tr> <tr> <td class=\"indent1\">Celiac disease</td> </tr> <tr> <td class=\"indent1\">Child neglect</td> </tr> <tr> <td class=\"indent1\">Malnutrition and failure to thrive (children &#8804;3 years of age)</td> </tr> <tr> <td class=\"indent1\">Lactose intolerance</td> </tr> <tr> <td class=\"indent1\">Drug use (eg, amphetamines, methylphenidate)</td> </tr> <tr> <td class=\"subtitle2_single\">Other conditions</td> </tr> <tr> <td class=\"indent1\">Malignancy</td> </tr> <tr> <td class=\"indent1\">Tuberculosis</td> </tr> <tr> <td class=\"indent1\">Human immunodeficiency virus</td> </tr> <tr> <td class=\"indent1\">Primary immunodeficiency</td> </tr> <tr> <td class=\"indent1\">Other chronic infections</td> </tr> <tr> <td class=\"indent1\">Giardiasis and other intestinal parasites</td> </tr> <tr> <td class=\"indent1\">Cystic fibrosis</td> </tr> <tr> <td class=\"indent1\">Superior mesenteric artery syndrome</td> </tr> <tr> <td class=\"indent1\">Cyclic vomiting</td> </tr> <tr> <td class=\"indent1\">Pancreatitis</td> </tr> <tr> <td class=\"indent1\">Liver disease</td> </tr> <tr> <td class=\"indent1\">Rheumatologic disease</td> </tr> <tr> <td class=\"indent1\">Hyperthyroidism</td> </tr> <tr> <td class=\"indent1\">Hypercalcemia</td> </tr> <tr> <td class=\"indent1\">Chronic lead poisoning</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 87727 Version 1.0</div></div></div>"},"87728":{"type":"graphic_diagnosticimage","displayName":"Hydrocephalus in leptomeningeal disease","title":"Hydrocephalus in leptomeningeal disease","html":"<div class=\"graphic\"><div style=\"width: 645px\" class=\"figure\"><div class=\"ttl\">Hydrocephalus in leptomeningeal disease</div><div class=\"cntnt\"><img style=\"width:625px; height:428px;\" src=\"images/RADIOL/87728_Hydrocephalus_leptomeningea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">FLAIR imaging at baseline (A) and at the time of diagnosis of leptomeningeal metastases (B). The image in panel A demonstrates normal ventricular size (arrow). The image in panel B demonstrates new hydrocephalus, with ventricular enlargement (arrowhead) and periventricular hyperintensity (arrows) consistent with transependymal flow of cerebrospinal fluid.</div><div class=\"graphic_footnotes\">FLAIR: fluid-attenuated inversion recovery. </div><div class=\"graphic_reference\">Courtesy of Joseph Farnam, MD.</div><div id=\"graphicVersion\">Graphic 87728 Version 2.0</div></div></div>"},"87731":{"type":"graphic_picture","displayName":"Leiomyoma colonoscopy","title":"Leiomyoma ","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Leiomyoma </div><div class=\"cntnt\"><img style=\"width:504px; height:520px;\" src=\"images/GAST/87731_Leiomyoma_endoscopy_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Colonoscopic view of a&nbsp;sessile&nbsp;6 mm nonbleeding submucosal nodule with a smooth contour that on histology&nbsp;was consistent with a leiomyoma.</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD.</div><div id=\"graphicVersion\">Graphic 87731 Version 2.0</div></div></div>"},"87732":{"type":"graphic_picture","displayName":"Leiomyoma low power histology","title":"Leiomyoma low power histology","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Leiomyoma low power histology</div><div class=\"cntnt\"><img style=\"width:576px; height:444px;\" src=\"images/GAST/87732_Leiomyoma_histology_1A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of&nbsp;a biopsy specimen from a&nbsp;6 mm rectal nodule demonstrates nodular expansion of the muscularis mucosa displacing an unremarkable overlying epithelium.</div><div class=\"graphic_reference\">Courtesy of Douglas Hartman, MD.</div><div id=\"graphicVersion\">Graphic 87732 Version 1.0</div></div></div>"},"87733":{"type":"graphic_picture","displayName":"Leiomyoma high power histology","title":"Leiomyoma high power histology","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Leiomyoma high power histology</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/GAST/87733_Leiomyoma_histology_1B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view&nbsp;of a biopsy specimen from a 6 mm rectal nodule demonstrates&nbsp;haphazard arrangement of smooth muscle cells consistent with a leiomyoma.</div><div class=\"graphic_reference\">Courtesy of Douglas Hartman, MD.</div><div id=\"graphicVersion\">Graphic 87733 Version 1.0</div></div></div>"},"87734":{"type":"graphic_picture","displayName":"Neurofibroma in the colon","title":"Neurofibroma in the colon","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Neurofibroma in the colon</div><div class=\"cntnt\"><img style=\"width:504px; height:493px;\" src=\"images/GAST/87734_Neurofibroma_endoscopy_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Colonoscopic view of a&nbsp;5 mm submucosal nodule in the proximal sigmoid colon that on histology was consistent with a neurofibroma.</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD.</div><div id=\"graphicVersion\">Graphic 87734 Version 1.0</div></div></div>"},"87735":{"type":"graphic_picture","displayName":"Neurofibroma low power histology","title":"Neurofibroma low power histology","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Neurofibroma low power histology</div><div class=\"cntnt\"><img style=\"width:576px; height:333px;\" src=\"images/GAST/87735_Neurofibroma_histology_2A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a neurofibroma in the sigmoid colon&nbsp;demonstrates nodular expansion of the lamina propria and submucosa.</div><div class=\"graphic_reference\">Courtesy of Douglas Hartman, MD.</div><div id=\"graphicVersion\">Graphic 87735 Version 2.0</div></div></div>"},"87736":{"type":"graphic_picture","displayName":"Neurofibroma high power histology","title":"Neurofibroma high power histology","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Neurofibroma high power histology</div><div class=\"cntnt\"><img style=\"width:576px; height:431px;\" src=\"images/GAST/87736_Neurofibroma_histology_2B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of a neurofibroma in the sigmoid colon shows&nbsp;proliferating bundles of spindle cells with wavy nuclei and strands of pink collagen. To determine the type of spindle cell present, an S-100 immunohistochemical stain is required.</div><div class=\"graphic_reference\">Courtesy of Douglas Hartman, MD.</div><div id=\"graphicVersion\">Graphic 87736 Version 1.0</div></div></div>"},"87737":{"type":"graphic_picture","displayName":"Neurofibroma low power histology with S-100 stain","title":"Neurofibroma low power histology with S-100 stain","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Neurofibroma low power histology with S-100 stain</div><div class=\"cntnt\"><img style=\"width:576px; height:324px;\" src=\"images/GAST/87737_Neurofibroma_histology_2C.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a neurofibroma in the sigmoid colon with S-100 stain. The S-100&nbsp;stain is diffusely positive consistent with the neural origin of spindle cells and confirms the diagnosis of a benign neurofibroma.</div><div class=\"graphic_reference\">Courtesy of Douglas Hartman, MD.</div><div id=\"graphicVersion\">Graphic 87737 Version 1.0</div></div></div>"},"87738":{"type":"graphic_picture","displayName":"Gastrointestinal neuroendocrine tumor","title":"Gastrointestinal neuroendocrine tumor ","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Gastrointestinal neuroendocrine tumor </div><div class=\"cntnt\"><img style=\"width:504px; height:513px;\" src=\"images/GAST/87738_Gastr_endo_cell_tumor_endo3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Colonoscopic&nbsp;view of a 10 mm submucosal nodule in the rectum that on&nbsp;histology was consistent with a neuroendocrine (carcinoid) tumor.</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD.</div><div id=\"graphicVersion\">Graphic 87738 Version 1.0</div></div></div>"},"87739":{"type":"graphic_picture","displayName":"Gastrointestinal neuroendocrine tumor low power histology","title":"Gastrointestinal neuroendocrine (carcinoid) tumor low power histology","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Gastrointestinal neuroendocrine (carcinoid) tumor low power histology</div><div class=\"cntnt\"><img style=\"width:576px; height:431px;\" src=\"images/GAST/87739_Gastr_endo_tumor_histo_3A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a gastrointestinal neuroendocrine (carcinoid) tumor&nbsp;reveals expansion of the lamina propria and submucosa by aggregates of small blue tumor cells.</div><div class=\"graphic_reference\">Courtesy of Douglas Hartman, MD.</div><div id=\"graphicVersion\">Graphic 87739 Version 1.0</div></div></div>"},"87740":{"type":"graphic_picture","displayName":"Gastrointestinal neuroendocrine tumor high power histology","title":"Gastrointestinal neuroendocrine (carcinoid) tumor high power histology","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Gastrointestinal neuroendocrine (carcinoid) tumor high power histology</div><div class=\"cntnt\"><img style=\"width:576px; height:431px;\" src=\"images/GAST/87740_Gastr_endo_tumor_histo_3B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of&nbsp;a gastrointestinal&nbsp;neuroendocrine (carcinoid) tumor&nbsp;reveals a trabecular or ribbon-like pattern of the tumor cells. This is the most common architectural pattern of a rectal carcinoid tumor. Immunohistochemical staining with synaptophysin confirms the diagnosis.</div><div class=\"graphic_reference\">Courtesy of Douglas Hartman, MD.</div><div id=\"graphicVersion\">Graphic 87740 Version 1.0</div></div></div>"},"87741":{"type":"graphic_picture","displayName":"Juvenile polyposis colonoscopy","title":"Juvenile polyposis","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Juvenile polyposis</div><div class=\"cntnt\"><img style=\"width:598px; height:262px;\" src=\"images/GAST/87741_Juvenile_polyposis_endsc_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Colonoscopy in a patient with juvenile polyposis reveals multiple pedunculated polyps ranging in size from 5 to 15 mm (panels A and B).</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD.</div><div id=\"graphicVersion\">Graphic 87741 Version 1.0</div></div></div>"},"87742":{"type":"graphic_picture","displayName":"Juvenile polyp low power histology","title":"Juvenile polyp low power histology","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Juvenile polyp low power histology</div><div class=\"cntnt\"><img style=\"width:576px; height:431px;\" src=\"images/GAST/87742_Juvenile_polyposis_histo_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a juvenile polyp reveals an edematous lamina propria that is expanded by inflammatory cells. The crypts are cystically dilated and filled with mucus and inflammatory cells (asterisks).</div><div class=\"graphic_reference\">Courtesy of Douglas Hartman, MD.</div><div id=\"graphicVersion\">Graphic 87742 Version 1.0</div></div></div>"},"87743":{"type":"graphic_picture","displayName":"Melanosis coli colonoscopy","title":"Melanosis coli ","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Melanosis coli </div><div class=\"cntnt\"><img style=\"width:598px; height:232px;\" src=\"images/GAST/87743_Melanosis_coli_endoscopy_5.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Colonoscopy in a patient with melanosis coli reveals&nbsp;dark colored mucosa in the entire colon (panel A) but&nbsp;sparing the ileocecal valve (panel B, arrow).</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD.</div><div id=\"graphicVersion\">Graphic 87743 Version 1.0</div></div></div>"},"87744":{"type":"graphic_picture","displayName":"Melanosis coli medium power histology","title":"Melanosis coli medium power histology","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Melanosis coli medium power histology</div><div class=\"cntnt\"><img style=\"width:576px; height:460px;\" src=\"images/GAST/87744_Melanosis_coli_histology_5.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Medium power view of a random colon biopsy specimen in a patient with melanosis coli&nbsp;reveals pigment laden macrophages in the&nbsp;lamina propria&nbsp;(oval). This pigment is not melanin but is secondary to lipofuscin deposition in macrophages.</div><div class=\"graphic_reference\">Courtesy of Douglas Hartman, MD.</div><div id=\"graphicVersion\">Graphic 87744 Version 1.0</div></div></div>"},"87745":{"type":"graphic_picture","displayName":"Cytomegalovirus colitis colonoscopy","title":"Cytomegalovirus colitis ","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Cytomegalovirus colitis </div><div class=\"cntnt\"><img style=\"width:598px; height:245px;\" src=\"images/GAST/87745_CMV_colitis_endoscopy_6AB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Colonoscopy in a patient with&nbsp;cytomegalovirus (CMV)&nbsp;reveals multiple 3 to 5 mm&nbsp;ulcerations (circle)&nbsp;surrounded by erythema and intervening&nbsp;areas of normal appearing colon.</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD.</div><div id=\"graphicVersion\">Graphic 87745 Version 1.0</div></div></div>"},"87746":{"type":"graphic_picture","displayName":"Cytomegalovirus colitis low power histology","title":"Cytomegalovirus colitis low power histology","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Cytomegalovirus colitis low power histology</div><div class=\"cntnt\"><img style=\"width:576px; height:426px;\" src=\"images/GAST/87746_CMV_colitis_histology_6A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of&nbsp;biopsies of the colon in a patient with cytomegalovirus (CMV) colitis reveals&nbsp;ulceration of the superficial epithelium&nbsp;and loss of colonic crypts.</div><div class=\"graphic_reference\">Courtesy of Douglas Hartman, MD.</div><div id=\"graphicVersion\">Graphic 87746 Version 2.0</div></div></div>"},"87747":{"type":"graphic_picture","displayName":"Cytomegalovirus colitis immunohistochemical stain","title":"Cytomegalovirus colitis immunohistochemical stain","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Cytomegalovirus colitis immunohistochemical stain</div><div class=\"cntnt\"><img style=\"width:576px; height:431px;\" src=\"images/GAST/87747_CMV_colitis_histology_6C.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of a colon biopsy specimen with an&nbsp;immunohistochemical stain for&nbsp;cytomegalovirus (CMV)&nbsp;colitis confirms the diagnosis of CMV colitis.&nbsp;</div><div class=\"graphic_reference\">Courtesy of Douglas Hartman, MD.</div><div id=\"graphicVersion\">Graphic 87747 Version 2.0</div></div></div>"},"87748":{"type":"graphic_picture","displayName":"Cytomegalovirus colitis high power histology","title":"Cytomegalovirus colitis high power histology","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Cytomegalovirus colitis high power histology</div><div class=\"cntnt\"><img style=\"width:576px; height:431px;\" src=\"images/GAST/87748_CMV_colitis_histology_6B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view&nbsp;of biopsies of the colon in a patient with cytomegalovirus (CMV)&nbsp;colitis reveals&nbsp;severe acute and chronic inflammation.&nbsp;A lesional cell (circle) with characteristic cytomegaly and both nuclear and cytoplasmic inclusions is diagnostic of a CMV infection. CMV inclusions are usually found in stromal and endothelial cells and rarely in epithelial cells.</div><div class=\"graphic_reference\">Courtesy of Douglas Hartman, MD.</div><div id=\"graphicVersion\">Graphic 87748 Version 2.0</div></div></div>"},"87750":{"type":"graphic_picture","displayName":"Collagenous colitis low power histology","title":"Collagenous colitis low power histology","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Collagenous colitis low power histology</div><div class=\"cntnt\"><img style=\"width:576px; height:430px;\" src=\"images/GAST/87750_Collagenou_colitis_histo_7A.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power view of a random colon biopsy in a patient with&nbsp;collagenous colitis&nbsp;reveals&nbsp;intact crypt architecture with a prominent pink stripe underneath the epithelial surface (arrows).</div><div class=\"graphic_reference\">Courtesy of Douglas Hartman, MD.</div><div id=\"graphicVersion\">Graphic 87750 Version 1.0</div></div></div>"},"87751":{"type":"graphic_picture","displayName":"Collagenous colitis high power histology","title":"Collagenous colitis high power histology","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Collagenous colitis high power histology</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/GAST/87751_Collagenou_colitis_histo_7B.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power view of&nbsp;a random&nbsp;colon biopsy specimen in a patient with collagenous colitis&nbsp;reveals lymphocytic infiltration of the superficial epithelium and an excess of chronic inflammatory cells in the lamina propria. The pink stripe noticed on low power view&nbsp;is subepithelial collagen deposition (arrow), which has entrapped superficial blood vessels (circle).&nbsp;</div><div class=\"graphic_reference\">Courtesy of Douglas Hartman, MD.</div><div id=\"graphicVersion\">Graphic 87751 Version 1.0</div></div></div>"},"87752":{"type":"graphic_picture","displayName":"Ischemic colitis colonoscopy","title":"Ischemic colitis ","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Ischemic colitis </div><div class=\"cntnt\"><img style=\"width:598px; height:224px;\" src=\"images/GAST/87752_Ischem_colitis_sigmoid_8AB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Colonoscopy in a patient with ischemic colitis reveals&nbsp;long shallow ulcers in the descending colon and&nbsp;splenic flexure (panels A and B).</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD.</div><div id=\"graphicVersion\">Graphic 87752 Version 1.0</div></div></div>"},"87753":{"type":"graphic_picture","displayName":"Ischemic colitis histology","title":"Ischemic colitis histology","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Ischemic colitis histology</div><div class=\"cntnt\"><img style=\"width:598px; height:266px;\" src=\"images/GAST/87753_Ischemic_colitis_histol_AB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">At low power (panel A), there are two biopsy fragments, one of which is normal colonic mucosa (bottom)&nbsp;while the other fragment (top)&nbsp;is hemorrhagic and has cleared out spaces within the fragment. At higher power (panel B), this hemorrhagic fragment has sloughed epithelial cells within the cleared out spaces. There is chronic inflammation within the lamina propria. The cleared out spaces represent ghosts of colonic glands that have undergone ischemia.</div><div class=\"graphic_reference\">Courtesy of Douglas Hartman, MD.</div><div id=\"graphicVersion\">Graphic 87753 Version 1.0</div></div></div>"},"87754":{"type":"graphic_picture","displayName":"Clostridium difficile colitis colonoscopy","title":"Clostridium difficile colitis ","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Clostridium difficile colitis </div><div class=\"cntnt\"><img style=\"width:598px; height:237px;\" src=\"images/GAST/87754_Clos_diff_colit_sigmoid_9AB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Endoscopic appearance of Clostridium difficile (C. difficile) colitis (panels A and B)&nbsp;with diffuse pseudomembranes through the examined&nbsp;colon with scant areas of visible colonic mucosa. While pseudomembranes are not diagnostic of C. difficile colitis, in the appropriate clinical setting, visualization of pseudomembranes&nbsp;nearly always reflects a C. difficile infection.</div><div class=\"graphic_reference\">Courtesy of Andres Gelrud, MD.</div><div id=\"graphicVersion\">Graphic 87754 Version 1.0</div></div></div>"},"87755":{"type":"graphic_picture","displayName":"Clostridium difficile colitis low power histology","title":"Clostridium difficile colitis low power histology","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Clostridium difficile colitis low power histology</div><div class=\"cntnt\"><img style=\"width:576px; height:433px;\" src=\"images/GAST/87755_Clost_diffic_colitis_hist_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low power showing viable colonic mucosa (solid bracket), ischemic colonic mucosa (dashed bracket), and pseudomembrane (dotted bracket) present on the surface.</div><div class=\"graphic_reference\">Courtesy of Douglas Hartman, MD.</div><div id=\"graphicVersion\">Graphic 87755 Version 1.0</div></div></div>"},"87756":{"type":"graphic_picture","displayName":"Clostridium difficile colitis high power histology","title":"Clostridium difficile colitis high power histology","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Clostridium difficile colitis high power histology</div><div class=\"cntnt\"><img style=\"width:576px; height:431px;\" src=\"images/GAST/87756_Clost_diffic_colitis_hist_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High power showing the component of the pseudomembrane: fibrin (concentrated within bracket and intermingled with inflammatory cells) and acute inflammatory cells (solid circles). The ischemic glands (dashed circle) can be seen adjacent to the viable glands (dotted circle).</div><div class=\"graphic_reference\">Courtesy of Douglas Hartman, MD.</div><div id=\"graphicVersion\">Graphic 87756 Version 1.0</div></div></div>"},"87757":{"type":"graphic_table","displayName":"Response criteria MF and SS","title":"Response criteria in mycosis fungoides and SÃ©zary syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Response criteria in mycosis fungoides and S&eacute;zary syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"6\">Response in specific tissues</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"2\">Location</td> <td class=\"subtitle2\" colspan=\"2\">Response</td> <td class=\"subtitle2\" colspan=\"2\">Definition</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\" colspan=\"2\">Skin*</td> <td colspan=\"2\">CR</td> <td colspan=\"2\">100 percent clearance of skin lesions.<sup>&#182;</sup></td> </tr> <tr> <td colspan=\"2\">PR</td> <td colspan=\"2\">50 to 99 percent clearance of skin disease from baseline without new tumors (T3) in patients with T1, T2, or T4 only skin disease.</td> </tr> <tr> <td colspan=\"2\">SD</td> <td colspan=\"2\">&#60;25 percent increase to &#60;50 percent clearance in skin disease from baseline without new tumors (T3) in patients with T1, T2, or T4 only skin disease.</td> </tr> <tr> <td colspan=\"2\">PD<sup>&#916;</sup></td> <td colspan=\"2\"> <p>&#8805;25 percent increase in skin disease from baseline; OR</p> <p>New tumors (T3) in patients with T1, T2, or T4 only skin disease; OR</p> Loss of response: in those with complete or partial response, increase of skin score of greater than the sum of nadir plus 50 percent baseline score.</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">Relapse</td> <td colspan=\"2\">Any disease recurrence in those with complete response.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\" colspan=\"2\">Lymph nodes<sup>&#9674;</sup></td> <td colspan=\"2\">CR</td> <td colspan=\"2\">All lymph nodes are now &#8804;1.5 cm in greatest transverse (long axis) diameter by method used to assess lymph nodes at baseline or biopsy negative for lymphoma; in addition, lymph nodes that were N3 classification and &#8804;1.5 cm in their long axis and &#62;1 cm in their short axis at baseline, must now be &#8804;1 cm in their short axis or biopsy negative for lymphoma.</td> </tr> <tr> <td colspan=\"2\">PR</td> <td colspan=\"2\">Cumulative reduction &#8805;50 percent of the SPD of each abnormal lymph node at baseline and no new lymph node &#62;1.5 cm in the diameter of the long axis or &#62;1 cm in the diameter of the short axis if the long axis is 1 to 1.5 cm diameter.</td> </tr> <tr> <td colspan=\"2\">SD</td> <td colspan=\"2\">Fails to attain the criteria for CR, PR, and PD.</td> </tr> <tr> <td colspan=\"2\">PD<sup>&#916;</sup></td> <td colspan=\"2\"> <p>&#8805;50 percent increase in SPD from baseline of lymph nodes; OR</p> <p>Any new node &#62;1.5 cm in the long axis or &#62;1 cm in the short axis if 1 to 1.5 cm in the long axis that is proven to be N3 histologically; OR</p> Loss of response: &#62;50 percent increase from nadir in SPD of lymph nodes in those with PR.</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">Relapse</td> <td colspan=\"2\">Any new lymph node &#62;1.5 cm in the long axis in those with CR proven to be N3 histologically.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\" colspan=\"2\">Viscera</td> <td colspan=\"2\">CR</td> <td colspan=\"2\">Liver or spleen or any organ considered involved at baseline should not be enlarged on physical exam and should be considered normal by imaging; no nodules should be present on imaging of liver or spleen; any post treatment mass must be determined by biopsy to be negative for lymphoma.</td> </tr> <tr> <td colspan=\"2\">PR</td> <td colspan=\"2\">&#8805;50 percent regression in any splenic or liver nodules, or in measureable disease (SPD) in any organs abnormal at baseline; no increase in size of liver or spleen and no new sites of involvement.</td> </tr> <tr> <td colspan=\"2\">SD</td> <td colspan=\"2\">Fails to attain the criteria for CR, PR, or PD.</td> </tr> <tr> <td colspan=\"2\">PD<sup>&#916;</sup></td> <td colspan=\"2\"> <p>&#62;50 percent increase in size (SPD) of any organs involved at baseline; OR</p> <p>New organ involvement; OR</p> Loss of response: &#62;50 percent increase from nadir in the size (SPD) of any previous organ involvement in those with PR.</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">Relapse</td> <td colspan=\"2\">New organ involvement in those with CR.</td> </tr> <tr> <td rowspan=\"5\" colspan=\"2\">Blood<sup>&#167;</sup></td> <td colspan=\"2\">CR<sup>&#165;</sup></td> <td colspan=\"2\">B0</td> </tr> <tr> <td colspan=\"2\">PR<sup>&#135;</sup></td> <td colspan=\"2\">&#62;50 percent decrease in quantitative measurements of blood tumor burden from baseline in those with high tumor burden at baseline (B2).</td> </tr> <tr> <td colspan=\"2\">SD</td> <td colspan=\"2\">Fails to attain criteria for CR, PR, or PD.</td> </tr> <tr> <td colspan=\"2\">PD<sup>&#916;</sup></td> <td colspan=\"2\"> <p>B0 to B2; OR</p> <p>&#62;50 percent increase from baseline and at least 5000 neoplastic cells/microL<sup>[1]</sup>; OR</p> Loss of response: in those with PR who were originally B2 at baseline, &#62;50 percent increase from nadir and at least 5000 neoplastic cells/microL.</td> </tr> <tr> <td colspan=\"2\">Relapse</td> <td colspan=\"2\">Increase of neoplastic blood lymphocytes to &#8805;B1 in those with CR.</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"6\">Global response score</td> </tr> <tr> <td class=\"subtitle2\">Global score<sup>&#134;</sup></td> <td class=\"subtitle2\">Definition</td> <td class=\"subtitle2\">Skin</td> <td class=\"subtitle2\">Nodes</td> <td class=\"subtitle2\">Blood</td> <td class=\"subtitle2\">Viscera</td> </tr> <tr class=\"divider_bottom\"> <td>CR</td> <td>Complete disappearance of all clinical evidence of disease</td> <td>CR</td> <td colspan=\"3\">All categories have CR/NI.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">PR</td> <td class=\"divider_bottom\" rowspan=\"2\">Regression of measurable disease</td> <td>CR</td> <td colspan=\"3\">All categories do not have a CR/NI and no category has a PD.</td> </tr> <tr class=\"divider_bottom\"> <td>PR</td> <td colspan=\"3\">No category has a PD and if any category involved at baseline, at least one has a CR or PR.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">SD</td> <td class=\"divider_bottom\" rowspan=\"2\">Failure to attain CR, PR, or PD representative of all disease</td> <td>PR</td> <td colspan=\"3\">No category has a PD and if any category involved at baseline, no CR or PR in any.</td> </tr> <tr class=\"divider_bottom\"> <td>SD</td> <td colspan=\"3\">CR/NI, PR, SD in any category and no category has a PD.</td> </tr> <tr class=\"divider_bottom\"> <td>PD</td> <td>Progressive disease</td> <td colspan=\"4\">PD in any category.</td> </tr> <tr> <td>Relapse</td> <td>Recurrence disease in prior CR</td> <td colspan=\"4\">Relapse in any category.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; SPD: sum of the maximum linear dimension (major axis) X longest perpendicular dimension (minor axis); NI: noninvolved.<br />* Based on modified Severity Weighted Assessment Tool score.<br />Â¶ A biopsy of normal appearing skin is unnecessary to assign a complete response. However, a skin biopsy should be performed of a representative area of the skin if there is any question of residual disease (persistent erythema or pigmentary change) where otherwise a complete response would exist. If histologic features are suspicious or suggestive of mycosis fungoides/SÃ©zary syndrome (see histologic criteria for early mycosis fungoides<SUP>[2]</SUP>), the response should be considered a partial response only.<br />Î Whichever criterion occurs first.<br /><FONT class=lozenge>â</FONT> Peripheral and central lymph nodes.<br />Â§ As determined by absolute numbers of neoplastic cells/microL.<br />Â¥ If a bone marrow biopsy was performed at baseline and determined to unequivocally be indicative of lymphomatous involvement, then to confirm a global CR where blood assessment now meets criteria for B0, a repeat bone marrow biopsy must show no residual disease or the response should be considered a PR only.<br />â¡ There is no PR in those with B1 disease at baseline as the difference within the range of neoplastic cells that define B1 is not considered significant and should not affect determination of global objective response.<br />â  It is recommended that not only the proportion of patients who achieve a response or an unfavorable outcome be calculated but a life table account for the length of the interval during which each patient is under observation also be generated.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 1996; 87:4990.</li>&#xD;&#xA;    <li>Sacks H, Chalmers TC, Smith H Jr. Randomized versus historical controls for clinical trials. Am J Med 1982; 72:233.</li>&#xD;&#xA;</ol>&#xD;&#xA;From: Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and S&eacute;zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2011; 29:2598-607. Reprinted with permission. Copyright &copy; 2011 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87757 Version 3.0</div></div></div>"},"87759":{"type":"graphic_figure","displayName":"Genetic polymorphisms obesity risk","title":"Genetic polymorphisms associated with obesity risk","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Genetic polymorphisms associated with obesity risk</div><div class=\"cntnt\"><img style=\"width:572px; height:510px;\" src=\"images/ENDO/87759_Gen_polymorphism_obes_risk.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Obesity-susceptible loci discovered in four waves of genome-wide association studies for BMI (blue), three waves of genome-wide association studies for waist circumference (purple)&nbsp;and WHRadj (red), and two waves of genome-wide association studies for extreme and early-onset of obesity (green). Each Venn diagram represents the loci of one paper.</div><div class=\"graphic_footnotes\">BMI: body mass index; WHRadj: waist-to-hip ratio (adjusted).</div><div class=\"graphic_reference\">Reproduced from: Loos RJF. The genetic determinants of common obesity-susceptibility. In: Adipose tissue biology. Symonds ME (Ed), New York, Springer 2011. Copyright &copy; 2011; with kind permission from Springer Science + Business Media B.V.</div><div id=\"graphicVersion\">Graphic 87759 Version 3.0</div></div></div>"},"87760":{"type":"graphic_table","displayName":"Bone turnover markers","title":"Bone turnover markers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bone turnover markers</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Resorption markers</td> </tr> <tr> <td class=\"subtitle2_single\">Type I collagen degradation products</td> </tr> <tr> <td class=\"indent1\">Pyridinium crosslinks (PYD and DPD)</td> </tr> <tr> <td class=\"indent1\">C- and N-telopeptides (CTX, ICTP, NTX)</td> </tr> <tr> <td class=\"subtitle2_single\">Enzymes</td> </tr> <tr> <td class=\"indent1\">Tartrate-resistant acid phosphatase (TRACP) 5b*</td> </tr> <tr> <td class=\"indent1\">Cathepsin K</td> </tr> <tr> <td class=\"indent1\">Matrix metalloproteinases (MMPs)</td> </tr> <tr> <td class=\"subtitle1_single\">Formation markers</td> </tr> <tr> <td class=\"subtitle2_single\">Matrix proteins</td> </tr> <tr> <td class=\"indent1\">Procollagen type I propeptides</td> </tr> <tr> <td class=\"indent2\">C-terminal (PICP)</td> </tr> <tr> <td class=\"indent2\">N-terminal (PINP)*</td> </tr> <tr> <td class=\"indent1\">Osteocalcin (OC)</td> </tr> <tr> <td class=\"subtitle2_single\">Enzymes</td> </tr> <tr> <td class=\"indent1\">Bone isoform of alkaline phosphatase (BALP)*</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Not cleared by the kidney.</div><div class=\"graphic_reference\">Source: Leeming DJ, Alexandersen P, Karsdal MA, et al. An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice. Eur J Clin Pharmacol 2006; 62:781.</div><div id=\"graphicVersion\">Graphic 87760 Version 4.0</div></div></div>"},"87761":{"type":"graphic_table","displayName":"Causes of elevated BSAP","title":"Causes of elevated bone-specific alkaline phosphatase","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of elevated bone-specific alkaline phosphatase</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Severe hyperparathyroidism</td> </tr> <tr> <td>Hyperthyroidism</td> </tr> <tr> <td>Paget disease of bone</td> </tr> <tr> <td>Metastatic carcinoma to bone</td> </tr> <tr> <td>Osteomalacia</td> </tr> <tr> <td>Severe 25-hydroxyvitamin D deficiency (&#60;10 ng/mL)</td> </tr> <tr> <td>Recent large bone fracture</td> </tr> <tr> <td>Immobilization/space travel</td> </tr> <tr> <td>Treatment with teriparatide or 1-84 parathyroid hormone</td> </tr> <tr> <td>High bone turnover osteoporosis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Source: Miller PD. Unrecognized and unappreciated secondary causes of osteoporosis. Endocrinol Metab Clin North Am 2012; 41:613.</div><div id=\"graphicVersion\">Graphic 87761 Version 2.0</div></div></div>"},"87762":{"type":"graphic_diagnosticimage","displayName":"Brain MRI findings in leptomeningeal metastases","title":"Brain MRI findings in a patient with leptomeningeal metastases","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Brain MRI findings in a patient with leptomeningeal metastases</div><div class=\"cntnt\"><img style=\"width:527px; height:596px;\" src=\"images/RADIOL/87762_Lepto_metas_pat_medullo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brain magnetic resonance imaging (MRI) of a patient with medulloblastoma (*) with leptomeningeal dissemination. Pre (A) and post (B, C) contrast T1-weighted sequences in the axial (A, B) and coronal planes (C) demonstrate diffuse leptomeningeal enhancement tracking along the cerebellar folia (arrows). Subtle nodular leptomeningeal enhancement is also visible in the cerebral hemispheres (arrowheads).</div><div class=\"graphic_reference\">Courtesy of Joseph Farnam, MD.</div><div id=\"graphicVersion\">Graphic 87762 Version 2.0</div></div></div>"},"87763":{"type":"graphic_diagnosticimage","displayName":"Sagittal brain MRI in leptomeningeal metastases","title":"Sagittal brain MRI in a patient with leptomeningeal metastases","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Sagittal brain MRI in a patient with leptomeningeal metastases</div><div class=\"cntnt\"><img style=\"width:597px; height:304px;\" src=\"images/RADIOL/87763_Met_lept_dis_medull_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brain magnetic resonance imaging in a patient with medulloblastoma (arrow) with leptomeningeal dissemination. Pre (A) and post contrast (B) T1-weighted sequences demonstrate diffuse abnormal enhancement involving the leptomeninges of the cerebellum (arrowhead) and the ventral surface of the brainstem (dashed arrow).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging. </div><div class=\"graphic_reference\">Courtesy of Joseph Farnam, MD.</div><div id=\"graphicVersion\">Graphic 87763 Version 2.0</div></div></div>"},"87764":{"type":"graphic_diagnosticimage","displayName":"Barium enema cecal volvulus ","title":"Barium enema cecal volvulus ","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Barium enema cecal volvulus </div><div class=\"cntnt\"><img style=\"width:598px; height:324px;\" src=\"images/RADIOL/87764_Barium_enema_cecal_volv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The single-contrast barium enema (A) shows a contrast column reaching the region of the cecum via the decompressed descending colon, transverse colon, and ascending colon. As it reaches the region of the cecum, it is obstructed, manifesting with beak-shaped morphology (arrow) with no contrast entering the air-filled and distended cecum (between arrowheads). In B, the site of the volvulus is again noted (arrow). These findings confirm the diagnosis of a cecal volvulus.</div><div id=\"graphicVersion\">Graphic 87764 Version 2.0</div></div></div>"},"87765":{"type":"graphic_diagnosticimage","displayName":"Scout and coronal computerized tomography cecal volvulus","title":"Scout and coronal computerized tomography (CT) cecal volvulus","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Scout and coronal computerized tomography (CT) cecal volvulus</div><div class=\"cntnt\"><img style=\"width:598px; height:438px;\" src=\"images/RADIOL/87765_Scout_coron_com_tom_vol.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The scout film (A) shows a dilated cecum (arrow). The CT scan reformatted in the coronal plane (B) shows a large air pocket trapped in the cecal volvulus (arrow).</div><div id=\"graphicVersion\">Graphic 87765 Version 1.0</div></div></div>"},"87766":{"type":"graphic_diagnosticimage","displayName":"Computerized tomography cecal volvulus","title":"Computerized tomography (CT) cecal volvulus","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Computerized tomography (CT) cecal volvulus</div><div class=\"cntnt\"><img style=\"width:599px; height:235px;\" src=\"images/RADIOL/87766_Comp_tomo_cecil_volvul.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The axial CT scan (A) shows an air contrast level trapped in the dilated cecum (arrow). In image B the counterclockwise \"whirl sign\" is evident (arrowhead).</div><div id=\"graphicVersion\">Graphic 87766 Version 1.0</div></div></div>"},"87767":{"type":"graphic_diagnosticimage","displayName":"Multicentric Castleman disease imaging","title":"Multicentric Castleman disease","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Multicentric Castleman disease</div><div class=\"cntnt\"><img style=\"width:598px; height:375px;\" src=\"images/RADIOL/87767_Multicentcastlemandis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The&nbsp;posteroanterior&nbsp;(PA) chest x-ray is from a 45-year-old male who presented after falling off a ladder. A mass is noted in the region of the right costophrenic angle (arrow). A diagnosis of multicentric Castleman disease was made after computed tomography (CT) scan and pathological examination. <br />(B)&nbsp;A vascular mass in the right posterior sulcus (arrow). <br />(C)&nbsp;A coronally reconstructed view of the right sided mass.</div><div class=\"graphic_reference\">Courtesy of Priscilla J Slanetz, MD, MPH, FACR.</div><div id=\"graphicVersion\">Graphic 87767 Version 3.0</div></div></div>"},"87768":{"type":"graphic_table","displayName":"Pediatric renal angina criteria","title":"Pediatric renal angina criteria","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pediatric renal angina criteria</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Level of risk based on clinical status</td> <td class=\"subtitle1\">Renal angina threshold</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Moderate-risk patients</td> </tr> <tr> <td class=\"indent1\">Patients admitted to PICU</td> <td> <p>Doubling of serum Cr</p> <p><strong>OR</strong></p> <p>eCrCl decrease &#62;50 percent</p> <p><strong>OR</strong></p> ICU fluid overload &#62;15 percent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">High-risk patients</td> </tr> <tr> <td class=\"indent1\"> <p>Acute decompensated heart failure</p> Stem cell transplant recipient</td> <td> <p>Serum Cr increase &#8805;0.3 mg/dL</p> <p><strong>OR</strong></p> <p>eCrCl decrease 25 to 50 percent</p> <p><strong>OR</strong></p> ICU fluid overload &#62;10 percent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Very-high-risk patients</td> </tr> <tr> <td class=\"indent1\">Receiving mechanical ventilation and one or more vasoactive medications</td> <td> <p>Any serum Cr increase</p> <p><strong>OR</strong></p> <p>eCrCl decrease &#62;25 percent</p> <p><strong>OR</strong></p> ICU fluid overload &#62;5 percent</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PICU: pediatric intensive care unit; Cr: creatinine; eCrCl: estimated creatinine clearance; ICU: intensive care unit.</div><div class=\"graphic_reference\">Reproduced from: Basu RK, Chawla LS, Wheeler DS, et al. Renal angina: an emerging paradigm to identify children at risk for acute kidney injury. Pediatr Nephrol 2012; 27:1067. Copyright &copy; 2012; with kind permission from Springer Science + Business Media B.V.</div><div id=\"graphicVersion\">Graphic 87768 Version 3.0</div></div></div>"},"87769":{"type":"graphic_table","displayName":"Reducing the supply of fibril precursors in systemic amyloidosis","title":"Reducing the supply of fibril precursors in systemic amyloidosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Reducing the supply of fibril precursors in systemic amyloidosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disease</td> <td class=\"subtitle1\">Aim of treatment</td> <td class=\"subtitle1\">Example of treatment</td> </tr> <tr> <td>AA amyloidosis</td> <td>Suppress the acute phase response and thereby reduce the production of serum amyloid A protein</td> <td> <p>Anti-inflammatory and immunosuppressive therapy in patients with rheumatoid arthritis and Crohn disease (eg, anti-TNF antibodies, humanized anti-IL6 receptor antibody)</p> <p>Colchicine for patients with familial Mediterranean fever</p> Surgery for patients with osteomyelitis and rare cytokine-producing tumors</td> </tr> <tr> <td>AL amyloidosis</td> <td>Suppress production of monoclonal immunoglobulin light chains</td> <td>Chemotherapy directed at plasma cell dyscrasia</td> </tr> <tr> <td>Hereditary amyloidosis</td> <td>Eliminate source of genetically variant protein</td> <td>Orthotopic liver transplantation for patients with familial amyloid polyneuropathy secondary to variant transthyretin or renal amyloidosis secondary to variant fibrinogen A &#945;-chain</td> </tr> <tr> <td>&#946;<sub>2</sub>-microglobulin amyloidosis</td> <td>Reduce plasma concentration of &#946;<sub>2</sub>-microglobulin</td> <td>Renal transplantation</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted by permission from: Macmillan Publishers Ltd: Nature Clinical Practice Nephrology. Gillmore JD, Hawkins PN. Drug insight: Emerging therapies for amyloidosis. Nat Clin Pract Nephrol 2006; 2:263. Copyright &copy; 2006. <a href=\"http://www.nature.com/nrneph\" target=\"_blank\">www.nature.com/nrneph</a>.</div><div id=\"graphicVersion\">Graphic 87769 Version 3.0</div></div></div>"},"87770":{"type":"graphic_figure","displayName":"Clinical and genomic features of medulloblastoma subgroups","title":"Clinical and genomic features of medulloblastoma subgroups*","html":"<div class=\"graphic\"><div style=\"width: 655px\" class=\"figure\"><div class=\"ttl\">Clinical and genomic features of medulloblastoma subgroups*</div><div class=\"cntnt\"><img style=\"width:635px; height:633px;\" src=\"images/NEURO/87770_Clin_genom_feat_medull_sub.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">%: percent;<EM> BCOR</EM>: BCL6 co-repressor;<EM> CDK6</EM>: cyclin-dependent kinase 6; CGNPs: cerebellar granule neuron precursors; <EM>CTDNEP1</EM>: CTD nuclear envelope phosphatase 1; <EM>CTNNB1</EM>: Î²-catenin; EGL: external granule cell layer; <EM>GLI2</EM>: GLI family zinc finger 2; <EM>KDM6A</EM>: lysine-specific demethylase 6A; LCA: large cell and anaplastic; <EM>LDB1</EM>: LIM domain binding 1; <EM>LRP1B</EM>: low density lipoprotein receptor-related protein 1B; MBEN: medulloblastoma with extensive nodularity; MLL: mixed lineage leukaemia; <EM>OTX2</EM>: orthodenticle homeobox 2; <EM>PTCH1</EM>: patched 1; SCNA: somatic copy number aberration; SHH: sonic hedgehog; <EM>SNCAIP</EM>: Î±-synuclein interacting protein; <EM>SPTB</EM>: spectrin-Î² erythrocytic; SVZ: subventricular zone; <EM>TCF4</EM>: transcription factor 4; <EM>TNXB</EM>: tenascin XB.<BR>* Subgroup frequency, demographics, clinical features and cytogenetic profiles were derived from a cohort of 827 medulloblastomas distributed into subgroups described by Northcott et al. (2012).<BR>Î Driver genes are determined by the relative frequency of mutations or SCNAs affecting the genes in each subgroup, as described in recent medulloblastoma sequencing and copy number studies.</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd: Nature Reviews Cancer. Northcott PA, Jones DT, Kool M, et al. Medulloblastomics: the end of the beginning. Nat Rev Cancer 2012; 12:818. Copyright &copy; 2012. <a href=\"http://www.nature.com/nrc\" style=\"font-style: italic;\" target=\"_blank\">www.nature.com/nrc</a>.</div><div id=\"graphicVersion\">Graphic 87770 Version 1.0</div></div></div>"},"87774":{"type":"graphic_diagnosticimage","displayName":"Meckels diverticulitis","title":"Meckels diverticulitis","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Meckels diverticulitis</div><div class=\"cntnt\"><img style=\"width:597px; height:347px;\" src=\"images/RADIOL/87774_Meckels_diverticulitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The abdominal CT scan in this 82-year-old patient with Meckel's diverticulitis demonstrates an air-filled diverticulum (arrow) surrounded by significant induration (arrowhead). A stone is demonstrated within the diverticulum (dashed arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography<BR></div><div id=\"graphicVersion\">Graphic 87774 Version 1.0</div></div></div>"},"87775":{"type":"graphic_diagnosticimage","displayName":"Bleeding Meckels diverticulum on CT scan","title":"Bleeding Meckels diverticulum on CT scan","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Bleeding Meckels diverticulum on CT scan</div><div class=\"cntnt\"><img style=\"width:598px; height:317px;\" src=\"images/RADIOL/87775_Bleed_Meck_div_CT_scan.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hemorrhage into a Meckel's diverticulum is demonstrated by high-density material within the diverticulum (arrow in A and B).</div><div id=\"graphicVersion\">Graphic 87775 Version 1.0</div></div></div>"},"87777":{"type":"graphic_diagnosticimage","displayName":"Ruptured Meckels diverticulum on CT","title":"Ruptured Meckel's diverticulum on CT","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">Ruptured Meckel's diverticulum on CT</div><div class=\"cntnt\"><img style=\"width:597px; height:436px;\" src=\"images/RADIOL/87777_Rupt_Meckel_divert_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 21-year-old male had a surgically proven ruptured Meckel's diverticulum. The nonspecific CT findings include induration of the omentum (arrow) with bubbles of free air noted in the subumbilical region (arrowhead) suggesting a ruptured viscus. A thick walled bowel loop with contrast in the lumen noted in image C (short arrow) was thought to represent a focal region of abnormal small bowel, and likely represented the ruptured Meckel's diverticulum. Free fluid is noted in the cul de sac (dashed arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 87777 Version 2.0</div></div></div>"},"87778":{"type":"graphic_picture","displayName":"Trophozoites of Naegleria fowleri","title":"Trophozoites of <em>Naegleria fowleri</em>","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Trophozoites of <em>Naegleria fowleri</em></div><div class=\"cntnt\"><img style=\"width:401px; height:310px;\" src=\"images/ID/87778_Trophozoites_Naegleria_fowl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a Wright's stain of cerebrospinal fluid from the patient drawn at the time of hospital admission (A, bar = 100 microns), an ameba is visible in the center of the field, indicated by the arrow, and abundant polymorphonuclear cells are present. Brain tissue stained with hematoxylin and eosin (B, bar = 10 microns and C, bar = 100 microns) demonstrates perivascular amebic infiltrates and an amebic micro-abscess with surrounding tissue necrosis. Examples of amebae are indicated by the arrows. <em>Naegleria fowleri</em>&ndash;specific immunofluorescent antibody staining (D, bar = 10 microns) highlights amebic infiltrates.</div><div class=\"graphic_reference\">From: Kemble SK, Lynfield R, DeVries AS, et al. Fatal Naegleria fowleri infection acquired in Minnesota: Possible expanded range of a deadly thermophilic organism. Clin Infect Dis 2012; 54:805. By permission of the Infectious Diseases Society of America . Copyright &copy; 2013 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 87778 Version 2.0</div></div></div>"},"87779":{"type":"graphic_diagnosticimage","displayName":"CT imaging of a patient with PAM","title":"CT imaging of a patient with PAM","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">CT imaging of a patient with PAM</div><div class=\"cntnt\"><img style=\"width:583px; height:389px;\" src=\"images/ID/87779_CT_img_of_a_patient_wt_PAM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Arrow, A) Contrast-enhanced CT brain scan shows right basal ganglia infarction.<br />(Arrowhead, B) Enhancing exudates in the perimesencephalic cistern.</div><div class=\"graphic_footnotes\">CT: computed tomography; PAM: primary amebic meningoencephalitis.</div><div class=\"graphic_reference\">Reproduced with permission from: the American Society of Neuroradiology, Singh P, Kochhar R, Vashista RK, et al. Amebic meningoencephalitis: Spectrum of imaging findings. Am J Neuroradiol 2006; 27:1217; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 87779 Version 2.0</div></div></div>"},"87780":{"type":"graphic_picture","displayName":"Pathological findings in PAM","title":"Pathological findings in PAM","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pathological findings in PAM</div><div class=\"cntnt\"><img style=\"width:275px; height:508px;\" src=\"images/GAST/87780_Pathological_findings_PAM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Section of brain from a case of primary meningoencephalitis caused by <em>Naegleria fowleri</em>. A portion of a blood vessel (B) and the surrounding perivascular region are seen. Numerous trophic amoebae are present in the perivascular space. Hematoxylin-eosin stain. Bar measures 12 microm.</div><div class=\"graphic_footnotes\">PAM: primary amebic meningoencephalitis.</div><div class=\"graphic_reference\">Reproduced from: Schuster FL, Visvesvara GS. Free-living ameoebae as opportunistic and non-opportunistic pathogens of humans and animals. Int J Parasitol 2004; 34:1001. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87780 Version 1.0</div></div></div>"},"87781":{"type":"graphic_picture","displayName":"Cyst of Acanthamoeba in brain tissue","title":"Cyst of <em>Acanthamoeba</em> in brain tissue","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Cyst of <em>Acanthamoeba</em> in brain tissue</div><div class=\"cntnt\"><img style=\"width:576px; height:383px;\" src=\"images/ID/87781_Cyst_Acanthamoeba_brain.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photomicrograph depicted a magnified view of brain tissue within which was a centrally located <EM>Acanthamoeba</EM> spp cyst. <EM>Acanthamoeba</EM> spp are opportunistic free-living amebae, capable of causing granulomatous amebic encephalitis in individuals with compromised immune systems.</div><div class=\"graphic_reference\">Reproduced from: The Public Health Image Library, Centers for Disease Control and Prevention. Photo by George Healy, PhD.</div><div id=\"graphicVersion\">Graphic 87781 Version 2.0</div></div></div>"},"87782":{"type":"graphic_picture","displayName":"Talar head and neck palpation","title":"Talar head and neck palpation","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Talar head and neck palpation</div><div class=\"cntnt\"><img style=\"width:513px; height:244px;\" src=\"images/EM/87782_Talar_head_neck_palpat.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Scott Koehler, MD.</div><div id=\"graphicVersion\">Graphic 87782 Version 1.0</div></div></div>"},"87783":{"type":"graphic_picture","displayName":"Talar dome palpation","title":"Talar dome palpation","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Talar dome palpation</div><div class=\"cntnt\"><img style=\"width:513px; height:178px;\" src=\"images/EM/87783_Talar_dome_palpat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To palpate the dome of the talus, the ankle is plantar flexed and palpation is performed at the lower margin of joint line between the tibia and the talus. This is proximal to the area palpated when examining the talar head.</div><div class=\"graphic_reference\">Courtesy of Scott Koehler, MD.</div><div id=\"graphicVersion\">Graphic 87783 Version 1.0</div></div></div>"},"87784":{"type":"graphic_picture","displayName":"Posterolateral palpation of talus","title":"Posterolateral palpation of talus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Posterolateral palpation of talus</div><div class=\"cntnt\"><img style=\"width:504px; height:373px;\" src=\"images/EM/87784_Posterolat_palpat_talus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Deep palpation of the posterolateral aspect of the talus is depicted.</div><div class=\"graphic_reference\">Courtesy of Scott Koehler, MD.</div><div id=\"graphicVersion\">Graphic 87784 Version 2.0</div></div></div>"},"87785":{"type":"graphic_picture","displayName":"Palpation of lateral process of talus","title":"Palpation of lateral process of talus","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Palpation of lateral process of talus</div><div class=\"cntnt\"><img style=\"width:513px; height:195px;\" src=\"images/EM/87785_Palp_lateral_proce_tal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lateral process of the talus is best palpated at the anterior aspect of the inferior margin of the lateral malleolus, as shown in the photograph.</div><div class=\"graphic_reference\">Courtesy of Scott Koehler, MD.</div><div id=\"graphicVersion\">Graphic 87785 Version 1.0</div></div></div>"},"87786":{"type":"graphic_picture","displayName":"Palpation of posteromedial talus","title":"Palpation of posteromedial talus","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Palpation of posteromedial talus</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/EM/87786_Palpation_postero_talus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">As with the lateral talus, palpation of the medial talus is performed at the posterior, inferior, and anterior margins of the malleolus. Deep palpation posterior to the medial malleolus is shown in the photograph.</div><div class=\"graphic_reference\">Courtesy of Scott Koehler, MD.</div><div id=\"graphicVersion\">Graphic 87786 Version 1.0</div></div></div>"},"87788":{"type":"graphic_diagnosticimage","displayName":"Radiologic imaging in Balamuthia mandrillaris amebic infection","title":"Radiologic imaging in <EM>Balamuthia mandrillaris </EM>amebic infection","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Radiologic imaging in <EM>Balamuthia mandrillaris </EM>amebic infection</div><div class=\"cntnt\"><img style=\"width:457px; height:237px;\" src=\"images/ID/87788_Radiol_ima_ameb_infect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) Brain MRI showing a focal lesion surrounded by edema on the left temporal lobe that uptakes the gadolinium contrast on the T1-weighted image.<br />(Panel B) Brain MRI showing two hyperintense focal lesions located on the left frontal and temporal lobes on the fluid attenuated inversion recovery (FLAIR) sequence.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 87788 Version 2.0</div></div></div>"},"87790":{"type":"graphic_table","displayName":"Paclitaxel carboplatin ovarian","title":"Weekly paclitaxel with every three week carboplatin chemotherapy for advanced ovarian cancer<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Weekly paclitaxel with every three week carboplatin chemotherapy for advanced ovarian cancer<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Carboplatin</td> <td>AUC* = 6 mg/mL per min</td> <td>Dilute in 250 mL normal saline (NS) and administer over one hour.<sup>&#182;</sup></td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Paclitaxel</td> <td>80 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL NS and administer over one hour (final concentration range 0.3 to 1.2 mg/mL); special tubing needed.<sup>&#916;</sup><sup>[2]</sup></td> <td>Days 1, 8, and 15</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE on day 1;<br /> LOW on days 8 and 15.</li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Premedicate with dexamethasone plus both an H1 and an H2 receptor antagonist prior to paclitaxel administration.</li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Carboplatin is an irritant. Paclitaxel can cause significant tissue damage; avoid extravasation.</li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF is not recommended (risk of febrile neutropenia approximately 9%<sup>[1]</sup>).</li> <li>Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Each carboplatin dose should be calculated based upon renal function by use of the Calvert formula.*</li> <li>Refer to UpToDate topic on \"Dosing of anticancer agents in adults\".</li> <li>A lower starting dose of paclitaxel may be needed in patients with liver impairment.<sup>[2]</sup></li> <li>Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential weekly.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Serum electrolytes and liver and renal function prior to each new treatment cycle.</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in neurologic function prior to each new treatment cycle.</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Initiation of each new treatment cycle should be delayed until the ANC is &#62;1000 cells/microL and/or for a platelet count &#62;75,000/microL. The day 8 and 15 doses of paclitaxel should be omitted for an ANC &#60;500 cells/microL and/or for a platelet count &#60;50,000/microL. The day 1 carboplatin dose should be decreased to AUC 5 mg/mL per min for febrile neutropenia, ANC &#60;500 cells/microL for seven or more days, platelet count &#60;10,000/microL, platelet count between 10,000 and 50,000/microL with bleeding, or any intracycle hematologic toxicity resulting in a treatment delay for longer than one week. If these hematologic toxicities recur despite carboplatin dose reduction to AUC 5 mg/mL per min, reduce carboplatin dose to AUC 4 mg/mL per min for subsequent cycle. Discontinue treatment for failure to recover adequate blood counts within three weeks.</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Renal/hepatic toxicity</strong></td> <td colspan=\"3\"> <ul> <li>Alterations in renal function during therapy may require a recalculation of the carboplatin dose.<sup>[3]</sup> Paclitaxel dose may need to be adjusted for hepatic impairment on day 1 of each cycle.</li> <li>Refer to UpToDate topics on \"Dosing of anticancer agents in adults\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Neurotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>For &#8805;grade 2 peripheral neuropathy, reduce paclitaxel dose to 70 mg/m<sup>2</sup> for all subsequent doses.<sup>[1]</sup> If neuropathy persists or recurs despite dose reduction, paclitaxel should be further reduced to 60 mg/m<sup>2</sup>.</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte colony-stimulating factors; CBC: complete blood count; ANC: absolute neutrophil count.<br />* AUC (area under the dose-concentration Ã time curve) is converted to a patient-specific carboplatin dose (in mg) according to renal function by using the Calvert formula. The Calvert formula is total dose (mg) = (target AUC) Ã (glomerular filtration rate [GFR] + 25). If using measured serum creatinine, limit the maximal GFR for the calculation to 125 mL/min. Refer to UpToDate topic on \"Dosing of anticancer agents in adults\".<br />Â¶ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />Î Paclitaxel can be administered in NS, 5% dextrose in water (D5W) or NS/D5W at varying concentrations between 0.3 to 1.2 mg/mL. Use glass or polypropylene bottles or polypropylene or polyolefin plastic bags, and administer through polyethylene-line administration sets with a microporous membrane 0.22 microns or less.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Katsumata N, et al. Lancet 2009; 374:1331.</LI>&#xD;&#xA;<LI>Paclitaxel injection. United States Prescribing Information. US National Library of Medicine. (Available online at http://dailymed.nlm.nih.gov, accessed May 16, 2012).</LI>&#xD;&#xA;<LI>Carboplatin injection. United States Prescribing Information. US National Library of Medicine. (Available online at http://dailymed.nlm.nih.gov, accessed May 16, 2012).</LI></OL></div><div id=\"graphicVersion\">Graphic 87790 Version 8.0</div></div></div>"},"87791":{"type":"graphic_picture","displayName":"Erythroderma histology","title":"Histologic features of erythroderma associated with cutaneous T cell lymphoma or inflammatory dermatoses","html":"<div class=\"graphic\"><div style=\"width: 477px\" class=\"figure\"><div class=\"ttl\">Histologic features of erythroderma associated with cutaneous T cell lymphoma or inflammatory dermatoses</div><div class=\"cntnt\"><img style=\"width:457px; height:515px;\" src=\"images/DERM/87791_Erythrodermahistology.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Morphologic features in representative samples of erythrodermic CTCL and inflammatory dermatoses. A, C, and E show examples of erythrodermic CTCL, whereas B, D, and F are from the EID group.<BR>(A) In this SS, skin biopsy did not allow a definite diagnosis, only showing a perivascular lymphocytic infiltrate without atypical lymphocyte, with an overlying hyperplastic and parakeratotic epidermis with slight spongiosis.<BR>(B) In this erythrodermic drug reaction sample, a common perivascular lymphocytic infiltrate is seen, whereas no interface dermatitis and no apoptotic keratinocytes are identified.<BR>(C) This SS sample shows a very discrete infiltrate in the dermis, but atypical lymphocytes and Pautrier microabcesses can be identified in the epidermis.</div><div class=\"graphic_footnotes\">CTCL: cutaneous T cell lymphoma; EID: erytrodermic inflammatory dermatoses; SS: SÃ©zary syndrome.</div><div class=\"graphic_reference\">Reproduced with permission from: Ram-Wolff C, Martin-Garcia N, Bensussan A, et al. Histopathologic diagnosis of lymphomatous versus inflammatory erythroderma: a morphologic and phenotypic study on 47 skin biopsies. Am J Dermatopathol 2010; 32:755. DOI: <A href=\"http://journals.lww.com/amjdermatopathology/Abstract/2010/12000/Histopathologic_Diagnosis_of_Lymphomatous_Versus.2.aspx\" target=_blank>10.1097/DAD.0b013e3181cfbfbf</A>. Copyright Â© 2010 International Society of Dermatopathology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 87791 Version 6.0</div></div></div>"},"87792":{"type":"graphic_picture","displayName":"Pityriasis rubra pilaris","title":"Erythroderma in pityriasis rubra pilaris","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erythroderma in pityriasis rubra pilaris</div><div class=\"cntnt\"><img style=\"width:432px; height:576px;\" src=\"images/DERM/87792_Pityriasis_rubra_pilaris.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse erythroderma with characteristic islands of sparing in a patient with pityriasis rubra pilaris.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87792 Version 3.0</div></div></div>"},"87793":{"type":"graphic_picture","displayName":"Keratoderma pityriasis rubra pilaris","title":"Palmar keratoderma in pityriasis rubra pilaris","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Palmar keratoderma in pityriasis rubra pilaris</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87793_Keratoderm_pityr_rubra_pila.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Palmar hyperkeratosis associated with pityriasis rubra pilaris.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87793 Version 3.0</div></div></div>"},"87794":{"type":"graphic_picture","displayName":"Talonavicular joint palpation","title":"Talonavicular joint palpation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Talonavicular joint palpation</div><div class=\"cntnt\"><img style=\"width:374px; height:408px;\" src=\"images/EM/87794_Talonavicular_joint_palp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The dorsal aspect of the talonavicular joint can be palpated just proximal and lateral to the medial prominence of the navicular bone.</div><div class=\"graphic_reference\">Courtesy of Scott Koehler, MD.</div><div id=\"graphicVersion\">Graphic 87794 Version 2.0</div></div></div>"},"87795":{"type":"graphic_picture","displayName":"Erythrodermic pemphigus foliaceous","title":"Pemphigus foliaceous","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Pemphigus foliaceous</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87795_Erythr_pemphigus_foliaceous.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The skin is erythrodermic and covered with large scales and crusts in this patient with pemphigus foliaceous.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87795 Version 3.0</div></div></div>"},"87796":{"type":"graphic_picture","displayName":"Pemphigus foliaceous face","title":"Pemphigus foliaceous","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Pemphigus foliaceous</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87796_Pemphigus_foliaceous_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scales and crusts on a diffuse erythematous base with bacterial superinfection in a patient with pemphigus foliaceous.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87796 Version 3.0</div></div></div>"},"87797":{"type":"graphic_figure","displayName":"Incidence of GBS in nonpregnant adults by race and age","title":"Incidence of invasive group B streptococcal (GBS) disease among nonpregnant adults, by age (A) and by race (B), 1990-2007","html":"<div class=\"graphic\"><div style=\"width: 657px\" class=\"figure\"><div class=\"ttl\">Incidence of invasive group B streptococcal (GBS) disease among nonpregnant adults, by age (A) and by race (B), 1990-2007</div><div class=\"cntnt\"><img style=\"width:637px; height:651px;\" src=\"images/ID/87797_Incid_GBS_nonpreg_adults.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">From: Skoff TH, Farley MM, Petit S, et al. Increasing Burden of Invasive Group B Streptococcal Disease in Non-Pregnant Adults, 1990-2007. Clin Infect Dis 2009; 49:85. By permission of the Infectious Diseases Society of America. Copyright &copy; 2013 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 87797 Version 3.0</div></div></div>"},"87814":{"type":"graphic_figure","displayName":"Conditioning regimens dose intensities","title":"Dose intensity of selected conditioning regimens used for allogeneic hematopoietic cell transplantation","html":"<div class=\"graphic\"><div style=\"width: 484px\" class=\"figure\"><div class=\"ttl\">Dose intensity of selected conditioning regimens used for allogeneic hematopoietic cell transplantation</div><div class=\"cntnt\"><img style=\"width:464px; height:410px;\" src=\"images/HEME/87814_Cond_reg_dose_intensities.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">BU: busulfan; CY: cyclophosphamide; TBI: total body irradiation; Flu: fludarabine (various dosing schedules); AraC: cytosine arabinoside; ATG: antithymocyte globulin (or thymoglobulin); 131I: anti-CD45 antibody conjugated to 131I; GVT: graft versus tumor.<BR>* \"High-dose\" TBI (800 to 1320 cGy).<BR><FONT class=bullet>â¢</FONT> \"Low-dose\" TBI (200 to 400 cGy).</div><div class=\"graphic_reference\">This research was originally published in Blood. Deeg HJ, Sandmaier BM. Who is fit for allogeneic transplantation? Blood 2010; 116:4762. Copyright Â© 2010 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 87814 Version 1.0</div></div></div>"},"87815":{"type":"graphic_table","displayName":"Selection of patients allo-HCT","title":"Selection of patients for allogeneic hematopoietic cell transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selection of patients for allogeneic hematopoietic cell transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Good risk candidates</td> </tr> <tr> <td>Young age</td> </tr> <tr> <td>No comorbid conditions</td> </tr> <tr> <td>No active infections</td> </tr> <tr> <td>Lymphohematopoietic disease in remission or responsive to therapy</td> </tr> <tr> <td>Good socioeconomic support system</td> </tr> <tr> <td>HLA-matched donor</td> </tr> <tr> <td>Low risk of post-transplantation relapse</td> </tr> <tr> <td class=\"subtitle1_single\">High risk candidates</td> </tr> <tr> <td>Older age</td> </tr> <tr> <td>Comorbid conditions present</td> </tr> <tr> <td>Refractory/relapsed disease (diagnosis-dependent)</td> </tr> <tr> <td>Aggressive prior therapy</td> </tr> <tr> <td>High risk/complex karyotype</td> </tr> </tbody></table></div><div class=\"graphic_reference\">This research was originally published in Blood. Deeg HJ, Sandmaier BM. Who is fit for allogeneic transplantation? Blood 2010; 116:4762. &copy; 2010 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 87815 Version 1.0</div></div></div>"},"87816":{"type":"graphic_figure","displayName":"Coude catheter orientation during placement","title":"Coude catheter orientation during placement","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Coude catheter orientation during placement</div><div class=\"cntnt\"><img style=\"width:522px; height:512px;\" src=\"images/SURG/87816_Coude_catheter.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 87816 Version 1.0</div></div></div>"},"87818":{"type":"graphic_table","displayName":"MOPQRST mnemonic","title":"MOPQRST mnemonic for assessment of patient symptoms in palliative care","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">MOPQRST mnemonic for assessment of patient symptoms in palliative care</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"90%\"></colgroup> <tbody> <tr> <td class=\"centered\">M</td> <td>Meaning of the symptom</td> </tr> <tr> <td class=\"centered\">O</td> <td>Onset of the symptom</td> </tr> <tr> <td class=\"centered\">P</td> <td>Palliating and provoking factors</td> </tr> <tr> <td class=\"centered\">Q</td> <td>Quality of the symptom</td> </tr> <tr> <td class=\"centered\" rowspan=\"2\">R</td> <td>Related factors/symptoms</td> </tr> <tr> <td>Region and radiation</td> </tr> <tr> <td class=\"centered\">S</td> <td>Severity of the symptom</td> </tr> <tr> <td class=\"centered\">T</td> <td>Temporality of the symptom</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 87818 Version 2.0</div></div></div>"},"87820":{"type":"graphic_picture","displayName":"Supraperiosteal local infiltration","title":"Supraperiosteal (local) infiltration","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Supraperiosteal (local) infiltration</div><div class=\"cntnt\"><img style=\"width:445px; height:476px;\" src=\"images/EM/87820_Supraperio_loc_infiltrat.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For supraperisoteal infiltration, insert the needle into the mucobuccal fold centered on the tooth to be anesthetized. The bevel of the needle should be facing the bone. Aim towards the maxilla and, once contact is made with the bone, withdraw the needle&nbsp;one mm. Aspirate to ensure you are not in a vessel and inject one to two mL local anesthetic at the apex of the root tip.</div><div class=\"graphic_reference\">Reproduced with permission from: Dubash BD, Hershkin AT, Seider PJ, Casey GM. Oral and Maxillofacial Regional Anesthesia. New York Society of Regional Anesthesia. Copyright &copy; NYSORA. <a href=\"http://www.nysora.com/\" style=\"font-style: italic;\" target=\"_blank\">www.nysora.com</a>.</div><div id=\"graphicVersion\">Graphic 87820 Version 1.0</div></div></div>"},"87821":{"type":"graphic_figure","displayName":"Initiation of ovarian transposition procedure","title":"Initiation of ovarian transposition procedure","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Initiation of ovarian transposition procedure</div><div class=\"cntnt\"><img style=\"width:512px; height:566px;\" src=\"images/OBGYN/87821_Ovarian-transposition.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Laparoscopic lateral ovarian transposition. The ovarian ligaments (1-see arrow) and the mesovarium (2) are divided. If mobility is inadequate, a relaxing incision on the peritoneum inferior to the ovary (3) may be needed.</div><div id=\"graphicVersion\">Graphic 87821 Version 1.0</div></div></div>"},"87822":{"type":"graphic_picture","displayName":"Transected utero-ovarian ligament and fallopian tube","title":"Transected utero-ovarian ligament and fallopian tube","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Transected utero-ovarian ligament and fallopian tube</div><div class=\"cntnt\"><img style=\"width:504px; height:315px;\" src=\"images/OBGYN/87822_Transect_uter_fall_tube.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 87822 Version 1.0</div></div></div>"},"87823":{"type":"graphic_picture","displayName":"Pityriasis rubra pilaris nails","title":"Nail abnormalities in pityriasis rubra pilaris","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Nail abnormalities in pityriasis rubra pilaris</div><div class=\"cntnt\"><img style=\"width:576px; height:432px;\" src=\"images/DERM/87823_Pityria_rubra_pilaris_nails.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nail thickening and subungual hyperkeratosis in patient with pityriasis rubra pilaris.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87823 Version 3.0</div></div></div>"},"87824":{"type":"graphic_table","displayName":"Risk of HUS recurrence according to genetic mutation","title":"Table showing the risk of HUS recurrence according to genetic mutation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Table showing the risk of HUS recurrence according to genetic mutation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Gene</td> <td class=\"subtitle1\">Protein location</td> <td class=\"subtitle1\">Functional impact</td> <td class=\"subtitle1\">Mutation frequency in aHUS<br /> (percent)</td> <td class=\"subtitle1\">Recurrence frequency after transplantation<br /> (percent)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Mutation</td> </tr> <tr> <td class=\"indent1\"><em>CFH</em></td> <td>Plasma</td> <td>Loss</td> <td>20-30</td> <td>75-90</td> </tr> <tr> <td class=\"indent1\"><em>CFI</em></td> <td>Plasma</td> <td>Loss</td> <td>2-12</td> <td>45-80</td> </tr> <tr> <td class=\"indent1\"><em>CFB</em></td> <td>Plasma</td> <td>Gain</td> <td>1-2</td> <td>100</td> </tr> <tr> <td class=\"indent1\"><em>C3</em></td> <td>Plasma</td> <td>Gain</td> <td>5-10</td> <td>40-70</td> </tr> <tr> <td class=\"indent1\"><em>MCP</em></td> <td>Membrane</td> <td>Loss</td> <td>10-15</td> <td>15-20</td> </tr> <tr> <td class=\"indent1\"><em>THBD</em></td> <td>Membrane</td> <td>Loss</td> <td>5</td> <td>1 case</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Genetic polymorphism (frequency in control populations)</td> </tr> <tr> <td class=\"indent1\">Homozygous <em>CFHR1</em>del (3 to 8 percent)</td> <td>Circulating</td> <td>Undetermined</td> <td>14-23 (&#62;90 percent in patients with anti-CFH antibodies)</td> <td>NA</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">aHUS: atypical hemolytic uremic syndrome; CFH/I/B: complement factor H/I/B; C3: complement C3; MCP: membrane cofactor protein; THBD: thrombomodulin; NA: not available.</div><div class=\"graphic_reference\">Reprinted by permission from: Macmillan Publishers Ltd: Nature Reviews Nephrology. Zuber J, Le Quintrec M, Sberro-Soussan R, et al. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 2011; 7:23. Copyright &copy; 2011. <a href=\"http://www.nature.com/nrneph\" target=\"_blank\">www.nature.com/nrneph</a>.</div><div id=\"graphicVersion\">Graphic 87824 Version 2.0</div></div></div>"},"87825":{"type":"graphic_picture","displayName":"Pityriasis rubra pilaris keratoderma 2","title":"Keratoderma associated with pityriasis rubra pilaris","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Keratoderma associated with pityriasis rubra pilaris</div><div class=\"cntnt\"><img style=\"width:576px; height:427px;\" src=\"images/DERM/87825_Pityr_rubra_pilaris_kerato2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A waxy keratoderma with an orange hue is characteristic of pityriasis rubra pilaris.</div><div class=\"graphic_reference\">Reproduced with permission from: <A style=\"FONT-STYLE: italic\" href=\"http://www.visualdx.com/\" target=_blank>www.visualdx.com</A>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 87825 Version 3.0</div></div></div>"},"87827":{"type":"graphic_table","displayName":"OCEANS gyn protocol","title":"Carboplatin and gemcitabine plus bevacizumab chemotherapy for platinum-sensitive recurrent epithelial carcinoma of the ovary, peritoneum, or fallopian tube<SUP>[1]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Carboplatin and gemcitabine plus bevacizumab chemotherapy for platinum-sensitive recurrent epithelial carcinoma of the ovary, peritoneum, or fallopian tube<SUP>[1]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 21 days.<br /> <strong>Total cycles:</strong> 6 to 10.<br /> Following completion of chemotherapy, single agent bevacizumab maintenance therapy may be continued on an every three week schedule until disease progression or toxicity. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Gemcitabine</td> <td>1000 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL NS and administer over 30 minutes.</td> <td>Days 1 and 8</td> </tr> <tr> <td>Carboplatin</td> <td>AUC* = 4 mg/mL per min IV</td> <td>Dilute in 250 mL normal saline (NS)<sup>&#182;</sup> and administer over one hour.</td> <td>Day 1</td> </tr> <tr class=\"divider_bottom\"> <td>Bevacizumab</td> <td>15 mg/kg IV</td> <td>Dilute into a total volume of 100 mL NS.<sup>&#182;</sup> Administer first dose over 90 minutes, before carboplatin and gemcitabine. If well tolerated, the second infusion may be administered over 60 minutes. If well tolerated, all subsequent infusions may be administered over 30 minutes.<sup>&#916;</sup><sup>[2]</sup></td> <td>Day 1</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MODERATE on day 1;<br /> LOW on day 8. </li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>There is no standard premedication regimen. </li> <li>Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Carboplatin and gemcitabine are irritants. </li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Primary prophylaxis with G-CSF is not indicated (risk of febrile neutropenia &#60;2%).<sup>[1]</sup> </li> <li>Refer to UpToDate topic on \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li>Each carboplatin dose should be calculated based upon renal function by use of the Calvert formula.* A lower starting dose for gemcitabine may be needed in patients with liver impairment. </li> <li>Refer to UpToDate topics \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Dosing of anticancer agents in adults\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>CBC with differential prior to treatment on days 1 and 8. </li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess electrolytes and liver and renal function prior to each new cycle of treatment. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess changes in neurologic function, blood pressure, and risk for bleeding prior to each new cycle of treatment. Urine protein/creatinine ratio should be obtained when appropriate. </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Myelotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>For initiation of each new treatment cycle, ANC &#8805;1500 cells/microL, hemoltobin (Hb) &#8805;8.5 g/dL, and platelet count &#8805;100,000/microL.<sup>[1]</sup> If day 8 ANC 1000 to 1499 cells/microL and/or platelets 75,000 to 99,999/microL, reduce gemcitabine dose by 50%. If day 8 ANC &#60;1000 cells/microL and/or platelets &#60;75,000/microL, omit gemcitabine dose.<sup>[3]</sup> </li> <li>For intracycle febrile neutropenia, ANC &#60;500 cells/microL for more than five days, ANC &#60;100/microL for more than three days, or any platelet count &#60;25,000/microL, reduce gemcitabine dose to 800 mg/m<sup>2</sup> for both days 1 and 8. If toxicities recur despite dose reduction, permanently delete the day 8 gemcitabine dose. </li> <li>Discontinue carboplatin and gemcitabine if hematologic recovery does not occur within three weeks. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Thrombotic microangiopathy</strong></td> <td colspan=\"3\"> <ul> <li>Thrombotic microangiopathy (TMA, also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with gemcitabine, in individuals who have received a large or small cumulative dose.<sup>[3]</sup> Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP. </li> <li>Refer to UpToDate topic on \"Drug-induced thrombotic microangiopathy\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Nephrotoxicity</strong></td> <td colspan=\"3\"> <ul> <li>Alterations in renal function during therapy may require a recalculation of the carboplatin dose. </li> <li>Refer to UpToDate topic on \"Dosing of anticancer agents in adults\". </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Pulmonary toxicity</strong></td> <td colspan=\"3\"> <ul> <li>A variety of manifestations of pulmonary toxicity have been reported with gemcitabine.<sup>[3]</sup> Discontinue gemcitabine immediately and permanently. </li> <li>Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\". </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other toxicity</strong></td> <td colspan=\"3\"> <ul> <li>For severe (grade 3 or 4) non-hematologic toxicities, gemcitabine should be held or decreased by 50% based on clinical judgement.<sup>[1]</sup> Discontinue bevacizumab for hypertensive crisis or hypertensive encephalopathy, serious (&#8805;grade 2) hemorrhage, arterial thromboembolism, nephrotic syndrome, gastrointestinal perforation, fistula formation, or reversible posterior leukoencephalopathy syndrome (RPLS), severe venous thromboembolism, and severe heart failure.<sup>[1,2]</sup> Do not administer bevacizumab within 28 days of surgery or until wounds are fully healed.<sup>[2]</sup> </li> <li>Refer to UpToDate topics on \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\" and \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\". </li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte colony-stimulating factors; CBC: complete blood count; ANC: absolute neutrophil count.<br />* AUC (area under the dose-concentration Ã time curve) is converted to a patient-specific carboplatin dose (in mg) according to renal function by using the Calvert formula. The Calvert formula is total dose (mg) = (target AUC) Ã (GFR + 25). If using measured serum creatinine, limit the maximal GFR for the calculation to 125 mL/min. Refer to UpToDate topic on \"Dosing of anticancer agents in adults\".<br />Â¶ Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br />Î Do not administer or mix bevacizumab with dextrose solutions.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Aghajanian C, et al. J Clin Oncol 2012; 30:2039.</LI>&#xD;&#xA;<LI>Bevacizumab injection. United States Prescribing Information. US National Library of Medicine. (Available online at http://dailymed.nlm.nih.gov, accessed November 16, 2012).</LI>&#xD;&#xA;<LI>Gemcitabine hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at http://dailymed.nlm.nih.gov, accessed November 16, 2012).</LI></OL></div><div id=\"graphicVersion\">Graphic 87827 Version 12.0</div></div></div>"},"87829":{"type":"graphic_waveform","displayName":"ECG with TCA poisoning - Severe cardiac toxicity","title":"ECG with TCA poisoning: Severe cardiac toxicity","html":"<div class=\"graphic\"><div style=\"width: 621px\" class=\"figure\"><div class=\"ttl\">ECG with TCA poisoning: Severe cardiac toxicity</div><div class=\"cntnt\"><img style=\"width:601px; height:495px;\" src=\"images/EM/87829_ECG_TCA_poison_sev_card_tox.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Steven Sahalnick, MD.</div><div id=\"graphicVersion\">Graphic 87829 Version 1.0</div></div></div>"},"87830":{"type":"graphic_waveform","displayName":"ECG with TCA poisoning - After treatment","title":"ECG with TCA poisoning: After treatment","html":"<div class=\"graphic\"><div style=\"width: 621px\" class=\"figure\"><div class=\"ttl\">ECG with TCA poisoning: After treatment</div><div class=\"cntnt\"><img style=\"width:601px; height:515px;\" src=\"images/EM/87830_ECG_TCA_poison_after_treat.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Steven Sahalnick, MD.</div><div id=\"graphicVersion\">Graphic 87830 Version 1.0</div></div></div>"},"87832":{"type":"graphic_waveform","displayName":"ECG with TCA poisoning - Resolution","title":"ECG with TCA poisoning: Resolution","html":"<div class=\"graphic\"><div style=\"width: 621px\" class=\"figure\"><div class=\"ttl\">ECG with TCA poisoning: Resolution</div><div class=\"cntnt\"><img style=\"width:601px; height:497px;\" src=\"images/EM/87832_ECG_TCA_poison_resolution.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Steven Sahalnick, MD.</div><div id=\"graphicVersion\">Graphic 87832 Version 1.0</div></div></div>"},"87833":{"type":"graphic_picture","displayName":"Pathological findings in B mandrillaris amebic infection","title":"Pathological findings in <EM>Balamuthia mandrillaris </EM>amebic infection","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Pathological findings in <EM>Balamuthia mandrillaris </EM>amebic infection</div><div class=\"cntnt\"><img style=\"width:515px; height:425px;\" src=\"images/ID/87833_Path_find_B_ameb_infect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panel A) At scanning magnification, a pattern of ill-defined granulomas occupying the reticular dermis (hematoxylin and eosin [H&amp;E],&nbsp;x40).<br />(Panel B) The granulomatous pattern is usually accompanied by the presence of multiple giant cells (H&amp;E, x400).<br />(Panel C) A trophozoite with ample cytoplasm, round nucleus, and nucleolus (H&amp;E, x1000).<br />(Panel D) A round trophozoite, with bubbly cytoplasm and eccentric located nucleus (H&amp;E, x1000).</div><div id=\"graphicVersion\">Graphic 87833 Version 3.0</div></div></div>"},"87839":{"type":"graphic_picture","displayName":"Sclerokeratitis","title":"Sclerokeratitis due to ocular tuberculosis","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Sclerokeratitis due to ocular tuberculosis</div><div class=\"cntnt\"><img style=\"width:515px; height:179px;\" src=\"images/ID/87839_Sclerokeratitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Recurrent sclerokeratitis resulting in multiple corneal peripheral scars. The patient also has active scleritis. (B) Chest computed tomography (CT) revealed enlarged lymph nodes with necrosis involving pretracheal, paratracheal, and subcarinal groups, with the largest lymph node measuring 1.89 x 1.35 cm.</div><div id=\"graphicVersion\">Graphic 87839 Version 2.0</div></div></div>"},"87840":{"type":"graphic_picture","displayName":"Anterior chamber granuloma","title":"Anterior chamber granuloma due to ocular tuberculosis","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Anterior chamber granuloma due to ocular tuberculosis</div><div class=\"cntnt\"><img style=\"width:515px; height:197px;\" src=\"images/ID/87840_Ant_chamber_granuloma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Anterior chamber granuloma with granulomatous keratic precipitates and hypopyon. Aspiration of the granuloma demonstrated acid-fast bacilli in Ziehl-Neelsen stain. (B) Following antituberculous treatment, the posterior segment demonstrates healed pigmented scars along the vasculature.</div><div id=\"graphicVersion\">Graphic 87840 Version 2.0</div></div></div>"},"87841":{"type":"graphic_picture","displayName":"Anterior uveitis due to ocular TB","title":"Anterior uveitis due to ocular tuberculosis","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Anterior uveitis due to ocular tuberculosis</div><div class=\"cntnt\"><img style=\"width:516px; height:389px;\" src=\"images/ID/87841_Ant_uveitis_ocular_TB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Granulomatous keratic precipitates and posterior synechiae in 12-year-old girl. (B) Fundus examination shows neuroretinitis in the right eye. (C) Fundus examination shows optic neuritis in the left eye.</div><div id=\"graphicVersion\">Graphic 87841 Version 2.0</div></div></div>"},"87842":{"type":"graphic_picture","displayName":"Choroidal TB","title":"Posterior uveitis due to ocular tuberculosis","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Posterior uveitis due to ocular tuberculosis</div><div class=\"cntnt\"><img style=\"width:515px; height:389px;\" src=\"images/ID/87842_Choroidal_TB.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A 35-year-old woman presented with massive subretinal abscess and optic nerve granuloma with neovascularisation in her left eye. Her mantoux test was necrotic positive, and ultrasonography demonstrated thickened choroid. (B) Interval improvement was observed after one month of antituberculous therapy. (C) Resolution of funduscopici findings and choroidal thickening was observed after three months of antituberculous therapy.</div><div id=\"graphicVersion\">Graphic 87842 Version 2.0</div></div></div>"},"87843":{"type":"graphic_picture","displayName":"Serpiginous-like choroiditis","title":"Serpiginous-like choroiditis due to ocular tuberculosis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Serpiginous-like choroiditis due to ocular tuberculosis</div><div class=\"cntnt\"><img style=\"width:504px; height:370px;\" src=\"images/ID/87843_Serpigin_like_choroiditis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Highly pigmented serpiginous-like choroiditis in a patient with pulmonary tuberculosis.</div><div id=\"graphicVersion\">Graphic 87843 Version 2.0</div></div></div>"},"87846":{"type":"graphic_table","displayName":"Measures of right heart function","title":"Measures of right heart function","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Measures of right heart function</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"65%\"></colgroup><colgroup width=\"35%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Parameter</td> <td class=\"subtitle1\">Optimal value</td> </tr> <tr> <td>Mean right atrial pressure (RAP)</td> <td>&#60;15 mmHg</td> </tr> <tr> <td>RAP/PCWP ratio</td> <td>&#60;0.6</td> </tr> <tr> <td>Pulmonary vascular resistance</td> <td>&#60;4 Wood units</td> </tr> <tr> <td>Transpulmonary gradient (TPG)</td> <td>&#60;15 mmHg</td> </tr> <tr> <td>Right ventricular ejection fraction (RVEF)</td> <td>&#62;30 percent</td> </tr> <tr> <td>Right ventricular stroke work index (RVSWI)</td> <td>&#62;250 mmHg x mL/m<sup>2</sup></td> </tr> <tr> <td>Tricuspid annular plane systolic excursion (TAPSE)</td> <td>&#62;0.75 cm</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">TPG = (Mean pulmonary artery pressure) - (PCWP).</div><div class=\"graphic_footnotes\">PCWP: pulmonary capillary wedge pressure.</div><div class=\"graphic_reference\">Courtesy of Donna Mancini, MD.</div><div id=\"graphicVersion\">Graphic 87846 Version 4.0</div></div></div>"},"87847":{"type":"graphic_figure","displayName":"Patterns of left ventricular remodeling","title":"Patterns of left ventricular remodeling","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Patterns of left ventricular remodeling</div><div class=\"cntnt\"><img style=\"width:480px; height:513px;\" src=\"images/CARD/87847_Patternsofleftventricularremodeling.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>The schematic demonstrates the relationship between left ventricular (LV) end-diastolic volume (LVEDV, represented here by the size of the inner circle) and LV mass (LV mass, represented here by the size of the shaded region) for various patterns of remodeling.</LI>&#xD;&#xA;<LI>Relative wall thickness (RWT) is the ratio of wall thickness to left ventricular diastolic dimension (RWT = 2x [diastolic posterior wall thickness]/left ventricular internal diastolic dimension).</LI>&#xD;&#xA;<LI>With concentric remodeling, LVEDV is normal or reduced, LV mass is normal, and RWT is increased (and LV mass/LVEDV is increased).</LI>&#xD;&#xA;<LI>With concentric hypertrophy, LVEDV is normal or reduced, LV mass is increased, and RWT is increased (and LV mass/LVEDV is increased).</LI>&#xD;&#xA;<LI>With eccentric remodeling, LVEDV is increased, LV mass is normal to reduced, and RWT is normal to reduced (and LV mass/LVEDV is normal to reduced).</LI>&#xD;&#xA;<LI>With eccentric hypertrophy, LVEDV is increased, LV mass is increased, and RWT is normal to reduced (and&nbsp;LV mass/LVEDV is normal to reduced).</LI></UL></div><div class=\"graphic_reference\">Courtesy of William Gaasch, MD, Tufts University School of Medicine.</div><div id=\"graphicVersion\">Graphic 87847 Version 4.0</div></div></div>"},"87852":{"type":"graphic_diagnosticimage","displayName":"MRI drug induced cardiomyopathy","title":"Magnetic resonance imaging of hydroxychloroquine-induced cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Magnetic resonance imaging of hydroxychloroquine-induced cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:599px; height:310px;\" src=\"images/RADIOL/87852_MRI_drug_induc_cardiomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance imaging (MRI) using black blood imaging in a 76-year-old female with longstanding rheumatoid arthritis treated with hydroxychloroquine (panel A) shows a thickened left ventricle (arrow) and a small pericardial effusion (arrowhead). The delayed T1-weighted sequence following gadolinium (panel B) shows mid-ventricular delayed enhancement (arrows). These findings are consistent with a nonischemic cardiomyopathy. Cardiac catheterization showed restrictive physiology.</div><div id=\"graphicVersion\">Graphic 87852 Version 2.0</div></div></div>"},"87853":{"type":"graphic_picture","displayName":"Histopathology of cardiomyocytes with cytoplasmic vacuoles","title":"Histopathology of cardiomyocytes with cytoplasmic vacuoles in hydroxychloroquine cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Histopathology of cardiomyocytes with cytoplasmic vacuoles in hydroxychloroquine cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:504px; height:377px;\" src=\"images/RADIOL/87853_Histo_cardio_cyto_vac.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The histopathology using H and E stain, with 300x magnification, reveals cardiomyocytes with abundant cytoplasmic vacuoles.</div><div class=\"graphic_footnotes\">H and E: hematoxylin and eosin.</div><div class=\"graphic_reference\">Courtesy of Aleksandr Perepletchikov, MD.</div><div id=\"graphicVersion\">Graphic 87853 Version 1.0</div></div></div>"},"87854":{"type":"graphic_picture","displayName":"Hydroxychloroquine-induced cardiomyopathy 400X","title":"Hydroxychloroquine-induced cardiomyopathy showing cardiomyocytes with Luxol stain ","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Hydroxychloroquine-induced cardiomyopathy showing cardiomyocytes with Luxol stain </div><div class=\"cntnt\"><img style=\"width:502px; height:376px;\" src=\"images/RADIOL/87854_Hydroxch_ind_card_card.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The histopathology, using Luxol fast blue stain with 400x magnification, highlights the vacuolated myocardial cells which contain blue intracytoplasmic granules (arrow), characteristic of abundant lysosomes.</div><div class=\"graphic_reference\">Courtesy of Aleksandr Perepletchikov, MD.</div><div id=\"graphicVersion\">Graphic 87854 Version 2.0</div></div></div>"},"87855":{"type":"graphic_picture","displayName":"EM hydroxychloroquine cardiomyopathy","title":"Electron microscopy of cardiomyocytes in hydroxychloroquine cardiomyopathy","html":"<div class=\"graphic\"><div style=\"width: 521px\" class=\"figure\"><div class=\"ttl\">Electron microscopy of cardiomyocytes in hydroxychloroquine cardiomyopathy</div><div class=\"cntnt\"><img style=\"width:501px; height:369px;\" src=\"images/RADIOL/87855_EM_cardio_hydroxy_card.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The EM at 17600x magnification shows sarcomere drop out (between thick arrows) caused by proliferation of lysosomes&nbsp;that are at various stages of condensation. The arrowhead points to a lysosome with a single membrane prior to condensation. The thin yellow arrow points to a lysosome with lamellated membrane structures that has undergone condensation.</div><div class=\"graphic_footnotes\">EM: electron microscopy.</div><div class=\"graphic_reference\">Courtesy of J Alroy, MD.</div><div id=\"graphicVersion\">Graphic 87855 Version 2.0</div></div></div>"},"87857":{"type":"graphic_diagnosticimage","displayName":"Chest x-ray coarctation of the aorta 3 sign","title":"Chest radiograph of a patient with coarctation of the aorta","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of a patient with coarctation of the aorta</div><div class=\"cntnt\"><img style=\"width:513px; height:340px;\" src=\"images/RADIOL/87857_Chest_xray_aort_3_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posterior-anterior (PA) chest radiograph of a patient with coarctation of the aorta (A) shows soft tissue fullness in the region of the ectatic subclavian artery (arrow) and with subtle rib notching best appreciated in the fourth right rib (arrowhead). The lateral examination (B) shows the characteristic 3 sign consisting of the enlarged and distorted aortic knob and subclavian artery forming the upper portion of the 3, the waist at the site of the coarctation (arrow), and the lower portion formed by the post-stenotic dilatation of the proximal descending aorta.</div><div id=\"graphicVersion\">Graphic 87857 Version 2.0</div></div></div>"},"87858":{"type":"graphic_diagnosticimage","displayName":"Aortogram coarctation of the aorta 3 sign","title":"Aortogram coarctation showing aorta \"3\" sign","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortogram coarctation showing aorta \"3\" sign</div><div class=\"cntnt\"><img style=\"width:333px; height:504px;\" src=\"images/RADIOL/87858_Aortogrm_coarc_aort_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The aortogram shows the \"3\" sign consisting of&nbsp; the enlarged and distorted aortic knob and subclavian artery forming the upper portion of the 3, the waist at the site of the coarctation (arrow), and the lower portion formed by the post stenotic dilatation of the proximal descending aorta.</div><div id=\"graphicVersion\">Graphic 87858 Version 1.0</div></div></div>"},"87859":{"type":"graphic_table","displayName":"Consensus Sleep Diary instructions","title":"Consensus Sleep DiaryÂ instructions","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Consensus Sleep Diary&nbsp;instructions</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">General instructions</td> </tr> <tr> <td class=\"indent1\"> <p><strong>What is a sleep diary?</strong></p> A sleep diary is designed to gather information about your daily sleep pattern.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>How often and when do I fill out the sleep diary?</strong></p> It is necessary for you to complete your sleep diary every day. If possible, the sleep diary should be completed within one hour of getting out of bed in the morning.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>What should I do if I miss a day?</strong></p> If you forget to fill in the diary or are unable to finish it, leave the diary blank for that day.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>What if something unusual affects my sleep or how I feel in the daytime?</strong></p> If your sleep or daytime functioning is affected by some unusual event (such as an illness or an emergency), you may make brief notes on your diary.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>What do the words \"bed\" and \"day\" mean on the diary?</strong></p> This diary can be used for people who are awake or asleep at unusual times. In the sleep diary, the word \"day\" is the time when you choose or are required to be awake. The term \"bed\" means the place where you usually sleep.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>Will answering these questions about my sleep keep me awake?</strong></p> This is not usually a problem. You should not worry about giving exact times, and you should not watch the clock. Just give your best estimate.</td> </tr> <tr> <td class=\"subtitle1_single\">Sleep diary item instructions</td> </tr> <tr> <td>Use the guide below to clarify what is being asked for each item of the sleep diary.</td> </tr> <tr> <td class=\"indent1\"><strong>Date:</strong> Write the date of the morning you are filling out the diary.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>1. What time did you get into bed?</strong></p> Write the time that you got into bed. This may not be the time you began \"trying\" to fall asleep.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>2. What time did you try to go to sleep?</strong></p> Record the time that you began \"trying\" to fall asleep.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>3. How long did it take you to fall asleep?</strong></p> Beginning at the time you wrote in question 2, how long did it take you to fall asleep?</td> </tr> <tr> <td class=\"indent1\"> <p><strong>4. How many times did you wake up, not counting your final awakening?</strong></p> How many times did you wake up between the time you first fell asleep and your final awakening?</td> </tr> <tr> <td class=\"indent1\"> <p><strong>5. In total, how long did these awakenings last?</strong></p> What was the total time you were awake between the time you first fell asleep and your final awakening? For example, if you woke 3 times for 20 minutes, 35 minutes, and 15 minutes, add them all up (20 + 35 + 15 = 70 minutes or 1 hour and 10 minutes).</td> </tr> <tr> <td class=\"indent1\"> <p><strong>6a. What time was your final awakening?</strong></p> Record the last time you woke up in the morning.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>6b. After your final awakening, how long did you spend in bed trying to sleep?</strong></p> After the last time you woke up (item #6a), how many minutes did you spend in bed trying to sleep? For example, if you woke up at 8:00&nbsp;AM but continued to try and sleep until 9:00 AM, record 1 hour.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>6c. Did you wake up earlier than you planned?</strong></p> If you woke up or were awakened earlier than you planned, check yes. If you woke up at your planned time, check no.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>6d. If yes, how much earlier?</strong></p> If you answered \"yes\" to question 6c, write the number of minutes you woke up earlier than you had planned on waking up. For example, if you woke up 15 minutes before the alarm went off, record 15 minutes here.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>7. What time did you get out of bed for the day?</strong></p> What time did you get out of bed with no further attempt at sleeping? This may be different from your final awakening time (eg, you may have woken up at 6:35&nbsp;AM but did not get out of bed to start your day until 7:20 AM).</td> </tr> <tr> <td class=\"indent1\"> <p><strong>8. In total, how long did you sleep?</strong></p> This should just be your best estimate, based on when you went to bed and woke up, how long it took you to fall asleep, and how long you were awake. You do not need to calculate this by adding and subtracting; just give your best estimate.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>9. How would you rate the quality of your sleep?</strong></p> \"Sleep quality\" is your sense of whether your sleep was good or poor.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>10. How restful or refreshed did you feel when you woke up for the day?</strong></p> This refers to how you felt after you were done sleeping for the night, during the first few minutes that you were awake.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>11a. How many times did you nap or doze?</strong></p> A nap is a time you decided to sleep during the day, whether in bed or not in bed. \"Dozing\" is a time you may have nodded off for a few minutes, without meaning to, such as while watching TV. Count all the times you napped or dozed at any time from when you first got out of bed in the morning until you got into bed again at night.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>11b. In total, how long did you nap or doze?</strong></p> Estimate the total amount of time you spent napping or dozing, in hours and minutes. For instance, if you napped twice, once for 30 minutes and once for 60 minutes, and dozed for 10 minutes, you would answer \"1 hour 40 minutes.\" If you did not nap or doze, write \"N/A\" (not applicable).</td> </tr> <tr> <td class=\"indent1\"> <p><strong>12a. How many drinks containing alcohol did you have?</strong></p> Enter the number of alcoholic drinks you had where 1 drink is defined as one 12 oz beer (can), 5 oz wine, or 1.5 oz liquor (one shot).</td> </tr> <tr> <td class=\"indent1\"> <p><strong>12b. What time was your last drink?</strong></p> If you had an alcoholic drink yesterday, enter the time of day in hours and minutes of your last drink. If you did not have a drink, write \"N/A\" (not applicable).</td> </tr> <tr> <td class=\"indent1\"> <p><strong>13a. How many caffeinated drinks (coffee, tea, soda, energy drinks) did you have?</strong></p> Enter the number of caffeinated drinks (coffee, tea, soda, energy drinks) you had where for coffee and tea, one drink = 6 to 8 oz, while for caffeinated soda one drink = 12 oz.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>13b. What time was your last caffeinated drink?</strong></p> If you had a caffeinated drink, enter the time of day in hours and minutes of your last drink. If you did not have a caffeinated drink, write \"N/A\" (not applicable).</td> </tr> <tr> <td class=\"indent1\"> <p><strong>14. Did you take any over-the-counter or prescription medication(s) to help you sleep?</strong></p> If so, list medication(s), dose, and time taken: List the medication name, how much and when you took EACH different medication you took tonight to help you sleep. Include medication available over the counter, prescription medications, and herbals (example: \"Sleepwell 50 mg 11:00 PM\"). If every night is the same, write \"same\" after the first day.</td> </tr> <tr> <td class=\"indent1\"> <p><strong>15. Comments:</strong></p> If you have anything that you would like to say that is relevant to your sleep, feel free to write it here.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Camey CE, Buysse DJ, Ancoli-Israel S, et al. The Consensus Sleep Diary: Standardizing prospective sleep self-monitoring. Sleep 2012; 35:287. Copyright Â© 2012 American Academy of Sleep Medicine.</div><div id=\"graphicVersion\">Graphic 87859 Version 6.0</div></div></div>"},"87861":{"type":"graphic_table","displayName":"Causes of an immobile arm in children","title":"Causes of an immobile arm in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of an immobile arm in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Life- and limb-threatening conditions</td> </tr> <tr> <td>Complicated fracture or dislocation with associated neurovascular compromise, open fracture, or compartment syndrome</td> </tr> <tr> <td>Septic arthritis</td> </tr> <tr> <td>Osteomyelitis</td> </tr> <tr> <td>Necrotizing cellulitis or fasciitis</td> </tr> <tr> <td>Stroke</td> </tr> <tr> <td>Bone tumor or malignancy (eg, osteogenic sarcoma, acute lymphoblastic leukemia)</td> </tr> <tr> <td class=\"subtitle1_single\">Common conditions</td> </tr> <tr> <td>Radial head subluxation (nursemaid elbow)</td> </tr> <tr> <td>Fracture of the clavicle, humerus, or bones of the forearm</td> </tr> <tr> <td>Soft tissue injury</td> </tr> <tr> <td class=\"subtitle1_single\">Other conditions</td> </tr> <tr> <td>Vasoocclusive crisis in patient with sickle cell disease</td> </tr> <tr> <td>Hemarthrosis in patient with hemophilia or other bleeding disorder</td> </tr> <tr> <td>Systemic inflammatory process with arthritis (eg, collagen vascular disease, Lyme disease, inflammatory bowel disease)</td> </tr> <tr> <td>Conversion disorder</td> </tr> <tr> <td>Complex regional pain syndrome</td> </tr> <tr> <td>Todd paralysis</td> </tr> <tr> <td>Complex migraine</td> </tr> <tr> <td>Brachial plexus abnormality (eg, Erb or Klumpke palsy, brachial plexus impingement)</td> </tr> <tr> <td>Mononeuropathy</td> </tr> <tr> <td>Congenital syphilis (pseudoparalysis of Parrot)</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 87861 Version 1.0</div></div></div>"},"87862":{"type":"graphic_table","displayName":"Timing of neuraxial anesthesia during antithrombotic therapy","title":"Timing of neuraxial anesthesia during antithrombotic therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Timing of neuraxial anesthesia during antithrombotic therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Anticoagulant</td> <td class=\"subtitle1\">Interval from last dose to placement/removal</td> <td class=\"subtitle1\">Interval from placement/removal to next dose</td> <td class=\"subtitle1\">Notes</td> </tr> <tr class=\"divider_bottom\"> <td>Warfarin</td> <td>4 to 5 days, verify INR &#60;1.5; no monitoring needed for single dose within 24 hours of placement</td> <td>&nbsp;</td> <td>Continue regular neurologic evaluation until 24 hours after removal. If dosed with catheter in place, check INR daily and remove when INR &#60;1.5; if INR 1.5-3.0, remove catheter with caution, monitor neurologic status until INR stabilized; if INR &#62;3, hold/reduce warfarin dose. Use of antihemostatic medications that do not influence INR may increase risk of bleeding complications.</td> </tr> <tr> <td class=\"sublist1_start\">Heparin (unfractionated)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>When heparin given for &#62;4 days, check platelets (risk of HIT) prior to insertion or removal</td> </tr> <tr> <td class=\"sublist1\">Therapeutic dosing (IV)</td> <td class=\"sublist_other\">2 to 4 hours, check for normal aPTT</td> <td class=\"sublist_other\">1 hour</td> <td class=\"sublist_other\">Bloody/difficult needle placement may increase bleeding risk with subsequent IV heparin; use with caution</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\">Prophylactic dosing (SC)</td> <td class=\"sublist_other\"> <p>Delaying heparin injection until after placement may reduce risk</p> <p>&nbsp;</p> </td> <td class=\"sublist_other\"> <p>1 hour</p> </td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1_start\">Low molecular weight heparin (LMWH)</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Anti-Xa level is not predictive of the risk of bleeding. Do not use with antoplatelet or oral anticoagulant medications as this increases risk of spinal hematoma.</td> </tr> <tr> <td class=\"sublist1\">Therapeutic dosing (SC) (enoxaparin 1 mg/kg every 12 hours; enoxaparin 1.5 mg/kg daily; dalteparin 100 to 120 U/kg every 12 hours; dalteparin 200 U/kg daily; nadroparin 86 U/kg every 12 hours; nadroparin 171 U/kg daily; tinzaparin 175 U/kg daily)</td> <td class=\"sublist_other\">&#62;24 hours</td> <td class=\"sublist_other\">6 to 8 hours (placement), &#62;4 hours (removal), delay 24 hours after traumatic placement; twice-daily dosing, first dose &#62;24 hours postop; once-daily dosing first dose 6 to 8 hours postop, second dose 24 hours later</td> <td class=\"sublist_other\">Do not use therapeutic dosing with catheter in place</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\">Prophylactic dosing (SC) (enoxaparin 30 mg every 12 hours; enoxaparin 40 mg daily; dalteparin 2500 to 5000 U daily; nadroparin 2850 U daily; nadroparin 38 U/kg daily; tinzaparin 50 to 75 U/kg daily; tinzaparin 3500 U daily)</td> <td class=\"sublist_other\">10 to 12 hours</td> <td class=\"sublist_other\">6 to 8 hours (placement), &#62;4 hours (removal), delay 24 hours after traumatic placement; twice-daily dosing, first dose &#62;24 hours postop; once-daily dosing, first dose 6 to 8 hours postop, second dose 24 hours later</td> <td class=\"sublist_other\">Do not use twice-daily dosing with catheter in place, due to increased risk of spinal hematoma</td> </tr> <tr class=\"divider_bottom\"> <td>Fondaparinux</td> <td>36 to 42 hours (European guidelines)</td> <td>6 to 8 hours; avoid use after traumatic neuraxial placement</td> <td>Do not use with catheter in place. (European guidelines allow epidural catheter with prophylactic dosing.) Limited clinical experience.</td> </tr> <tr> <td class=\"sublist1_start\">Factor Xa inhibitors</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>(European guidelines) Antithrombotic effect monitored with PT, aPTT, Heptest</td> </tr> <tr> <td class=\"sublist1\">Rivaroxaban</td> <td class=\"sublist_other\">3 days&#182;</td> <td class=\"sublist_other\">6 hours&#182;</td> <td class=\"sublist_other\"> <p>AHA recommends 3 to 5 days after last dose; wait 24 hours to redose</p> <p>European guidelines 22 to 26 hours after last dose, wait 4 to 6 hours to redose</p> <p>FDA wait 18 hours for 20 to 45 years old, 26 hours 60 to 76 years old, wait 6 hours to redose, 24 hours to redose after traumatic puncture</p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\">Apixaban</td> <td class=\"sublist_other\">3 days&#182;</td> <td class=\"sublist_other\">6 hours&#182;</td> <td class=\"sublist_other\">European guidelines 26 to 30 hours after last dose, wait 4 to 6 hours to redose </td> </tr> <tr> <td class=\"sublist1_start\">Thrombin inhibitors</td> <td>Avoid neuraxial techniques</td> <td>&nbsp;</td> <td>aPTT or thrombin time</td> </tr> <tr> <td class=\"sublist1\">Dabigatran</td> <td class=\"sublist_other\">&nbsp;5 days&#182;</td> <td class=\"sublist_other\">&nbsp;6 hours&#182;</td> <td class=\"sublist_other\">AHA recommends 5 days after last dose (7 days for renal failure); wait 4 hours to redose</td> </tr> <tr> <td class=\"sublist1\">Argatroban</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\">Hirudin derivatives (desirudin, bivalirudin)</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Antiplatelet medication</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Bleeding time does not predict hemostatic problems</td> </tr> <tr> <td class=\"sublist1_start\">P2Y12 receptor blockers</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Clopidogrel</td> <td class=\"sublist_other\">7 days</td> <td class=\"sublist_other\">After catheter removal</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Prasugrel</td> <td class=\"sublist_other\">7 to 10 days</td> <td class=\"sublist_other\">6 hours after catheter removal</td> <td class=\"sublist_other\">European guidelines</td> </tr> <tr> <td class=\"sublist1\">Ticlodipine</td> <td class=\"sublist_other\">14 days</td> <td class=\"sublist_other\">After catheter removal</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\">Ticagrelor</td> <td class=\"sublist_other\">5 to 7 days&#182;</td> <td class=\"sublist_other\">6 hours after catheter removal&#182;</td> <td class=\"sublist_other\">European guidelines 5 days after last dose, wait 6 hours to redose</td> </tr> <tr> <td class=\"sublist1_start\">GP IIb/IIIa inhibitors</td> <td>&nbsp;</td> <td>Contraindicated for 4 weeks after surgery; monitor neurologic status if given after neuraxial technique</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Tirofiban</td> <td class=\"sublist_other\">4 to 8 hours</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr> <td class=\"sublist1\">Eptifibatide</td> <td class=\"sublist_other\">4 to 8 hours</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1\">Abciximab</td> <td class=\"sublist_other\">24 to 48 hours</td> <td class=\"sublist_other\">&nbsp;</td> <td class=\"sublist_other\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Aspirin</td> <td>May continue dosage</td> <td>May continue dosage</td> <td>Affects platelet function for the life of the platelet. Avoid neuraxial techniques on aspirin if early postoperative use of other antihemostatic drugs (including heparin) is anticipated.</td> </tr> <tr class=\"divider_bottom\"> <td>NSAIDs (nonsteroidal antiinflammatory drugs)</td> <td>May continue dosage</td> <td>May continue dosage</td> <td>Effect on platelet function normalizes within 3 days. Avoid neuraxial techniques on NSAIDs if early postoperative use of other antihemostatic drugs (including heparin) is anticipated. COX-2 inhibitors (celecoxib) have minimal effect on platelet function.</td> </tr> <tr> <td>Herbal medications (garlic, ginkgo, ginseng)</td> <td>May continue dosage</td> <td>May continue dosage</td> <td>Concurrent use with other antihemostatic drugs may increase bleeding risk</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Recommendations in this table reflect those that appear in the guidelines of the ASRA&nbsp;third edition<SUP>1</SUP>, unless otherwise&nbsp;specified.&nbsp;</div><div class=\"graphic_footnotes\">INR: international normalized ration; PT: prothrombin time; aPTT: activated partial thromboplastin time; HIT: heparin-induced thrombocytopenia; IV: intravenous; SC: subcutaneous; AHA: American Heart Association; ASRA: American Society of Regional Anesthesia and Pain Medicine.<br />Â¶ From ASRA draft guidelines in anticipation of revisions to Third Edition of ASRA guidelines<SUP>1</SUP></div><div class=\"graphic_reference\">Data from:<br /><ol>&#xD;&#xA;<li>Horlocker TT, Wedel DJ, Rowlingon JC, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med 2010; 35:64.</li>&#xD;&#xA;<li>Gogarten W, Vandermuelen E, Van Aken H, et al. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol 2010; 27:999.</li>&#xD;&#xA;<li>Wysokinski WE, McBane RD. Periprocedural bridging management of anticoagulation. Circulation 2012; 126:486.</li></ol></div><div id=\"graphicVersion\">Graphic 87862 Version 3.0</div></div></div>"},"87863":{"type":"graphic_diagnosticimage","displayName":"Solid small renal mass","title":"Solid small renal mass","html":"<div class=\"graphic\"><div style=\"width: 768px\" class=\"figure\"><div class=\"ttl\">Solid small renal mass</div><div class=\"cntnt\"><img style=\"width:748px; height:653px;\" src=\"images/ONC/87863_Solidsmallrenalmass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiphasic CT scan demonstrates an incidentally discovered 2.0 cm right renal mass in a 53-year-old woman who is otherwise healthy and has normal renal function.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 87863 Version 3.0</div></div></div>"},"87864":{"type":"graphic_diagnosticimage","displayName":"Complex cystic small renal mass","title":"Complex cystic small renal mass","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Complex cystic small renal mass</div><div class=\"cntnt\"><img style=\"width:598px; height:295px;\" src=\"images/ONC/87864_Complcysticsmrenalmass.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT without (A) then with (B) intravenous contrast shows a 3.8 cm right renal cyst with a mural nodule (circle) that increases &gt;15 Hounsfield units (HU) in attenuation with contrast.</div><div class=\"graphic_footnotes\">CT: computed tomography; Avg: average; Dev: deviation.</div><div id=\"graphicVersion\">Graphic 87864 Version 2.0</div></div></div>"},"87865":{"type":"graphic_table","displayName":"Proportion of RCCs in renal masses","title":"Proportion of renal cell carcinomas (RCC) in renal masses by size","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Proportion of renal cell carcinomas (RCC) in renal masses by size</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Size</td> <td class=\"subtitle1\">RCC</td> <td class=\"subtitle1\">Benign</td> </tr> <tr> <td class=\"centered\">0 to &#60;1 cm</td> <td class=\"centered\">43 (54 percent)</td> <td class=\"centered\">37 (46 percent)</td> </tr> <tr> <td class=\"centered\">1 to &#60;2 cm</td> <td class=\"centered\">132 (78 percent)</td> <td class=\"centered\">38 (22 percent)</td> </tr> <tr> <td class=\"centered\">2 to &#60;3 cm</td> <td class=\"centered\">266 (78 percent)</td> <td class=\"centered\">75 (22 percent)</td> </tr> <tr> <td class=\"centered\">3 to &#60;4 cm</td> <td class=\"centered\">285 (80 percent)</td> <td class=\"centered\">71 (20 percent)</td> </tr> <tr> <td class=\"centered\">All sizes</td> <td class=\"centered\">726 (77 percent)</td> <td class=\"centered\">221 (23 percent)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Frank I, Blute ML, Cheville JC, et al. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol 2003; 170:2217.</div><div id=\"graphicVersion\">Graphic 87865 Version 3.0</div></div></div>"},"87913":{"type":"graphic_diagnosticimage","displayName":"Pneumomediastinum in amyopathic dermatomyositis","title":"Pneumomediastinum in amyopathic dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Pneumomediastinum in amyopathic dermatomyositis</div><div class=\"cntnt\"><img style=\"width:513px; height:258px;\" src=\"images/PULM/87913_Pneumomedi_amyopa_derm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest computed tomography (CT) images from a patient with amyopathic dermatomyositis. The axial (A) and coronal (B) images show a pneumomediastinum and subcutaneous emphysema.</div><div id=\"graphicVersion\">Graphic 87913 Version 1.0</div></div></div>"},"87914":{"type":"graphic_diagnosticimage","displayName":"Interstitial lung disease in amyopathic dermatomyositis","title":"Interstitial lung disease in amyopathic dermatomyositis","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Interstitial lung disease in amyopathic dermatomyositis</div><div class=\"cntnt\"><img style=\"width:471px; height:461px;\" src=\"images/PULM/87914_Inters_lung_amyopath_derm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest computed tomography (CT) showing increased reticular markings and ground glass opacities at the lung bases in a patient with amyopathic dermatomyositis. More cephalad cuts showed a pneumomediastinum.</div><div id=\"graphicVersion\">Graphic 87914 Version 1.0</div></div></div>"},"87919":{"type":"graphic_table","displayName":"OPTN classification for nodules in cirrhotic livers","title":"Classification system for nodules seen on images of cirrhotic livers from the Organ Procurement and Transplantation Network (OPTN)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification system for nodules seen on images of cirrhotic livers from the Organ Procurement and Transplantation Network (OPTN)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Class and description</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">OPTN class 0</td> </tr> <tr> <td class=\"indent1\">Incomplete or technically inadequate study</td> <td>Repeat study required for adequate assessment; automatic priority MELD points cannot be assigned on basis of an imaging study categorized as OPTN class 0</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">OPTN class 5</td> </tr> <tr> <td class=\"indent1\">Meets radiologic criteria for HCC</td> <td>May qualify for automatic exception, depending on tumor stage*</td> </tr> <tr> <td class=\"indent1\">Class 5A: &#8805;1 cm and &#60;2 cm measured on late arterial or portal venous phase images</td> <td>Increased contrast enhancement in late hepatic arterial phase AND washout during later phases of contrast enhancement AND peripheral rim enhancement (capsule or pseudocapsule)</td> </tr> <tr> <td class=\"indent1\">Class 5A-g: same size as OPTN class 5A HCC</td> <td>Increased contrast enhancement in late hepatic arterial phase AND growth by 50% or more documented on serial CT or MR images obtained &#8804;6 months apart</td> </tr> <tr> <td class=\"indent1\">Class 5B: maximum diameter &#8805;2 cm and &#8804;5 cm</td> <td>Increased contrast enhancement in late hepatic arterial phase AND either washout during later contrast phases OR peripheral rim enhancement (capsule or pseudocapsule) OR growth by 50% or more documented on serial CT or MR images obtained &#8804;6 months apart (OPTN class 5B-g)</td> </tr> <tr> <td class=\"indent1\">Class 5T: prior regional treatment for HCC</td> <td>Describes any residual lesion or perfusion defect at site of prior UNOS class 5 lesion</td> </tr> <tr> <td class=\"indent1\">Class 5X: maximum diameter &#8805;5 cm</td> <td>Increased contrast enhancement in late hepatic arterial phase AND either washout during later contrast phases OR peripheral rim enhancement (capsule or pseudocapsule)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">NOTE: OPTN class number denotes whether an imaging examination is nondiagnostic (OPTN class 0) or the study includes an image that contains at least one treated or untreated HCC (OPTN class 5). OPTN class 5 is further subdivided by adding a capital letter to denote UNOS stage 1 disease (OPTN class 5A), UNOS stage 2 disease (OPTN class 5B), a treated HCC (OPTN class 5T), or HCC beyond acceptable size for transplantation (OPTN class 5X). The <EM>g</EM> in OPTN class 5A-g and OPTN class 5B-g is used to indicate that growth was used to arrive at the HCC diagnosis.</div><div class=\"graphic_footnotes\">MELD: Model for End Stage Liver Disease score; HCC: hepatocellular carcinoma; CT: computed tomography; MR: magnetic resonance; UNOS: United Network for Organ Sharing.<br />* As assessed according to the American Liver Tumor Study Group modification of the standard TNM staging system (stage II, T2N0M0).</div><div class=\"graphic_reference\">Reproduced with permission from: Wald C, Russo MW, Heimbach JK, et al. New OPTN/UNOS Policy for Liver Transplant Allocation: Standardization of Liver Imaging, Diagnosis, Classification, and Reporting of Hepatocellular Carcinoma. Radiology 2013; 266:376-382. Copyright &copy; 2013 Radiological Society of North America.</div><div id=\"graphicVersion\">Graphic 87919 Version 3.0</div></div></div>"},"87920":{"type":"graphic_table","displayName":"Clinical and laboratory findings in pemphigus","title":"Key clinical and laboratory findings in pemphigus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key clinical and laboratory findings in pemphigus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"11%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Epidemiology</td> <td class=\"subtitle1\">Autoantigens</td> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Histopathology</td> <td class=\"subtitle1\">Direct immunofluorescence</td> <td class=\"subtitle1\">Indirect immunofluorescence</td> <td class=\"subtitle1\">ELISA</td> <td class=\"subtitle1\">Variants</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Pemphigus vulgaris</strong></td> <td>Primarily middle-aged adults</td> <td>Desmoglein 1 and desmoglein 3, others</td> <td>Mucosal erosions; flaccid bullae and erosions on skin</td> <td>Suprabasal acantholysis; \"row of tombstones\" pattern of basal keratinocytes</td> <td>Intercellular deposition of IgG</td> <td>Intercellular deposition of IgG; monkey esophagus is preferred substrate</td> <td>Desmoglein 3 or both desmoglein 1 and desmoglein 3 autoantibodies</td> <td>Pemphigus vegetans and pemphigus herpetiformis</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Pemphigus foliaceus</strong></td> <td>Primarily middle-aged adults; endemic form most common in children and young adults</td> <td>Desmoglein 1</td> <td>Fragile blisters, shallow erosions, erythematous patches, crusts; mucosal involvement absent</td> <td>Subcorneal or granular layer acantholysis</td> <td>Intercellular deposition of IgG</td> <td>Intercellular deposition of IgG; normal human skin or monkey esophagus is preferred substrate</td> <td>Desmoglein 1 autoantibodies</td> <td>Endemic pemphigus foliaceus (fogo sevalgem), pemphigus erythematosus, and pemphigus herpetiformis</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Paraneoplastic pemphigus</strong></td> <td>Primarily adults, but may occur at any age</td> <td>Envoplakin, periplakin, others</td> <td>Severe stomatitis, variable cutaneous findings (eg, blisters, erosions, lichenoid lesions), bronchiolitis obliterans</td> <td>Variable findings; suprabasal acantholysis, keratinocyte necrosis, and lichenoid interface dermatitis are most common</td> <td>Intercellular and/or basement membrane zone deposition of IgG and/or C3</td> <td>Intercellular deposition of IgG; rat bladder is preferred substrate</td> <td>Envoplakin and periplakin autoantibodies</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"9\">IgA pemphigus</td> </tr> <tr> <td class=\"indent1\">Subcorneal pustular dermatosis-type IgA pemphigus</td> <td>Any age</td> <td>Desmocollin 1</td> <td>Vesicles, pustules, crusts on skin; annular, circinate, or herpetiform morphology; mucosal involvement usually absent</td> <td>Subcorneal clefts and pustules; minimal acantholysis; mixed infiltrate in dermis</td> <td>Intercellular deposition of IgA</td> <td>Intercellular deposits of IgA on monkey esophagus*</td> <td>Desmocollin 1 autoantibodies<sup>&#182;</sup></td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Intraepidermal neutrophilic dermatosis</td> <td>Any age</td> <td>Poorly defined</td> <td>Vesicles, pustules, crusts on skin; annular, circinate, or herpetiform morphology; mucosal involvement usually absent</td> <td>Intraepidermal pustules; minimal acantholysis; mixed infiltrate in dermis</td> <td>Intercellular deposition of IgA</td> <td>Intercellular deposits of IgA on monkey esophagus*</td> <td>Desmoglein 1 and 3 autoantibodies have been reported in some patients</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Indirect immunofluorescence is negative in around 50 percent of patients with IgA pemphigus.<br />Â¶ Test availability restricted to specialized laboratories.</div><div id=\"graphicVersion\">Graphic 87920 Version 2.0</div></div></div>"},"87938":{"type":"graphic_figure","displayName":"Risks and benefits of MHT","title":"Risks and benefits of menopausal hormone therapy (MHT)","html":"<div class=\"graphic\"><div style=\"width: 577px\" class=\"figure\"><div class=\"ttl\">Risks and benefits of menopausal hormone therapy (MHT)</div><div class=\"cntnt\"><img style=\"width:557px; height:523px;\" src=\"images/ENDO/87938_Rsk_bnft_MHT.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Updated summary of the effects of orally administered CEE alone or combined with MPA in women ages 50 to 59 years during intervention phase of WHI. One set of analyses examined the risks and benefits of these agents in women ages 50 to 59 years. This figure plots these data, which are expressed here as excess risks and benefits per 1000 women using MHT for five years. Because women deciding to use MHT are more likely to continue this for a period of years rather than one year, this figure is constructed according to that assumption. WHI studies were not powered for age-related subset analyses, and none of the data presented in the figure are statistically significant. Nonetheless, this figure represents the best estimates that are available at the present time and are likely more reliable than similar estimates based on observational studies as reported previously in The Endocrine Society Scientific Statement.<br />The HR (95% CI) values for the bars in the figure are listed here with reference to the alphabetical designations shown next to the bars: (a) HR 0.60 (0.35-1.04); (b) HR 1.34 (0.82-2.19); (c) HR 0.82 (0.50-1.34); (d) HR 1.21 (0.81-1.80); (e) HR 0.99 (0.53-1.85); (f) HR 1.51 (0.81-2.82); (g) HR 1.53 (0.63-3.75); (h) HR 2.05 (0.89-4.71); (i) HR 1.66 (0.76-3.67); (j) HR 3.01 (1.36-6.66); (k) HR 0.71 (0.30-1.67); (l) HR 0.79 (0.29-2.18); (m) HR 1.00 (ns-ns); (n) HR 1.12 (0.45-2.75); (o) HR 0.62 (0.30-1.29); (p) HR 0.90 (0.72-1.11); (q) HR 0.82 (0.68-1.00); (r) HR 5.01 (0.59-42.9); (s) HR 0.17 (0.02-1.45); (t) HR 0.70 (0.46-1.09); (u) HR 0.67 (0.43-1.04); (v) HR 0.83 (0.67-1.04); and (w) HR 0.85 (0.66-1.09). (RJ Santen, et al. Competency in menopause management: whither goest the internist? <em>J Women's Health (Larchmt)</em> 2014; 23:281, courtesy of Mary Ann Liebert, Inc).</div><div class=\"graphic_footnotes\">CEE: conjugated equine estrogen; E: estrogen; E+P: estrogen-progestin; HR: hazard ratio; MHT: menopausal hormone therapy; MPA: medroxyprogesterone acetate; WHI: Women's Health Initiative.</div><div class=\"graphic_reference\">Republished with permission of The Endocrine Society, from: Stuenkel CA, Davis SR, Gompel A, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2015. Copyright &copy; 2015; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 87938 Version 5.0</div></div></div>"},"87967":{"type":"graphic_picture","displayName":"Lariat device for tissue approximation ","title":"Lariat device for tissue approximation ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Lariat device for tissue approximation </div><div class=\"cntnt\"><img style=\"width:303px; height:163px;\" src=\"images/CARD/87967_Lariat_devic_tiss_approxim.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2014 SentreHEART, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87967 Version 1.0</div></div></div>"},"87981":{"type":"graphic_table","displayName":"Approach to staging vulvar cancer","title":"Approach to staging vulvar cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Approach to staging vulvar cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Size of lesion</td> <td class=\"subtitle1\">Depth of invasion (mm)</td> <td class=\"subtitle1\">Location</td> <td class=\"subtitle1\">Operation</td> <td class=\"subtitle1\">Inguinofemoral lymphadenectomy or sentinel lymph node evaluation*<sup>&#182;</sup></td> </tr> <tr> <td rowspan=\"2\">T1a</td> <td>&#8804;1</td> <td>Lateral<sup>&#916;</sup> or central</td> <td>Radical local excision</td> <td>No</td> </tr> <tr> <td>&#62;1</td> <td>Lateral<sup>&#916;</sup></td> <td>Radical local excision</td> <td>Ipsilateral</td> </tr> <tr> <td rowspan=\"2\">T1b</td> <td rowspan=\"2\">&ndash;</td> <td>Central</td> <td>Radical local excision</td> <td>Bilateral</td> </tr> <tr> <td>Lateral</td> <td>Radical local excision</td> <td>Ipsilateral</td> </tr> <tr> <td>T2: Any size with extension to adjacent perineal structures (lower/distal 1/3 urethra, lower/distal 1/3 vagina, anal involvement)</td> <td>&ndash;</td> <td>&ndash;</td> <td>Modified radical<sup>&#9674;</sup> and/or chemoradiation</td> <td>Bilateral</td> </tr> <tr> <td>Extensive T3-T4 disease (upper/proximal 2/3 of urethra, upper/proximal 2/3 vagina, bladder mucosa, rectal mucosa, or fixed to pelvic bone)</td> <td>&ndash;</td> <td>&ndash;</td> <td>Neoadjuvant chemoradiation<sup>&#167;</sup> and selected surgery</td> <td>&ndash;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Many institutions also offer sentinel node biopsy to patients with a tumor diameter up to &lt;4 cm.<br />Â¶ Bilateral lymphadenectomy is performed if unilateral node is positive.<br />Î Further than 1 cm from midline.<br /><FONT class=lozenge>â</FONT> Modified radical vulvectomy (terminology includes radical hemivulvectomy, anterior or posterior modified radical vulvectomy).<br />Â§ Can consider chemoradiation as primary treatment or postoperative radiation for patients with high risk of local recurrence (those with stage IVA disease, positive or close margins, and a large number of groin nodes).</div><div class=\"graphic_reference\">Reproduced from: Fuh KC, Berek JS. Current management of vulvar cancer. Hematol Oncol Clin North Am 2012; 26:45. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 87981 Version 5.0</div></div></div>"}};